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Abstract
Chronic lack of sleep has been shown to be deleterious to our health. A variable 
number tandem repeat (VNTR) polymorphism in PERIODS (PER3) gene 
(rs57875989), has been reported to associate with diurnal preference, sleep 
propensity, vulnerability to sleep loss, and risk of cancer and mental illnesses. 
Although sleep loss at the molecular level in animal models has been studied 
extensively, there is a paucity of data in humans. The aim o f the current study was to 
investigate the dependent and independent effects of the PER3 VNTR polymorphism 
and sleep loss on gene expression.
Men and women homozygous for either the long (PER35/S) or short {PER34/4) PER3 
VNTR polymorphism underwent 7 sleep-wake cycles of either sleep restriction (SR) 
(6  h sleep) or sleep extension (SE) (10 h sleep) in a cross-over design, followed by 
40-h constant routine (CR), during which time blood samples for assessing global 
gene expression were collected 3-hourly.
Compared to SE, SR resulted in greater changes in expression in genes involved in 
neuronal plasticity, immune response, cellular stress response, energy metabolism, 
sleep-deprivation response, and clock genes in comparison to the effects o f CR, 
suggesting that effects of chronic sleep loss result in more severe consequences than 
acute lack of sleep. Entrained timing of habitual sleep and wakefulness was shown to 
correlate with the timing of NR1D1 (REV-ERBa), NR1D2 (REV-ERBp), BHLHE41 
(DEC2), CSNK1D and TIMELESS expression, suggesting a prominent role for these 
genes in the regulation of sleep-wake behaviour. Additionally, REV-ERBa and REV- 
ERBJ3 phase of expression showed correlations with sleep-wake timing in PER34/4, 
but not in PER3S/5. Additional genes identified as differentially expressed between the 
PER3 homozygotes were involved in immune function, 
phosphorylation/dephosphorylation, chronotype determination, and neurophysiology. 
A stably expressed reference gene, (3-actin, for real-time PCR analysis of circadian 
time-series data in blood was also identified.
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1 Introduction
1.1 Circadian rhythms
Environmental changes, such as temperature, light, abundance in food, and threat 
from predators change during the course of a day. These and many other 
environmental factors cycle in a consistent pattern called the circadian rhythm (from 
Latin circa diem -  about a day). In order for organisms to adapt and survive in these 
ever changing conditions, they need to be able to predict the changes and modify their 
physiology and behaviour in a predictive, rather then a responsive manner (Dibner, et 
al. 2010). It is therefore essential for an organism to measure time as it occurs in the 
environment.
The central clock (also called the central circadian oscillator) lies in the 
suprachiasmatic nuclei (SCN) in the hypothalamus, and is the core time keeping 
system in the body. The intrinsic period generated by the central circadian oscillator is 
not exactly 24 h. It therefore has to be re-synchronised to the environment on a daily 
basis using external environmental cues (primarily light). In mammals, as in most 
other photo-sensitive organisms, each cell in the body contains its own autonomous 
clock and cell physiology shows circadian oscillations in activity. These are called 
peripheral clocks. Although they can keep time even when isolated from the rest of 
the body, they quickly desynchronise in vitro. In order for an organism to keep precise 
track of time, all the clocks in the body need to be synchronised. Synchronisation is 
achieved by the central oscillator in the SCN via various signalling pathways (such as 
glucocorticoid pathway or feeding), as described later.
1.1.1 The central circadian oscillator
The central circadian oscillator or the ‘master’ clock is located in the SCN, which 
consists o f approximately 2 0 ,0 0 0  neurons that lie just above the optic chiasmum in the 
anterior hypothalamus of the brain (Moore and Eichler 1972). Each nucleus consists 
of about 10,000 y-aminobutyric acid (GABA-ergic) neurons segregated into two 
regions: a core region characterised by cells that also express vasoactive intestinal 
polypeptide (VIP) and gastrin releasing peptide (GRP), and a shell region containing
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arginine-vasopressin (AVP) releasing neurons as well as calretinin (CAR) producing 
neurons, reviewed in (Moore, et al. 2002).
The SCN generates the circadian oscillations through autonomous 
transcription/translation based feedback, involving positive and negative regulators. 
These will be discussed later. An SCN slice continues to show oscillations in gene 
expression in culture for months without loosing precision and each individual SCN 
neuron maintains robust circadian timekeeping when dispersed into primary culture 
(Liu, et al. 2007). The SCN neurons are thus self-sustained biological clocks.
SCN lesions in mammals eliminated circadian rhythms in activities such as drinking, 
locomotor activity, body temperature, oestrus cycling and secretion of hormones 
(Meyer-Bemstein, et al. 1999). Transplanting the SCN from a donor animal results in 
the recipient animal showing the activity period o f the donor (Ralph, et al. 1990). The 
central circadian oscillator is responsible for directing all physiological and 
behavioural rhythms in the body. Even under constant conditions, these persist with 
an intrinsic period (also referred to as x) very close to that of the Earths’s rotation, 
even in the absence of timing cues to which it could entrain. The endogenous 
circadian rhythm is an intrinsic property o f an organism .In humans the first attempts 
to quantify t failed. The reported t in humans ranged from 13 to 65 h as assessed by 
Aschoff and Weaver more than 50 years ago (Czeisler, et al. 1999). In 1999 free- 
running t in human volunteers was re-assessed by using three phase markers. The 
average estimated period in healthy men was shown to be 24.18h (Czeisler et al. 
1999).
Melatonin is an endocrine hormone, produced by the pineal gland and released into 
the blood stream. The production of melatonin is induced by low light levels and 
suppressed by day (blue) light. Melatonin is thus synthesised during the night and its 
levels peak at around the time of core body temperature nadir. Because its fluctuating 
levels are controlled by the central clock, melatonin has become an established 
marker of endogenous circadian phase, and is thought to be the most reliable marker 
(Klerman, et al. 2002). Melatonin is degraded in the liver, but a small amount is
2
excreted in urine and saliva. The time of blood plasma, urine or saliva melatonin peak 
onset as measured in dim light conditions is called dim light melatonin onset (DLMO) 
and is often used as a measure o f endogenous circadian phase (Mallo, et al. 1990). 
Other established markers o f circadian phase include cortisol levels as measured in 
the blood, saliva or urine, as well as core body temperature.
1.1.2 Entrainment of the central oscillator to the environment
An important ability of the central clock is that it can reset its phase in response to 
external time cues (also called zeitgebers), most importantly external light, and by 
doing so can synchronise the body’s internal clock with the ambient 24-h cycle. This 
is important because the central oscillator free-runs at a slightly different period than 
that found in the environment, as the environmental period (day length) changes over 
seasons. Besides this, humans can change time zones or work in shifts or at night. The 
body clock is able to keep track of these modifications, and adapt.
In mammals light is received via the retina in the eyes. Intrinsically photosensitive 
retinal ganglion cells (RGC), containing the photopigment melanopsin, relay photic 
information to the SCN via the retinohypothalamic tract (RHT) (Berson 2003). 
Melanopsin is a blue-light sensitive photophigment located in the inner retina and not 
involved in image formation (Provencio, et al. 2000). The core of the SCN is 
therefore entrained to the environmental light/dark cycles by a direct retinal 
innervation. Light-dependent activation of VIP neurons and other retinorecipient 
neurons via the RHT initiates intra- and intercellular cascades of gene expression, first 
in the SCN core and then spreading into the shell via GAB A, VIP and GRP signalling 
pathways (Hattar, et al. 2002; Tanaka, et al. 1993). This pathway is sufficient to 
entrain the SCN clockwork to solar time by brief exposures to light at dawn and/or 
dusk (Khalsa, et al. 2003). It is only during these time frames that the circadian clock 
can be reset and adapt to the current solar time. It has also been shown that enucleated 
hamsters loose the ability to entrain to the light-dark cycle (Yamazaki, et al. 1999)
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1.1.3 Peripheral oscillators and their synchronisation
The first mammalian peripheral oscillator was discovered in cultured neural retinas of 
the Syrian golden hamster, which exhibited circadian rhythms of melatonin synthesis 
for several days in culture (Tosini and Menaker 1996). Soon after, Period (Per) 
mRNA oscillations were detected in several mouse tissues; liver, skeletal muscles, 
and testis (Zylka, et al. 1998b), and this prompted the search for other peripheral 
oscillators. Since then, peripheral oscillators have been identified in almost all tissues 
and cells in the mammalian body, apart from testis, where a functional molecular 
clock has not been confirmed (Yamamoto, et al. 2004). The central oscillator in the 
SCN maintains rhythmicity in self-sustained oscillations ex vivo for over 30 cycles, 
whereas peripheral rhythms dampen after 2-7 cycles (Yamazaki, et al. 2000). Per2 
promoter constructs were used to drive gene expression of firefly luciferase (Per2- 
luc) in several mouse tissues in a circadian fashion, which persisted for up to three 
weeks in culture (Yoo, et al. 2004). These findings also showed that lesions in the 
SCN did not result in abolished circadian rhythmicity in peripheral tissues but rather 
caused phase desynchrony among tissues from the same animal, suggesting that 
peripheral oscillators are also self-sustaining, a feature thus far only ascribed to the 
central circadian oscillator.
While the SCN receives light timing cues to synchronise it to the environment, it also 
sends timing information to peripheral oscillators of the body in order to synchronise 
all clocks in the body. This is important because most processes in the body are 
carried out by several tissues and organs at certain times of the light/dark cycle. It is 
therefore important for all parts of the machinery to be in working mode at the same 
time. The SCN influences the peripheral oscillators by several output mechanisms, 
which can be direct or indirect, schematically shown in Figure 1.1.
One of the direct synchronising mechanisms is via the pituitary-adrenocortical axis. 
This can be influenced by humoral (glucocorticoid hormone) or neural (adrenaline) 
stimulation. Glucocorticoid hormones are involved in multiple functions, including 
anti-inflammatory action, can affect mood and cognition, and regulation of protein, 
fat, and glucose metabolism. The glucocorticoid receptor is found in many cells types
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but not in the SCN (Rosenfeld, et al. 1993). G lucocorticoids have been show n to 
change the phase o f  circadian gene expression in som e peripheral tissues (B alsalobre, 
et al. 2000). SCN -lesioned m ice show ed a strong induction o f  rhythm ic Per2  
expression in the liver, w hen adrenalin w as periodically  injected. Furtherm ore, 
electrical stim ulation o f  the sym pathetic nerves increased P e r l  transcrip tion in the 
m ouse liver. These findings indicate that the sym pathetic nervous system  also plays 
an im portant role in conveying central clock inform ation to som e peripheral tissues 
(Terazono, et al. 2003).
The peripheral oscillators can also be influenced by external tim e cues. The m ost 
im portant such tim e cue (zeitgeber) is food intake. Food intake has been show n to act 
upon the food entrained oscillator (FEO) independently  o f  the SCN (M artinez-M erlos, 
et al. 2004). This zeitgeber has been shown to uncouple the central and peripheral 
oscillators, w hen food w as restricted (D am iola, et al. 2000). The effect o f  food intake 
on peripheral clocks is m ediated by the m etabolites derived from  the ingested food 
(such as glucose and retinoic acid) and the horm ones secreted as a response to 
abundance or lack o f  food (H irota and Fukada 2004)
R etino-hypotha lam ic
pathway:
external light signals
central clock /  P itu itary-adrenocortica l axis:
humoral signals (glucocorticoid hormone) 
neural signals (adrenaline)
feeding liver
S 3  ('"O ) [peripheral clocks
h eart V ,  feeding ©<
Figure 1.1 Central and peripheral oscillators.
(M odified from H irota and Fukada 2004)
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1.1.4 Diurnal preference
Diurnal preference or chronotype is a strictly human behavioural measure and refers 
to the time of day when individuals feel most alert, awake, and cognitively and 
physically at their peak. Individuals who feel at their best in the morning after they 
wake up are referred to as early- or morning-type or ‘larks’, while people who 
preferred to stay up late and feel more alert in the evenings are referred to as late- or 
evening-type or ‘owls’. Most people, however, are somewhere in between and show 
features of both chronotypes. Several tools in the form of questionnaires have been 
developed to assess individual’s chronotype. One of the earliest and most commonly 
used questionnaire is the Home-Ôstberg Momingness-Eveningness (HO) 
questionnaire (Home and Ostberg 1976) still widely used today. Another 
questionnaire is the Munich Chronotype Questionnaire (MCQ) (Roenneberg, et al. 
2003), which differentiates between work and free days, measures chronotype based 
on mid-sleep point on free days, and takes the amount of daylight a person is exposed 
to into account.
Chronotype distribution is almost normal, slightly skewed towards late chronotype as 
determined by both the HO and MCQ. When individuals with extremely long or short 
nocturnal sleep duration were compared, the chronotype distribution did not differ 
between the two groups (Roenneberg, et al. 2007; Zavada, et al. 2005).
As assessed by the MCQ, the early chronotypes fall asleep about 2 hours before the 
late types on work days, and wake up only 30 minutes before (Roenneberg et al. 
2003). This leads to considerably shorter sleep in late types. Additionally, late 
chronotypes need longer after wake-up time to feel fully alert. This is more 
pronounced on workdays, probably due to the fact that late chonotypes obtain less 
sleep. On free days, neither chronotype nor sleep duration affect the time needed to 
become fully awake (Roenneberg et al. 2003), shown in Figure 1.2.
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Figure 1.2 Habitual sleep and wake times of late to early chronotype individuals on work and 
free days.
(M odified from R oenneberg et al. 2003)
Because w ork com m itm ents in the m orning usually start at the sam e tim e for all on 
w orkdays, late chronotypes accum ulate a sleep debt due to their late bed tim es. By 
contrast, due to social com m itm ents on free days, the early chronotypes try to com ply 
w ith social pressure to stay up late, and hence accum ulate a sleep debt over the free 
days, because their w ake up tim e during w ork and free days rem ains about the same. 
Therefore, the social clock w akes the late chronotypes too early on w ork  days, and the 
biological clock w akes the early chronotypes too early on free days (R oenneberg et al. 
2003).
Chronotype has also been show n to change w ith age (Dijk, et al. 2000; Duffy, et al. 
2001). Children are usually  early chronotypes progressively  becom ing late 
chronotypes as they get older, reaching their ‘la test’ at around the tim e w hen they 
becom e adults (age 20). W ith age peop le’s chronotype gradually  becom es early again 
and becom es even earlier than when they w ere children after the age o f  60. These
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changes have been suggested to be governed by hormonal changes (Roenneberg et al. 
2007).
Extreme chronotypes result in illnesses such as advanced- (ASPD) or delayed-sleep 
phase disorder (DSPD). ASPD is a genetic disease caused by a mutation in a kinase 
involved in the molecular clock (described in section 1 .3 .1 .2 ) resulting in a shorter 
circadian period. DSPD, on the other hand, can be caused by several factors, 
including longer circadian period, phase misalignement between endogenous clock 
and sleep-wake cycles, impaired photic entrainment and/or altered sleep homeostasis 
(reviewed in Hida, et al. 2012).
The two chronotypes differ in the phase of entrainment, which in turn depends on the 
strength of the zeitgeber (light being a strong zeitgeber) as well as the individual’s 
free-running period. Early chronotypes have a longer interval between their core body 
temperature nadir, melatonin peak and wake-up time, while late chronotypes wake up 
soon after the temperature and melatonin phase, but this relationship has also been 
shown to change with age (Duffy, et al. 1999). Additionally, the length of the intrinsic 
circadian period was found to negatively correlate with self-reported chronotype; 
early chronotype associates with a shorter intrinsic period (Duffy et al. 2001). 
Individuals with a period shorter than 24 h thus need to be delayed, while those with a 
longer period need to be advanced by daily light cues, in order to be entrained to the 
approximately 24-h day/night cycle.
How much the internal clock is shifted when single light pulses during constant 
conditions are administered has been established by producing phase response curves 
(PRC) (Beersma and Daan 1993). For each circadian time a PRC indicates how much 
the internal clock is shifted (either advanced or delayed). A PRC for a strong 
zeitgeber such as light is therefore steeper than that for a weak zeitgebers. The phase 
of entrainment with strong zeitgebers is similar for those with a shorter and longer 
intrinsic circadian period, resulting in a narrow chronotype distribution. Weak 
zeitgebers, on the other hand, entrain at very different phases, which result in a wider 
chronotype distribution. The lack of exposure to strong zeitgebers in modem society
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(not enough exposure to natural daylight) thus results in a wide distribution of 
chronotypes (discussed in Roenneberg et al. 2003).
The study of chronotypes is important for a better understanding of the society, for 
improving safety during shift-work, and for chronotherapy (administration o f drugs at 
a time appropriate for an individual’s circadian phase). Also, by understanding 
chronotypes, illnesses such as ASPD or DSPD may perhaps one day be treatable.
1.2 Sleep
Sleep has been described as ‘by the brain, and for the brain’ (Hobson 2005), but the 
real reason why humans and all animals sleep, remains to be uncovered. Sleep is not 
just an absence of wakefulness, but rather an active state which has been shown to be 
finely regulated (Landolt 2008).
Sleep can be divided into two structural types: non-rapid eye movement (NREM), and 
rapid eye movement (REM) sleep. NREM usually takes up about 75%, while REM 
sleep only about 25% of sleep time. Electroencephalography (EEG) is used to 
measure brain activity and identity features specific for each sleep stage. Most o f the 
pioneering work in this field was carried out by Alfred L. Loomis and his colleagues 
in the 1930s (reviewed in Landolt 2008).
While wakefulness is characterised by low-amplitude, fast-frequency EEG alpha 
waves, NREM sleep is marked by loss of alpha, and gain of low-frequency theta 
waves, which are interrupted by characteristic high-frequency sleep spindles and K- 
complexes, as identified by EEG. The final stage of NREM sleep is marked by deep 
or slow-wave sleep (SWS), characterised by high-amplitude, low-frequency delta 
waves. Slow-wave sleep is the most physically restorative part o f sleep, and is most 
increased after extensive exercise or other activities where catabolism has been 
increased. It is also a marker of sleep pressure as delta waves are more prominent 
immediately after sleep loss. It is the time of de novo synthesis of macromolecules in 
the brain such as proteins and RNA, part o f which are then later used during REM
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sleep. REM sleep is characterised by rapid movement of the eyes and low-amplitude 
EEG. It is also a time when atonia sets in to prevent individuals form acting out their 
dreams, which are most vivid during this time. REM sleep is most induced after 
periods of extensive learning or stress, and thus might be involved in memory 
consolidation (Iber, et al. 2007; Schulz 2008).
1.2.1 Function of sleep
Although sleep is universal and all animals and humans spend roughly 1/3 o f their life 
asleep, no one certain function of sleep has yet been defined. At present, three main 
concepts on why we sleep exist: Energy saving, information processing and synaptic 
plasticity, and restoration of key cellular components of macromolecule biosynthesis 
(Mignot 2008).
During wakefulness energy demands are elevated, and in humans the brain consumes 
around 30% of total energy. For diurnal animals to time their peak activity to the time 
of food availability, maximum temperatures and visibility, sleep has developed as a 
method of energy preservation during the time of unfavourable conditions i.e. during 
the night. However, sleep is also a time when thermoregulation is partially 
unregulated (Parmeggiani 2003), and while NREM sleep is associated with lower 
energy expenditure, REM sleep is associated with elevated levels o f oxygen 
consumption (Parmeggiani 2003; Zhang, et al. 2007). Additionally, hibernating 
mammals need to interrupt periods of torpor (a time of hypothermia and energy 
conservation) and elevate their body temperatures in order to sleep, so even during 
this inactive state of hibernation or torpor sleep is still essential (Daan, et al. 1991). It 
is therefore unlikely that sleep primarily evolved as a mechanism for energy 
conservation in mammals (Mignot 2008).
Sleep deprivation has been shown to affect cognition, attention, and memory. 
Learning and memory are both improved when they are followed by sleep, indicating 
that information processing must take place during sleep (Stickgold 2005). 
Wakefulness is a time o f activity and learning (information acquisition) resulting in
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long-term synaptic potentiation of cortical networks, which eventually becomes 
unsustainable (Tononi and Cirelli 2003). Sleep, on the other hand, is a time of 
synaptic strength downscaling to an energetically sustainable level, as proposed by the 
synaptic homeostasis hypothesis, leaving only the most robust connections intact 
(Tononi and Cirelli 2003, 2006).
During sleep, an increase in proteins involved in synthesis of complex 
macromolecules has been observed (Mackiewicz, et al. 2007). Identified transcripts 
show involvement in cholesterol and protein synthesis, as well as intracellular 
transport, and endo / exocytosys. This will be discussed in section 1.3.3.
1.2.2 Regulation of sleep
The transition between sleep and wakefulness occurs in the hypothalamus through the 
‘flip-flop’ switch. This is a mutually inhibitory interaction between the ventrolateral 
preoptic nucleus (VLPO) (sleep promoting) and monoaminergic cell groups (arousal 
system) in the brain. During sleep, the VLPO neurons fire rapidly and inhibit the 
monoaminergic cell groups and orexin neurons, thus disinhibiting and reinforcing 
their own (VLPO) neurons. Likewise, during wakefulness, monoaminergic neuron 
firing rate is increased, resulting in VLPO inhibition and suppression o f the orexin 
neurons, and disinhibition of their own (monoaminergic) neurons (Saper, et al. 2001; 
Saper, et al. 2005). The inability of the brain to efficiently regulate the transition 
between sleep and wakefulness results in neurological disorders. One such disorder is 
narcolepsy, which is characterised by sudden bouts o f irresistible sleep in individuals 
occurring at any time of the day. These individuals begin their sleep cycle by falling 
directly into REM sleep instead of NREM sleep, as is observed in healthy individuals. 
Because REM sleep is accompanied by atonia, which prevents the sleeper to act out 
their dreams, individuals suffering from narcolepsy often also suffer from cataplexy, a 
sudden loss of voluntary muscle movement. Abnormalities in hypothalamic orexin 
neurotransmission have been shown to play a key role in narcolepsy and cataplexy. In 
humans the disease occurs sporadically and is caused by the loss of 70,000 orexin 
neurons in the hypothalamus (Chabas, et al. 2003). Although the exact cause o f the 
condition is not known, correlations with certain variations in the HLA genes exist.
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The loss o f  orexin neurons is therefore m ost likely an autoim m une event, w here 
orexin producing neurons are targeted (Lin, et al. 2001). Anim al m odels o f  
narcolepsy, w here either the orexin receptor or orexin ligand gene has been disrupted 
have also been developed (Lin, et al. 1999).
The regulation o f  sleep and w akefulness has been proposed to be m aintained by tw o 
distinct com ponents w hich w ork together in the ‘tw o-process m odel o f  sleep 
regulation’ (B eersm a 1998; B orbely 1982; D aan, et al. 1984), as shown in Figure 1.3. 
One com ponent is the hom eostatic process or hour-glass oscillator (referred to as 
process S in the m odel). This com ponent keeps track o f  sleep propensity over the 
course o f  the sleep-w ake cycle. Sleep propensity  is low upon w aking, exponentially  
increases during the w aking period until it reaches the turning point, w hen sleep 
occurs. The hom eostatic com ponent (sleep pressure) then dissipates again during 
sleep. A nother com ponent o f  this m odel is the circadian process or endogenous 
oscillator (referred to as process C in the m odel). The circadian com ponent is 
described in section 1.1.1.
Process C
Sw w s w s
Figure 1.3 Schematic representation of the two process model of sleep regulation.
Sleep propensity ('p rocess S ’, solid line) augm ents during tim e aw ake (W ) and returns to baseline 
levels in the m orning after sleep (S), circadian process ( ‘process C ,  dotted line) fluctuates w ith an 
intrinsic period x (M odified from B eersm a 1998).
The hom eostatic and circadian process w ork  together to regulate the sleep/w ake 
tim ing. As tim e aw ake accum ulates, the hom eostatic propensity to fall asleep 
increases. L ikew ise, the circadian drive for w akefulness increases as the biological
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day progresses and is at its peak ju s t before the peak in m elatonin secretion is reached, 
som etim es called the wake m aintenance zone. Im m ediately follow ing the m elatonin 
peak, the circadian drive for w akefulness decreases and this m akes the hom eostatic 
propensity  to fall asleep m ore prom inent. This leads to sleep. The hom eostatic sleep 
propensity  decreases only after the onset o f  sleep. This is follow ed by an increase in 
circadian drive to sleep and the peak  is reached at around core body tem perature 
nadir, generally in the early m orning o f  the biological day. A t this tim e the circadian 
drive for w akefulness reaches its nadir, and in individuals who have stayed aw ake 
during this tim e, alertness and cognitive perform ance reach their low est point. D uring 
the biological night, sleep-dependent sleep propensity decreases and circadian drive 
for w akefulness increases. This leads to aw akening. B esides the hom eostatic and 
circadian com ponent o f  sleep regulation, social factors (waking up w ith an alarm  
clock to go to w ork, or staying aw ake late at night for w ork or social com m itm ents) 
are a m ajor influence on sleep-w ake behaviour. The effects o f  social factors on the 
sleep-w ake cycle w ill im pinge on the hom eostatic and circadian oscillator, w hich in 
turn also feed back on to the sleep-w ake cycle and affects the sleep and w ake tim es 
(D ijk and Lockley 2002; D ijk and von Schantz 2005), as shown in F igure 1.4.
/ — x  S ocia l  factors
SLEEP-WAKE CYCLE
Intrinsic
clock
Sleep
horneostat
External light-dark 
cy c le
Figure 1.4 Regulation of sleep by the sleep wake-cycle, the intrinsic clock and the sleep 
horneostat.
(M odified from D ijk and Lockley 2002)
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1.2.3 Studying sleep
To effectively study the wakefulness and sleep-related body functions, and to be able 
to tease apart the contributions of the endogenous and exogenous factors, two study 
protocols are often used; constant-routine (CR) (Mills, et al. 1978) and forced 
desynchrony (FD) (Kleitman and Kleitman 1953). In the CR protocol, the sleep-wake 
cycle is replaced by constant wakefulness and the internal and external factors 
influencing the sleep-wake cycle are separated. External factors such as the light-dark 
and social cycles are kept constant by keeping the subjects in dim light, in bed in a 
semi-recumbent position, at constant temperature, scheduling their food intake to 
small hourly snacks rather than fewer large meals (Duffy and Dijk 2002). By 
minimising the influence of external cues, rhythms run closer to their intrinsic period. 
But the homeostatic and circadian process cannot be separated by the CR protocol. In 
order to achieve this, a FD protocol has to be applied. In this protocol, subjects are 
kept on a daily schedule that is different from the range of the endogenous period of 
on average 24.2 h (Czeisler et al. 1999), either being longer (around 28 h), or shorter 
(around 20 h), while they still spend 1/3 of the sleep-wake cycle in bed. The sleep 
horneostat is thus forced to a period much different than 24.2 h and the circadian 
oscillator cannot entrain. The circadian oscillator will therefore free run at its intrinsic 
period (around 24.2 h). In this way the homeostatic and circadian component o f sleep- 
wake regulation is separated and each can be studied independently, as well as their 
interaction (Dijk, et al. 1999; Hiddinga, et al. 1997).
1.3 Molecular correlates of circadian rhythms and sleep
1.3.1 Clock genes
The mammalian clock genes and their respective clock proteins are responsible for the 
auto-regulated, self-sustaining clock mechanism found in almost all cells and tissues, 
and are organised hierarchically (Lowrey and Takahashi 2004; Reppert and Weaver 
2002).
The core mammalian clock genes are Clock (King, et al. 1997), Npas2 (Reick, et al.
2001) and Sm all (also called Arntl, MopS) (Bunger, et al. 2000), which represent the
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positive limb of the molecular clock, and period genes Perl (Sun, et al. 1997; Tel, et 
al. 1997), Per2 (Bae, et al. 2001; Shearman, et al. 1997), Per3 (Takumi, et al. 1998; 
Zylka et al. 1998b), as well as cryptochrome genes Cryl and Cry2 (Kume, et al. 1999; 
van der Horst, et al. 1999), which make up the negative limb of the molecular clock. 
CLOCK, NPAS2, and BMAL1 are basic helix-loop-helix-(PER-ARNT-SIM) (bHLH- 
PAS) proteins, the PERs are PAS proteins, and the CRYs are derived from 
flavoproteins. Additional genes involved in the clock mechanism are orphan nuclear 
receptors RevErba (N rld l)  (Preitner, et al. 2002), and Rora (itora)(Sato, et al. 2004), 
as well as two kinases Csnkle (Casein kinase I s) and C snkld  (Casein kinase I 5) (Xu, 
et al. 2005)
1.3.1.1 The molecular clock
The clock genes make up the core feed-back loop which consists of a positive and 
negative limb. Clock mRNA and protein are constitutively expressed (Maywood, et 
al. 2003) while Em ail transcription peaks in the middle of circadian night. At the 
beginning of a circadian day, a heterodimeric complex formed by CLOCK and 
BMAL1 proteins, through their PAS domains, forms in the cytoplasm and is 
translocated to the nucleus where it activates the transcription of the Per and Cry 
genes by binding to their promoters through an E-box regulatory sequence (positive 
limb) (Gekakis, et al. 1998; Hogenesch, et al. 1998; Jin, et al. 1999; van der Horst et 
al. 1999). This leads to Per and Cry mRNA accumulation in the nucleus towards the 
end of the circadian day. At this time the mRNA is exported out of the nucleus and 
translated into PER and CRY proteins in the cytosol. At the beginning of the circadian 
night the concentrations of both proteins are at their peak. The proteins are activated 
by phosphorylation and interact to form PER/CRY heterodimers. The heterodimers 
are translocated back in to the nucleus where they interact with the CLOCK/BMAL1 
complex to inhibit the transcription of Per and Cry (negative limb). The inhibition is 
mainly due to the action of the CRY protein repressing though the hi stone acetyl 
transferase activity (Etchegaray, et al. 2003), while the PER proteins serve as 
translocation adapters (Loop, et al. 2005). The PER and CRY proteins are then 
degraded and during their absence the circadian system re-enters the positive limb 
phase. The core molecular clock is schematically shown in Figure 1.5.
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Figure 1.5 A model of positive and negative feedback loops of the molecular circadian clock.
N ot all interactions are shown.
Besides the core feedback loop the circadian clock is m ade up o f  additional secondary 
loops, w hich help stabilise the prim ary loop. Perhaps the m ost im portant is the loop 
bridging the positive and negative limb o f  the core loop. Here the CLO CK /BM A L1 
heterodim er binds and activates R evErba  and R ora  as it does the P er  and Cry genes. 
R E V -E R B a and R O R a then com pete for the R etinoic acid-aelated orphan receptor 
response elem ent (RO RE) located in the E m a il  prom oter. R O R a as w ell as R O R p 
and RORy activate transcription o f  E m a il  w hile R E V -E R B a represses it (P reitner et 
al. 2002). BM AL1 thus attenuates its ow n transcrip tion and CLO CK /BM A L1 
accum ulation is therefore m ainly BM AL1 dependent. R E V -E R B a plays a critical role 
in the tim ing o f  BM AL1 accum ulation, heterodim erisation w ith C LO C K , 
translocation o f  the heterodim er to the nucleus and initiation o f  a new  cycle (Lee, et 
al. 2001). The R O R  and R EV -ERB proteins can function differently in the SCN and 
peripheral clocks (G uillaum ond, et al. 2005). R O R a is slightly rhythm ically  expressed
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in peripheral tissues, but oscillates with a rhythmic pattern in the SCN. REV-ERBa 
and (3 bind to the RORE1 and RORE2 binding site while ROR proteins preferentially 
bind to RORE1.
The ROR proteins are encoded by 3 genes; a, (3, y. The a gene encodes splice 
isoforms a\ - a^ and y gives rise to yi, y2. The different temporal and spatial 
expression of Rev-Erb and Ror genes between central and peripheral clocks as well as 
differences between expression in peripheral tissues result in functional differences 
between circadian oscillators (Guillaumond et al. 2005). REV-ERBa might also 
control the transcription of Clock and Cry, as RevErba KO (knock-out) mice show 
little or no oscillation in Clock and Cry transcription (Preitner et al. 2002). RORai 
upregulates the expression of RevErba by interacting through the direct repeat (DR)-2 
response element (Rev-DR2) located in the RevErba promoter. RevErba, however, 
downregulates its own transcription via the same element (Migita, et al. 2004).
Npas2 is a paralogue of Clock, and Bmal2 is a paralogue of Bmall. While NPAS2 can 
function interchangeably with CLOCK in the SCN (DeBruyne, et al. 2007a) but not in 
peripheral oscillators (DeBruyne, et al. 2007b), Bmal2 does not show rhythmicity in 
its expression in the SCN (Okano, et al. 2001), and its expression is dependent on 
Bmall (Bunger et al. 2000). Expression of Bmal2 from a constitutive promoter was 
shown to rescue the circadian clock and Bm all KO phenotypes (Shi, et al. 2010).
Timeless was initially shown to be constitutively expressed and does not seem to 
function as a clock gene in mammals (Zylka, et al. 1998a). However, TIMELESS has 
been shown to be important for the resetting of the molecular clock, as it directly 
interacts with PER proteins, and together with the PERs negatively regulates the 
BMAL1/CLOCK complex, which in turn is involved in PERI expression activation 
(Sangoram, et al. 1998). TIMELESS was also shown to be rhythmically expressed in 
the rat SCN, and to associate with the mammalian PER protein, thus indicating to be 
the functional homologue of the Drosophila Timeless (Barnes, et al. 2003). Tip 
(Timeless-like protein), however, has been shown to be expressed in the SCN as well 
as peripheral tissues, and the protein has been shown to interact with PER2. Sangoram
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et al. thus conclude that TLP may be an important element in the circadian molecular 
clock system.
GSK3P phosphorylates and stabilises the orphan nuclear receptor REV-ERBa, a 
negative component of the circadian clock. Inhibition of GSK3P leads to rapid 
proteasomal degradation of REV-ERBa and activation of clock gene Bm all (Yin, et 
al. 2006). GSK3P phosphorylation thus stabilises REV-ERBa. CRY2 is 
phosphorylated by GSK3p resulting in degradation of CRY2 by a proteasome 
pathway (Harada, et al. 2005). GSK3P also phosphorylates BMAL1 and in doing so 
primes it for ubiquitination, which affects the efficiency and amplitude of circadian 
gene expression. In the absence of GSK3P, BMAL1 becomes stabilised, the BMAL1 
oscillations are dampened (Sahar, et al. 2010) and the circadian period of cells in vitro 
is shortened (Hirota, et al. 2008).
CSNK1E has been identified as one of the key regulator proteins involved in 
regulating and fine-tuning the circadian clock. It has been shown to bind to and 
phosphorylate the PER proteins and in this way control the rate at which the PER 
proteins are translocated into the nucleus (Vielhaber, et al. 2000) and later degraded. 
CSNK1E primes the PER2 protein for degradation by the 26S proteasome, by 
phosphorylating the protein and recruiting an additional ubiquitin ligase adapter 
protein pTrCP (Eide, et al. 2005). CSNK1E phosphorylates BMAL1 resulting in 
activation of BMAL1-dependent transcription while MAPK-mediated 
phosphorylation o f BMAL1 inhibits CLOCK/BMAL1 -induced transcription (Sanada, 
et al. 2002). CRY proteins, however, can only be phosphorylated by the CSNK1E 
when they are simultaneously bound to the kinase and PERI or PER2. CLOCK is not 
a substrate for CSNK1E (Eide, et al. 2002). CSNK1D is the most closely related 
kinase to CSNK1E. It also phosphorylates PER proteins which results in protein 
instability, similar to CSNK1E (Camacho, et al. 2001). CSNK1E was shown to be 
highly expressed in the mouse brain (Camacho et al. 2001).
FBXL3 (F-box and leucine-rich repeat protein) contains F-box protein-protein 
interaction sites, strongly interacts with CRY1 and CRY2, and has been shown to play
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a key role in ubiquitination of CRYs followed by proteasomal degradation (Siepka, et 
al. 2007). p300 is a bistone acetyltransferase which binds to the CLOCK/BMAL 1 
complex, acetylates H3 (histone 3) and by doing so remodels the chromatin so as to 
enhance P erl and Per2 transcription. During the night the CRY protein binds to the 
CLOCK/BMALl/p300 complex causing p300 to dissociate resulting in a decreased 
HAT activity o f the complex and decreased transcription of P erl and Per2 
(Etchegaray et al. 2003).
The Cryl gene contains 2 E-boxes (transcription factor enhancer binding sites) in its 
promoter through which the CLOCK/BMAL 1 complex binds and activates Cry 
transcription. Two sites close to the E-boxes show rhythmic patterns in daily 
hypersensitivity which correlates with the rhythm of Cry mRNA abundance. Per and 
Cry genes are thus both under CLOCK/BMAL 1 transcriptional control as well as 
regulated by acétylation and deacetylation of the H3 in the chromatin. REV-ERB 
binds to two sites in the Cryl promoter and inhibits its transcription. It is most likely 
due to this repressor that the Per and Cry genes, although under similar transcriptional 
control, differ in their peak expression times (Etchegaray et al. 2003)
DEC1 (STRA13, SHARP2, BHLHB2) and DEC2 (SHARP 1, BHLHB3) inhibit 
CLOCK/BMAL 1 induced transcription in two ways; either by binding to E-boxes 
located in promoters of CLOCK/BMAL 1 target genes where they compete with the 
CLOCK/BMAL 1 complex, or by binding directly to BMALL Their transcription is 
activated by CLOCK/BMAL 1 (Butler, et al. 2004) and both are rhythmically 
expressed in the SCN. Their oscillations are much dampened in other brain tissues. 
DEC proteins are strong negative components of the circadian system. (Honma, et al.
2002). The expression of D ecl and Dec2 is regulated by RORa, but not REV-ERBa. 
The rhythmicity is not affected by this (Ozaki, et al. 2012). D ecl but not Dec2 
expression is enhanced by a single light pulse in a phase-dependent manner and is 
probably due to direct action o f light on the RHT (Honma et al. 2002).
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1.3.1.2 Clock gene polymorphisms in humans
Several polymorphisms have been identified in human clock genes which have been 
shown to affect sleep and wakefulness in different ways.
In the CLOCK gene a single nucleotide polymorphism (C3111T) has been identified 
at position 3111 in the 3’ untranslated region. The polymorphism is a C to T 
nucleotide substitution. The 3111C allele carriers were shown to have an increased 
eveningness tendency according to the HO questionnaire, compared to 311 IT allele 
carriers (Katzenberg, et al. 1998). However, later studies failed to replicate these 
findings (Pedrazzoli, et al. 2007; Robilliard, et al. 2002). An eveningness preference 
was also identified in 3111C allele carriers among a group of patients with bipolar 
disease in a Korean population (Lee, et al. 2010). CLOCK  gene variants have also 
been shown to be associated with sleep duration (Allebrandt, et al. 2010), as well as 
with energy intake and cytokine sleep factors (Garaulet, et al. 2010).
In the CSNK1D gene, a missense mutation (T44A) was found which results in 
decreased enzymatic activity of the CSNK1D and a shorter circadian period in mice 
and humans, and has been associates with ASPD (Xu et al. 2005).
A point mutation in human DEC2 gene has been associated with shorter sleep length 
and the authors speculate this might be due to altered homeostasis (He, et al. 2009).
A polymorphism in exon 18 of PERI (T2434C) was found to be associated with 
extreme diurnal preference. Carriers of the 2434C allele were reported to be 
associated with morning preference (Carpen, et al. 2006).
The PER2 gene can harbour a missense mutation (A2106G) in the phosphorylation 
site, causing individuals with the mutation to have a glycine in place of serine at this 
location. The mutation results in hypophosphorylation by CSNK1E, which in turn 
alters individual’s intrinsic circadian period, resulting in ASPD (Toh, et al. 2001), but
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this has only been found in one family. An additional mutation (C111G) was 
identified just upstream from the start codon. The 111G mutation has been shown to 
be associated with extreme morning preference. The authors predict the mutation 
might alter the secondary structure of the transcript, and as such be a possible 
candidate allele for advanced sleep phase syndrome (Carpen, et al. 2005).
In the PER3 gene 20 sequence variations were described in one individual with 
DSPD; 17 single-nucleotide polymorphisms (SNP), two insertion/deletions and one 
variable number tandem repeat polymorphism (VNTR) located in exon 18. One of the 
single SNPs was shown to be associated with DSPD (Ebisawa, et al. 2001).
The VNTR polymorphism identified by Ebisawa et al is an 18-amino-acid motif 
repeated multiple times, and it is unique to primates (Jenkins, et al. 2005). In humans 
the motif is repeated either 4 (PER34/4) or 5 (PER35/5) times. The shorter PER34/4 
allele has been shown to be associated with DSPD and evening preference, while the 
longer PER35/S allele is associated with morning preference (Archer, et al. 2003; 
Jones, et al. 2007; Lazar, et al. 2012). Later a chronotype association was also 
confirmed in a Brazilian population, however the association with DSPD was found 
in PER3S/5 homozygotes (Pereira, et al. 2005). Some studies also failed to replicate 
the involvement of the PER3 VNTR polymorphism as a predictor of chronotype 
(Barclay, et al. 2011; Osland, et al. 2011). The timing of sleep was shown to correlate 
with PER3 mRNA expression in leukocytes in PER3S/5 homozygotes only (Archer, et 
al. 2008)
PER35/5 homozygotes have been shown to have a shorter sleep latency compared to 
PER34/4 homozygotes as well as spend more time in SWS. The PER35/5 carriers also 
proved to be more vulnerable to a night of sleep loss, as they displayed more slow 
rolling eye movements (marker of inattention and drowsiness), more EEG theta 
activity during wakefulness (a marker of sleepiness), and their cognitive functions 
drastically declined in the early hours of the morning after sleep deprivation, 
compared to PER34/4 homozygotes (Groeger, et al. 2008; Viola, et al. 2007). 
Compared to PER34/4 homozygotes, PER35/S homozygotes displayed a widespread
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reduction in activation in several brain regions as determined by fMRI (functional 
magnetic resonance imaging) in the morning after a night of sleep loss (Vandewalle, 
et al. 2009). PER35/5 have been shown to be more susceptible to blue-enriched light, 
as it suppressed the evening rise in endogenous melatonin levels, and attenuated 
waking EEG theta activity in PER35/5 homozygotes, but not in PER34/4 homozygotes 
(Chellappa, et al. 2012).
PER3 has been associated serum hormone levels; the longer allele has been shown to 
be associated with higher serum levels of insulin like growth factor I (Chu, et al. 
2008). PER34/4 homozygotes either suffering from fatigue, depressive symptoms, or 
sleep disruption have been shown to have lower IL6 concentrations compared to 
PER35/s homozygotes (Guess, et al. 2009). The PER3S/5 allele has also been shown to 
be associated with breast cancer development, even more so in younger women (Zhu, 
et al. 2005). The elevated IL6 expression found in long allele homozygotes might thus 
be involved in tumorigenesis of this allele.
Frequency of the short PER3 allele was higher in male heroin users compared to non­
users control group, but not in females (Zou, et al. 2008). PER3 has also been shown 
to be associated with the onset of bipolar disorder (Nievergelt, et al. 2006). PER3S/5 
homozygotes have been shown to be prone to an earlier onset of bipolar disorder than 
PER34/4 homozygotes (Benedetti, et al. 2008), and are more prone to postpartum onset 
of bipolar disorder (Dallaspezia, et al. 2011). In mood disorders sleep is also 
disrupted.
Genetic variation in BMAL1 has been linked to fertility (Kovanen, et al. 2010), but no 
links with sleep or circadian parameters have yet been made. No polymorphisms in 
CRY1, CRY2, BMAL1, or NPAS2 genes have been associated with sleep-wake or 
circadian regulation in humans.
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1.3.2 Non transcriptional molecular oscillations
Besides the molecular clock governed by transcriptional and translational feedback 
loops described in section 1.3.1.1, non transcriptional cellular mechanisms have also 
been identified. Mature red blood cells are naturally anucleate and are thus ideal for 
studying non transcriptional cellular rhythms. It has been shown that in red blood 
cells, peroxiredoxins (antioxidant enzymes) undergo 24-hour redox cycles persisting 
for several days in constant conditions. Additionally, these rhythms are temperature 
compensated and entrainable (O'Neill and Reddy 2011), both defining features of 
circadian rhythms.
1.3.3 Sleep and wakefulness induced genes
It has been shown that sleep-related and wakefulness-related genes belong to different 
functional categories meaning that sleep and wakefulness may favour different 
cellular processes. Wakefulness-related transcripts are involved in transcriptional 
activation, memory acquisition, energy metabolism, excitatory neurotransmission, and 
cellular stress. Sleep-related transcripts, on the other hand, include key components of 
the translational machinery, and genes involved in long-term memory formation. 
Sleep-related transcripts are also involved in membrane trafficking and maintenance, 
including synaptic vesicle turnover, and cholesterol metabolism. Thus in mammals, 
wakefulness-related genes may help the brain to face high energy demands and high 
transcriptional activity, as well as cope with the cellular stress that may derive from 
these processes (Cirelli 2005).
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1.3.3.1 Genes induced by 3 hours of wakefulness
Short periods of wakefulness, either spontaneous or after sleep deprivation, induce 
two groups of genes. Immediate early genes (IEG) and genes involved in 
mitochondrial metabolism.
1.3.3.1.1 Immediate early genes
IEG are those whose transcription is induced by pre-existing cell proteins without 
requiring de novo protein synthesis. IEGs such as c-fos (FBJ murine osteosarcoma 
viral oncogene homolog), Egr/(early growth response) (Ngfi-a), c-jun (jun proto­
oncogene), junB  (junB proto-oncogene), encode transcription factors like FOS and 
JUN which bind to the DNA regulatory regions and can control the expression of 
other target genes (Sheng, et al. 1990). Studies using in situ hybridisation and 
immunocytochemistry have shown that the expression of c-fos and EGR1 is high in 
most brain regions of rats which had been either spontaneously awake or sleep 
deprived for different periods of time, and low if  the animals had spent most o f the 
previous 3-8 hours asleep (Pompeiano, et al. 1997; Pompeiano, et al. 1994). In 
animals that were kept awake, the expression o f c-fos was high in most regions o f the 
neocortex and allocortex, c-fos is not uniformly expressed in all neurons, and its 
expression is not proportional to the length of sleep deprivation. Levels of c-fos are 
higher after three hours, than after 24 hours of sleep deprivation. After 14 days of 
sleep deprivation, only a few FOS-positive cells are visible in the cerebral cortex with 
no specific localisation to any area or layer (Cirelli, et al. 1995). It has been suggested 
that c-fos, other IEG and other genes involved in synaptic plasticity are being 
expressed at higher levels during waking than during sleep, because o f the 
noradrenergic system o f the locus coeruleus, which are involved in regulating arousal 
behaviour and therefore active during waking (Cirelli 2005). Other IEG genes include 
Arc (activity-regulated cytoskeleton-associated protein), R if  (zink finger protein) 
related gene (implicated in transcriptional regulation) and SmarcA2 (SNF2/SWI2 
related, matrix associated, actin dependent regulator of chromatin) (global activator of 
transcription) (Cirelli and Tononi 1998; Cirelli and Tononi 2000a).
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It has also been shown that, depending on the behavioural state, transcription factor 
CREB (cAMP responsive element binding protein) is differentially phosphorylated. 
CREB plays an important role in consolidation of long-term memory in the 
hippocampus and the cerebral cortex (Cirelli 2002; Cirelli and Tononi 2000a).
1.3.3.1.2 Genes involved in mitochondrial metabolism
The other group of genes induced by a few hours of wakefulness are genes involved 
in mitochondrial metabolism; Coxl (cytochrome c oxidase, subunit I), Ndujv2 
(NADH dehydrogenase, subunit II) and 12S rRNA. Interestingly, only the enzyme 
subunits coded by the mitochondria and not by the nuclear genome were differentially 
expressed during wakefulness. It is not surprising that neurons and glia cells need to 
adapt to the increased metabolic demands of the brain during wakefulness as the 
glucose metabolism is 20-30% higher during this time (discussed in Cirelli 2002; 
Cirelli and Tononi 1998).
1.3.3.2 Genes induced by 8 hours of wakefulness
Immediate early genes are also induced after 8 h of wakefulness but not the same ones 
as after just a few hours. Immediate early genes like Chop (DditS) (DNA-damage- 
inducible transcript 3), 1er5 (immediate early response 5), Ngfî-B (Nr4Al) (nuclear 
receptor 4, Al), N-ras (neuroblastoma RAS viral oncogene homolog) and StatS 
(signal transducer and activator of transcription) are only induced after longer periods 
of wakefulness. Many of these may play a role in the induction o f late genes during 
wakefulness (Cirelli 2002).
1.3.3.2.1 Genes involved in metabolism
Because energy demand is higher during wakefulness than during sleep it is not 
surprising that several genes involved in metabolism, are upregulated after long 
periods of wakefulness and sleep deprivation. Such genes are: G lutl (SLC2A1) and 
Vgf (nerve growth factor inducible). GLUT1 is a glucose transporter in the 
mammalian blood-brain barrier and is involved in glucose transportation from the 
blood to the neurons and glia cells (Bell, et al. 1990). VGF is involved in
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synaptogenesis but has also been shown to be induced in the hypothalamus during 
fasting (Hahm, et al. 1999). Therefore, it is not surprising that the cortex expresses 
more of this protein in order to keep up with the high energy demand of the waking 
brain (Cirelli 2002).
1.3.3.2.2 Heat shock proteins
Another group of genes that are upregulated during wakefulness are the heat shock 
proteins and the chaperons such as HSP60, HSP70 (includes GRP78 (BiP) and 
GRP75), and ERP72. Heat shock proteins and chaperons are involved in degradation 
of misfolded and unfolded proteins, or participate in their re-folding. BiP has been 
shown to be upregulated in response to different types of stress. It is surprising to see 
BiP induced in a physiological condition such as wakefulness. However, due to the 
high level of protein synthesis during wakefulness, it is easy to see how high levels of 
heat shock proteins and chaperons may be required to assist with folding, re-folding 
and protein degradation (Cirelli 2002; Cirelli and Tononi 2000b).
1.3.3.2.3 Neurotransmitter machinery
Another group o f genes whose levels increase during wakefulness are components of 
the neurotransmission machinery, both presynaptic and postsynaptic. This includes 
genes involved in vesicle and synapse formation, subunits o f neurotransmitter 
receptors and neurotransmitter transporters, a-amino-3-hydroxyl-5-methy 1-4- 
isoxazole-propionate (AMPA) receptor is the most common synaptic receptor found 
in the brain. Subunits GluR2 and GluR3 (glutamate receptor 2 and 3) have been 
shown to be upregulated during wakefulness and sleep deprivation (Cirelli and 
Tononi 2000b). This may represent a response to the brain's high levels of synaptic 
activity during wakefulness in comparison to sleep (Cirelli 2002). Also, a subunit of 
the N-methyl-D-aspartate (NMDA) glutamate receptor, involved in synaptic 
plasticity, is upregulated during wakefulness or sleep deprivation (SD) in with respect 
to sleep (Cirelli and Tononi 2000b). Most likely as a response to increased levels of 
neurotransmitters in the awake brain, the levels of synapse- and vesicle-related genes 
(such as secretogranin II and synaptotagmin IV) are increased during wakefulness 
(Cirelli and Tononi 2000b). One subunit of the predominant nicotinic acetylcholine
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receptor in the brain was upregulated during wakefulness and sleep deprivation 
(Cirelli and Tononi 2000b). NTT4, a neurotransmitter transporter, is associated with 
synaptic vesicles and nerve terminals and is also upregulated during waking and SD 
(Cirelli and Tononi 2000b).
1.3.3.2.4 Other genes
Metallothioneins (MT), found in all tissues, seem to be important for zinc uptake, 
storage, distribution and release. MT3 is upregulated during wakefulness compared to 
sleep (Cirelli and Tononi 2000b). Calmodulin is involved in neurotransmitter release 
and synaptic function, in neurotransmitter synthesis, microtubule function, and Ca2+- 
mediated regulation of gene expression. Calmodulin has also been found to be 
upregulated by wakefulness and sleep deprivation (Cirelli and Tononi 2000b). 
Hemoglobin alpha 1/2 chain was found to be upregulated during 6 hours of SD in a 
proteomic profiling study (Cirelli, et al. 2009). The expression of B dnf (brain derived 
neurotrophic factor), its receptor TrkB (neurotrophic tyrosine kinase) and adhesion 
molecule F3 are also induced during spontaneous wakefulness or SD (Cirelli and 
Tononi 2000a).
1.3.3.3 Genes induced by long periods of sleep deprivation
Up-regulation of genes as a response to wakefulness and sleep deprivation fades when 
sleep deprivation is prolonged to a few days. Most of the previously upregulated 
genes return to their initial level or are downregulated. One exception is 
arylsulfotransferase (AST). The AST sulfonates norepinefrin, dopamin and serotonin. 
High levels of AST may, therefore, represent a response to the uninterrupted activity 
of the central noradrenergic system. Levels of AST are proportional to sleep 
deprivation and, therefore, constitute a homeostatic response to sleep deprivation 
(Cirelli and Tononi 2000b). AST could also present a molecular marker of sleep 
deprivation.
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Another gene whose increased expression is prolonged during extended wakefulness 
and sleep deprivation is Sgkl (serum glucocorticoid -  induced serine/threonine 
kinase). SGK1 is involved in proliferation, anti-proliferation, and sodium homeostasis 
(Cirelli and Tononi 2000b).
In a proteomic study haemoglobin beta chains and cytochrome C were also found to 
be upregulated during prolonged periods of SD (7 days) (Cirelli et al. 2009). 
Haemoglobins bind, transport and scavenge gasses. Cytochrome C is a crucial 
component of the electron transport chain in the mitochondria, responsible for the 
production of ATP (adenosine triphosphate). Higher expression of these two proteins 
after extended wakefulness is therefore probably a response to elevated energy 
demands during this time. In response to stress, cytochrome C is also released into the 
cytoplasm which triggers programmed cell death (Ow, et al. 2008), and the elevated 
levels of cytochrome C observed in this study could also be a result of the induction 
of apoptosis due to stress.
The expression of Rarb (retinoic acid receptors B) has been shown to be increased 
during wakefulness and has been shown to be involved in the mesolimbic 
dopaminergic pathways. RARB receptors have been thought to influence complex 
behaviour through either brain development and plasticity or dopaminergic 
neurotransmission (Maret, et al. 2005).
1.3.3.4 Inflammatory response
Poor sleep has been shown to be a predictor of chronic disease and mortality. It is 
therefore important to consider inflammatory mechanisms associated with sleep loss 
and sleep deprivation. Cardiovascular diseases, diabetes mellitus, arthritis, and 
cancers have all been linked to inflammatory processes initiated by sleep loss.
In laboratory settings sleep deprivation has been shown to affect the immune response 
(Bom, et al. 1997; Irwin, et al. 1996) resulting in changed levels of inflammatory 
markers such as IL1 (interleukin 1), IL6 (interleukin 6), TNFa (tumour necrosis factor
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a), as well as INFy (interferon y), CRP (C-reactive protein), and NFkB (nuclear factor 
kB), to name but a few (Everson 2005; Irwin, et al. 2006; Irwin, et al. 2008; van 
Leeuwen, et al. 2009).
INFy is produced by natural killer (NK) cells (Feng, et al. 2006) and NK cell activity 
has been shown to be significantly reduced after a night o f sleep loss (Irwin, et al. 
1994). After sleep restriction or sleep deprivation experiments IL1 and IL6 have both 
been shown to be markedly elevated compared to control conditions (Irwin et al. 
2006; Pandey and Kar 2011; van Leeuwen et al. 2009). NFkB is involved in 
transcription regulation of many genes including pro-inflammatory. It has been 
demonstrated that NFkB concentrations are increased in peripheral blood after partial 
sleep deprivation, and regain baseline levels after a night of recovery sleep (Irwin et 
al. 2008). CRP levels were also found to increase during both sleep restriction and 
total sleep deprivation (Meier-Ewert, et al. 2004) as assessed in healthy adult 
volunteers.
1.4 Clock genes in peripheral tissues
Clock genes were soon found to be expressed, not only in the central pacemaker (the 
SCN), but also in all other peripheral tissues, and also in 30-year-old immortalised rat 
fibroblasts after serum shock (Balsalobre, et al. 1998). The clocks in peripheral tissues 
are sometimes referred to as slave oscillators because at the beginning it seemed, that 
only the SCN could express clock genes in a self-sustaining manner, where as the 
expression of clock genes in peripheral tissues was not self-sustained in vitro and the 
rhythmic expression dissipated after a few cycles.
However, additional experiments soon showed that mouse explants do have rhythmic 
clock gene expression even after three weeks in culture (Yoo et al. 2004). Moreover, 
single cell experiments in rat fibroblasts revealed highly robust self-sustained 
oscillators in these cells (Nagoshi, et al. 2004). It appears, though, that that a 
functional SCN is needed to synchronise the cellular oscillators on a daily basis.
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Molecular oscillators in peripheral cells can affect cell and tissue physiology in two 
ways; either by core clock genes influencing the expression o f other genes directly or 
via clock controlled genes (Stratmann and Schibler 2006).
The circadian clock has been shown to play a role in cell division in the liver during 
liver regeneration following partial hepatectomy. Cells enter mitosis irrespective of 
time at which the hepatectomy was performed. It was shown that WEE1 (a tyrosine 
kinase), a protein whose levels oscillate robustly and are under direct control of the 
circadian oscillator, is the prime candidate for being the key circadian regulator o f cell 
division (Matsuo, et al. 2003). Additionally, it was shown that in fibroblast cytokine 
expression is restricted to defined time windows, and mitosis evokes phase shifts in 
circadian cycles (Nagoshi et al. 2004).
Metabolism of glucose, cholesterol, and fatty acids has also been shown to be under 
the influence o f the circadian clock. Impaired regulation of these pathways results in 
disorders called ‘metabolic syndrome’. It has been shown that Clock and Bmall 
deficient mice show metabolic abnormalities much like those seen in ‘metabolic 
syndrome’; Clock mutant mice showed altered feeding patterns, were hyperphagic, 
obese, hyperglycaemic, hyperinsulinémie, and showed other metabolic disorders 
(Turek, et al. 2005), Clock and Bmall deficient mice show abolished gluconeogenesis 
(Rudic, et al. 2004), and Bm all has been shown to play an important role in regulation 
of adipose differentiation and lipogenesis in mature adipocytes (Shimba, et al. 2005).
1.4.1 Human leukocytes
Leukocytes make up about 1% of the blood volume in an adult. All leukocytes subsets 
derive from a single multipotent hematopoietic stem cell, and can be grouped into 
four groups: granulocytes (neutrophils, eosinophils, basophils), monocytes,
lymphocytes (B cells, and T cells), and natural killer (NK) cells. All leukocyte subsets 
vary in number and proportion in a circadian manner. Abundance o f granulocytes, NK 
cells, and monocytes differentiated into macrophages peaks during the day, while 
lymphocyte abundance peaks during the night (Suzuki, et al. 1997).
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It has been shown previously that specific groups of leukocytes show differential 
susceptibility to sleep loss and total sleep deprivation. NK cell activity in humans has 
been shown to be reduced after a night of partial sleep loss (Irwin et al. 1994). Also, 
the number of leukocyte subsets differs between early and late types; the ratio of 
lymphocytes was higher in early types while the ratio of granulocytes was elevated in 
late type individuals. However, the amount of sleep obtained per night does not have 
an effect on the relative proportion of leukocytes (Adachi, et al. 2010). Also, when the 
expression profile of PERI was tested in mononuclear and polynuclear cells, no 
differences between the cell types were observed (Kusanagi, et al. 2004).
A circadian molecular clock was first revealed in human peripheral mononuclear cells 
in 2003, when PERI, PER2, PERS, and DEC1 were first shown to be expressed in a 
circadian manner in these cells in three individuals during CR (Boivin, et al. 2003). 
Later PER2, BMAL1 and REV-ERBa were shown to be expressed in peripheral blood 
monocytes across the sleep-wake cycle, but PER2 and BMAL1 appeared to reach the 
expression maxima at two different times, resulting in the formation o f two groups of 
volunteers, early and late group. Additionally, PER2 and BMAL1 were in phase and 
not in anti-phase, as anticipated. The same study also showed REV-ERBa to be 
expressed constitutively (Teboul, et al. 2005). Additionally, 10 clock genes were 
assessed in peripheral blood monocytes across a modified CR; PERI expression was 
rhythmic in six subjects, and PER2 and PERS in five subjects. In contrast CRY1 was 
rhythmically expressed in two, and CRY2 and DEC2 only in one subject each. 
CLOCK  and BMAL1 did not show a rhythmic expression profiles in peripheral blood 
monocytes (Kusanagi, et al. 2008). PERI and PER2 expression were identified as 
more robustly rhythmic as they remained rhythmic in both light-dark conditions and 
during CR, while BMAL1 expression was attenuated slightly during CR (James, et al. 
2007). Light during night time in simulated shift work conditions was shown to 
attenuate the PER2 mRNA rhythms but not BMAL1 (Kavcic, et al. 2011). 
Additionally, PERS expression has also been shown to be shifted by light exposure 
(Ackermann, et al. 2009).
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When leukocyte expression of BMAL1, PER2, and PER3 was correlated with sleep- 
wake parameters, only PER3 maximum in expression showed significant correlations 
with sleep time, mid-sleep time, melatonin onset and maximal cortisol levels, but not 
wake time. When volunteers were split according to their PER3 VNTR genotype, the 
correlations, including with wake time, remained significant only in PER35/S 
homozygotes. BMAL1 maximum also correlated with sleep time in PER35/5 
homozygotes (Archer et al. 2008).
It has been shown that Per2 plays a role in modulating INFy production in NK cells, 
and IL ip  production in macrophages in response to induced endotoxic shock in mice 
(Liu, et al. 2006), and Bm all deficient mice show a deficiency in B lymphocyte 
development (Sun, et al. 2006). During periods of acute systemic inflammation the 
activity of the circadian clock in the peripheral leukocytes is altered dramatically and 
possibly even uncoupled from the central clock (Haimovich, et al. 2010a). These 
studies suggest a role for the molecular clock genes in the immune system.
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1.5 Bloodomics
Blood is a circulating tissue composed of plasma and cells (erythrocytes, leukocytes 
and platelets), which comes into contact with every organ and tissue in the body, and 
conveys bioactive molecules such as oxygen and nutrients, as well as antibodies, 
cytokines and hormones (reviewed in Mohr and Liew 2007).
Blood is already being used for molecular profiling of human disease and disease risk. 
Blood cells are affected by various malignancies such as immune disorders, and other 
inflammatory illnesses such as cardiovascular disease, and cancer. Additionally, 
peripheral blood cells have been shown to respond to environmental, physiological or 
pathological insults occurring anywhere in the body. Indeed peripheral blood cells 
have been shown to share over 80% of the transcriptome with other tissues, such as 
brain, kidney, colon, heart, liver, lung, stomach, prostate, and spleen (Liew, et al. 
2006). Additionally, blood cells have been shown to express organ-specific genes, 
including those previously thought to be specific to other tissues, such as hormone 
responsive transcription factors and neurotransmitter receptors (Nicholson, et al. 
2004). Transcriptional profiling studies o f peripheral blood cells have shown that gene 
expression patterns show differences among individuals, but are stable in an 
individual over time. Besides this, peripheral blood is easily accessible compared to 
obtaining tissue biopsies, and can be collected periodically in order to obtain a 
temporal profile of activity (reviewed in Mohr and Liew 2007).
Like most cells in the body, blood cells are equipped with circadian clock 
components, and their function is synchronised by the SCN. These properties make 
the blood a feasible and readily available tissue for studying the temporal organisation 
of the molecular clock in humans and other larger mammals.
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1.6 Aims and hypotheses
This study will investigate how sleep deprivation in humans affects gene expression 
of selected genes (clock genes, sleep genes and sleep-deprivation-related genes) as 
measured in peripheral leukocytes, whether circadian processes regulate entrained 
sleep-wake timings, the effect o f the homeostatic components on expression of 
selected genes, and the effect of the PER3 VNTR polymorphism on clock gene and 
global gene expression.
It was hypothesised that the PER3 VNTR polymorphism and sleep deprivation will 
affect human whole blood gene expression.
A 40-h constant routine (CR) will be used as a sleep deprivation tool during which 
global gene expression will be monitored in a 3-hourly manner providing full gene 
expression profiles. For 7 dark-light cycles prior to CR, sleep will either be extended 
(SE) or restricted (SR) in a cross over-design. This manipulation will result in lowered 
(SE) or elevated (SR) homeostatic sleep pressure enabling the study of homeostatic 
sleep propensity effects on global gene expression.
The aims of the work at hand were fourfold:
1. To examine the relationship between clock gene expression in peripheral blood and 
entrained sleep wake timing, and how they differ in the PER3 VNTR homozygous 
genotypes
2. To examine how sleep loss in the form of sleep restriction and sleep deprivation 
affects the expression of previously identified sleep and sleep-deprivation-related 
genes
3. To explore how gene expression in peripheral blood differs between the two 
homozygous PER3 VNTR genotypes
4. To identify a suitable RT-QPCR reference gene to be used in circadian time series 
analysis
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2 Methods
2.1 Procedures
All procedures undertaken in this study had been reviewed and received a favourable 
opinion from the University of Surrey Ethics committee (EC/2007/110/FHMS) and 
were approved by the Institutional Review Board of the Air Force Research 
Laboratory (F-WR-2008-0012H).
The recruitment and screening of volunteers (section 2.2) was carried out by the 
principal post-doctoral researcher responsible for the study and by the Clinical 
Research Centre (CRC) recruitment team, with the help of other researchers working 
on the project, including myself. All genotyping (section 2.6) was performed by me. 
The habitual sleep-wake schedule for the selected volunteers was characterised by the 
principal post-doctoral researcher (section 2.3). The laboratory manipulation protocol 
(section 2.4) was carried out by all researchers working on the project, including 
myself. The blood samples were collected by qualified nursing staff from the CRC 
(section 2.5). The pre-processing of collected blood and plasma samples (section 2.5.1 
and 2.5.2 ) was carried out by me and an additional post-doctoral researcher. Whole 
blood RNA extractions (section 2.7), RNA quantification (section 2.8), RNA quality 
control (section 2.9) and the preparation of microarrays (section 2.10) were carried 
out by me, as well as all real time QPCR work (section 2.11).
Dim light melatonin onset (section 2.12.1) was computed by the principal post­
doctoral researcher. Microarray feature extraction (section 2.12.2.1), data 
normalisation (section 2.12.2.2) was performed by two bioinformatics post-doctoral 
researchers working on the project. The expression profiles (section 2.12.2.3) and 
mixed model analysis (section 2.12.2.4) were performed by me with help from 
principal post-doctoral researcher.
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A list of stably expressed genes (Table 6.2), as well as all lists o f differentially 
expressed genes discussed in Chapter 5 (Appendix I to Appendix L) were computed 
and prepared by a bioinformatics post-doctoral research fellow.
2.2 Recruitment and screening
Volunteers were recruited by advertising the study on the Clinical Research Centre’s 
recruitment web page, as well as posters and word of mouth. A quick telephone 
interview was conducted to confirm that the volunteer fulfilled the general inclusion 
and exclusion criteria outlined in Table 2.1. If  the volunteer was found to be eligible 
for the study they were invited to the facilities for a full screening.
Inclusion criteria 
Age: 20-35
Body Mass Index: Males: 20-33, Females: 18.5-33 
Alcohol consumption: < 1 4  units/week 
Caffeinated beverage consumption: < 5 cups/day 
Exclusion criteria
Pregnant, breast feeding or planning a pregnancy
Sleep disorders
Acute or chronic disease
On medication
Smoker
Travelled over time zones within the past two months 
Shift worker (in the past two months)
Blood donation 6 weeks prior
Unavailable during time o f  the laboratory session
Table 2.1 Inclusion and exclusion criteria for the study.
A detailed explanation o f the study protocol to the volunteers was performed by one 
of the researchers involved in the study and a tour of the facilities, where the 
laboratory study will take place, was provided. Private time for personal questions 
was allocated for each volunteer, where they were given the opportunity to ask 
questions and raise any additional concerns. Volunteers were also provided with a 
written document with detail information about the study (Appendix A). A written
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informed consent was obtained from each volunteer prior to the screening procedure 
(Appendix B). Each volunteer provided a sample of their buccal tissue, by swabbing 
the inside cheek are with a sterile swab. This was used for PER3 genotyping
described in section 2.6. Then volunteers were asked to complete a series of
questionnaires. Only questionnaires used in this thesis are listed in Table 2.2. The 
questionnaires can be found in Appendix D. A full list o f questionnaires completed by
the volunteers can be found in Appendix C.
Questionnaire Reference
Medical Questionnaire (MQ)
Munich Chronotype Questionnaire (MCQ) (Roenneberg et al. 2003)
Home-Ostberg diurnal preference Questionnaire (HO) (Home and Ostberg 1976)
Pittsburg Sleep Quality Index (PSQI) (Buysse, et al. 1989)
British Sleep Survey (BSS) (Groeger, et al. 2004)
Karolinska Sleep Diary (KSD) (Akerstedt, et al. 1994)
Table 2.2 Questionnaires administered to volunteers during screening.
Only questionnaires relevant to the work described in this thesis are listed.
Subjects were selected only on the basis of their genotype and were matched in 
triplets for gender, age, and ethnicity. A total of 675 volunteers (262 females) were 
screened in order to select 36 volunteers to participate in the laboratory study. A total 
of 12 volunteers homozygous for the short {PER34/4), 14 volunteers homozygous for 
the long (PER35/5) allele, and 10 heterozygotes {PER34/5) were recruited for the study. 
However, only homozygous volunteers were considered for the final stages of data 
analysis. The samples derived from heterozygous volunteers will be studied at a later 
time and will not be presented in this thesis.
2.3 Characterisation of habitual sleep-wake schedule
In total, 47 volunteers were asked to record their sleep wake schedule by wearing an 
Actiwatch (Cambridge Neurotechnology, Cambridge, UK)) on their non-dominant 
wrist and completing a diary for a duration of sleep two weeks prior to the study. The 
Actiwatch measured the movement and light exposure of the volunteer, and in the
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diary they recorded their sleep-wake timing and quality o f sleep. After 7 days, the 
data were analysed and habitual sleep and wake times computed. The sleep midpoint 
was calculated for each volunteer and used to assign an individual sleep-wake 
schedule o f 8 h sleep and 16 h wakefulness to each volunteer, where the sleep mid 
point was kept constant. The volunteers had to adhere to the assigned sleep-wake 
schedule during the week prior to the study. Prior to the laboratory study the 
compliance was checked by analysing the actigraphy data and sleep diary.
2.4 Manipulation protocol
Volunteers participating in the study were asked to spend 11 days at the sleep 
laboratories at the Clinical Research Centre of the University of Surrey, Guildford, on 
two occasions, each time undergoing a different sleeping regime. The time between 
the two legs o f the study was at least 10 days. The volunteers slept in individual sleep 
laboratories and spent most of their awake time in the common volunteer lounge 
exposed to daylight, where they were allowed to watch DVDs, play board games and 
interact with other volunteers and staff. Napping during the day was not permitted and 
volunteers were continuously monitored by staff. On each occasion the first two 
sleep-wake cycles were considered baseline and the volunteers were asked to sleep 8 
h during the night and stay awake for the remaining 16 h of the sleep-wake cycle, 
according to their pre-assigned sleep-wake schedule, which they had adhered to the 
week prior to the study. The two baseline sleep-wake cycles were followed by 7 
cycles o f either sleep restriction (SR) or sleep extension (SE). The sleep wake 
schedules for SR and SE condition are shown in Figure 2.1. During the SR condition 
volunteers spent 6 h in bed and stayed awake for the remaining 18 h of each sleep- 
wake cycle, whereas during the SE condition they were asked to stay in bed for 10 h 
and stay awake for 14 h o f each cycle. The midpoint o f the sleep episodes was kept 
constant regardless o f condition and corresponded to the habitual sleep midpoint as 
determined using actigraphy prior to the study (explained in section 2.3). The order of 
the two conditions was balanced between genotypes and subjects were randomly 
assigned to one o f the two orders. During both occasions at the facility the 7 cycles o f 
either SR or SE were followed by approximately 40 h o f constant wakefulness during 
a CR protocol. On the morning of CR volunteers were asked to remain in their bed 
after they woke up. They were placed in a semi-recumbent position, the light levels
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w ere kept at a constant intensity o f  less than 10 lux, tem perature w as kept constant 
and m eals w ere replaced by sm all hourly snacks consisting o f  a small nutritious snack 
bar and drink (Fortisip) (N utricia, G aithersburg, M D ) adjusted for body weight. After 
the CR protocol the volunteers underw ent a 12-h recovery sleep.
A. Sleep extension  protocol
i— ) 1 > —
00:00 06:00 12:00 18:00 00:00 06:00 12:00 18:00 00:00 
Clock time
B. Sleep restriction protocol
Day 1 
Day 2 
Day 3 
Day 4 
Day 5 
Day 6 
Day 7 
Day 8 
Day 9 
Day 10 
Day 11
00:00 06:00 12:00 18:00 00:00 06:00 12:00 18:00 00:00 
Clock tim e
Figure 2.1 The sleep-wake schedule during the sleep extension (panel A) and sleep restriction 
(panel B) protocol, double plotted.
Day 1 -  arrival and base line sleep (8h), Day 2-8 -  extended (10b) or restricted (6h) sleep per night. 
D ay 9 -  constant routine (39-40H), Day 10 - constant routine and recovery sleep (12h). B lack bars -  
sleep episodes, grey bars -  constant routine, red lines -  hourly m elatonin sam pling, green bars -  3- 
hourly w hole blood sam pling.
: hi luj
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2.5 Blood sampling
An indwelling cannula was placed in the participants forearm by a qualified 
phlebotomist (one cannula in each arm) for the duration of CR to allow for frequent 
sampling. Blood samples were collected by qualified nursing staff from the CRC. 
After each blood sample was taken the cannula was flushed with 0.9% w/v saline 
solution to minimise blockage.
2.5.1 Blood sampling for determining melatonin levels
A 4 ml blood sample for determining melatonin levels was collected into a lithium 
heparin vacuum tube (Teklab, Collinsville, IL) every hour by a qualified nurse. The 
sample was then centrifuged at 4°C for 10 min at 1,620 x g  to separate the blood 
plasma from the rest of the blood. The plasma was transferred to a new labelled 
cryotube and frozen at -70°C. At the end of each session melatonin in plasma was 
measured by radioimmunassay with a limit of detection of 3.4 pg/mL (Stockgrand, 
University of Surrey, Guildford, Surrey, UK).
2.5.2 Blood sampling for global gene expression analysis in whole blood
Blood samples for analysing global gene expression in whole blood were collected 
every 3 hours. The total sampling time within the CR was 27 h. A total of 720 (10 
samples per volunteer per condition) whole blood samples were planned to be 
collected; of these, 520 samples were to be collected from homozygous volunteers. 
Only numbers relating to homozygous volunteers will be mentioned, as only 
volunteers homozygous for the PER5 VNTR genotype were investigated in this study. 
Four volunteers (two from each homozygous genotype) did not provide blood 
samples during the second laboratory session (two in each condition) resulting in a 
loss of 40 samples. Additionally, 4 samples could not be collected due to blocked 
veins. A total of 476 were thus collected from homozygous volunteers. During further 
laboratory processing 4 samples were lost due to a centrifuge malfunction (tubes 
broke in the centrifuge). A further 18 samples were of low quality (as described in 
section 2.9), and six samples were of too low concentration (described in section 2.8). 
A total o f 448 samples for whole blood gene expression analysis were thus obtained.
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A 2.5 ml blood sample was collected into a PAXgene vacuutainer tube (PreAnalytiX, 
Hombrechtikon, Switzerland) containing a RNA stabilisation solution, every three 
hours during the CR protocol. The tubes were inverted 10 times and incubated in an 
up-right position for 4 h at room temperature. The tubes were then frozen at -70°C in 
a horizontal position, as per manufacturer’s instructions. The PAXgene tubes contain 
a stabilising agent which penetrates and lyses all blood cells immediately upon blood 
entering the tube, and complexes nucleic acids. Whole blood RNA, including free- 
circulating RNA can therefore be stabilised and later extracted.
2.6 Genotyping
Volunteers provided buccal tissue from the inside cheek area using a buccal swab 
(Epicentre Biotechnologies, Madison, WI). The swabs were frozen immediately after 
and transferred to the molecular laboratory on ice where they were processed.
2.6.1 Extracting DNA from the buccal swab
The frozen swabs were thawed and dipped into 400 pi o f TNES [lOmM 2-Amino-2- 
hydroxymethyl-propane-1,3-diol (Tris) pH 7.5, 400 mM NaCl, 100 mM ethylene- 
diaminetetraacetic acid (EDTA), 0.6% sodium dodecyl sulphate (SDS)] and swirled 
vigorously in order to transfer the cells of buccal tissue in to the solution. Twenty- 
three pi o f 10 mg/ml Proteinase K (Promega, Madison, WI) was added to each sample 
and the samples were incubated at 55°C for 1 h. 111 pi of 5 M NaCl was added, 
samples were mixed and centrifuged at 15,700 x g  for 10 minutes to form a pellet of 
cell walls and proteins. The supernatant was transferred to a new tube and 1 volume 
of chilled 95% ethanol was added. The sample was mixed and centrifuged as above 
for 5 minutes. The supernatant was decanted taking care not to disturb the invisible 
pellet of DNA. The samples were then washed using 200 pi of chilled 70% ethanol 
and centrifuged again for 5 minutes. The supernatant was again removed and the 
pellet air-dried for 15 minutes. The pellet was resuspended in 200 pi of DNase-free 
water and vortexed thoroughly to resuspend the DNA. The samples were frozen and 
kept at -20°C.
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2.6.2 PCR (Polymerase Chain Reaction)
The PCR was used to amplify the fragment of the PER3 gene containing the VNTR 
using primers as described in Lazar et al (2012).
The initial mix was made using the following reagents per sample:
15 pi GreenTaq HotStart Mastermix (also containing the loading dye) (Promega)
2 pi 10 pM stock forward human PER3 primer (Sigma-Aldrich, St. Louis, MO)
2 pi 10 pM stock reverse human PER3 primer (Sigma-Aldrich)
8 pi DNase-free water
These volumes were multiplied by the number of samples +1 sample for negative 
control and +1 sample to accommodate for pipetting errors. The initial mix was then 
aliquoted into labelled 0.2 ml thin-wall PCR tubes (27 pi in to each) and 3 pi of 
extracted DNA sample was added. For the negative control 3 pi o f DNase-free water 
was added to 27 pi of the mix. The tubes were then spun down briefly to ensure all 
the reagents had travelled to the bottom of the tube and no bubbles were visibly 
present. The PCR tubes with the initial mix and samples were loaded into the PCR 
machine. The cycling conditions are shown in Table 2.3.
Time Temperature
3 min 95°C
40 cycles 
1 min 95°C
1 min 58°C
1 min 72°C
5 min 72°C
oo 4°C
Table 2.3 Cycling conditions for PCR used for PER3 genotyping.
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2.6.3 Electrophoresis
U sing TAB buffer (40m M  Tris, 20m M  acetic acid, and Im M  ED TA ) a 2%  agarose- 
TA E gel w as m ade and 1 gl o f  10 m g/m l ethidium  brom ide w as added per 25 ml o f  
gel. The set gel w as subm erged into TAB buffer in the buffer tank and the sam ples 
w ere loaded into the w ells on the gel. The electrophoresis was run at 0.7 V /cm .The 
electrophoresis w as perform ed until the yellow  front o f  the loading dye (pre-m ixed 
w ith the G reenTaq ElotStart M asterm ix, as described above) reached the edge o f  the 
gel. The gel was then carefully  rem oved from  the buffer cham ber and photographed 
while shining UV light through it to v isualise the ethidium  brom ide stained DN A 
fragm ents.
2.6.4 Determining the genotype
For each loaded sam ple either one or two fragm ents appeared on the gel as show n in 
Figure 2.2. The fragm ents w ere com pared am ongst the sam ples therefore no positive 
control or ladder w as needed. I f  the sam ple had only one fragm ent w hich had 
m igrated a shorter distance from  the wells the volunteer w as a long repeat 
hom ozygote (PER355). I f  the fragm ent had m igrated further the individual w as a short 
repeat hom ozygote (PER34 4). I f  tw o fragm ents appeared for one volunteer they w ere 
a heterozygote (PER34 :i). An exam ple o f  a gel is shown in Figure 2.2.
P E R 355 P E R 345 PER3 44
Figure 2.2 An example of an electrophoresis gel showing the three different PER3 VNTR  
genotypes.
PER3'’ ' -  PER3 hom ozygote for the long allele, PER344- PER3 hom ozygote for the short allele, 
PER342-  PER3 heterozygote.
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Samples where the genotyping results were not clear (the fragments could not be 
distinguished as long or short allele) were re-genotyped and run on the gel with a 
control. Samples of volunteers chosen to participate in the laboratory study and back­
up volunteers were also re-genotyped for confirmation. The re-determined genotype 
of samples matched the original results in 100% of the time.
2.7 Whole blood RNA extraction
Frozen PAXgene tubes containing 2.5 ml of blood in RNA stabilisation solution were 
thawed at room temperature. Whole blood RNA extraction was performed using the 
QIAcube (Qiagen, Venlo, The Netherlands), which enabled automated RNA 
extraction, and the PAXgene Blood RNA Kit. The manufacturer’s instructions were 
followed exactly (Blood RNA kit Handbook April, 2008) The extracted whole blood 
RNA was collected into new RNase free tubes and transferred to ice. The RNA was 
then stored at -80°C.
2.8 RNA quantification
RNA was quantified spectrophotometrically using the Nano-drop instrument (ND- 
1000, Nanodrop Technologies, Wilmington, DE). The pedestal was cleaned with 95% 
ethanol and distilled water. The instrument was then blanked with 0.5 -  2 pi o f the 
same RNA resuspension buffer used to resuspend RNA. The samples were placed on 
the pedestal of the Nano-drop one at a time and the absorbance was measured at 260 
nm. The software calculated the concentration of RNA based on this reading. An 
example of the read out is shown in Figure 2.3. Ratios 260/280 and 260/230 indicated 
the level of RNA purity. A ratio of absorbance at 260 nm and 280 nm was expected to 
be around 2.0. A ratio of considerably less than 2.0 could indicate protein 
contamination. A ratio of absorbance at 260 nm and 230 nm was expected to be 
around 2.0 -  2.2. A lower value indicates possible nucleic acid contamination.
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S a m p le #  IS
Figure 2.3 An example of results obtained from the ND-1000.
The RNA concentration, absorbance at 260 nm, 230 nm, 280 nm, ratios between 260/280 nm and 
260/230 nm are shown.
2.9 RNA quality control
The quality o f  the extracted RNA was determ ined by using the 2100 B ioanalyzer 
(A gilent Technologies, Santa Clara, CA) w hich uses Lab-on-a-C hip technology. The 
2100 B ioanalyzer Lab-on-a-C hip is a m icrofluidics-based autom ated electrophoresis 
instrum ent. The sam ples and reagents w ere pipetted in to the w ells o f  a “chip” as 
specified in the protocol (RNA 6000 N ano K it G uide A ugust, 2006) and analysed 
using the A gilent 2100 B ioanalyzer. The sam ples are pushed from  the well in to the 
separation channel and the sam ple contents are electrophoretically  separated. 
Com ponents are detected and results translated into an electrophoresis-like im age and 
electropherogram s as in F igure 2.4. The software calculated the integrity o f  the RN A 
by using an algorithm  to produce a RIN (RNA  integrity num ber) for each sam ple. The 
RIN  ranges from  0-10, 0 representing com pletely degraded RN A  and 10 representing 
fully intact RNA.
Ribosom al RNA (rRNA ) is used to check how  intact the R N A  sam ple is. In an intact 
RNA sam ple the 28S and 18S rRNA species are approxim ately 5 kb and 2 kb in size, 
respectively, and give a theoretical ratio o f  2.7. H ow ever, the larger species is less 
stable so a ratio o f  2.0 is m ore frequently observed. In the electrophoresis-like im age 
the bands are segregated according to seize. The 28S and 18S species are v isualised 
by the B ioanalyzer as fragm ents at a precise location in the electrophoresis-like im age
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and as peaks in the electropherogram . The 28S species is shown as the m ore abundant 
fragm ent and the higher peak in the electrophoresis-like im age and electropherogram , 
respectively. I f  an RN A sam ple is degraded the rRNA will also be degraded. This will 
be seen as a sm eared 28S fragm ent along the electrophoresis-like im age and very faint 
bands in place o f  the 28S and 18S fragm ent. In the electropherogram  the 28S peak 
will be sm aller than in an intact RNA sam ple.
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Figure 2.4 An example of an electrophoresis like image (left panel) electropherogram (right 
panel) as obtained from the 2100 Bioanalyzer.
On the left panel the broader (28S rRN A) and th inner band (18S rRNA) are clearly visible. On the right 
panel the higher (28S rRN A) and lower (18S rRN A) peak are shown.
2.10 Preparation of microarrays
Because the concentrations o f  extracted RNA w ere very  high, 100 ng o f  resuspended 
RN A w as pipetted in to a new  tube and dried using a speed vac. The dried pellet w as 
then respuspended in 1.5 pL o f  w ater. O ne-colour labelling protocol (O ne-C olour 
M icroarray-B ased Gene E xpression A nalysis Low  Input Q uick Am p Labelling kit v6 
Decem ber, 2009) w as follow ed for the labelling, hybridisation and w ashing steps. 
Briefly, 100 ng o f  extracted RNA w as labelled using the Low  Input Q uick A m p 
Labeling kit (A gilent Technologies). The labelled sam ples w ere purified using
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RNeasy Mini kit (Qiagen, Crawley, UK) and dye incorporation was checked 
spectrophotometrically using the specific setting on Nano-drop, as specified in the 
protocol. The samples were hybridised to Whole Human Genome 4 x 44K custom 
oligonucleotide microarray (G2514F, AMADID 026817; Agilent Technologies) 
overnight. The slides were then washed, and scanned as specified in the protocol.
To minimise unwanted batch effects, all 10 extracted RNA samples derived from the 
same volunteer during one condition (SE or SR) were processed in one experiment. 
All 20 labelled RNA samples from one volunteer (both conditions) were hybridised 
on five 4 x 44K Whole Human Genome slides in a single experiment.
One modification was made to the protocol: after the Transcription Master Mix was 
added, the samples were incubated for 4 h instead of 2 h, as specified in the protocol. 
This modification was made based on prior experience of senior researchers from our 
group, as it yields better Cyanine 3-CTP incorporation.
2.11 Real time QPCR
2.11.1 cDNA synthesis
A 2.22 ng/pl stock dilution of each RNA sample was made by diluting 100 ng 
template RNA in 45 pi nuclease free water. The stock was then used to synthesise 
cDNA.
2.11.1.1 In-house protocol
For each reaction 1 pi Oligo dT primers (300 ng/pl) (Promega), 2 pi 
deoxyribonucleotide triphosphate (dNTP) mix (10 mM of each) (Promega) and 3 pi 
nuclease-free water was added to 18 pi (40ng) of RNA template stock dilution in a 
0.2 ml thin-wall PCR tube. The tubes were incubated at 65°C for 5 min before being 
transferred to ice and then spun down briefly. 8 pi 5x First-Strand Buffer (Invitrogen, 
Life Technologies, Carlsbad, CA), 4 pi 0.1M dithiothreitol (DTT) (Invitrogen), 2 pi 
RNaseOUT recombinant Ribonuclease Inhibitor (40 U/pl) (Invitrogen), and 2 pi
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Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase (200U/pl) 
(Invitrogen) were added to each tube. The tubes were then incubated at 37°C for 60 
min followed by 70°C for 15 min. The synthesised cDNA was stored at -20°C.
2.11.1.2 PrimerDesign protocol
1.5 pi Oligo dT primer (PrimerDesign, Southampton, UK) was added to each 13.5 pi 
(30ng) RNA template stock dilution in a 0.2 ml thin wall PCR tube. The tubes were 
incubated at 65°C for 5 min before being transferred to ice and then spun down 
briefly. 3 pi 1 OX qScript buffer (PrimerDesign), 1.5 pi dNTP mix (PrimerDesign) (10 
mM of each), 3 pi 100 mM DTT (PrimerDesign), 6 pi nuclease free water, and 1.5 pi 
qScript enzyme (PrimerDesign) were added to each tube. The tubes were then 
incubated at 55°C for 20 min followed by 70°C for 15 min. The synthesised cDNA 
was cooled on ice, diluted 1:10 and stored at -2O°C.
2.11.2 QPCR (Quantitative PCR)
2.11.2.1 Preparing a gDNA serial dilution standard curve
A genomic DNA (gDNA) standard curve was prepared using human gDNA 
(Promega) stock solution. The mass of the haploid human genome is around 3.5 pg, 
therefore 1 ng of gDNA contains around 286 copies of a single copy gene (Yun, et al. 
2006). Mass of gDNA was calculated for 100,000 copies. A 5-fold serial dilution was 
prepared containing either 101, 102, 103, 104, 105 copies o f gDNA per reaction.
2.11.2.2 In-house QPCR protocol (TaqMan)
QPCR reactions were prepared on Optical 96-well plates (Applied Biosystems, Life 
Technologies, Carlsbad, CA). For each reaction 2.5 pi of cDNA (2.5ng of RNA 
template) was added to 1 pi forward primer (10 pmol/pl), 1 pi reverse primer (10 
pmol/pl), 0.5 pi probe (5 pmol/pl), 12.5 pi ABsolute™ QPCR ROX (500 nM) mix 
(Thermo Scientific, Waltham, MA), and 7.5 pi nuclease-free water. Each sample was 
run using primers targeting the gene of interest as well as targeting a housekeeping 
gene (primer/probe sequences are listed in section 2.11.4). A gDNA standard curve 
(explained in section 2.11.2.1) was run on each plate and used to calculate the copy
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number of each gene of interest present in each reaction. All reactions were run in 
duplicates. A positive control, reaction containing known good quality cDNA, as well 
as negative control (a reaction where cDNA was replaced by water) was also run on 
each plate. The plate was sealed using Adhesive Plate Seal (Thermo Scientific), 
vortexed and centrifuged at 1,500 x g for 4 min. The plates were run on AB 7500 
Real-Time PCR System (Applied Biosystems, Life Technologies) and the following 
cycling conditions were used: 10 min at 95°C (enzyme activation), 15 s at 95°C 
(dénaturation -  40 cycles), 1 min at 60°C (data collection -  40 cycles).
The average between duplicates was calculated. The gDNA standard curve was used 
to calculate the number of copies of selected gene in each reaction. The copy number 
of the gene of interest was normalised to the of the reference gene. The work 
described in this thesis only uses the PER3 primer/probe (Table 2.5). Other RT-QPCR 
work is not presented.
2.11.2.3 PrimerDesign QPCR protocol (Perfect probe)
For each QPCR reaction 5 pi of diluted cDNA (0.5ng of RNA template) was added to 
10 pi Precision 2X qPCR Mastermix (2x reaction buffer, 0.025 U/pl Taq Polymerase, 
5 mM MgCb, dNTP Mix (200pM each dNTP)), 1 pi o f Primer/Probe mix (6 pmol/pl 
each primer, 3 pmol/pl probe), and 4 pi nuclease free water. Each sample was run 
using primers targeting the gene o f interest as well as targeting a housekeeping gene. 
A gDNA standard curve, as well as positive and negative controls was also run on 
each plate, as described in section 2.11.2.1 (above). All reactions were run in 
duplicate. The plate was sealed using Adhesive Plate Seal (Thermo Scientific, Life 
Technologies), vortexed and centrifuged at 1500 xg for 4 min. The plates were run on 
AB 7500 Real-Time PCR System (Applied Biosystems, Life Technologies) and the 
following cycling conditions were used: 10 min at 95°C (enzyme activation), 15 s at 
95°C (dénaturation -  50 cycles), 35 s at 5O°C (data collection -  50 cycles), 15 s at 
72°C (extension -  50 cycles).
The PerfectProbe design is a cross between the Molecular Beacon and Taqman 
technology. The Molecular Beacon probes, when not hybridised, are strongly
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quenched using a loop structure which results in very low background levels. When 
the probe is hybridised the loop structure is stretched out and fluorescence is emitted. 
The Taqman probes are not as strongly quenched before hybridisation as the probe 
and the quencher are further apart, leading to some fluorescence emission and thus 
slightly higher background fluorescence levels. After hybridisation the probe is 
cleaved by the resulting is a strong fluorescence signal. The PerfectProbe has a loop 
probe structure to ensure low background levels of fluorescence, and is cleaved after 
hybridisation leading to a strong fluorescence signal. This approach increases the 
background to signal ratio, making the probes more sensitive.
2.11.3 Software for RT-QPCR analysis
2.11.3.1 geNorm analysis in qbase
The data obtained using the geNorm Reference gene Selection kit (as described in 
section 2.11.2.3) was uploaded to the geNorm software (access to software available 
as part of the geNorm Reference gene Selection kit). An index of stability called M 
index was calculated for each tested gene. M index is the average pairwise variation 
of a gene compared to all other tested genes in a sample. The lower the M index the 
more stable a gene is compared to the remaining genes. The least stable gene was 
omitted after each iteration until only the most stable pair remained. All tested genes 
were then ranked in order of stability for a particular sample. The authors called this 
algorithm and software geNorm (Vandesompele et al 2002).
2.11.3.2 NormFinder analysis
The data obtained using the geNorm Reference gene Selection kit was also analysed 
using the NormFinder algorithm (Andersen, et al. 2004). The algorithm was installed 
as an add-in to MS Excel and the expression values were fed to the software. Subjects 
and time points were specified, as required. The algorithm log transformed the data. It 
uses a model-based approach for expression variance estimation and produces a 
Stability value for each gene. A ranked list of genes according to their stability was 
obtained.
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2.11.4 Primers and probes
2.11.4.1 Primer probe sets targeting reference genes
The primer/probe sets targeting reference genes listed in Table 2.4 were selected from 
a list o f potential reference genes based on our own microarray data (explained in 
detail in Chapter 6). Together with the PER3 primer/probe set shown in Table 2.5, the 
primer/probes were designed using Primer Express software version 3.0 (Applied 
Biosystems, Life Technologies) and manufactured by Sigma-Aldrich. The primers 
and probes were designed to target the same exon as the corresponding probes used 
on the microarrays.
Gene Gene Name Agilent Probe Name Primers and Probe
ACTS
EEF2
Actin beta
Eukaryotic 
translation elongation 
factor 2
A_24_P226554
A_24_P87763
Forward GGATCGGCGGCTCCAT 
Reverse TACTCCTGCTTGCTGATCCACAT 
Probe TGGCCTCGCTGTCCACCTTCCA 
Forward GCATTAAGAGGTTTATTTGGGTACATG  
Reverse GCGTGTTCCTTTCCCCTTTC 
Probe CCCGCAGTGGCTTTTGCCCC
Table 2.4 Reference genes selected from our data set -- Group A.
Gene Gene Name Agilent Probe Name Primers and Probe
PER3 Period homolog 3 A_24_P291231 Forward CGCAGAACTGTCAGAGCATGA  
Reverse ACCTGGGAGTGCGTGAATG  
Probe CTCCTCCTGTGGGTGGA
Table 2.5 PER3 primers and probe sequence used for kit comparison tests.
The primer/probe sets targeting reference genes listed in Table 2.6 were selected, 
designed and manufactured by PrimerDesign and were included in the classic geNorm 
kit.
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Gene Gene Name
ACTB Actin beta
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
m e Ubiquitin C
B2M Beta-2-microglobulin
YWHAZ Phospholipase A2
RPL13A Ribosomal protein LI3a
18S 18S rRNA gene
CYC1 Cytochrome c-1
EIF4A2 Eukaryotic translation initiation factor 4A, isoform 2
SDHA Succinate dehydrogenase complex
TOPI Topoisomerase (DNA) I
ATP5B ATP synthase
Table 2.6 Reference genes included in the classis geNorm kit - Group B.
Primer and probe sequences were not made publicly available.
2.12 Statistical analysis
2.12.1 Determining dim light melatonin onset (DLMO)
DLMO was computed for each volunteer in each condition separately. Firstly, the 
baseline melatonin level was established using the median melatonin concentration of 
the first five samples collected. Secondly, the maximum level was determined using 
the median of the highest three concentrations. More than one sample was used to 
avoid identifying local maxima or minima. Thirdly, the 25% difference between the 
baseline and maximum level was computed and added to the baseline level. This was 
the melatonin level observed at DLMO. In order to find the exact clock time at which 
DLMO occurred, linear regression was run between the sample just before and just 
after the computed melatonin level.
For each volunteer within each condition the melatonin samples were grouped into 3- 
hourly bins, each bin thus containing three samples, for each subject. The bin where 
DLMO occurred was designated bin 0 (zero). Where actual clock time is shown bin 0 
corresponds to midnight.
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2.12.2 Statistical analysis of microarray data
The microarray data has been submitted to the GEO archive (Gene Expression 
Omnibus, http://www.ncbi.nlm.nih.gov/geo/) and can be accessed using accession 
number GSE39445.
2.12.2.1 Feature extraction
The intensity data obtained by scanning the microarrays were extracted using Agilent 
Feature Extraction Software, version 10.7 (Agilent Technologies). The purpose of the 
software is mainly twofold: spatial detrending and multiplicative detrending. The 
spatial detrending algorithm calculates the fitted surface of the whole array, and then 
subtracts it from all the values on the array. This removed the overall trend in the 
array. The multiplicative detrending is an algorithm designed to compensate for linear 
variation in intensities which result from non-homogenous processing across the slide, 
due to different chemical reaction times, and can result in a “dome effect”. This 
removed areas of high and low expression (for more details see user manualAgilent 
Feature Extraction Software vl0 .7  October, 2009).
Besides this, the Feature Extraction software was also used to place a grid on top of 
the array matrix and by doing so identifying each spot on the array with its Agilent 
probe code. The software also identified and flagged a probe (feature) if any o f the 
following four criteria were not met: (1) Feature intensity was above minimum 
detection level. The minimum detection level was a single value per array and is 
calculated based on the spike-ins (synthesised polyadenylated transcripts in 
predetermined ratios, added to each sample prior to hybridisation, and used for quality 
control); (2) Feature intensity was positive and statistically significantly different 
from background; (3) Feature was found. A feature was considered found if  two 
conditions were true: the difference between the feature signal and the local 
background signal was more than 1.5 times the local background noise and the spot 
diameter was at least 0.3 times the nominal spot diameter; (4) Feature was not an 
outlier. A feature is an outlier if  the pixel noise o f the feature exceeded a threshold 
established for a "uniform" feature.
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2.12.2.2 Cleaning and normalisation of microarray data
The pre-processed (by Feature Extraction) log] intensity data were exported into R 
Bioconductor package limma (www.r-project.org). Probes (features) that had been 
flagged by the Feature Extraction software were removed and not used in further 
analysis. All array expression data were normalised to the 75th percentile, as 
recommended by Agilent. The intensity data which has been cleared of unusable 
features and has been normalised will be referred to as expression data.
2.12.2.3 Expression profiles of selected genes
From the microarray expression data obtained, a gene expression matrix for each of 
the following genes was extracted using the R Bioconductor package limma: 
AF063695, ARNTL (BMAL1, M0P3), ARNTL2 (BMAL2, M 0P9), BDNF, BHLHE40 
(DEC1, SHARP2), BHLHE41 (DEC2, SHARP1), CLDN5, CRP, CRY1, CRY2, 
CSNK1D, CSNK1E, DRD2, GSTM5, HBA1, HBA2, HBB, HOMER1, HSPA5, HSPA9, 
HSPD1, IFNy, ILlfl, IL6, KLRC2, LGALS9, MAGED4B, MEG3, NDUFV2, NFkB2, 
NIPSNAP1, N0XA1, NPAS2, NPDC1, NR1D1 {REV-ERBa), NR1D2 {REV-ERBp), 
NTRKB, PAK2, PDIA4, PERI, PER2, PER3, RORA, RORB, SGK1, SLC2A1, 
TIMELESS, TMEM176A, TMEM176B and TNFa.
The gene expression matrix for each probe contained expression data (logi intensities 
normalised to the 75th percentile) for all homozygous volunteers, collected during the 
CR following both SE and SR condition. Using SAS version 9.1 (Cary, NC) gene 
expression profiles of all subjects were aligned by DLMO phase. Due to the aligning 
process the first (-9) and last bin (+21) did not contain data from all subjects, and 
were therefore excluded from the analysis. Only bins -6 to +18 were thus considered. 
The expression profiles were z-transformed, except where not stated, and least 
squares mean was computed per timepoint. All plotted expression data are in log2. An 
example of a z-transformed expression profile produced for a selected gene is shown 
in Figure 2.5.
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Figure 2.5 Example of an expression profile generated for selected genes.
The expression values are shown as least squares means, have been z-transform ed [(x-mean)/standard 
deviation] (y-axis) and the phase o f  expression has been aligned to melatonin phase (x-axis).
2.12.2.4 Mixed-model analysis
M ixed m odel analysis (PRO C M IX ED  (in SAS 9.1)) w as used to com pute the m ain 
effects o f  tim e (D LM O ), condition, genotype (fixed variables), and the interaction 
betw een these m ain effects on the expression profile o f  each probe (dependent 
variable), w ith repeated m easures w ithin subjects (random  variable). To identify 
significant differences in m ain effects in specific tim e points p o s t hoc, d ifferences o f  
least squares m ean w ere com puted.
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3 Correlation between clock gene expression in 
peripheral blood cells and entrained sleep- 
wake timings
3.1 Introduction
Sleep, its timing during the 24-hour day-night cycle, and its duration can show 
considerable variation between individuals (reviewed in Groeger et al. 2004). Besides 
social and work commitments, sleep is primarily regulated by the interaction of the 
homeostatic and circadian processes (Borbely 1982). In the SCN, the molecular clock 
(the circadian component of sleep regulation) is responsible for generating rhythms 
with an average period length in humans o f approximately 24.2 h via transcription- 
translation feed-back loops involving clock genes, and post-transcriptional 
modifications and clearance (degradation) of clock proteins. The circadian clock 
system controls the rhythmic timing and occurrence of sleep and wakefulness (Hida et 
al. 2012), and SCN lesioned mice have been shown to exhibit a decrease in 
wakefulness and sleep consolidation (Easton, et al. 2004). In humans differences in 
phase, period, and chronotype have been shown to correlate with circadian markers 
such as melatonin and body temperature (Duffy et al. 1999; Duffy et al. 2001), as well 
as with the expression of some of the clock genes (Archer et al. 2008).
The circadian clock has been shown to be involved in the regulation o f sleep via 
various clock gene knock-out animal studies (Laposky, et al. 2005; Wisor, et al. 
2002). Polymorphisms within clock genes have also been shown to affect individuals’ 
sleep-wake timing and diurnal preference, as described in the Introduction section
1.3.1.2. While a large variation in the timing of sleep as well as diurnal preference can 
be observed in the healthy population, extremes lead to clinical conditions such as 
ASPD and DSPD.
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Preferred sleep-wake timing and diurnal preference can be studied using numerous 
validated questionnaires developed in the recent years, such as the HO (Home and 
Ostberg 1976), MCQ (Roenneberg et al. 2003), PSQI (Buysse et ah 1989), BSS 
(Groeger et ah 2004), and others. These questionnaires differ mainly in the times to 
which they refer and ask about. Some ask about average or usual sleep habits while 
others refer to the previous week or previous night. Besides questionnaires, sleep 
diaries note the exact timing o f individuals’ sleep-wake times.
The aim of this part of the study was to examine whether individual differences in 
preferred sleep-wake timing were related to intrinsic clock gene expression in blood. 
Correlations were computed between the peak timing and amplitude o f mRNA 
expression of canonical clock genes in peripheral blood, and individual reported 
sleep-wake timings, as assessed by multiple questionnaires. We chose to assess sleep- 
wake parameters several times and used questionnaires referring to different periods 
in the not so distant past, to eliminate findings by chance. In our analysis, we only 
chose to consider results where multiple questionnaires showed the same trends in 
correlations with the clock genes.
3.2 Hypothesis
• The clock genes ARNTL (BMAL1, MOPS), ARNTL2 {BMAL2, MOP9), BHLHE40 
(DEC1, SHARP2), BHLHE41 (DEC2, SHARP1), CLOCK, CRY1, CRY2, 
CSNK1D, CSNK1E, NPAS2, NR1D1 {REV-ERBa), NR1D2 {REV-ERBp), PERI, 
PER2, PERS, RORA, RORB and TIMELESS will be rhythmically expressed in 
peripheral blood cells.
• Rhythmic expression of clock genes will be attenuated after SR compared to SE.
• The rhythmic expression of clock genes will correlate with sleep-wake time.
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3.3 Aims
• To assess the expression of peripheral circadian clock genes in whole blood 
samples collected during a 40-h CR protocol.
• To examine how restricted sleep opportunity (SR) affects clock gene expression 
patterns (phase and amplitude) in peripheral blood, compared to extended sleep 
(SE).
• To determine whether a correlation exists between clock gene expression (phase 
and amplitude) and entrained sleep-wake parameters.
• To examine whether there are PER3 VNTR genotype differences in the 
associations between clock gene expression and entrained sleep-wake parameters.
3.4 Methods
3.4.1 Protocol
All 26 volunteers (12 PER34/4 and 14 PER35/5) took part in the laboratory study. 
Volunteers were recruited and screened as described in section 2.2, and genotyped as 
detailed in section 2.6. Their habitual sleep-wake schedule was assessed as described 
in section 2.3. Volunteers spent a total o f 11 days in the Clinical Research Centre of 
the University of Surrey and underwent 2 sleep-wake cycles of baseline sleep, 7 
sleep-wake cycles of extended (10 h) or restricted (6 h) sleep opportunity, followed by 
approximately 40 hours of CR, as described in section 2.4. During the CR period, 
samples for assessing plasma melatonin levels, as well as whole blood gene 
expression, were collected hourly and 3-hourly, respectively, as described in section 
2.5.
3.4.2 Samples
RNA was extracted from the blood samples as described in the section 2.7, and 
quantified spectrophotometrically as detailed in 2.8. The quality of the extracted RNA 
was determined using microfluidic technology as described in section 2.9. 
Microarrays were prepared as described and referenced in section 2.10. The quality of
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the microarray data was checked and normalised as described in section 2.12.2.1 and
2.12.2.2, respectively.
3.4.3 Sleep-wake parameters
The sleep-wake parameters of individuals were collected using MQ, PSQI, HO, 
MCQ, BSS and KSD during screening (described in Methods section 2.2). Parameters 
describing the number of hours spent in bed per night, bedtime, wakeup time, and 
sleep latency (the time it takes to fall asleep) were extracted from the questionnaires 
and used for the purpose of this analysis. The parameters are compiled in Table 3.1.
Usual times/on average: During the past month:
MQ Sleep per night PSQI Bedtime
MCQ Work bedtime PSQI Get up time
MCQ Work wake up PSQI Actual sleep hours
MCQ Work sleep latency PSQI Sleep latency
MCQ Work get up time PSQI Time in bed
MCQ Free bedtime During the past week:
MCQ Free sleep latency BSS Avg. bedtime
MCQ Free wake up time BSS Avg. get up time
HO Get up time BSS Actual sleep hours
HO Bedtime Last night:
HO Need o f  sleep KSD Bedtime
KSD Try start to sleep
KSD Sleep latency
KSD Get up time
Table 3.1 Sleep-wake parameters used in analysis.
MQ = medical questionnaire, MCQ = Munich Chronotype Questionnaire, HO = Home-Ostberg diurnal 
preference Questionnaire, PSQI = Pittsburg Sleep Quality Index, BSS = British Sleep Survey, KSC = 
Karolinska Sleep Diary.
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3.4.4 Expression profiles of selected clock genes
From the expression data obtained by microarrays, expression data for the following 
canonical clock genes were extracted: genes ARNTL (BMAL1, MOPS), ARNTL2 
(BMAL2, MOP9), BHLHE40 (DEC1, SHARP2), BHLHE41 {DEC2, SHARP1), 
CLOCK, CRY1, CRY2, CSNK1D, CSNK1E, NPAS2, NR1D1 {REV-ERBa), NR1D2 
(REV-ERBfS), PERI, PER2, PER3, RORA, RORB and TIMELESS. The probes 
detecting these genes are listed in Table 3.2.
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Gene Agilent probe name
ARNTL (BMAL1, MOP3)
ARNTL2 (BMAL2, MOP9)
ARNTL2 (BMAL2, MOP9)
ARNTL2 (BMAL2, M0P9)
BHLHE40 (DEC1, SHARP2)
BHLHE41 {DEC2, SHARP 1)
CLOCK
CRY1
CRY1
CRY2
CRY2
CRY2
CSNK1D
CSNK1D
CSNK1E
CSNK1E
CSNK1E
NPAS2
NPAS2
NR1D1 {REV-ERBa),
NR1D1 {REV-ERBa),
NR1D2 {REV-ERBf3)
NR1D2 {REV-ERBp)
PERI
PERI
PER2
PER2
PER3
PER3
PER3
PER3
RORA
RORA
RORA
RORB
TIMELESS
TIMELESS
A_23_P162037
A_23_P53345
A_23_P76145
A_32_P399546
A_23_P 146486
A_23_P139500
A_23_P419038
A_23_P36665
A_24_P407235
A_23_P127394
A_23_P388027
A_24_P158587
A_23_P207896
A_24_P318544
A_23_P29263
A_23_P40664
A_24_P918436
A_23_P218597
A_23_P415984
A_23_P420873
A_24_P250227
A_23_P302709
A_24_P943472
A_23_P89589
A_24_P93916
A_23_P209320
A_23_P411162
A_23_P201461
a _24_P230948
a _24_P291231
C PID 476
A_23_P26124
A_32_P7721
A_32_P40272
A_23_P71699
A_23_P53276
A 24 P231004
Table 3.2 Canonical clock genes used in analysis and their respective Agilent probe
CPID denotes that this was a custom made probe.
names.
Expression profiles o f selected clock genes were analysed and plotted as described in 
Methods section!. 12.2.3. The effect o f time and condition were computed using 
mixed-model analysis as detailed in Methods section 2.12.2.4.
3.4.5 Sine wave fitting and computing mean fitted clock gene phase 
maxima and amplitudes
Using a non-linear regression procedure (PROC NLIN (SAS 9.1)), a sine function 
was fitted to the expression data for each subject. The function fitted was: 
Value(timei) = Mesor + Amplitude x sin(7r(timei-phase)/24.2), where Mesor, Phase 
and Amplitude were free parameters, timej was time of sample collection expressed in 
DLMO bin, and Value was the z-scored expression value obtained by microarray 
analysis. A time-series was considered rhythmic if  the 95% confidence interval o f the 
fitted amplitude did not include 0. For each probe, expression data for the volunteers 
where a sine curve could not be fitted or did not meet this criterion were excluded 
from further analysis. The timing of phase maximum (will be referred to as phase 
maximum) and amplitude o f the fitted function (shown in Figure 3.1) were extracted 
for each probe from each subject.
Timing of Phase Maximum
Time (DLMO Mu)
Figure 3.1 A schematic representation of the computed parameters for fitted sine functions.
Amplitude and Timing o f  Phase Maximum (referred to as Phase Maximum).
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3.4.6 Correlating sleep-wake parameters with peak gene expression
Correlations between fitted expression phase maxima and amplitudes, and sleep-wake 
parameters were computed using Pearson’s correlation followed by Fisher’s Z 
transformation (PROC CORR (SAS 9.1)), to correct for covariance. R values 
presented here are thus z-transformed.
3.5 Results
3.5.1 Expression profiles of canonical clock genes
3.5.1.1 Expression profiles and mean fitted phase maxima
Effect of phase, as measured by melatonin rhythm (DLMO), was assessed on mRNA 
levels o f selected clock genes during CR. The expression profiles o f clock genes 
where the mRNA levels differed across time are shown in Figure 3.2. Thirteen clock 
genes showed a significant effect of melatonin phase on their expression: BMAL1, 
DEC2, CLOCK, CRY2, CSNK1D, CSNK1E, REV-ERBa, REV-ERBfi, PERI, PER2, 
PER3, RORA, and TIM. An expression profile was considered rhythmic if  the 95% 
confidence interval did not include 0. All 13 expression profiles showing effect of 
phase were rhythmic. RORB and DEC1 were not expressed in our samples. BMAL2, 
CRY1, and NPAS2 did not oscillate in peripheral blood and were not differentially 
expressed across time.
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Figure 3.2 Effect of time on clock gene mRNA levels.
Effect o f  tim e was com puted in SAS using PROC M IX ED , only clock genes show ing significant effect 
o f  tim e are presented. All expression levels are z-transform ed and plotted against m elatonin phase. A 
sine curve was fitted to data using PROC NLIN.
Expression levels for each subject for all tim e points are show n w ith individual dots, fitted sine curve is 
shown as a solid line. M elatonin phase (DLM O) w as determ ined as described in section 2.12.1.
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To assess the tim ing o f  peak expression o f  all the rhythm ically expressed clock genes, 
the tim ing o f  m ean fitted phase m axim a w ere com puted for all clock gene probes, as 
shown in Figure 3.3 and Table 3.3. All three PER  (betw een 4:13 and 7:46) and CRY2  
(2.37) transcripts peaked in the early hours o f  the m orning, and BM AL1  w as 
expressed in the evening (19:03). Both probes targeting CSNK 1D  show  expression at 
a very sim ilar tim e (16:25 and 17:25), w hile probes targeting C SN K 1E  show ed peaks 
in expression tim ing that differed by several hours. RORA  was expressed around mid 
night.
DEC2 (A_23_P139500) I------*------ 1
RORA (A_23_P26124) I-------------• --------------- 1
CSNK1E (A_24_P918436) I---- • ---- 1
TIMELESS (A_23_P53276) I---------------• --------------- 1
NPAS2 (A_23_P218597) h— • -----1
BMAL1 (A_23_P162037) I— • ----1
CSNK1E (A_23_P29263) I--------- • ----------1
CSNK1D (A_23_P207896) I------------ • ------------ 1
CSNK1D (A_24_P318544) I----- • ----- 1
PER1 (A_23_P89589) - I----- • ----- 1
PER? (A_23_P201461)- I---------• ---------1
PER2 (A_23_P209320) - I-------• -------1
PER3 (A_24_P230948)- I---------• ---------1
PER? (A_24_P291231)- I------- • ------- 1
PER3 (CPID_476)- I—• — |
REV-ERBJ3 (A_23_P302709) - I------ • ------ 1
RORA (A_32_P40272) - I------------• ------------1
CRY2 (A_23_P127394)- I---------- • -----------1
REV-ERBa (A_24_P250227) - I------------- • --------------1
REV-ERBp (A_24_P943472) - I-------------- • -------------- 1
RORA (A_32_P7721)- I--------• -------- 1
REV-ERBcc (A_23_P420873). I-------------- • -------------- 1
PER2 (A_23_P411162) - I------------ e------------ 1
CSNK1E (A_23_P40664).
I---------------• ---------------1
18 21 0 3 6 9 12 15 18 21 24 3 6
Clock Time (h)
Figure 3.3 Mean fitted z-score phase maxima (±SD) for multiple clock gene probes.
Tim ing o f  fitted m axim a w ere com puted using PRO C N L IN  in SAS. X -axis show s the actual clock 
tim e (m elatonin phase translated into clock time, as explained in section 2.12.1). The space betw een the 
two vertical grey lines represents one 24-hour cycle.
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Gene name Agilent probe name Timing of phase 
maximum (h:min)
SD (h:min)
CSNK1E A_23_P40664 00:18 03:01
PER2 A_23_P411162 00:51 06:20
REV-ERBa A_23_P420873 01:40 02:18
RORA A_32_P7721 01:56 06:36
REV-ERBp A_24_P943472 02:06 02:30
REV-ERBa A_24_P250227 02:31 02:08
CRY2 A_23_P127394 02:37 04:26
RORA A_32_P40272 03:18 05:34
REV-ERBp A_23_P3 02709 03:44 02:44
PER3 CPID_476 04:13 02:42
PER3 A_24_P291231 04:15 04:04
PER3 A_24_P230948 05:02 03:22
PER2 A_23_P209320 06:10 04:07
PER3 A_23_P201461 06:43 03:28
PERI A_23_P89589 07:46 01:46
CSNK1D A_24_P318544 16:25 03:07
CSNK1D A_23_P207896 17:24 05:20
CSNK1E A_23_P29263 18:23 04:50
ARNTL A_23_P162037 19:03 06:03
NPAS2 A_23_P218597 20:40 06:21
TIMELESS A_23_P53276 21:04 03:48
CSNK1E A_24_P918436 23:02 06:19
RORA A_23_P26124 23:08 05:31
DEC2 A_23_P139500 23:38 06:33
Table 3.3 Mean fitted z-score phase maxima for multiple clock gene probes. 
SD-standard deviation.
3.5.1.2 Effect of prior sleep (sleep condition) on expression profiles
Next, the effect o f extended (SE) and restricted (SR) sleep opportunity on clock gene 
expression profiles during CR was investigated. Expression profiles of 12 clock genes 
were affected by the sleeping condition: DEC2, CRY1, CRY2, CSNK1D, CSNK1E, 
REV-ERBa, REV-ERBp, PERI, PER2, PER3, RORA and TIMELESS. BMAL1 
expression was not affected by the sleeping condition prior to CR. The profiles were 
plotted in Figure 3.4. A fitted curve could not be obtained for DEC2 and PERI 
profiles following SR, and non-fitted data are thus presented. CRY1 was not
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rhythm ically  expressed, as already m entioned above. The non-fitted expression curves 
are therefore shown.
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Figure 3.4 Effect of sleep condition (extended , restricted —) on expression levels of clock genes 
during CR.
E ffect o f  condition w as com puted  in SAS using PR O C  M IX ED , only clock  genes show ing sign ifican t e ffec t o f  
condition  are presented. All expression  levels are z-transform ed and p lo tted  against m elatonin  phase. A sine curve 
w as fitted  to data from  each condition using  PR O C  N L IN . F o r expression  levels o f  DEC 2  and  PER I a sine curve 
could not be fitted for the data co llected  after restricted  sleep opportunity , the non-fitted  data  is therefore show n. 
CRY1 w as c o n s titu tiv e^  expressed , therefore a sine curve w as not fitted  and only the non-fitted  data  are show n. 
W here the phase o f  expression  m axim um  differed  betw een conditions a dashed vertical line represen ts the tim ing  
o f  the m axim um . M elatonin  phase (D LM O ) w as determ ined as described in section 2.12.1.
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Following SR the phases o f expression of CSNK1D, REV-ERBfi, RORA, and 
TIMELESS were advanced, while the phase of CSNK1E was delayed, as shown in 
dashed vertical lines in Figure 3.4. Amplitude o f most genes, where a condition effect 
was detected and profiles could be determined, was lower after SR compared to SE, 
except for RORA.
3.5.2 Correlations between mean fitted clock gene phase maxima and 
amplitudes, and sleep-wake parameters
3 5.2.1 Correlations between mean fitted clock gene maxima and sleep- 
wake parameters
Correlation analysis were performed between individuals’ sleep-wake parameters and 
timing of clock gene peak expression (maxima). Results o f the correlation analysis are 
shown in Appendix E. Correlation plots are shown only for those genes where 
multiple questionnaires assessing one parameter (for example bedtime, or wake time) 
were found to significantly correlate with the expression of the clock gene. A 
summary of all the correlations is shown in Figure 3.11.
PERI showed a negative correlation with amount of time spent in bed per night 
according to data collected with three separate questionnaires (MQ Sleep per night, 
PSQI Actual sleep hours, and PSQI Time in bed). The correlations are shown in 
Figure 3.5. PER3 correlated positively with MQ Sleep per night.
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PER1 (A_23_P89589)12:00
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6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5
Sleep time
■ MQ Sleep per night (r = -1.22, P = 0.01)
▼ PSQI Actual sleep hours (r = -1.47, P = 0.003)
•  PSQI Time in bed (r = -1.06, P = 0.03)
Figure 3.5 Correlations between amount of sleep time per night and timing of clock gene peak 
expression.
Only PERI peak expression significantly negatively correlated w ith am ount o f  sleep individuals gained 
per night. The correlation w as significant for reports obtained by 3 different questionnaires. The 
questionnaires are listed below  each graph and the z-transform ed correlation coefficient (r) and 
significance level (? ) are listed in parenthesis.
Param eters describing bedtim e (show n in F igure 3.6) m ost strongly correlated w ith 
peak tim ings o f  D EC2, C SNK1D , R EV-E RBa, REV-ERBfi, P E R I  and TIM. Peak 
tim ings o f  both REV-ERB/3  probes positively correlated w ith bedtim e param eters. One 
o f  the RE V -E R B p  probes show ed a significant correlation w ith all questionnaires 
related to bedtim e (PSQI Bedtim e, BSS A vg bedtim e, M CQ  W ork bedtim e, M C Q  
Free bedtim e, K SD  Bedtim e, KSD Try start to sleep, HO Bedtim e, and H O  N eed  o f  
sleep).
CSNK 1D  and R E V -E RB a  correlated positively w ith the follow ing 4 questionnaires: 
C SNK 1D  w ith PSQI Bedtim e, BSS Avg bedtim e, M CQ  W ork bedtim e, HO B edtim e, 
HO N eed o f  sleep. REV -E R B a  correlated w ith PSQI Bedtim e, BSS Avg bedtim e, 
M CQ W ork bedtim e, HO Bedtim e, and HO N eed o f  sleep.
D EC 2  and TIM ELESS  individual peak tim es in expression also correlated positively  
with five questionnaires: D EC 2  show ed significant correlations w ith PSQI B edtim e, 
BSS A vg bedtim e, M CQ  W ork bedtim e, K SD  B edtim e, KSD Try start to sleep.
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TIMELESS correlated positively with PSQI Bedtime, MCQ Work bedtime, KSD 
Bedtime, KSD Try start to sleep, and HO Need of sleep. CRY2 showed a positive 
correlation with KSD Bedtime, and HO Need of sleep.
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• MCQ Work bedtime (r = 0.65, P = 0.04)
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•  KSD Try start to sleep  (r= 1.06, P = 0.01)
•  HO Need of sleep  (r= 0.81, P = 0.01)
Figure 3.6 Correlations between reported bedtimes and timing of clock gene peak expression.
Peak expression  levels o f  REJ'-ERBjB, REV-ERBa, CSNK1D, D E C 2  and TIMELESS all corre la ted  positively  w ith  
reported bed tim es in several questionnaires. The questionnaires are listed below  each graph and the z-transform ed  
correlation  coeffic ien t (r) and significance level (P) are listed  in parenthesis.
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Param eters referring to w ake up tim e (Figure 3.7) significantly  correlated w ith REV- 
ER B a  and REV-ERBp. R E V -E R B a  and R E V -E R B p  correlated positively  w ith PSQI 
Getup time, BSS Avg getup tim e, M CQ W ork getup time, M CQ  Free w akeup tim e), 
HO Getup time. The significance o f  correlations hold true for both RE V -E R B p  probes, 
except for M CQ  Free w akeup time, w here for one probe the correlation w as 
borderline significant (P = 0.058).
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MCQ Work getup time (r= 0.89, P = 0.01) 
HO Getup time (r = 0.81, P = 0.01)
HO Getup time (r= 0.81, P = 0.01)
PSQI Getup time (r= 0.87, P = 0.01)
BSS Avg getup time (r = 0.79, P = 0.01) 
MCQ Work getup time (r = 0.81, P = 0.01) 
HO Getup time (r = 0.84, P = 0.01)
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•  PSQI Getup time (r = 0.73, P = 0.01)
• BSS Avg getup time (r= 0.59, P = 0.04)
•  MCQ Work getup time (r= 0.71, P = 0.01)
• MCQ Free wakeup time (r = 0.57, P = 0.05)
• HO Getup time (r= 1.16, P < 0.0001)
Figure 3.7 Correlations between reported wake times and timing of clock gene peak expression; 
Peak expression levels of REV-ERBR, and REV-ERBa, positively correlated with reported wake 
times in several questionnaires.
The questionnaires are listed below  each graph and the z-transform ed correlation coefficient (r) and 
significance level (P) are listed in parenthesis.
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The strongest correlation betw een sleep latency param eters and peak expression 
tim ing w as observed for REV-ERBJ3 (Figure 3.8), as it significantly positively 
correlated w ith three o f  the 4 questionnaires asking about sleep latency: M CQ  W ork 
sleep latency, M CQ  Free sleep latency, KSD Sleep latency. C SN K JD  also show ed a 
positive correlation w ith M C Q  Free sleep latency.
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Sleep latency (min)
• MCQ Work sleeplatency (r = 0.74, P = 0.02)
•  MCQ Free sleeplatency (r = 0.72, P = 0.02)
•  KSD S leep  latency (r = 0.74, P = 0.02)
Figure 3.8 Correlations between reported sleep latency and timing of clock gene peak expression.
Only the tim ing o f  REV-ERBR m RNA peak levels significantly correlated w ith sleep latency as 
assessed by 3 separate questions. The questionnaires are listed below  each graph and the z-transform ed 
correlation coefficient (r) and significance level (P) are listed in parenthesis.
3.S.2.2 Correlations between mean fitted clock gene am plitudes and 
sleep-wake timings
C orrelation analyses w ere perform ed betw een ind iv iduals’ sleep-w ake param eters and 
peak expression am plitude o f  clock genes Results o f  correlation analysis are shown in 
A ppendix F. A sum m ary o f  all the correlations is show n in Figure 3.12.
The am plitude o f  P E R I  correlated negatively w ith the tim e spent in bed according to 
the PSQI Actual sleep hours and BSS Actual sleep hours.
Individual bed-tim e strongly correlated w ith am plitudes o f  P E R I  and C SNK 1D , as 
shown in Figure 3.9. P E R I  show ed a positive correlation w ith PSQ I B edtim e, BSS
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Avg. bedtim e, KSD Bedtim e, KSD Try start to sleep, HO Bedtim e, HO N eed o f  sleep. 
A m plitudes o f  PER2  m R N A  negatively correlated w ith PSQ I Bedtim e. C SNK 1D  
d isplayed a negative correlation w ith bed tim ings according to the BSS Avg. bedtim e, 
M CQ  Free bedtim e, KSD Bedtim e.
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03:00cro
•  PSQI Bedtime (r = 1.04, P = 0.04)
• B SS  Avg bedtime (r = 1.14, P = 0.02)
•  KSD Bedtime (r=  1.55, P = 0.01)
•  KSD Try start to s leep  (r = 1.59, P = 0.01)
•  HO Bedtime (r = 1.20, P = 0.02)
^  • HO N eed of s leep  time (r = 1.31, P = 0.01)-a 0)
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cro 03:00
•  B SS Avg bedtime (r = -0.69, P = 0.04)
• MCQ Free bedtime (r = -0.80, P = 0.02)
•  KSD Bedtime (r = -0.67, P = 0.05)
Figure 3.9 Correlations between reported bed times and clock gene mean fitted amplitude.
PERI mRNA levels correlated positively w hile CSNK1D  m RN A  expression am plitudes correlated 
negatively w ith habitual bed times. The questionnaires are listed below  each graph and the z- 
transform ed correlation coefficient (r) and significance level (P) are listed in parenthesis.
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The strongest negative correlation betw een w ake up tim e and expression am plitude 
w as shown for PER 2  (Figure 3.10). This w as true for wake tim e determ ined by 3 
questionnaires; PSQI Getup tim e, BSS Avg. getup tim e, M CQ  W ork getup time. In 
addition BM AL1  also show ed a negative correlation w ith one questionnaire; M CQ 
Free w akeup tim e, as did REV-E RBp, and KSD  W ake up time.
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•  PSQI Getup time (r = -1 .05 , P = 0.01)
•  BSS Avg getup time (r = -0.85, P = 0.02)
•  MCQ Work getup time (r = -1.09, P = 0.01)
Figure 3.10 Correlations between reported wake times and clock gene mean fitted amplitude.
PER2 mRNA levels significantly negatively correlated w ith w ake tim ings. The questionnaires are 
listed below  each graph and the z-transform ed correlation coefficient (r) and significance level (P) are 
listed in parenthesis.
Sleep latency correlated positively w ith expression am plitudes o f  D EC 2, and 
negatively w ith am plitudes o f  PER3  and PER2. D EC 2  correlated w ith PSQ I Sleep 
latency, M CQ  W ork sleep latency. PER 3  show ed negative correlations w ith M C Q  
W ork sleep latency and M C Q  Free sleep latency, w hile PER2  correlated w ith PSQ I 
Sleep latency and M CQ Free sleep latency.
In sum m ary, am ount o f  sleep obtained per n ight seem ed to be m ost influenced by the 
tim ing o f  the P E R I  peak, while tim ing o f  ind iv iduals’ bed tim e w as affected by peak  
tim ings o f  several clock genes: REV-ERBp, R E V -E R B a, DEC 2, CSNK 1D , P E R I  and 
TIM. W ake tim es corresponded significantly w ith the tim ing o f  R E V -E R B a  and R E V - 
ERBp. R eported sleep latency seem ed to be m ost strongly influenced by the tim ing  o f
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the REV-ERBp peak (summarised in Figure 3.11). Amplitudes of CSNK1T) and PERI 
most strongly influenced reported bedtimes (summarised in Figure 3.12).
Sleep per night
MQ Sleep per night
PSQI Actual sleep hours
PSQI Time in bed
BSS Actual sleep hours
Bedtime
PSQI Bedtime
BSS Avg bedtime
MCQ Work bedtime
MCQ Free bedtime
KSD Bedtime
KSD Try start to sleep
HO Go to bed
HO Need of sleep
Wake time
PSQI Getup time
BSS Avg getup time
MCQ Work wakeup
MCQ Work getup time
MCQ Free wakeup time
KSD Getup time
HO Getup time
Sleep latency
PSQI Sleep latency min
MCQ Work sleep latency
MCQ Free sleep latency
KSD Sleep latency
Figure 3.11 Significant (P < 0.05) correlations (marked in grey) between clock gene expression 
maxima and entrained sleep-wake timings as assessed by several questionnaires.
Number o f  volunteers contributing data is shown in the top row (N).
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Sleep per night
MQ Sleep per niqht
PSQI Actual sleep hours ■
PSQI Time in bed
BSS Actual sleep hours ■
Bedtime ■
PSQI Bedtime ■■
BSS Avg bedtime ■ ■
MCQ Work bedtime
MCQ Free bedtime ■
KSD Bedtime ■ ■
KSD Try start to sleep ■
HO Go to bed ■
HQ Need of sleep ■
Wake time ■
PSQI Getup time ■
BSS Avg getup time ■
MCQ Work wakeup
MCQ Work getup time ■
MCQ Free wakeup time
KSD Getup time
HO Getup time
Sleep latency
PSQI Sleep latency min ■MCQ Work sleep latency ■ ■
MCQ Free sleep latency ■ ■ ■
KSD Sleep latency I■ n n
Figure 3.12 Significant (P < 0.05) correlations (marked in grey) between clock gene expression 
amplitudes and entrained sleep-wake timings as assessed by several questionnaires.
Number o f  volunteers contributing data is shown in the top row (N).
3.5.3 Genotype-dependent correlations between clock gene expression 
and entrained sleep-wake timing
Correlation plots are shown only for those genes where multiple questionnaires 
assessing one parameter were found to significantly correlate with the expression of 
the clock gene in one PER3 homozygous genotype but not the other, and where the 
number of individuals contributing data was above 7 in each genotype. Results of 
correlation analysis are shown in Appendix G and Appendix H. A summary o f all the 
correlations is shown in Figure 3.16 and Figure 3.17.
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C orrelations betw een clock gene m axim a and sleep w ake tim ings w ere com pared 
between the tw o hom ozygous PER3  genotypes. C orrelations for R E V -E R B a, and 
R E V -E R B p  displayed m ost variation betw een the two genotypes. C orrelations 
betw een bed tim es and peak expression tim ing w ere significant in CSNK1D, REV- 
ERBa, and R E V -E R B p  in P E R 34 4 but not in P E R 35 5 hom ozygotes, w hile those for 
TIM ELESS  w ere found to be significant in P E R 35 5 hom ozygotes only, as show n in 
Figure 3.13.
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BSS Avg bedtime 
KSD Bedtime 
KSD Try start to sleep
Figure 3.13 Genotype-dependent correlations between clock gene maxima and reported 
bedtimes.
The genotype for which the correlations w ere significant is m arked w ith *.
CSNK1D, REV-ERBa, and REV-ERBR correlations w ere significant in PER3^4 hom ozygotes, w hile 
those for TIMELESS w ere significant for PER3^ J hom ozygotes
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C orrelations betw een sleep latency and m axim um  expression tim ing o f  R E V -E R B p  
significantly correlated w ith param eters assessing sleep latency in P E R 34/4 
hom ozygotes (Figure 3.14), and R E V -E R B a  expression am plitude significantly  
correlated w ith bed tim es in P E R 35/5 (Figure 3 .1 5 /
1.0 
0.9  
0-8 
I  0.7
Sa. 0.6 
0.5  
0.4
REV-ERBp (A_23_P302709)
PER34/4 PER35/5
•  PSQI Sleeplatency 
—<—  MCQ Work sleeplatency 
—▼ MCQ Free sleeplatency
Figure 3.14 Genotype-dependent correlations between clock gene maxima and reported sleep 
latencies.
The correlations w ere significant in PER3^4 hom ozygotes (m arked w ith *).
The correlations w ere only significant for REV-ERBR.
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Figure 3.15 Genotype-dependent correlations between clock gene amplitudes and reported 
bedtimes.
The correlations w ere significant in PER3^3 hom ozygotes (m arked w ith *)
The correlations were only significant for REV-ERBa.
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In sum m ary, R E V -E R B a  and REV-E RBfi d ifferentially  correlated w ith sleep w ake 
tim ings betw een the two genotypes. A dditionally, C SNK 1D  and TIM E LE SS  also show  
differential correlation betw een genotypes. The results are sum m arised in Figure 3.16 
and Figure 3.17.
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Figure 3.16 Significant (P < 0.05) correlation (marked in dark grey) between clock gene 
expression maxima and entrained sleep-wake timings as assessed by several questionnaires, 
shown for each genotype.
Number o f  volunteers contributing data per genotype is shown in the top two rows (N). For each 
significant correlation in one genotype, the corresponding (non-significant) genotype field is marked in 
light grey, for ease o f  comparison between the two genotypes.
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Figure 3.17 Significant (P < 0.05) correlation (marked in dark grey) between clock gene 
expression amplitudes and entrained sleep-wake timings as assessed by several questionnaires, 
shown for each genotype.
Number of volunteers contributing data per genotype is shown in the top two rows. For each significant correlation 
in one genotype, the corresponding (non-significant) genotype field is marked in light grey, for ease of comparison 
between the two genotypes.
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3.6 Discussion
3.6.1 Clock gene expression profiles
Whole blood expression profiles of all canonical clock genes were examined. BMAL1, 
DEC2, CLOCK, CRY2, CSNK1D, CSNK1E, REV-ERBa, REV-ERBp, PERI, PER2, 
PER3, RORA, and TIMELESS were all rhythmically expressed during CR. Expression 
of CRY1 and NPAS2 was not rhythmic in peripheral blood, and DEC1 and BMAL2 
were not expressed.
DEC1 has been shown to be involved in T cell development, as well as homeostasis 
of T cells (Miyazaki, et al. 2010). BMAL2 expression profiles have also been assessed 
in leukocytes in patients with Parkinson’s disease and healthy controls (Ding, et al.
2011). It was thus unexpected not to find them expressed in blood cells in our study. 
This finding perhaps indicated a role of SD in the lack of expression of these two 
genes.
BMAL1 mRNA levels peaked at 19:02 ± 6:03. This is almost 4 h later than our group 
had reported previously (Archer et al. 2008), where expression o f clock genes in 
peripheral blood was assessed by RT-QPCR in subjects undergoing CR. In our 
current study, there were no differences in expression profiles of BMAL1 between the 
two sleep conditions, suggesting that sleep condition (SE, SR) prior to undergoing CR 
does not effect BMAL1 expression. This also indicates that the fact that volunteers 
were not subjected to sleep manipulation prior to undergoing CR in 2008 is not the 
cause of the differences in BMAL1 mRNA peak timing. BMAL1 expression was in 
anti-phase to that of the expression of PER mRNA, as has been shown before (Archer 
et al. 2008; Oishi, et al. 1998). Although Teboul et al. (2005) reported BMAL1 to be in 
phase with PER2 expression in peripheral monocytes, they conclude that this could be 
a consequence of their other finding, which indicated that REV-ERBa, a strong 
inhibitor o f BMAL1 expression, was not rhythmically expressed in their study. In our 
study REV-ERBa as well as REV-ERBfi was strongly rhythmic in whole blood 
samples, and their expression was affected by prior sleep history. This implies that the 
timing of BMAL1 peak expression should also have followed a similar trend, but this 
was not the case.
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Transcript levels of PERI (7:46 ± 1:46), PER2 (6:10 ± 4:07) and PER3 (04:12 ± 
02:42; 04:15 ± 04:04; 05:02 ± 03:22; 06:43 ± 03:28) all peaked in the early hours of 
the morning. Although this is consistent with previous studies, the exact peak timings 
differed by several hours. Kusanagi et al (2008) assessed expression profiles o f 10 
clock genes in 8 volunteers during CR and reported PERI expression peaked at 07:42, 
PER2 at 06:23 and PER3 at 05:57. This is very much in accordance with our findings. 
However, their study did not identify many of the rhythmic clock genes (such as 
BMAL1) as rhythmic, so the comparisons with our findings must be made with 
caution. Archer et al (2008) showed PER2 mRNA to peak at 8:06 and PER3 at 6:05 in 
peripheral blood samples, however they normalised the expression levels to those of 
GAPDH. When amplitudes were not normalised to GAPDH  the difference between 
findings reported here and those from 2008 were even greater. It has also been shown 
that all three PER genes are expressed at around 6 o’clock in the morning (Takimoto, 
et al. 2005), while the peak timings in PER expression in 3 subjects assessed by Bovin 
et al (2003) show an even greater scatter. The PER2 and PER3 genes seemed to show 
great inter-individual differences in both studies.
After our volunteers had been on a sleep restricting protocol in the days prior to the 
CR, the levels of PER mRNA were slightly dampened (this could only be computed 
for PER2 and PER3), shown in Figure 3.4 The dampening of PER2 expression has 
been reported in mice subjected to chronic stress (Jiang, et al. 2011; Kinoshita, et al.
2012). The dampened expression of PER2 and PER3 in our volunteers could therefore 
be the result o f additional stress they endured due to SR prior to undergoing CR.
REV-ERBa, REV-ERB/3 RNA levels both peaked in the very early hours o f the 
morning between 01:30 and 04:00 and had an inter-individual variation o f around 
02:50, which is not large, compared to other clock genes (the mean standard deviation 
for all clock genes was 04:17). This finding might suggest that they are potential 
markers o f circadian phase. REV-ERB transcription is activated by the 
CLOCK/BMAL1 heterodimer as is that of PERs. Given that both are under the 
CLOCK/BMAL1 control it is not surprising that both REV-ERBs and PERs peak at 
around the same circadian time. REV-ERBs then bind to the BMAL1 promoter and
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inhibit BMAL1 transcription. Peak REV-ERB thus precedes the trough of BMAL1 by a 
few hours. In our data the peak expression of one RORA probe preceded the peak in 
REV-ERBa mRNA suggesting a possible role of RORA in REV-ERBa upregulation, 
as has been shown previously (Migita et al. 2004). Our results show the mRNA of 
both REV-ERB paralogues to be strongly rhythmically expressed and oscillate with 
high amplitude.
The peak timing o f RORA RNA occurs around mid light period in mouse SON (Sato 
et al. 2004). This is very different from our findings in peripheral blood, where RORA 
transcription peaked around late night to early morning time. The BMAL1 peak in 
expression preceded the mRNA peak of RORA, which confirms CLOCK/BMAL1 to 
be a regulator of RORA expression, as previously shown (Akashi and Takumi 2005).
CSNK1D RNA levels peaked in the afternoon between 16:25 and 17:24. CSNK1E 
peak expression, however, were more varied as three probes targeting CSNK1E 
detected an average peak at very different times; 18:23, 23:02, and 0:18. CSNK1E 
and CSNK1D phosphorylate the PER proteins, and by doing so facilitate their 
translocation into the nucleus and their subsequent degradation (Camacho et al. 2001; 
Vielhaber et al. 2000). The different timing of peak expression o f both CSNK1 
paralogues was surprising as the kinase domain sequences of the two isoforms are 
97% identical and only differ in eight amino acids (Fish, et al. 1995; Graves, et al. 
1993). CSNK1E also phosphorylates the CRY proteins with the help of PERs. PERs 
act as a scaffold for CRYs and bring CSNK1E into close proximity with CRY. This 
enables CSNK1E to phosphorylate the CRY proteins. Our data show that CSNK1E 
was expressed at highest levels a few hours before the PER and CRY  peak, but 
CSNK1D peaked around the time of PER and CRY  trough. This possibly suggests that 
CSNK1D could have a more dominant role than CSNK1E in peripheral blood.
In the molecular clockwork CLOCK is constitutively expressed (Tei et al. 1997) and it 
is the rhythmic expression of BMAL1 which dictates the rhythmic pace of 
CLOCK/BMAL1 heterodimer transcriptional activity. We were surprised to see that 
in our data CLOCK showed a weak rhythmic profile. However, Preitner et al (2002)
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have also reported fluctuations in CLOCK mRNA levels in a peripheral tissue (liver). 
NPAS2, a paralogue of CLOCK in the SCN but not in peripheral tissues, was not 
rhythmically expressed in our study, as expected (DeBruyne et al. 2007a).
Both CRY1 and CRY2 have been shown to be rhythmically expressed in the SCN as 
well as peripheral tissues (Kume et al. 1999). In our data, CRY2 but not CRY1 was 
rhythmically expressed. It was surprising to see that lack of CRY1 rhythmicity did not 
have greater consequences on the rhythmic expression of other clock genes. The 
timing in CRY2 peak expression was in the early hours of the morning around the 
same time as those of PERs. As CRY and PER proteins form heterodimers and 
together act as transcription repressors, their concomitant timings of peak expression 
were not surprising.
There also seemed to be a distinct difference in clock gene timing in those expressed 
in the morning {REV-ERBs, PERs, CRY2) and those expressed in the evening 
(CSNKIs, BMAL1, NPAS2). RORA, TIMELESS and DEC2 seem to be expressed 
during the night to day transition. Although not enough data have been collected in 
this study to examine this in detail, it suggests a possible role for the morning and 
evening oscillators (Pittendrigh and Daan 1976) in the regulation o f the distribution of 
peak expression timings of these clock genes.
In the Agilent arrays used here, there are multiple probes designed and printed on the 
array for each gene (up to 10 per gene). These probes mostly target different exons 
within a gene. Although this explains how differences in peak expression timing 
occur for multiple probes targeting the same gene, it does not explain why this 
happens. This also implies that additional care must be taken when interpreting the 
data, and that multiple probes must always be used.
86
3.6.2 Correlations between mean fitted clock gene transcript maxima and 
amplitudes, and sleep-wake parameters
Correlations between individuals’ sleep-wake timing and timing in peak expression of 
13 canonical clock genes (detected by 22 probes) were computed. REV-ERBfi as well 
as REV-ERBa showed strongest correlations with most sleep-wake parameters. 
Amount of time spent in bed seemed to correlate with PERI peak timing. Amount of 
sleep obtained per night and individual bed times were most affected by differences in 
amplitude of PERI expression, while wake times and sleep latency more strongly 
correlated with PER2 amplitudes. Amplitudes in mRNA levels of CSNK1D 
negatively correlated with reported bed times.
3.6.2.1 PERI
Timing and amplitude of the peak expression of PERI RNA both negatively 
correlated with time spent in bed. An early and lower peak in expression was 
therefore associated with longer habitual sleep time per night. PERI peak expression 
amplitude also correlated positively with questions asking about habitual bed time. A 
low peak in PERI was associated with an earlier reported bed time.
Although the PERI gene expression is highly inducible by light in the SCN (Albrecht, 
et al. 1997; Sun et al. 1997; Tei et al. 1997) and its phase in expression can be shifted 
by brief light pulses during the night, light exposure was not available during the CR, 
when the samples were being collected, and direct photic induction would not have 
resulted in altered clock gene expression timing in a peripheral tissue. The peak in 
PER2 expression has been shown to follow induced PERI expression, lagging by 
about 4 h (Albrecht et al. 1997) I f  one would assume that PERI expression was in 
some way induced, PER2 expression would then have to follow suit;, this was not 
observed. In our data, the peak expression of PER2 and PER3 mRNA occurred earlier 
than that of PERL  Also, PER2 expression did not show a significant correlation with 
the amount of sleep obtained per night or reported usual bed time. As all 
environmental parameters, such as light, temperature, posture, food in take, were kept 
constant, it is highly unlikely that the expression of PERI was artificially induced.
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It seems that the amplitude and timing in PERI peak expression during constant 
conditions is an intrinsic property of an individual’s circadian system. But if PERI 
mRNA levels peak earlier in some individuals, causing a slight advance in their usual 
bed times, it seems somewhat strange that other clock genes expressed in a similar 
fashion, such as CRYs, PERs as well as CLOCK and BMAL1, which activate PER 
transcription, do not show a similar tendency. After all, it is the PER2 protein which 
plays a critical role in negative feed-back, together with CRY, while PERI affects the 
stability and nuclear entry o f PER2 and CRY1 (Bae et al. 2001), suggesting that PER2 
amplitude and phase should have a greater effect on the circadian clock than PERL  
PERI is also thought to affect clock function in a post-translational manner, possibly 
by regulating the stability of other circadian proteins (Bae et al. 2001). However, 
elevation in mRNA levels does not always necessarily result in elevated protein 
levels. It is therefore possible, that the early peak in PERI mRNA is not followed by a 
significant increase in PERI protein, which makes it difficult to draw conclusions 
about protein function from mRNA data.
The circadian clock in peripheral leukocytes lags behind the core circadian oscillator 
in the SCN by several hours (Boivin et al. 2003). In the SCN, PER transcripts reach 
their peak around the end of the circadian day and are translocated to the cytoplasm 
where they are translated into proteins along with the CRY  transcripts. PER and CRY 
proteins are thus most abundant at the beginning of circadian night. Taking all this 
into consideration, it might be possible for an early peak in PERI mRNA to result in 
an early accumulation of the PERI protein. Because the peak in PERI protein is 
reached just before or around people’s usual bed time, the timing o f the PERI peak 
could influence an individual’s bed time, although additional work would be needed 
to determine the exact mechanism. In the early morning, when the circadian cycle is 
reset by light, the PERI mRNA advance is lost and does not affect individuals’ wake 
timings.
The amplitude of PER2 expression in our study negatively correlated with wake 
times. Higher PER2 expression in peripheral blood thus resulted in earlier wake times. 
This could indicate that in these individuals the PER2 protein inhibited the activity of
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the CLOCK/BMAL 1 complex in a stronger manner, which resulted in a quicker 
inhibition of CLOCK/BMAL 1 responsive clock genes leading to an earlier re-start of 
the clockwork.
S.6.2.2 REV-ERBa and REV-ERBp
In our study, peak mRNA levels of REV-ERBfi positively correlated with habitual bed 
and wake times as well as with reported sleep latency. REV-ERBa expression 
correlated with bed and wake timings. Individuals who went to bed early and woke up 
early showed an earlier peak in REV-ERBa and REV-ERBfi mRNA levels. Amplitude 
did not differ between individuals.
In the circadian clockwork, the CLOCK/BMAL 1 complex translocates back to the 
nucleus and activates transcription of its target genes at the beginning of each 
circadian day. Transcription of REV-ERBa and REV-ERBp is activated by the 
CLOCK/BMAL 1 complex as it binds to the E-box in REV-ERB gene promoters. 
Expression of REV-ERBs is thus induced in the early hours of the morning. This was 
also shown in our data in peripheral whole blood. The REV-ERB proteins then act on 
the BMAL1 promoter and inhibit BMAL1 transcription. The REV-ERBs are involved 
in an auxiliary loop, which links the negative and positive loops and provides 
additional stability (Guillaumond et al. 2005; Preitner et al. 2002). Although it has 
been suggested previously (Relogio, et al. 2011), it seems the REV-ERB proteins 
might play a more important role in the molecular circadian clock than has been 
assumed. Perhaps this is possible because they directly (BMAL1 and CLOCK) and 
indirectly (PER and CRY) interact with many canonical clock genes. It has been 
shown that REV-ERBa deficient mice show a greater diversity in period length in 
constant (light or dark) conditions and suggests that REV-ERBa thus plays an 
important role in maintaining precision o f the circadian timing system (Preitner et al. 
2002). In the mouse liver, more than 90% of genes, otherwise rhythmically expressed, 
were perturbed in Rev-erbalRev-erbfi KO (Cho, et al. 2012). The authors emphasise 
that the magnitude of circadian disturbance observed was comparable to that seen in 
mice deficient in core clock genes indicating the functional impact o f REV-ERB in 
the molecular clock. Similarly, our results show that the expression o f both REV-ERB
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paralogues in human peripheral blood plays an important role in determining the 
phase of individual’s sleep-wake cycle.
Peak mRNA expression of neither REV-ERB activators (CLOCK  and BMAL1) nor 
inhibitors (PER and CRY) correlated with any of the sleep-wake parameters. This 
suggests that it is not the activation or inhibition of REV-ERB transcription which 
contributes to the timing of REV-ERB mRNA peak expression. Although it has 
recently been shown that in mouse liver cells REV-ERB paralogues and BMAL1 
cooperate in regulating clock and clock output genes (Cho et al. 2012), our findings in 
human peripheral blood cells show no such interaction. Furthermore we find no major 
role for BMAL1 expression on the timing of sleep and wakefulness. Perhaps 
individuals who show a later peak in REV-ERB expression accumulate REV-ERB 
mRNA slower than those with an earlier peak, thus delaying the observed peak. It is 
not clear from our experiments with what efficiency the mRNA is translated in to 
protein or how much of it is degraded prior to translation. The unknown amounts of 
REV-ERB proteins are then transferred back to the cytoplasm where they inhibit 
BMAL1 transcription. If  the mRNA peak in REV-ERB occurred earlier, one could 
assume that the protein peak might follow suite. It is not, however, possible to 
determine this from our data. If  the timing of the protein peak does follow the timing 
of the mRNA peak, it is difficult to see why the timing of inhibition of BMAL1 
translation is not evident in our correlation analyses. It is also possible that REV-ERB 
acts in the molecular circadian clock through other, unidentified mechanisms.
It was surprising to find that RORA only correlated with one wake parameter in our 
study. As REV-ERBs and RORs are involved in the same regulatory loop and have 
opposing roles in BMAL1 regulation we expected RORA to have an equally important 
role as REV-ERBs. This was not shown to be the case. Perhaps it is the counter 
activation of BMAL1 transcription through RORA which prevents BMAL1 mRNA 
peak timing to follow that of REV-ERB timing.
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3.6.2.3 CSNK1D
Habitual bed times positively correlated with timing o f CSNK1D peak expression and 
negatively with CSNK1D amplitude. Individuals whose CSNK1D expression peaked 
earlier and with greater amplitude, on average went to bed earlier.
Within the circadian clock machinery CSNK1D phosphorylates the PER proteins 
which leads to their degradation (Camacho et al. 2001). ASPD is a human phenotype 
characterised by early bed times and early wake times. Xu et al. (2005) identified a 
mutation in the human CSNK1D gene which decreases its phosphorylation activity 
and results in ASPD. Knock-in transgenic mice carrying the mutation showed a 
decreased period length. CSNK1D thus plays an important role in molecular time 
keeping.
In this study we showed that the peak in PER transcription levels were timed to early 
mornings and CSNK1D expression peaked in the afternoon. This is in accordance 
with reports showing that CSNK1D is involved in PER degradation. In individuals 
where CSNK1D peaked earlier, the PER protein degradation may have occurred 
sooner, which could result in earlier sleep time. Parameters assessing time spent in 
bed did not correlate with CSNK1D expression.
5.6.2.4 DEC2
Individuals in whom DEC2 mRNA levels reached peak expression earlier on average 
went to bed earlier. mRNA amplitudes also positively correlated with habitual 
reported sleep latency; individuals with lower DEC2 mRNA levels fell asleep more 
readily than those with higher DEC2 mRNA levels.
DEC2 expression is activated by the CLOCK/BMAL 1 complex through E-box 
binding. DEC proteins then inhibit CLOCK/BMAL 1 dependent gene expression by 
interacting with BMAL1 directly as well as by competing for the E-boxes in gene 
promoters of CLOCK/BMAL 1 target genes. DECs thus repress PER and CRY  
transcription, as well as their own. As PER, CRY, and DEC  transcription activation
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and inhibition is regulated by the same components negatively feeding back on to 
their own transcription, it is not clear why the expression patterns of PER, CRY  and 
DEC  is not more similar. An earlier timing in peak expression of DEC2 could result 
in an earlier repression of transcription of both PER and CRY, possibly leading to less 
PER and CRY  mRNA being synthesised and thus less PER and CRY proteins feeding 
back, or the peak in PER and CRY protein levels occurring earlier. By the end of the 
circadian day, either of these scenarios could potentially hasten the circadian clock, 
resulting in earlier bed times. A point mutation in human DEC2 has been shown to be 
responsible for shorter sleep requirements (He et al. 2009). Transgenic mice displayed 
lower NREM delta power density change (marker of sleep intensity) after sleep 
deprivation. The authors of that study conclude that it is the altered sleep homeostasis 
which enables them to cope with shorter sleep. Our data show high mRNA amplitudes 
of DEC2 positively correlated with longer sleep latencies, suggesting that high DEC2 
mRNA amplitudes may be responsible for lower homeostatic sleep pressure in these 
individuals.
3.6.2.S TIMELESS
The role of TIMELESS in mammalian circadian clock work has been questioned, as it 
was initially shown not to be rhythmically expressed in the SCN and retina, and its 
expression was not altered by light exposure (Sangoram et al. 1998; Zylka et al. 
1998a). Zylka et al. (1998a) postulate that the role of TIMELESS has perhaps been 
taken over by the three PER proteins, but Sanogoram et al. (1998) have shown that 
PERs and TIMELESS do in fact interact in vitro. Here, we show that TIMELESS 
expression is not only strongly rhythmic in a peripheral tissue, but that its expression 
may contribute to the timing of the circadian clock, as peak timing of TIMELESS 
mRNA levels positively correlated with reported entrained bed times. Hastings et al. 
(1999) reported that TIMELESS is not regulated by the circadian clock or the 
light/dark cycle. They also suggest that the negative feedback of TIMELESS occurs 
only after the actions of PER I. Therefore it was surprising to find that the peak timing 
of none of the PER mRNA correlated with sleep on- or off-set.
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3.6.3 Genotype-dependent correlations between clock gene transcript 
expression and entrained sleep-wake timing
REV-ERBa and REV-ERBp mRNA maxima positively correlated with assessed 
bedtimes in PER34/4, but not in PER35/5 homozygotes. Additionally, REV-ERB/3 
maxima also correlated positively with sleep latency in PER34/4 homozygotes, while 
REV-ERBa exhibited a negative correlation between amplitude and bedtimes in 
PER35/5 homozygotes. The REV-ERB paralogues thus seem to be differentially 
regulated between the two homozygous PER3 VNTR genotypes, although it is not 
clear from our results how these effects might be brought about. Within the circadian 
clock, the main role o f the REV-ERB paralogues seems to be the linking of the 
negative and positive feed-back loops, and by doing so contributing to the stability 
and robustness of the oscillations generated by the circadian clock (Teboul, et al. 
2009). REV-ERBa has been shown to be phosphorylated and thus stabilised by 
GSK3P (Yin et al. 2006). GSK3P has been implicated in signalling pathways involved 
in mental disorders including bipolar disease (Beaulieu 2012). The longer PER3 allele 
has been associated with increased susceptibility to bipolar disease, possibly 
implicating REV-ERBa in promoting this genotype specific vulnerability. Both REV- 
ERBa and REV-ERBp reversibly associate with heme, which is a prosthetic group 
enabling the interaction with various proteins, such as haemoglobin, myoglobin, and 
various cytochromes (Raghuram, et al. 2007). REV-ERB paralogues bound to heme 
have been shown to function as redox and NO/CO sensors (Marvin, et al. 2009). 
Additionally, food-derived lipid soluble nutrients as well as hormones have been 
shown to activate nuclear receptor proteins including REV-ERBa (Yang, et al. 2006). 
BMAL1, PERI, PER2, and PER3 expression in leukocytes o f type 2 diabetics has 
been shown to be lower compared to healthy controls (Ando, et al. 2009), although 
this finding has not been confirmed in white adipose tissue(Otway, et al. 2011). As 
REV-ERB paralogues are involved in expression regulation of BMAL1, which further 
regulates the expression of PERs, REV-ERBs might be implicated in the resulting low 
expression of certain clock genes in diabetics. REV-ERB paralogues can thus be 
modulated via heme, redox status and diatomic gases, have been shown to be 
activated via lipid soluble nutrients and hormones implicating REV-ERBs in 
metabolism regulation and modulation. As food availability is an important zeitgeber 
for peripheral clocks, REV-ERB paralogues might be involved in some aspects of
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phase shifting in these tissues, possibly resulting in different timing of sleep and 
wakefulness in PER3 VNTR genotypes.
In our study, CSNK1D maxima showed significant positive correlations with bedtime 
in PER54/4 homozygotes, but not in PER35/5. CSNK1D has been shown to be involved 
in the phosphorylation of PER proteins (Camacho et al. 2001). The tandem repeats 
within the PER3 protein harbour many potential phosphorylation sites. As the PER35 
protein contains 5 repeats of the VNTR, it also contains more possible 
phosphorylation sites. Thus, the kinase, although not differentially expressed between 
the two genotypes, might have a different effect on the longer and the shorter PER3 
protein. The phosphorylation step results in protein instability and is thus required for 
protein degradation. If  the PER3 protein was indeed differentially phosphorylated 
depending on the genotypes, this could result in the PER3 protein in PER35/5 
homozygotes being degraded at a quicker pace. This could then in turn lead to a more 
rapid turn over and re-setting of the circadian clock.
TIMELESS expression maxima positively correlated with bedtimes in PER3S/5 
homozygotes. SNPs in TIMELESS have been associated with bipolar disorder 
(Mansour, et al. 2006) and TIMELESS allelic variants have been shown to be 
associated with depression, fatigue, seasonal variations in mood, sleep duration, social 
activity, early morning awakenings, and sleep problems (Utge, et al. 2010), indicating 
a possible involvement of TIMELESS in these mood disorders. TIMELESS variants 
have also been shown to be associated with risk of breast cancer, and the level of 
hypomethylation of the TIMELESS promoter has been shown to be associated with 
the developmental stages of breast cancer (Fu, et al. 2011). The long PER3 allele has 
been shown to be associated with bipolar disorder and risk of breast cancer, possibly 
suggesting involvement o f TIMELESS in these PER3 VNTR genotype specific 
differences.
Our study, however, does not provide data which would enable us to explore the exact 
mechanisms of how REV-ERBs, CSNK1D and TIMELESS might differentially affect
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the PER3 proteins in the two PER3 VNTR homozygous genotypes either at the 
molecular of physiological level.
3.7 Conclusion
This part of the study has shown that restricted sleep prior to SD indeed resulted in 
lower expression values and attenuated rhythmicity in most examined clock genes, 
compared to when sleep was extended. When the correlation between the circadian 
process (clock gene expression) and entrained sleep-wake parameters was examined, 
REV-ERBa and REV-ERBfi phase of expression most strongly correlated with habitual 
sleep-wake timings, indicating an important and possibly novel role of REV-ERBs in 
the moleculat clock. REV-ERBa, REV-ERBfi and PER3 expression maxima, as well as 
REV-ERBa expression amplitude strongly correlated with entrained sleep-wake 
timings in PER34/4 but not PER3S/5, suggesting the differences in sleep-wake 
behavious observed between the two PER3 VNTR genotypes might be partly due to 
the differential regulation of these genes in the molecular clock. Additionally, 
TIMELESS has been found to be rhythmically expressed in peripheral blood and 
associated with the timing of entrained bedtime.
95
4 Expression of sleep and sleep-deprivation- 
related genes during sleep deprivation and 
sleep restriction
4.1 Introduction
In humans, wakefulness can be sustained for 16 hours without impairment of 
performance (Van Dongen, et al. 2003). However, when wakefulness is sustained and 
extended into the night, molecular and physiological mechanisms to cope with the 
stress of sleep deprivation, as well as mechanisms which limit the time spent awake 
are activated.
Although ‘why we sleep’ has been studied extensively, no clear answer has yet been 
provided. Currently three main concepts on why we sleep exist: energy saving, 
information processing and synaptic plasticity, and restoration of key cellular 
components of macromolecule biosynthesis (Mignot 2008).
Energy demands are elevated during wakefulness and SD, and in humans the brain 
consumes around 30% of total energy. For diuml species to time their peak activity to 
the time of food availability, maximum temperatures and visibility, sleep has 
developed as a method of energy preservation during the time of unfavourable 
conditions i.e. during the night. However, sleep is also a time when thermoregulation 
is partially unregulated (Parmeggiani 2003), and while NREM sleep is associated with 
lower energy expenditure, REM sleep is associated with elevated levels of oxygen 
consumption (Parmeggiani 2003; Zhang et al. 2007). It is therefore unlikely that sleep 
primarily evolved as a mechanism for energy conservation in mammals (Mignot 
2008). Wakefulness and SD have been shown to lead to an increase in metabolism of 
glucose and its transport, as marked by elevated Slc2al and Ndufv2 (Cirelli and 
Tononi 2000b). Although wakefulness is associated with increased glucose demand 
and elevated metabolism, when wakefulness is prolonged into sleep deprivation, the
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expression of genes coding for proteins involved in metabolic pathways are 
downregulated (Mackiewicz et al. 2007). The authors of this paper postulated that this 
downregulation is a wakefulness limiting mechanism.
Wakefulness is a time of synaptic potentiation of cortical networks, which is activated 
by ‘experience’, such as activities and learning (Tononi and Cirelli 2003). Sleep, on 
the other hand, is a time of synaptic strength downscaling to an energetically 
sustainable level, as proposed by the synaptic homeostasis hypothesis. The authors of 
this paper also suggest that sleep is the price we pay for plasticity. During 
wakefulness and SD Bdnf, Ngfi-a, Arc, p-creb and other signalling molecules are 
highly expresses in the brain (Cirelli and Tononi 2000a). Rarb has been shown to be 
involved in dopaminergic pathways and thus increased during time awake (Maret et 
al. 2005). Dopamine receptors, such as Drd2, are also abundantly expressed in the 
central nervous system, and involved in many neurological processes, including 
maintenance of wakefulness (Lena, et al. 2005). Whether Rarb and Drd2 are affected 
by SD has, to my knowledge, not been examined. Additionally, H om erla  and 
Nipsnapl have been shown to be expressed in the mouse brain and involved in 
synaptic potentiation as well as other processes. The expression of H om erla  has been 
shown to be elevated during SD, while Nipsnapl expression was downregulated 
(Maret, et al. 2007).
During sleep, an increase in proteins involved in synthesis of complex 
macromolecules has been observed (Mackiewicz et al. 2007). Wakefulness, on the 
other hand, is associated with transcription control of and later with and increase in 
cellular stress, as marked by an increase in the expression of heat-shock proteins and 
chaperones, such as HspaS, Hspa9, Hspdl (Cirelli and Tononi 2000b; Mackiewicz et 
al. 2007).
Additionally, chronic sleep restriction and also acute sleep deprivation have been 
shown to play a role in health outcomes of individuals, by affecting individuals’ 
immune response (Bom et al. 1997; Irwin et al. 1996) resulting in changed levels of 
inflammatory markers such as IL ip  (interleukin 1 (3), IL6, TNFa, as well as INFy,
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CRP, and NFkB, to name but a few (Everson 2005; Irwin et al. 2006; Irwin et al. 
2008; van Leeuwen et al. 2009). Impaired sleep has been linked to diabetes mellitus 
(Gottlieb, et al. 2005), high blood pressure (Prinz 2004), coronary heart disease 
(Ayas, et al. 2003), and obesity (Taheri, et al. 2004).
4.2 Aims
The aim o f this study was to examine how acute SD influences gene expression of 
selected genes in peripheral blood samples collected 3-hourly, and to examine how 
increased homeostatic sleep pressure (through restricted sleep opportunity) affects 
gene expression profiles of selected genes during SD, compared to when homeostatic 
pressure was low (through extended sleep opportunity).
4.3 Hypothesis
• Expression of neuronal plasticity-related genes {BDNF, NTRKB, DRD2, 
RARE) will increase during SD.
• Expression of immune response-related genes {TNFa, IL lp , IL6, CRP, INFy) 
will increase during SD, and will be higher after SR compared to SE.
• Cellular stress response genes {HSPA5, HSPA9, HSPD1, PDIA4, SGK1) will 
increase during SD, and will be higher after SR compared to SE.
• Metabolism-related genes {SLC2A1, NDUFV2) will increase during time of 
spontaneous wakefulness, but will decrease when SD is prolonged.
• Expression of HOMERla, NIPSNAP1, and NFkB I  will increase during SD.
4.4 Methods
4.4.1 Protocol
All 26 volunteers took part in the laboratory study. Volunteers were recruited and 
screened as described in section 2.2, and genotyped as detailed in section 2.6. Their 
habitual sleep-wake schedule was assessed as described in section 2.3. Volunteers 
spent a total of 11 days in the Clinical Research Centre of the University of Surrey
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and underwent two sleep-wake cycles of baseline sleep, 7 sleep-wake cycles of 
extended (10 h) or restricted (6 h) sleep opportunity, followed by approximately 40 
hours of CR, as described in section 2.4. During the CR period, samples for assessing 
plasma melatonin levels, as well as whole blood gene expression, were collected 
hourly and 3-hourly, respectively, as described in section 2.5.
4.4.2 Samples
RNA was extracted from the blood samples as described in the section 2.7, and 
quantified spectrophotometrically as detailed in 2.8. The quality of the extracted RNA 
was determined using microfluidic technology as described in section 2.9. 
Microarrays were prepared as described and referenced in section 2.10. The quality of 
the microarray data was checked and normalised as described in section 2.12.2.1 and 
2.12.2.2, respectively.
4.4.3 Expression profiles o f selected genes
Expression profiles o f selected sleep and SD-related genes were prepared as described 
in section 2.12.2.3. The effect of time and condition were computed as detailed in 
section 2.12.2.4. Using PROC NLIN (in SAS 9.1), a non-linear regression procedure, 
a sine function was fitted to the expression data for each subject. A time series was 
considered rhythmic if the 95% confidence interval of the fitted amplitude did not 
include 0. The probes detecting these genes are listed in Table 4.1.
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Protein name Gene symbol Probe name
Brain derived neurotrophic
factor BDNF A_32_P7316 
A_23_P127891
C-reactive protein CRP A_24_P342484
Dopamine D2 receptor DRD2 A_24_P283834
Homer protein homolog 1 HOMER1 A_23_P41917
Heat shock 70kD protein 5 HSPAS A_24_P98411
A_24_P18190
Heat shock 70kDa protein 9B HSPA9 A_24JP77676
Heat shock 60kDa protein 1 HSPD1 A_32_P25273
A_32_P76091
Interferon y IFNy A_23_P151294
Interleukin 1(3 ILip A_23_P79518
Interleukin 6 1L6 A_23_P71037
NADH dehydrogenase
(ubiquinone) flavoprotein 2 NDUFV2 A_23_P130418
Nuclear factor kB2 NFkBI A_23_P202156
Protein NIPSNAP homolog 1 NIPSNAP1 A_24_P237278
Neurotrophic tyrosine kinase,
receptor, type 2 NTRKB A_24_P343559 
A_23_P216779 
A_24_P415195
Protein disulfide-isomerase A4
precursor PDIA4 A_23_P42802
Retinoic acid receptor (3 RARB A_23_P71699
Serum/glucocorticoid regulated
kinase 1 SGK1 A_23_P19673
Solute carrier family 2,
facilitated glucose transporter
member 1 SLC2A1 A_23_P571
Tumour necrosis factor a TNFa A_23_P376488
A_24_P50759
Table 4.1 Sleep- and SD-related genes used in analysis and their respective Agilent probe names 
and proteins.
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4.5 R esults
4.5.1 Expression profiles of sleep and SD related genes during sleep 
deprivation
The expression profiles o f  19 genes hypothesised to be expressed in peripheral blood 
and involved in m aintaining or coping w ith w akefulness and SD in hum ans w ere 
exam ined in peripheral w hole blood sam ples. The expression profiles obtained after 
SE and SR w ere m erged for this part o f  the analysis. M ixed m odel analysis w as used 
to com pute effect o f  tim e on m RN A  levels. Sam ples w ere collected 3-hourly from 
volunteers during sleep deprivation. Four groups w ere identified: genes w hose m RN A  
levels w ere not detected in blood sam ples, genes which w ere not affected by sleep 
deprivation, genes upregulated, and genes dow nregulated during sleep deprivation.
4.5.1.1 Detection of sleep and SD related genes in peripheral blood 
samples
Seven o f  the selected transcripts (for genes D RD 2, RARB, BD N F, and N TR K B ) could 
not be detected in the blood sam ples.
4.5.1.2 Genes not affected by sleep deprivation
The expression levels o f  three genes, CRP, IL6, and IFNy, w ere not affected by sleep 
deprivation in our study. The effect o f  tim e, as determ ined by m ixed m odel analysis, 
on these expression profiles w as not significant F igure 4.1.
CRP (A_24_P342484)2
1
0
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18 21 0 3 6 9 12 15 18
IFNy (A_23_P151294) IL6 (A_23_P71037)
18 21 0 3 6 9 12 15 1i
Clock time
18 21 0 3 6 9 12 15 1i
Clock timeClock time
Figure 4.1 Gene expression profiles not affected by sleep deprivation.
Effect o f  tim e was com puted in SAS using m ixed-m odel analysis. All expression levels w ere z- 
transform ed and plotted against clock time. Error bars show  standard error.
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4.5.1.3 Genes upregulated during sleep deprivation
Three genes in our study w ere upregulated as a consequence o f  subjecting volunteers 
to sleep deprivation. These w ere: N F kB, TNFa, and SGK1  and their expression 
profiles are show n in Figure 4.2.
NFkB2 (A_23_P202156)
P < 0 .0001
2  -1
Q--2
Clock time
SGK1 (A_23_P19673)
P < 0 .0001
TNFa (A_24_P50759)
P < 0 .0 0 0 1
18 21 0 3 6 9 12 15 16
Clock time
18 21 0 3 6 9 12 15 16
Clock time
Figure 4.2 Gene expression profiles of genes upregulated during sleep deprivation.
Effect o f  tim e w as com puted in SAS using m ixed-m odel analysis, only sleep and SD related genes 
show ing significant effect o f  tim e are presented. All expression levels w ere z-transform ed and plotted 
against clock time. E rror bars show  standard error; P =  the significance levels o f  the effect, P < 0.05 
w as considered significant.
4.5.1.4 Genes downregulated during sleep deprivation
Expression levels o f  nine transcripts (for genes HSPA9, H SPAS, H SPD 1, PD IA4, 
N D U FV2, H O M ER1, N IPSN AP, and SLC 2A1) w ere dow nregulated in blood during 
sleep deprivation (Figure 4.3).
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Figure 4.3 Gene expression profiles downregulated during sleep deprivation.
E ffect o f  tim e w as com puted in SAS using m ixed-m odel analysis, only sleep and SD related genes 
show ing significant effect o f  tim e are presented. All expression levels w ere z-transform ed and plotted 
against clock tim e. E rror bars show  standard error; P = the significance levels o f  the effect, P <  0.05 
w as considered significant.
4.5.1.5 Genes expressed in a circadian m anner during sleep deprivation
I L ip  was the only gene found to be expressed in a circadian m anner. U sing PRO C 
N L IN  (in SAS 9.1), a non-linear regression procedure, a sine function w as fitted to 
the expression data for each subject. A tim e series w as considered rhythm ic if  the 
95%  confidence interval o f  the fitted am plitude did not include 0. Its expression 
profile is shown in Figure 4.4.
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Figure 4.4 The only gene expressed in a circadian manner.
Expression levels w ere z-transform ed and plotted against clock tim e. E rror bars show  standard error; P 
= the significance levels o f  the effect o f  tim e, P < 0.05 w as considered significant.
4.5.2 Effect of prior sleep (sleep condition) on expression profiles during 
sleep deprivation
V olunteers w ere subjected to either extended (10 h) or restricted (6 h) nightly sleep 
opportunity  for 7 consecutive nights prior to undergoing total sleep deprivation, in a 
cross-over design. The effect o f  extended and restricted sleep prior to sleep 
deprivation on m RN A  levels w as exam ined using m ixed m odel analysis in SAS.
4.5.2.1 Gene expression levels higher after extended sleep opportunity 
prio r to sleep deprivation
TNFa  and I L ip  m RN A levels during sleep deprivation w ere significantly  h igher 
follow ing 7 nights o f  extended, com pared to restricted sleep opportunity (Figure 4.5).
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Figure 4.5 Effect of sleep condition ( •  extended, o restricted) on expression levels of sleep and SD 
related genes during sleep deprivation, where expression was increased after extended sleep prior 
to CR.
Effect o f  condition w as com puted in SAS using m ixed-m odel analysis. Only sleep and SD related 
genes show ing significant effect o f  condition are presented. All expression levels w ere z-transform ed 
and plotted against clock time. E rror bars show  standard error; P = the significance levels o f  the effect, 
P < 0.05 w as considered significant. * = significant post hoc differences betw een conditions per tim e 
point w ere identified using differences o f  least squares m eans (p < 0.05 w as considered significant).
4.5.2.2 Gene expression levels higher after restricted sleep opportunity 
prio r to sleep deprivation
M RSA W f, m T W ,  and m R N A  levels
w ere significantly  higher during sleep deprivation follow ing 7 nights o f  sleep 
opportunity restricted to 6 h, com pared to follow ing 7 nights o f  10-h sleep 
opportunity, as show n in F igure 4.6.
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Figure 4.6 Effect o f sleep condition ( •  extended, o restricted) on expression levels of sleep and SD 
related genes during sleep deprivation, where expression was increased after restricted sleep 
prior to CR.
E ffect o f  condition w as com puted in SAS using m ixed-m odel analysis. Only sleep and SD related 
genes show ing significant effect o f  condition are presented. All expression levels w ere z-transform ed 
and plotted against clock time. E rror bars show  standard error; P = the significance levels o f  the effect, 
P <  0.05 w as considered significant, * =  significant post hoc differences betw een conditions per time 
point w ere identified using differences o f  least squares means (p < 0.05 w as considered significant).
4.6 Discussion
4.6.1 G ene expression  profiles
4.6.1.1 Genes whose expression could not be detected in blood
B D N F  and its receptor N TR K B  are prim arily involved in neurogenesis in the central 
and peripheral nervous system  (H uang and R eichardt 2001). B D N F  has been show n to 
be expressed and the protein secreted by im m une cells (T cells, B cells and 
m onocytes) in blood (K erschensteiner, et al. 1999), while N TR K B  has been show n to 
be expressed by stim ulated peripheral blood m onocytes (B esser and W ank 1999).
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BDNF  and NTRKB have also been shown to be expressed in other peripheral tissues. 
BDNF  has been found to be expressed in the retina (Perez and Caminos 1995) and 
prostate (Mirabella, et al. 2006). BDNF and NTRKB have been found in human saliva 
(Mandel, et al. 2009). Both transcripts have also been shown to be upregulated during 
spontaneous wakefulness and SD in rat brain (Cirelli and Tononi 2000a). BDNF 
mRNA has thus been shown to be expressed in blood preparations of healthy 
volunteers (Lee and Kim 2010) so the lack o f expression of BDNF  and its receptor 
NTRKB in our samples was unexpected.
Dopamine receptors, such as DRD2 are abundantly expressed in the central nervous 
system, and involved in many neurological processes. It has been demonstrated that 
the DRD2 plays an important role in the maintenance of wakefulness, as DRD2 KO 
mice were not able to remain awake for as long as their wild type littermates (Qu, et 
al. 2010). The DRD2 receptor has also been shown to be involved in haemodynamics 
o f the peripheral vasculature (Zhao, et al. 1990), as well as expressed on several 
leukocyte subpopulations (McKenna, et al. 2002). This led to the hypothesis that 
changes in DRD2 mRNA levels in whole blood samples would be detected. This was 
not the case, and DRD2 expression in the collected blood samples was not detected. 
Similarly, other groups could not detect DRD2 mRNA expression in leukocytes (Vile 
and Strange 1996). RARB is also involved in dopaminergic pathways, as well as 
determines the contributions of delta oscillations to the sleep EEG (Maret et al. 2005). 
RARB mRNA was also not expressed in whole blood samples.
4 6.1.2 Immune response related genes
Sleep deprivation and sleep debt have been shown to play a mayor role in inducing 
health problems o f various origins; diabetes mellitus (Gottlieb et al. 2005), high blood 
pressure (Prinz 2004), coronary heart disease (Ayas et al. 2003), and obesity (Taheri 
et al. 2004). The exact mechanisms by which decreased levels of sleep duration might 
impact human health are not clear. Several studies suggest that altered sleep durations 
may result in elevated cytokine levels known to play a role in regulating 
inflammation. In laboratory settings SD has been shown to elevate cytokine levels 
including CRP (Meier-Ewert et al. 2004; van Leeuwen et al. 2009), IL ip , IL6, and
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TNFa (Irwin et al. 2006; Pandey and Kar 2011). However, several other studies 
showed no effect o f sleep debt or sleep restriction on expression of the inflammatory 
genes CRP (Taheri, et al. 2007), IL6  and TNFa (van Mark, et al.).
Here, sleep deprivation expression profiles of 5 immunity related genes were 
examined. IL6, IFNy and CRP were not affected by sleep deprivation (Figure 4.1), 
TNFa was upregulated (Figure 4.2), while IL lfi was shown to be expressed in a 
circadian manner and upregulated as a cause o f SD (Figure 4.4).
TNFa is a cytokine mainly produced by activated macrophages and is involved in 
inflammatory immune response. Sleep deprivation and sleep debt have been shown to 
cause an elevation in cytokine production but several studies also show that the 
cytokines and the immune system are not affected by lack of sleep. In the present 
study it has been demonstrated that TNFa expression in peripheral whole blood was 
enhanced after prolonged wakefulness. Additionally, TNFa expression did not 
increase until the second day of SD and continued to rise until the SD protocol had 
come to an end. Surprisingly, the levels of expression during sleep deprivation were 
higher after extended compared to restricted sleep opportunity (Figure 4.5). This was 
not expected, as additional lack o f sleep during restricted sleep prior to sleep 
deprivation was expected to enhance the immune response.
IL6 has been shown to be upregulated by short term sleep deprivation (Irwin et al.
2006) as well as prolonged sleep restriction (Haack, et al. 2007). It was therefore 
surprising to find no effect on IL6 expression levels, neither by sleep deprivation, nor 
by sleep restriction. Although some reports show that IL6 expression was not related 
to poor sleep as assessed by the PSQI questionnaire (Okun, et al. 2009; van Mark et 
al. 2010), the main limitation of these studies is the infrequent sampling, mostly 
limited to one or two time points. Elevated cortisol levels have been shown to inhibit 
cytokine production. It may be possible, therefore, that cytokines in our study (IL6, 
TNFa) were indeed affected by the rise in cortisol production, and their levels did not 
rise or did not rise as vigorously as expected.
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IL ip  is a pro-inflammatory cytokine, known to be upregulated after infections, rather 
than SD or SR per se (van Leeuwen et ah 2009). In the study at hand it has been 
shown that IL lfl is rhythmically expressed both after SR and SE condition (Figure 
4.5). This was unexpected and should be explored further. The level o f mRNA 
expression was higher after SE compared to SR (Figure 4.5), which was unexpected. 
In any case, the levels of IL lp  mRNA rises towards the end of the CR protocol to a 
level exceeding that recorded at the beginning of sampling. Expression levels o ïIL lf i  
thus show an elevated expression as a result of SD. This finding is in accordance with 
the literature, reporting rising IL lfi levels after lack of sleep.
CRP is a hepatocyte protein involved in the protein response to an inflammatory 
stimulus (acute-phase response). In the liver, the expression of CRP is under the 
influence of IL6, and also ILlf} and TNFa (Castell, et al. 1990). In healthy individuals, 
the blood levels of CRP have been shown to be very stable (Meier-Ewert, et al. 2001). 
In our study, no effect o f either SD (Figure 4.1) or SR on the expression levels of 
CRP in blood was found. This was unexpected to a certain extent as CRP is a positive 
acute-phase response protein, meaning that its levels increase in response to infections 
or other trauma. However, CRP is under the influence of IL6, and no change in 
expression of IL6 was found either.
4.6.1.3 Cellular stress response
Extended wakefulness and SD have been shown to lead to cellular stress, including 
stress of the endoplasmic reticulum (ER) (reviewed in Mackiewicz, et al. 2009). This 
triggers the unfolded protein response (UPR). UPR is an adaptive response to stress in 
the ER and helps restore ER function by inducing the expression o f several heat shock 
proteins and chaperones (Kaufman 2002; Kozutsumi, et al. 1988). This increases the 
ER capacity for correct folding, as well as the degradation of misfolded proteins. The 
expression of genes coding for heat shock proteins and chaperones (HSPA9, HSPA5, 
HSPD1, and PDIA4) have previously been shown to be upregulated by wakefulness 
and lack of sleep (Cirelli and Tononi 2000b; Maret et al. 2007). Surprisingly, in the 
current study, these genes were upregulated during wakefulness, but were all 
downregulated during SD (Figure 4.3). However, in the published studies showing
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elevated levels of heat shock protein and chaperone expression, the studies compared 
wakefulness and SD to sleep. Although the expression levels were higher during SD 
compared to wakefulness and sleep, only one time point was usually analysed. This 
makes it difficult to compare these findings to our 24-hour expression profiles. Also, 
in our study, the sampling for expression profiles began in the afternoon after the 
volunteers had been awake since morning. Therefore, there is a paucity of data 
relating to wakefulness, but rather mostly to SD. Unfortunately, no material was 
collected while the volunteers were asleep. Our findings were thus in contrast to our 
expectations.
In our study the expression levels of HSPA9, HSPA5 and HSPD1 were all higher 
during SD following a protocol o f SR compared to SE (Figure 4.6). These findings 
suggest that chronic lack of sleep in the form of SR, never the less, increased gene 
expression of the heat shock proteins and chaperones. These results potentially point 
to the previously observed fact that chronic sleep restriction, resulting in elevated 
sleep pressure is more stressful and more damaging than acute sleep deprivation.
SGK1 codes for a serum/glucocorticoid regulated kinase 1 involved in the cellular 
stress response. Elevated levels of SGK1 mRNA have been linked to high blood 
pressure and diabetic nephropathy. Extended periods o f wakefulness and sleep 
deprivation have also been shown to increase SGK1 protein levels in the rat cerebral 
cortex (Cirelli et al. 2009). Lack o f sleep induces stress through the HPA 
(hypothalamic-pituitary-adrenal) axis (Gip, et al. 2004). When sleep deprivation in 
mice was no longer accompanied by the corticosterone surge seen in SD (stress 
response), several genes including SGK1 were no longer affected by SD (Mongrain, et 
al. 2010). Our findings show that SGK1 was indeed upregulated in volunteers as sleep 
deprivation accumulated (Figure 4.2). Expression levels of SGK1 were also increased 
after sleep restriction compared to sleep extension (Figure 4.6). This finding 
additionally confirms that the surge in SGK1 levels was most likely due to the stress 
endured by the volunteers during extended lack o f sleep.
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4.6.1.4 Energy metabolism
Wakefulness is accompanied by elevated energy demands, and thus enzymes involved 
in energy metabolism were hypothesised to be expressed at a higher level. Two genes 
involved in metabolism were investigated. NDUFV2 is a NADH dehydrogenase 
subunit involved in the respiratory chain in the mitochondria and SLC2A1 codes for a 
glucose transporter protein responsible for transporting glucose from the blood to the 
neurons and glia cells (Bell et al. 1990).
The expression of mitochondrially encoded enzymes has been shown to be increased 
after 3 hours o f wakefulness, but return to baseline levels after 8 hours (Cirelli 2002). 
NDUFV2 expression was downregulated during extended periods of SD (Figure 4.3), 
and not affected by prior sleep history. A slight peak in expression was detected in the 
early hours o f the morning (at around 0300h), so possibly the expression o f NDUFV2 
was indeed upregulated, albeit within a different time frame, during the initial hours 
of wakefulness, but returned to baseline after SD was prolonged. This is in 
accordance with the published literature (Cirelli 2002, 2006).
The demand for glucose is increased during wakefulness compared to sleep, and 
SLC2A1 as well as other genes involved in glucose metabolism are upregulated after 8 
hours of wakefulness and SD compared to sleep (Cirelli 2002). In contrast to 
published literature, SLC2A1 was found to be downregulated during the course o f SD 
(Figure 4.3). However, glucose metabolism was most likely increased by the lack of 
sleep obtained during the days prior to SD when volunteers’ sleep was restricted, as 
an increase in the expression o f SLC2A1 during SD after SR was observed, compared 
to when their sleep was extended (Figure 4.6).
4.6.1.5 Other genes
NIPSNAP1 is a gene of unknown function, but the protein has been shown to be 
involved in vesicular transport (Seroussi, et al. 1998) and calcium channel inhibition 
(Schoeber, et al. 2008). It has been found to be expressed in the post-synaptic density 
(PSD) of neurons (Satoh, et al. 2002), as well as in the mitochondria (Nautiyal, et al.
I l l
2010). NIPSNAP1 has been shown to be downregulated by wakefulness in mouse 
brain (Maret et al. 2007). NIP SNAP 1 was among the very few plasticity-related genes 
that were downregulated during wakefulness, according to the authors of this study. 
Our findings show NIPSNAP1 expression attenuated during SD in blood (Figure 4.3), 
which is in accordance with the published findings in the mouse brain (Maret et al.
2007). NIPSNAP1 expression was also increased after SR compared to SE, suggesting 
NIPSNAP1 expression might be under homeostatic, rather than circadian control 
(Figure 4.6).
HOMER proteins play a central role in Ca2+ signalling. They function as scaffolding 
proteins which couple surface receptors to intracellular Ca2+ release, and function as 
Ca2+ signalling buffers (Worley, et al. 2007). In the brain and also other tissues 
HOMER proteins are involved in the regulation of metabotropic glutamate receptor 
function through Ca2+ signalling and G-protein coupling (Xiao, et al. 1998). 
HOMERla, a short splice variant of HOMER1, has been shown to be involved in 
plasticity regulation and its expression has been shown to be induced by wakefulness 
and SD compared to sleep, in the mouse brain (Mackiewicz, et al. 2008; Maret et al. 
2007; Nelson, et al. 2004). The Agilent microarrays used in this study did not 
distinguish between HOM ERla  and other HOMER1 paralogues (HOMERlb and 
HOMERlc). The analysis was thus limited to HOMERL  Our findings suggest the 
opposite relationship in leukocytes to that reported in mouse brain, as HOMER1 was 
downregulated by SD (Figure 4.3). In neutrophil granulocytes, the most abundant 
leukocyte subpopulation, an increase in cytosolic Ca2+ precedes many proinflamatory 
activities, such as generation o f superoxide, adhesion to vascular endothelium, 
degranulation and so forth (Tintinger, et al. 2009). As HOMER1 is involved in Ca2+ 
signalling in different cell types it is possible it plays a similar role in leukocytes. As 
an inflammatory response was not observed during SD, it is perhaps not surprising 
that HOMER1 expression was downregulated in our study. Additionally, HOMER1 
expression was higher after SR compared to SE (Figure 4.6), suggesting that 
leukocyte HOMER1 levels could be regulated by the homeostatic rather than 
circadian process. Although this finding would have most prominent consequences in 
the brain, it is difficult to speculate whether the findings in leukocytes can be 
extrapolated to the brain.
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In the brain, both NIPSNAP1 and HOM ERla seem to be involved in synaptic 
plasticity which enables memory and learning. Both seem to function in the PSD; 
HOM ERla as a Ca2+ signalling molecule, while the function of NIPSNAP1 is not yet 
clear. In the brain their roles seem to be inversed; NIPSNAP1 is downregulated, while 
HOMER1 is upregulated during wakefulness and SD. However, the expression of 
both genes in leukocytes is downregulated during SD. In leukocytes Ca2+ signalling is 
required for differentiation and function (Cantrell 1996; Dolmetsch, et al. 1997; Esser, 
et al. 1998; Lewis 2001). TRP (transient receptor potential) channels are a group of 
ion channels permeable to various cations including Ca2+. Several o f the TRPC (TRP 
“canonical”), TRPV (TRP “vanilloid”), and one TRPM (TRP “melastatin”) channel 
have been identified in some of the leukocyte subtypes (Heiner, et al. 2003; Matza 
and Flavell 2009). NIPSNAP1 has been shown to be involved in regulation o f TRPV6 
channels (Schoeber et al. 2008) and HOMER 1 in gating of TRPC channels (Yuan, et 
al. 2003). Based on this a speculation could be made, that both NIPSNAP1 and 
HOMER 1 may be involved in Ca2+ signalling in leukocytes, but additional work 
would have to be carried out in order to confirm this.
NFkB is a transcription factor activated by various stimuli such as cytokines, reactive 
oxygen species (ROS) and bacterial products. NFkB activates the expression o f many 
genes implicated in many different processes, including cellular stress response (Ali 
and Sultana 2012), immune response (Cardozo, et al. 2001; Raymond, et al. 2007) and 
metabolism. It has already been shown that NFkB  expression is induced in human 
blood samples after partial sleep deprivation (Irwin et al. 2008). Here, this finding has 
been confirmed, as NFkB  expression was upregulated in volunteer’s blood when 
wakefulness turned to SD. NFkB is involved in many processes; TNFa regulates 
NFkB  (de Wit, et al. 1998), and NFkB  regulates TNFa (Schreiber, et al. 2006). 
Although SD affected the expression of both, it is difficult to say exactly whether the 
elevated levels of NFkB  mRNA affect the expression o f other genes (directly or 
indirectly), such as ILlf}, TNFa, and IL6, or whether SD caused enhanced activity of 
the immune system and upregulation of its genes and then these affect the expression 
of NFkB. The expression of NFkB and TNFa are both affected by SD as their 
expression was elevated during SD. However, based on our data, it appears that INFy
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and IL6 are no co-regulated with NFkB, as their expression over the course o f SD 
remained constant.
4.7 Conclusion
Here it was shown that not all inflamaotry markers are increased during sleep 
deprivation; only TNFa expression was elevated during acute sleep deprivation, while 
CRP, INFy and IL6  expression were not affected. ILp was expressed in a rhythmic 
manner suggesting some parts o f the immune system might be under circadian 
control. Genes involved in metabolism and cellular stress response were upregulated 
during wakefulness, but not during sleep deprivation. Althought opposing expression 
profiles have previously been reported for HOMER1 and NIPSNAP1 in rodent brain, 
in human blood we show that their expression was downregulated during sleep 
deprivation.
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5 PER3 VNTR genotype-dependent differential 
gene expression
5.1 Introduction
The PER3 coding-region VNTR polymorphism was first identified by Ebisawa et al 
(2001). The shorter PER34 allele has been reported to be associated with DSPD 
(described in 1.1.4) and evening preference, while the longer PER35 allele is 
associated with morning preference (Archer et al. 2003; Jones et al. 2007; Lazar et al. 
2012). A chronotype association was also found in a Brazilian population, however, 
the association with DSPD was found in PER35/5 homozygotes instead (Pereira et al. 
2005). The phase of PER3 mRNA expression in human leukocytes in PER3S/5 
homozygotes has been shown to be correlated with the timing of sleep and 
wakefulness (Archer et al. 2008).
PER35/5 homozygotes have been shown to live under a greater homeostatic sleep 
pressure compared to PER34/4 homozygotes, and to be more vulnerable to a night of 
sleep loss (Groeger et al. 2008; Viola et al. 2007). Compared to PER34/4 
homozygotes, PER3S/5 homozygotes displayed a reduction in activation in several 
brain regions as determined by fMRI in the morning after a night of sleep loss 
(Vandewalle et al. 2009). However, sleep restriction did not differentially affect sleep 
structure, sleepiness, and cognitive and executive function of individuals carrying the 
PER34/4, PER34/s, and PER3S/5 genotype in an investigation that did not control for 
circadian phase (Goel, et al. 2009). The evening rise in melatonin levels has been 
shown to be suppressed by blue-enriched light in PER35/5 homozygotes and their 
sleepiness (as measured by EEG theta activity) was attenuated, compared to PER34/4 
homozygotes (Chellappa et al. 2012). Homozygosity for the long PER3 allele has also 
been shown to correlate with an advanced phase in the circadian melatonin profile in 
older people (Viola, et al. 2012)
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The longer PERS allele has been shown to be associated with higher serum levels of 
insulin like growth factor I (Chu et al. 2008). PER34/4 homozygotes have been shown 
to have lower IL6 concentrations compared to PER35/5 homozygotes when samples in 
a population of patients suffering from either fatigue, depressive symptoms, or sleep 
disruption (Guess et al. 2009). The longer PER3 allele has also been shown to be 
associated with breast cancer development, even more so in pre-menopausal women 
(Zhu et al. 2005).
PER3 in particular VNTR genotype has also been shown to be associated with the 
onset of bipolar disorder (Nievergelt et al. 2006). PER3S/5 homozygotes have been 
shown to be prone to an earlier onset of bipolar disorder than PER34/4 homozygotes 
(Benedetti et al. 2008), and are more prone to post partum  onset of bipolar disorder 
(Dallaspezia et al. 2011).
5.2 Aims and hypothesis
The aim was to identify genes which were differentially expressed between the two 
homozygous PER3 VNTR genotypes. It was hypothesised that genes in peripheral 
blood samples will be differentially expressed between the PER34/4 and PER35/5 
homozygotes.
5.3 Methods
5.3.1 Protocol
All 26 volunteers (12 PER34/4 and 14 PER35/5) took part in the laboratory study. 
Volunteers were recruited and screened as described in section 2.2, and genotyped as 
detailed in section 2.6. Their habitual sleep-wake schedule was assessed as described 
in section 2.3. Volunteers spent a total of 11 days in the Clinical Research Centre of 
the University of Surrey and underwent two sleep-wake cycles o f baseline sleep, 7 
sleep-wake cycles of extended (10 h) or restricted (6 h) sleep opportunity, followed by 
approximately 40 hours of CR, as described in section 2.4. During the CR period, 
samples for assessing plasma melatonin levels, as well as whole blood gene
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expression, were collected hourly and 3-hourly, respectively, as described in section 
2.5.
5.3.2 Samples
RNA was extracted from the blood samples as described in the section 2.7, and 
quantified spectrophotometrically as detailed in 2.8. The quality of the extracted RNA 
was determined using microfluidic technology as described in section 2.9. 
Microarrays were prepared as described and referenced in section 2.10. The quality of 
the microarray data was checked and normalised as described in section 2.12.2.1 and
2.12.2.2, respectively.
5.3.3 Identification of differentially expressed genes between the two 
PER3  genotypes
The entire gene expression data set (both conditions and all subjects) was used to 
identify genes which showed genotype-dependent difference in expression. Two 
approaches were employed; ANOVA and a model fitting approach. Usually, several 
probes coded for one gene. Therefore, the analysis was carried out per probe.
5.3.3.1 ANOVA
To compute the effect of genotype on the expression levels of probes, repeated 
measurements ANOVA was used to model the expression of each probe. Factors used 
were genotype (PER34/4, PER3S/5), condition (sleep extension (SE), sleep restriction 
(SR)), and time. Random factor was subject. The analysis was done in statistical 
environment R.
5.3.3.2 Model fitting
This approach was developed by Storey et al (2005), and it is designed specifically for 
time series analysis and for identifying temporal changes in gene expression. The null 
hypothesis postulates that all data can be described by a single model and the 
alternative hypothesis postulates that there exists two different groups in the data and
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are best modelled independently. In our data, the null hypothesis model was obtained 
by fitting a function to the expression data for PER34/4 and PER35/5 combined. The 
alternative hypothesis was obtained by fitting a function to expression data for each 
genotype independently. Goodness o f fit (sum of squares of the residuals) for the 
model under the null hypothesis was compared to that of the alternative hypothesis 
via an F-statistic (Storey et al. 2005)
5.3.4 Analysis o f differentially expressed genes between the two PER3 
genotypes
A list of probes showing an effect o f genotype on expression profiles during the CR 
for each condition was obtained from each method. The probes obtained by the 
ANOVA method were ranked according to significance (p). The highest ranking 
probes identified by ANOVA were selected and their expression profiles were plotted 
(Methods section 1.13.2.1). The list of probes obtained using the model fitting 
approach was ranked according to the gap between the 95% confidence intervals in 
the two genotypes.
5.4 Results
5.4.1 Identification of differentially expressed genes between the two 
PER3 genotypes using ANOVA
Using repeated measurement ANOVA a list o f genes showing effect of PER3 VNTR 
genotype was produced. The full list o f probes for each condition can be found in 
Appendix I and Appendix J. Twenty differentially expressed genes, showing the 
greatest significance, identified by ANOVA, when the expression data from both 
conditions were merged, are listed Table 5.1.
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Gene name Agilent probe name
Fold change
(PER34MIPER3S/S)
p-value
NPDC1 A_23_P146572 -0.53 8.56x1 O'23
AF063695 A_24_P465799 -0.66 6.34 xlO"14
A_24_P400690 A_24_P400690 0.35 5.03 xlO'13
CLDN5 A_23_P6321 -0.38 1.97 xlO'12
LGALS9 A_23_P116557 0.35 3.09x10"
A_23_P3083 A_23_P3083 -0.35 2.47 xlO'10
C17orf59 A_23_P152955 -0.18 1.66x1 O'09
A_32_P194704 A_32_P194704 -0.27 2.75 xlO'09
NOXA1 A_23_P254353 0.22 3.46 x l0 ‘°9
HEXIM2 A_23_P377214 -0.19 8.22 xlO"09
TUBA1C A_24_P188071 -0.16 1.97x1 O'08
C16orf7 A_23_P129476 0.20 3.59 xlO"08
HYAL2 A_23_P57927 0.15 3.68 xlO'08
JUN A_23_P201538 -0.20 3.80 xlO'08
ST13 A_23_P68949 0.21 5.20 xlO"08
AASDHPPT A_24_P184230 -0.12 5.67 xlO"08
PDP1 A_23_P123336 -0.16 7.91 xlO'08
A_24_P298029 A_24_P298029 -0.14 3.45 xlO"07
LEPROT A_23_P1126 0.16 1.04 xlO"06
CDK5RAP2 A_23_P83110 -0.13 1.27 xlO"06
Table 5.1 Differentially expressed probes between the PER3 homozygotes with the lowest
pvalues, identified by ANOVA.
Expression data from both conditions (SE and SR) were merged.
5.4.1.1 Gene expression elevated in PER3S/5 homozygotes during CR
For some of the genes expression profiles were plotted across time. The expression of 
NPDC1, AF063695, CLDN5, and was higher in PER35/5 compared to PER34/4 
homozygotes. The expression profiles are shown in Figure 5.1 for each condition.
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Figure 5.1 Genotype dependent differentially expressed genes, as determined by repeated 
measure ANOVA and expressed at a higher level in PERS^ ( • )  compared to PER34/4 (o) 
homozygotes.
Error bars show  standard deviation, FC =  fold change, P = the significance levels o f  the effect, P < 0.05 
was considered significant, * = significant post hoc differences between genotypes per tim e point w ere 
identified using differences o f  least squares m eans (p <  0.05 w as considered significant).
5.4.1.2 Gene expression elevated in PER34 4 homozygotes during CR
Two genes {LG ALS9  and N O X A1) w ere found to be highly expressed in P E R 34 4 
hom ozygotes com pared to P E R 3So hom ozygotes. Both genes show ed a greater 
genotype difference after SR com pared to SE. T heir expression profiles are shown for 
each condition in Figure 5.2.
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Figure 5.2 Genotype dependent differentially expressed genes, as determined by repeated 
measure ANOVA and expressed at a higher level in PER344 (o) compared to PER33/3 ( • )  
homozygotes.
E rror bars show  standard deviation, FC = fold change, P = the significance levels o f  the effect, P < 0.05 
was considered significant, * = significant post hoc differences betw een genotypes per tim e point w ere 
identified using differences o f  least squares means (p < 0.05 w as considered significant).
5.4.2 Id en tifica tio n  o f d ifferen tia lly  expressed  genes betw een  th e  tw o 
P E R 3  genotypes using  a m odel fittin g  a p p ro ac h
Lists o f  probes identified to be d ifferentially  expressed betw een the tw o hom ozygous 
PER3  V N T R  genotypes w as produced for each condition. The full list can be found in 
A ppendix K and A ppendix L. The top 20 probes identified by m odel fitting are listed 
in Table 5.2 for SE and Table 5.3 for SR.
121
Gene name Agilent probe name
Fold change
(PER34/4IPER35/s)
Gap between 95%  
confidence intervals
TMEM176A A_23_P252082 2.29 1.60
TMEM176B A_23_P157007 2.41 1.52
BP418551 A_32_P117185 -2.29 0.91
GSTM5 A_24_P212021 -1.64 0.64
BP418551 A_24_P703642 -1.17 0.52
MEG3 A_24_P272993 -1.34 0.50
AJ697910 A_32_P76137 -1.28 0.47
ENST00000390271 A_24_P16004 -1.24 0.44
MAGED4B A_23_P159907 -0.86 0.43
KLRC2 A_23_P22232 -1.02 0.40
PAK2 A_23_P327307 -0.88 0.39
DSC1 A_23_P38696 1.11 0.36
HRASLS2 A_24_P364263 -1.03 0.35
HSD11B1 A_23_P63209 -1.07 0.34
BOD1L A_24_P931476 1.06 0.30
A_23_P159163 A_23_P159163 -0.79 0.26
BHLHE41 A_23_P139500 -0.79 0.26
A_24_P357847 -0.82 0.25
ITGA1 A_23_P256334 -0.68 0.25
A_24_P323298 A_24_P323298 -0.70 0.25
Table 5.2 Differentially expressed probes identified by model fitting approach in SE.
Probes are ranked in order o f greatest gap between the confidence intervals.
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Gene name Agilent probe name
Fold change 
(PER34/4IPER35/S)
Gap between 95%  
confidence intervals
TMEM176A A_23_P252082 2.30 1.56
TMEM176B A_23_P157007 2.44 1.50
BP418551 A_32_P117185 -2.44 0.99
A_23_P145724 1.69 0.67
BP418551 A_24_P703642 -1.22 0.52
MAGED4B A_23_P159907 -0.90 0.44
MEG3 A_24_P272993 -1.22 0.36
A_24_P519504 -1.12 0.33
A_23_P72252 A_23_P72252 -0.97 0.33
A_23_P84791 A_23_P84791 -0.99 0.33
LOC375010 A_32_P79190 -0.86 0.32
RASIP1 A_23_P119353 -1.18 0.31
AJ4_P323298 A_24_P323298 -0.76 0.30
A4K2 A_23_P327307 -0.82 0.30
DENND5B A_23_P366559 -0.68 0.30
EF178107 A_32_P51988 -0.72 0.28
KLRC2 A_23_P22232 -0.89 0.28
U21252 A_24_P608268 -0.76 0.28
BLK A_23_P31725 -0.61 0.25
LOCI 00132941 A_24_P161853 -0.73 0.25
Table 5.3 Differentially expressed probes identified by model fitting approach in SR.
Probes are ranked in order o f  greatest gap between the confidence intervals.
5.4.2.1.1 Gene expression higher in PER3S/S individuals during CR
Five transcripts were expressed at a higher level in PER35/5 individuals compared to 
PER34/4 individuals; MEG3, MAGED4B, KLRC2, PAK2, and GSTM5. Their 
expression profiles are compared between a single and two fitted models approach in 
Figure 5.3
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Figure 5.3Genotype dependent differentially expressed genes, as determined by model fitting and 
expressed at a higher level in PER355 (blue) compared to PER34 4 (red) individuals.
Expression is given in arbitrary units; L eft panels show n one model fitted to data; R ight panels show  
tw o distinct m odels fitted to data.
5.4.2.L2 Gene expression higher in PER34/4 individuals during CR
Expression profiles o f  two genes w hich displayed a higher expression in P E R 34/4 
com pared to P E R S ^5 hom ozygotes: TM EM 176A  and TM EM 176B. G enotype 
difference w as greater in SE com pared to SR condition for both probes. T heir 
expression profiles are com pared betw een a single and two fitted m odels approach in 
F igure 5.4.
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Figure 5.4 Genotype dependent differentially expressed genes, as determined by model fitting 
and expressed at a higher level in PER344 (red) compared to PER33/3 (blue) individuals (right 
panels).
Expression is given in arbitrary units; Left panels show n one m odel fitted to data; R ight panels show  
two distinct m odels fitted to data.
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5.5 Discussion
5.5.1 Immune function
Many o f the genes identified as highly differentially expressed between the 
homozygous PER3 genotypes are involved in immune function (AF063695, CLDN5, 
KLRC2, PAK2, LGALS9, NOXA1, TMEM176A, and TMEM176B). Additionally, P B K  
(phosphoinositide 3-kinase), CD22, BLNK  (B cell linker), and CALM1 (Calmodulin) 
were also identified in our list o f differentially expressed genes (Appendix K and 
Appendix L), which showed involvement in immune response and signalling.
Perhaps, to an extent, the finding that many of the genes identified as differentially 
expressed between the genotypes were involved in immune function is not surprising, 
considering the samples were collected from peripheral blood. When the data were 
split according to the genotype and were fed to a gene ontology software (MetaCore 
from GeneGo Inc, Thompson Reuters, New York, NY) for analysis, the pathway 
maps identified were related to immune function (data not shown). However, if  the 
same gene expression data obtained from leukocytes were analysed in the same way, 
but were divided in to two groups differentially expressed by gender, the pathway 
maps identified did not include immune response, but rather nitrogen metabolism and 
translation (not shown). This led us to believe that differences in immune function 
were valid and not an artefact of sampling tissue.
An additional challenge in studying gene expression in white blood cells presents the 
fact that the abundance of different cell sub-types has been shown to change over the 
24-h period (Bollinger, et al. 2009), and to be affected by sleep deprivation (Heiser, et 
al. 2000). Unfortunately, data on blood cell count was not collected, and so variations 
in cell numbers cannot be taken into account when interpreting these results.
5.5.1.1 Genes more highly expressed in PER3S/S homozygotes
B cells play a role in the humoral immune response, and are an essential component 
of the adaptive immune system. Their primary functions are to produce antibodies 
against antigens, to function as antigen-presenting cells themselves, and also to
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develop into memory B cells. Many of the identified differentially expressed genes 
showed involvement in B cell signalling and activation. CD22 is a lectin which 
functions as an important inhibitory co-receptor on B cells (Nitschke 2005) and 
modulates B cell receptor signalling via Ca2+-signalling (Doody, et al. 1995). CD22 
thus controls the signalling threshold of B cells and prevents B cell over stimulation. 
Mice deficient in CD22 display higher Ca2+ signalling in B cells, with higher basal 
activation and sensitivity to apoptosis (O'Keefe, et al. 1999; O'Keefe, et al. 1996). 
BLNK is a cytoplasmic linker protein involved in B cell development and signalling. 
It is involved in PLCy (phospholipase Cy) activation, through activation o f tyrosine 
kinases, which in turn leads to Ca2+ signalling and downstream processes affecting 
many biological functions (Fu, et al. 1998; Ishiai, et al. 1999; Kurosaki and Tsukada
2000). BLNK  mutations result in absent B cells and hypoglobulinemia. Calmodulin is 
a Ca2+-modulated protein and functions as a phosphorylase kinase 5. It functions as an 
intermediate messenger protein that relays Ca2+ signals. In this way, calmodulin is 
involved in a vast array of functions; inflammation, apoptosis, metabolism, memory 
and immune response (Jones, et al. 1989). In B cells it relays the Ca2+ signal from the 
IPs (inositol 3-phosphate) receptor to calcineurin. PI3K are a family o f intracellular 
signal transducer enzymes capable of phosphorylating the 3-hydroxyl group of the 
inositol ring of phosphatidylinositol. PI3K plays a role stimulating the AKT signalling 
pathway. Through this pathway, PI3K also plays a role in other cell processes, such as 
proliferation (Weber, et al. 2011). AF063695 encodes an immunoglobulin variable 
lambda fragment produced by B-lymphocytes.
T cells play a role in cell-mediated immunity and can have different functions 
depending on their sub-type. They are involved in maturation and activation of other 
immune cells, destroy infected cells, store memory of past infections, and are crucial 
for maintaining immune tolerance, among others. PAK2 has been shown to be a 
positive regulator of T cell activation (Chu, et al. 2004), as well as being involved in 
cytoskeleton reorganisation (Goeckeler, et al. 2000; Zeng, et al. 2000). PAK2 has 
been shown to be activated by cellular stress such as DNA damage (Tang, et al. 1998) 
and hyperosmolarity (Roig, et al. 2000). It has also been shown to mediate 
morphological changes found during apoptosis (Rudel and Bokoch 1997), and has an 
anti-apoptotic role in fibroblasts (Jakobi, et al. 2001). IL6 is an interleukin secreted by
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macrophages and T cells in response to infections. It can act as a pro- or anti­
inflammatory cytokine, and inhibits TNFa production. It has been shown to be 
associated with various illnesses such as diabetes (Kristiansen and Mandrup-Poulsen
2005), depression (Dowlati, et al. 2010), Alzheimer’s disease (Swardfager, et al. 
2010) and types of cancer (Barton 2005). Intravenous administration of IL6 has been 
shown to result in increased SWS in humans, and volunteers reported more fatigue, 
felt more inactive and less capable o f concentrating, compared to volunteers receiving 
placebo (Spath-Schwalbe, et al. 1998). Similar findings have also been reported in 
serum concentrations of IL6, where PER34/S and PER35/5 homozygotes were found to 
have elevated levels compared to PER34/4 homozygotes (Guess et al. 2009).
NK cells are a third type of lymphoid cell, which rapidly respond to virally infected 
and tumour cells. KLRC2 is C-type lectin, located on chromosome 12 in a region 
called the NK complex, a region containing many C-type lectins expressed in NK 
cells. KLRC2 is mostly expressed by the NK cells (Bancroft 1993). Additionally, 
KLRD1, another C-type lectin, also located in the NK complex region, is also 
differentially expressed in our data. KLRD1 is an antigen preferentially expressed in 
NK cells. It forms complexes with KLRC1 and KLRC2 and has been implicated in 
major hostcompatibility complex (MHC) class I histocompatibility antigen (HLA)-E 
molecule recognition in NK cells (the complex on the surface of NK cells interacts 
with HLA-E on target cells). HLA-E is a non-classical MHC class I protein, 
expressed on the cell surface. The KLRC/KLRD1 complex recognises the antigen and 
the stimulation of the KLRC1 or KLRC2/KLRD1 complex results in an inhibitory or 
activating effect on the cytotoxic activity of the NK cells, respectively (Braud, et al. 
1998; Houchins, et al. 1997).
Taken together these findings suggest that genes involved in immune function, which 
were found to be expressed at a higher level in PER35/5 homozygotes, seem to be 
involved in lymphoid cell function (B cells, T cells, and NK cells), possibly 
suggesting that the cellular mediated and humoral immune system is more active in 
PER3S/5 homozygotes.
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5.5.1.2 Genes more highly expressed PER34/4 homozygotes
Dendritic cells (DC) are the most potent antigen-presenting cells, along with 
macrophages and B cells. They can be o f myeloid or lymphoid origin. In the blood 
they are found in an immature state. When they come in contact with a pathogen or 
other foreign particles they become activated and travel to the lymph nodes, where 
they interact and activate T and B cells to trigger an adaptive immune response. 
TMEM176A and TMEM176B have been shown to be downregulated during DC 
maturation, and overexpression resulted in maturation inhibition (Louvet, et al. 2005). 
They have also been shown to be highly expressed in tolerated transplanted allografts 
(Louvet et al. 2005), as well as in rejected allografts reinfected with hepatitis C, but 
not in acutely rejected allografts, possibly suggesting a role for both proteins in innate 
immunity (Gehrau, et al. 2011).
Phagocytes include neutrophils and monocytes, along with DCs, macrophages and 
mast cells. They are responsible for removing foreign particles from the body through 
phagocytosis. One method o f phagocytosis is by engulfing the foreign material, which 
is followed by a respiratory burst. A respiratory burst produces toxic reactive oxygen 
species which kill and destroy the engulfed material in the phagocyte. NOXA1 is a 
NOX1 activator, and works together with other proteins to regulate NOX1 as well as 
NOX2 activity. The NOX2 system was discovered in phagocytic cells where it plays a 
role in host defence against microbes, by producing respiratory bursts (Babior 1999; 
Thrasher, et al. 1994). Although NOXA1 primarily activates NOX1, it has also been 
shown to also moderately activate NOX2 (Kawano, et al. 2012). As NOX2 is 
expressed in phagocytes and vascular smooth muscle cells, it seems more likely that 
the NOXA1 expression identified in this study was due to the NOX2 system, rather 
than the NOX1. Genes expressed at a higher level in PER34/4 homozygotes thus seem 
to be involved in functions of phagocytosis and antigen-presentation.
Taken together there seems to be a difference in the immune function between the 
PER34/4 and PER35/S homozygotes, and perhaps these differences could also explain 
the elevated inflammatory cytokine secretion found in PER35/5 compared to PER34/4
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homozygotes (Guess et al. 2009), and a higher occurrence of breast cancer in PER35/S 
homozygotes (Zhu et al. 2005).
5.5.2 Circadian clock
5.5.2.1 Phosporylation / Déphosphorylation
Also identified as differentially expressed between homozygous PER3 genotypes in 
our list o f genes were two period genes; PER2 in SE, and PERI in SR condition. 
However, out of 22 PERI probes and 40 PER2 probes on the array, only two PERI 
and one PER2 probe were found to be differentially expressed. Although disruption in 
the molecular circadian clock has been shown to lead to multiple disorders, some of 
which have been shown to correlate with the PER3 VNTR genotype, the fact that 
custom designed PERIOD  paralogue probes had been added to the arrays can not be 
ignored. In addition to the two Agilent probes for each gene found on the array, we 
designed and printed an additional 20 and 38 custom probes for PERI and PER2, 
respectively. The abundance of probes targeting these two transcripts could result in 
probes appearing differentially expressed by chance alone.
In the molecular circadian clock, the PER protein is the rate-limiting component of 
the PER/CRY complex formation. The timing and duration of PER nuclear entry and 
accumulation sets the phase and period o f the molecular clock. PER phosphorylation 
kinetics have been shown to play a key role in temporal regulation of PER. CSNK1E, 
CSNK1D, GSK3P and other kinases have been shown to phosphorylate the PER 
proteins, and PP1, but not PP2A, have been shown to act as PER phosphatases (Lee, 
et al. 2011). In our study PP1 (protein phosphatase 1) (PP1R16A in SR) and PP2A 
(protein phosphatase 2) (PPP2R1B and PPP2R2B in both conditions, and PPP2R5C  
in SR only) genes have been identified as differentially expressed between the two 
genotypes, being expressed at a higher level in PER35/S homozygotes. These findings 
suggest that the phosphorylation mechanisms may be differentially regulated in the 
two PER3 homozygous genotypes.
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S.5.2.2 Chronotype
In Drosophila, PP2A is involved in PER phosphorylation, as reduction of PP2A 
activity has been shown to result in reduced PER expression in central neurones, 
resulting in long circadian periods and arrhythmia (Sathyanarayanan, et al. 2004). 
Additionally, Drosophila with reduced PP1 activity have been shown to exhibit an 
extended circadian period, reduced amplitude in behavioural rhythms, and an altered 
response to light (Fang, et al. 2007).
In a small scale screening study, kinase inhibitors were used to find changes in period 
length in vitro in rat fibroblasts, and thus identify novel protein kinases involved in 
circadian cycle regulation. Potential kinases identified were CSNK1E and CSNK1D, 
DRB, PI3K, INK, AKT, and MAPK (Yagita, et al. 2009). In Drosophila, CAMK has 
been shown to play a role in phosphorylation of the Drosophila BMAL1/CLOCK 
complex homolog, CYC/CLOCK (Weber, et al. 2006). CAMK (calcium/calmodulin- 
dependent kinase), PI3K (phosphoinositide-3-kinase, regulatory subunit), MAPK 
(mitogen activated kinase) and MAPKIP (MAPK interacting protein) have also been 
identified as differentially expressed between the two genotypes in our study. All of 
these are protein kinases involved in phosphorylation of clock proteins and hence 
involved in circadian clock regulation.
PI3K has been shown to phosphorylate and activate AKT1 (Scheid and Woodgett
2001), while protein phosphatases, such as PP2A, function as AKT inhibitors 
(Beaulieu, et al. 2005). AKT1 in turn, via phosphorylation, inhibits GSK3P (Frame, et 
al. 2001). GSK3{3 plays a key role in the circadian clock, as it phosphorylates and thus 
destabilises CRY2 (Harada et al. 2005) and BMAL1 (Sahar et al. 2010) resulting in 
their degradation, and phosphorylates and stabilises REV-ERBa (Yin et al. 2006). 
SGK3 has been linked to Alzheimer’s disease, diabetes, cancer, schizophrenia and 
bipolar mood disorder. The Drosophila homologue of GSK3P, SHAGGY (SGG), 
when overexpressed in pacemaker neurons results in a circadian period shortened by 
about 3h. Down regulation of Ssg results in lengthened period. It seems plausible that 
differential expression of PI3K and PP2A results in differential phosphorylation of 
some of the core clock proteins, leading to changes in period lengths, possibly
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resulting in pronounced chronotype differences, and their consequences. However, 
additional work would need to be done in order to determine the exact mechanism by 
which this is achieved.
5.5.3 Neurophysiology
PP2A is a major brain phosphoseryl/phosphothreonyl phosphatase, and it is believed 
to cause abnormal hyperphosphorylation o f the tau protein1 (Weingarten, et al. 1975). 
Other protein phosphatases (PP1 and PP2B) have also been shown to 
hyperphosphorylate tau in vitro (Gong, et al. 1995). The tau protein is a microtubule 
associated protein, which assembles and stabilises microtubules (Grundke-Iqbal, et al. 
1986). Hyperphosphorylation of tau results in neurofibrillary tangles and impaired 
axoplasmic flow, leading to progressive neurodegeneration. Diseases caused by 
neurodegeneration associated with the tau protein are called tauopathies, of which the 
best known is Alzheimer’s disease, but also include types of dementia, Down’s 
syndrome and others. Hyperphosphorylation o f tau is also a mechanism used by the 
neurons to downregulate their own activity, albeit to a much lesser extent than in 
Alzheimer’s disease, and, unlike in Alzheimer’s disease the process is transient and 
reversible. Hypothermia induced by anaesthesia or hibernation has been shown to 
result in hyperphosphorylation of tau. Hypothermia also results in downregulation of 
PP2A, believed to be the cause of abnormal tau hyperphosphorylation (Arendt, et al. 
2003; Planel, et al. 2007).
In our data, PP2A mRNA was differentially expressed between the two homozygous 
genotypes. However, the level of expression was lower in PER34/4 compared to 
PER35/s homozygotes. This was surprising, as previous studies have shown that in the 
early hours of the morning after sleep deprivation PER3S/5 homozygotes show 
reduction in activation in several brain areas, compared to PER34/4 (Vandewalle et al. 
2009).
1 The tau protein is in no connection to the intrinsic circadian phase, also sometimes referred to as t
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Dopamine, when bound to D2 receptors, has been shown to exert dephosporylation 
and hence deactivation of AKT via PP2A (Andjelkovic, et al. 1996). Reduction in 
AKT activity thus leads to GSK3(3 activation, which leads to phosphorylation 
dynamics of several clock genes as described above. It has been postulated that 
modulation in GSK3 activity could represent a core risk factor for increased 
susceptibility to psychiatric illnesses under certain genetic and environmental 
conditions (Beaulieu 2012). Based on models developed for cancer biology, where the 
gain or loss of function of a single protein contributes to disease causation in a non- 
obligatory and non-exclusive fashion (Devilee, et al. 2001), activation of GSK3 is one 
of several factors which can contribute to mental disorders (discussed in Beaulieu 
2012).
BDNF and its receptor TRKB have been shown to be neurotrophins with mood- 
regulating effects (Schmidt and Duman 2007), which act through PI3K and AKT in 
order to regulate GSK3 phosporylation and thus its activity (Johnson-Farley, et al.
2006). Additionally, the PI3K-AKT regulatory pathway of GSK3 phosporylation can 
be affected by serotonin levels in the hipocampus (Cowen, et al. 2005).
NPDC1, a gene found to be expressed at a higher rate in PER35/5 compared to PER34/4 
homozygotes in our study, has also been shown to be expressed in neuronal tissue and 
involved in proliferation downregulation and suppression of transformation (Galiana, 
etal. 1995)
In summary, dopamine has been shown to exert its effects via the PP2A-AKT 
pathway, while serotonin and BDNF act via the PI3K-AKT signalling pathway. Both 
pathways affect GSK3 in an inhibitory way. GSK3 then regulates some o f the clock 
genes that could influence period length and hence chronotype, as well as play a role 
in the regulation of mood disorders. The differential expression of PI3K and PP2A in 
PER3 genotypes may thus lead to differential GSK3 regulation leading to disorders 
such as bipolar disease, which has been found to associate more with the PER3S/5 
genotype (Benedetti et al. 2008). Additionally, PP2A is also involved in tau protein 
phosphorylation dynamics, causing either irreversible neurodegeneration leading to
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pathologies such as Alzheimer’s disease, or causing reversible downregulation of 
neuronal activity, such as that seen during hypothermia. Studies have already shown 
that in the early hours of the morning after sleep deprivation PER3S/5 homozygotes 
show reduction in activation in several brain areas, compared to PER34/4 (Vandewalle 
et al. 2009). Findings in our study also suggest that the PER3 genotypes may differ in 
the regulation (on/off) of their neuronal activity.
TMEM176A and TMEM176B were also found to be highly expressed in PER34/4, 
compared to PER35/S homozygotes in our study. TMEM176A has previously been 
shown to be differentially expressed in a rat model o f depression; Flinders depression 
resistant rats showed a 35-fold increase in cortex, and 30-fold increase in 
hippocampus, compared to Flinders depression sensitive rats (Blaveri, et al. 2010). 
TMEM176B, on the other hand, is required for the development of the cerebellar 
granule cell layer, as TMEM176B KO mice show cerebellar ataxia (Maeda, et al. 
2006). TMEM176B has also been shown to suppress signalling via PI3K-AKT 
signalling pathways (Ryu, et al. 2010).
RORA was highly expressed in PER35/5 homozygotes compared to PER34/4 in our 
experiment. RORA has been shown to be highly expressed in cerebellar Purkinje cells, 
but not in granule cells (Nakagawa, et al. 1997). RORA deficient mice show many 
abnormalities, including ataxia and severe cerebellar atrophy (fewer Purkinje cells 
and loss of granule cell layer) (Doulazmi, et al. 2001; Hamilton, et al. 1996). RORA 
has been shown to regulate the maturation and differentiation of Purkinje cells rather 
than dendritogenesis (Boukhtouche, et al. 2006). RORA deficiency has also been 
linked to slower glutamate transport (Janmaat, et al. 2009).
In summary these observations suggest a difference in cerebellar cell layer 
differentiation and maturation between the two PER3 genotypes in humans, as well as 
a possible predisposition to depression in PER35/5 homozygotes.
135
An additional conclusion from our results and data analysis is that the model fitting 
approach identified many more differentially expressed genes compared to the more 
traditional ANOVA approach. Also, the differentially expressed genes for which a 
comprehensible function could be established through literature search were mostly 
found by the model fitting approach. This indicates that the model fitting approach is 
superior to the ANOVA method when analysing time series expression profiles.
5.6 Conclusion
It can be concluded that phagocytosis and antigen-presentation are more active in 
PER34/4 homozygotes, while cellular mediated and humoral immune functions are 
more pronounced in PER35/5 homozygotes. Transcripts of four kinases (CAMK, 
PI3K, MAPK, and MAPKIP) shown to be involved in clock gene phosphorylation 
were identified as differentially expressed between the two PER3 VNTR genotypes, 
suggesting a possible role for them in the regulation o f the circadian clock. 
Transcripts of PP2A, PP2B and PP1, phosphatases involved in hyperphosphorylation 
of the tau protein (protein involved in neurodegeneration), have also been shown to be 
differentially expressed between the two PER3 VNTR genotypes, indicating a 
possible difference in the regulation within neural tissues. PI3K and PP2A, who’s 
transcripts have also been shown to be differentially expressed, are involved in 
signalling pathways which mediate the effects of BDNF, serotonin and dopamine, by 
regulating the phosphorylation of GSK3, which has been shown to be involved in 
mood disorders and the molecular clock, possibly contributing to the differential 
susceptibility to mood disorders seen in the two PER3 VNTR genotypes.
The two transcripts shown to be most differentially expressed between the two 
homozygous PER3 VNTR genotypes code for transmembrane proteins TMEM176A 
and TMEM176B. TMEM176B along with RORA (another differentially expressed 
transcript) is involved in cerebellar cell layer differentiation, while TMEM176A has 
been linked to depression susceptibility in rats. Although it is not possible to directly 
draw conclusions about brain function based on findings in the blood, the findings 
presented here should be explored further, as they suggest differences in depression 
susceptibility between the two homozygous genotypes.
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6 Identification of suitable reference genes for 
RT-QPCR
6.1 Introduction
6.1.1 RT-QPCR assay
Reverse transcription quantitative PCR (RT-QPCR) is an in vitro method where 
defined RNA sequences within a sample can be enzymatically copied and then 
amplified and quantified. RT-QPCR offers great sensitivity and it enables expression 
quantification from as little as a single copy of RNA. The RT-QPCR assay consists of 
two steps. During the first step, RNA is reverse-transcribed to cDNA using reverse 
transcriptase. This step can be performed separately on all the samples at once or can 
take place simultaneously with the second step. During the second step, the selected 
target region of cDNA has to be primed for amplification. For this, two primers, 
which specifically bind up- and down-stream, respectively, o f the selected sequence, 
are used. The targets are enzymatically amplified using a thermostable DNA 
polymerase. Several reporter options exist which enable the user to keep track of the 
amplification process in real time. Two of the most commonly used are double­
stranded DNA-binding dyes (such as SYBR green) and the fluorescent reporter probe 
method (TaqMan). The SYBR green fluorescent dye binds specifically to double 
stranded DNA, where it emits green light. As the amount of target DNA product 
increases with every cycle, the amount of emitted light also increases. This is detected 
and quantified. In the second method, fluorescent reporter probes only bind to and 
detect the amplified target sequence. The advantage of using this method is its 
specificity, as non-specific amplification will not yield fluorescence. Upon 
completion o f each cycle the fluorescence emitted by amplification is quantified. Each 
cycle yields twice as much amplified target cDNA strands and hence twice as much 
fluorescence, until it reaches a plateau. A fluorescence threshold is arbitrarily chosen 
once linear amplification is established, and the cycle number, when the fluorescence 
threshold is reached is noted for each target being amplified. This is termed Ct (cycle 
threshold). A separate reaction is prepared for each sample and for each target gene. 
This is usually done in a 96-well plate.
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6.1.2 Internal controls
As RT-QPCR is a very sensitive assay, internal controls need to be applied to help 
control for variations in amounts o f starting material as well as varied efficiencies of 
enzymatic reactions. The most common practice is to use a reference gene, i.e. an 
mRNA which is known not to change in relative amount during the course of the 
experiment. A reference gene should be stably expressed over the course of 24 h in all 
tissues o f an organism and within all developmental stages, as well as being 
unaffected by the treatment or manipulation of the experiment. Although circadian 
and diurnal variation are not always taken into account. The expression o f the 
reference gene is assessed simultaneously with the gene of interest using the same 
cDNA source and assayed on the same 96-well plate. Once expression levels for the 
gene of interest and reference gene have been obtained, the gene o f interest can be 
normalised to the reference gene, hence eliminating variability between samples, 
reactions, tissues and to minimise experimental errors (e.g., pipetting errors).
6.1.3 Classic reference ‘housekeeping’ genes
Selecting an appropriate reference gene is not a trivial task and the literature is not 
uniform on recommendations, which are sometimes chosen by conjecture rather than 
experimental evidence. Three of the most frequently used genes for normalising gene 
expression encode GAPDH (glyceraldehyde-3-phosphate-dehydrogenase), ACTS ((3- 
actin) and 18S rRNA (ribosomal RNA) (reviewed in Bustin 2000; Suzuki, et al. 
2000).
GAPDH catalyses the breakdown of glucose for energy and carbon molecules and is 
therefore abundantly and ubiquitously expressed, and often used as an internal control 
in RT-QPCR experiments. However, published literature suggests that GAPDH  may 
not be an appropriate internal standard. Concentrations of GAPDH  mRNA have been 
shown to vary significantly between individuals (Bustin, et al. 1999), during the cell 
cycle, and during pregnancy (Cale, et al. 1997). Also, GAPDH  transcription efficiency 
responds to insulin, growth hormone, vitamin D, oxidative stress, hypoxia and 
apoptosis, reviewed in Bustin et al (reviewed in Bustin 2000)
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ACTB encodes a cytoskeleton protein, ubiquitously and abundantly expressed. 
Although one of the most widely used reference genes, the levels of transcription have 
been shown to vary considerably in mammalian cells cultured in low serum and 
exposed to high serum or growth factors, in breast epithelial cells in response to 
manipulation, in uroepithelial cell lines following bacterial exposure but not exposure 
to cytokines, in blastomeres from different embryos, in leukocytes of various 
malignancies and between activated and stable lymphocytes (Bas, et al. 2004), to 
name but a few (reviewed inBustin 2000)
rRNA transcription is also affected by many factors such as differentiating agents and 
tumour promoters (Spanakis 1993). Another drawback of using 18S or 28S rRNA as 
an internal control is its high abundance compared to mRNA which means that 
samples need to be diluted.
6.1.4 Considerations when selecting reference genes
No universal reference gene has yet been described that is optimal for use in all 
tissues, in all species and under all types of manipulation. While one reference gene 
might be appropriate for a certain tissue type and experimental paradigm, it may not 
be appropriate for another (Rosir, et al. 2010; Thellin, et al. 1999). The expression 
profiles of reference genes may vary between patients and healthy individuals, 
between males and females, adults and children, and so forth. It has been shown, for 
example, that the expression levels of B2M  (Beta-2 microglobulin) differ 112-fold 
between leukocytes and fetal brain tissue (Vandesompele, et al. 2002). It is also 
important to consider the experimental design when trying to identify a suitable 
reference gene. Gene expression levels in samples collected at different times o f the 
day may differ, which is an important consideration when collecting a time-series of 
samples, as in the experiments presented here. The majority of studies ignore the 
time-of-day effect, and as a result, other differences ascribed to factors such as inter­
individual differences may in fact be time-of-day differences. The ‘classic’ reference 
genes, such as ACTE  (Kusanagi et al. 2008; Takimoto et al. 2005) and GAPDH  
(Ishihara, et al. 2010; Mazzoccoli, et al. 2011), as well as others, such as CDK4 
(cyclin-dependent kinase 4) (Boivin et al. 2003; James et al. 2007), B 2 M (Haimovich,
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et al. 2010b) have also been used in studies exploring circadian rhythmicity of genes, 
albeit with little or no validation of the appropriateness of these reference genes. It is 
therefore important to keep these effects in mind when deciding on a reference gene, 
and to evaluate the reference gene within the samples where the reference gene will 
be used.
6.1.5 Reference genes identified for blood samples
At least two algorithms are in use when determining the stability and appropriateness 
of reference genes in selected samples. One such algorithm is the geNorm algorithm 
(Vandesompele et al. 2002). The geNorm algorithm determines the pair-wise 
variation for every reference gene with all other reference genes tested, and the 
software computes an M  index, which is a measure of stability. Another such 
algorithm is the NormFinder algorithm, which uses a model-based approach to 
estimate expression variance (Andersen et al. 2004).
In peripheral blood leukocytes, PPIB (peptidylprolyl isomerase B) has been shown to 
be a more stable reference gene, relative to ACTB and GAPDH, by examining the 
variance of its expression levels in blood samples (Pachot, et al. 2004). PPIB  was also 
one of the stably expressed genes in whole blood samples of multiple sclerosis 
patients and healthy controls (Stamova, et al. 2009). PPIB has been shown to be a 
valid reference gene along with PGK1 (phosphoglycerate kinase 1) in whole blood 
RNA samples (Falkenberg, et al. 2011) as well as paired with B2M  in monocytes 
using the geNorm algorithm (Piehler, et al. 2010). However, the same experiment 
analysed using NormFinder showed ACTB to be the reference gene o f choice in 
monocytes, while PPIB came in second place (Piehler et al. 2010). On the other hand, 
ACTB was shown to be the least stable reference gene in leukocyte RNA samples as 
determined by the geNorm algorithm (Vandesompele et al. 2002).
Moreover, YWHAZ (tyrosine 3 -monooxygenase/tryptophan 5-monooxygenase 
activation protein, zeta polypeptide) has been shown to be the least stably expressed 
gene in whole blood RNA samples amongst a group o f selected potential reference 
genes, as assessed by geNorm and NormFinder (Falkenberg et al. 2011), while
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YWHAZ along with UBC (ubiquitin C) were the most stably expressed genes in 
leukocytes from a selected group of genes tested (Vandesompele et ah 2002).
When canine whole blood RNA was extracted using the same PAXgene system as in 
our study, and expression of selected reference genes was analysed, SDHA, CG I4980, 
and TBP (TATA-binding protein) were identified as the most stably expressed, using 
three different algorithms to determine stability (Chimura, et ah 2011).
Other genes such as HuPO  (human acidic ribosomal protein) (Dheda, et ah 2004), 
TRAP1 (encoding heat shock protein 75), FPGS (folylpolyglutamate synthase), and 
DECR1 (2,4-dienoyl Co A reductase 1) (Stamova et ah 2009) were also found to be 
stably expressed in whole blood RNA samples in humans.
When daily rhythmic changes in gene expression were taken into consideration and 
samples were collected from healthy subjects and chronic myeloid leukaemia patients 
over an 18-hour period, ACTB was shown to be most stably expressed in peripheral 
blood leukocytes (Yang, et ah 2011). Also, ACTB  as well as B2M, GAPDH  and HPRT  
were not affected by sleep deprivation in rat whole blood (Lee, et ah 2009) and are 
therefore considered useful internal controls in sleep deprivation studies.
The choice of internal controls has long since moved on from the traditional use of 
ACTB, GAPDH  and 18S rRNA, which are essentially carry-overs from older, now 
obsolete quantification methods. Many authors have shown that other genes should 
also be considered when selecting a reference gene. The recommendations on the use 
of reference genes in leukocytes and whole blood samples vary and it is difficult to 
determine, based on published literature, which reference gene would be most 
appropriate for whole blood samples. Most authors also concluded that it is essential 
to identify reference genes under the specific experimental conditions used in the 
study and not to rely on published results (Piehler et al. 2010).
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6.1.6 Aims
In order to identify a reliable reference gene that could be used to normalise gene 
expression data in our samples and potentially in a wider range of paradigms, our own 
microarray dataset was screened for stably expressed genes. These will be referred to 
as Group A. Primers and probes for the detection of genes from Group A were 
designed in our laboratory. The expression profiles and stability of the chosen genes 
was evaluated on a subset of samples using RT-QPCR. Additionally, the increasingly 
popular geNorm Reference gene Selection kit (PrimerDesign) was used. The kit 
contained primers and probes for detection of 12 frequently used reference genes 
together with the geNorm analysis software. The stability of 12 reference genes 
(referred to as Group B) detected by the geNorm kit was tested on the same subset of 
samples. Expression stability of all 12 genes was analysed using the geNorm and 
NormFinder software. Expression levels as well as expression profiles o f all 12 genes 
were also compared and evaluated for stability.
As various suppliers were used for the RT-QPCR work, a comparison o f kits and 
protocols from different suppliers was made and compatibility between the two kits 
was assessed.
6.2 Methods
6.2.1 Identification and evaluation of stably expressed genes (Group A) 
from microarray data
Our dataset, comprising data from 475 microarrays was screened for stably expressed 
genes with the aim of identifying potential reference genes to use in further 
experiments. The following criteria were used: Flags, coefficient o f variation, effect 
of genotype, effect o f sleep condition and goodness of sine fit. The intensity data for a 
probe were flagged if any of the following four criteria were met: (a) If  the level o f 
intensity was below detection level; (b) If  the level of intensity was not positive and 
not above background level; (c) If  the probe was not found (d) if the intensity level o f 
a probe was identified as an outlier (described in detail in Methods section 2.12.2.3). 
The CV (coefficient of variation) was computed for each probe to assess the variation
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in expression levels. Only probes with CV in the lowest 25th percentile were 
considered for further analysis. Then, the effect of the manipulation protocol was 
assessed. Firstly, the effect o f genotype was assessed using a t-test. Probes affected by 
the PER3 VNTR genotype were identified as those with t-test a p-value > 0.01 in all 
time points. Secondly, the effect o f sleep history condition was assessed using a 
paired t-test. Probes with paired t-test p > 0.01 were considered unaffected by the 
sleep condition and therefore useful as potential reference genes. Finally, a sine curve 
was fitted to the expression profile of each probe. Probes where goodness o f fit was 
low (R2 < 0.8) were considered for further analysis. The criteria are summarised in 
Table 6.1. A score was assigned to each probe for each criterion, based on the number 
o f subjects in which the criterion was met. A list of 20 probes with the top sum of 
scores was generated (Table 6.2). From this list, probes targeting ACTB and EEF2 
were selected for use in further analysis. ACTB  was selected as it has been shown to 
be stably expressed at different times of the day (Mirabella et al. 2006; 2011), not to 
be affected by sleep deprivation (Lee et al. 2009), and is included in the geNorm 
Reference gene Selection Kit. EEF2 was selected as it encodes a translation 
elongation factor and is therefore abundantly expressed and because it ranked 2nd in 
stability on the list.
Criterion Description
Flags Described in the Methods section 2.12.2.3
(a) Feature intensity above minimum detection level; (b) Feature 
intensity was positive and statistically significantly different from 
background
(c) Feature was found; (d) Feature was not an outlier
Coefficient o f  variation Coefficient o f  variation fell in the lowest 25th percentile regardless o f
(CV) sleep condition
Effect o f genotype Effect o f genotype was non-significant in either sleep condition
Effect o f  sleep condition Effect o f  condition was non-significant
Sine fit Expression profiles o f  probes did not fit a sine curve in either sleep 
condition
Table 6.1 Criteria used to select stably expressed genes from microarray data.
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The cDNA as well as the QPCR reactions were prepared following the in-house 
protocols as described in the Methods section 2.11.1.land 2.11.2.2 using primer probe 
sets targeting either the ACTB  or EEF2 reference gene (as described in section
2.11.4.1 Methods 1.12.4.1). The CVs of individual expression profiles of ACTB and 
EEF2 were computed.
6.2.2 geNorm and NormFinder analysis of genes from Group B
The geNorm Classic Reference gene Selection kit protocol was followed as described 
in Methods section 2.11.1.2 and 2.11.2.3. The geNorm software was employed to 
analyse gene expression data obtained by the kit. Stability index M  was calculated for 
all genes as outlined in Methods section 2.11.3.1. As only 10 genes could be analysed 
with the geNorm software at any one time, the two least stable genes had to be 
excluded from the analysis. Different combinations of 10 genes were fed to the 
software. TOPI and B2M  constantly performed worst and were therefore excluded 
from further geNorm analysis so only EIF4A2, YWHAZ, RPL13A, ACTB, GAPDH, 
CYC1, ATP5B, 18S, UBC, and SDHA were considered further.
Gene expression data for all 12 genes included in the geNorm kit was analysed using 
the NormFinder algorithm (Andersen et al. 2004), Methods section 2.11.3.2. A ranked 
list o f genes according to their Stability was obtained.
6.2.3 Expression profiles of genes from Group B
In order to visually inspect the range and variability of gene expression levels of 
individual genes, expression levels as determined by threshold cycle (Ct) were plotted 
across the sampling period for each individual. Gene profiles were normalised to their 
respective means using the delta Ct (A Ct) method (Livak and Schmittgen 2001) (ACt 
= Ct(TPx) -  Ct(mean); where Ct(TPx) is Ct value at selected time point x, and Ct(mean) is 
computed mean Ct value) and transformed from exponential to linear form (2"ACt). 
Expression profiles of all genes were inspected for each individual separately, and 
standard deviations (SD) were computed. All expression levels outside the mean ±
1 SD were identified as outliers. In order to determine whether sleep deprivation had
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an effect on gene expression, all expression values were normalised to the expression 
in the first time point.
6.2.4 Evaluation o f compatibility between kits
The cDNA was synthesized using either the in-house (Methods section 2.11.1.1 and
2.11.2.2) or the PrimerDesign (Methods section 2.11.1.2 and 2.11.2.3) kit. cDNA 
samples prepared by both methods were then tested with either the custom made 
(Methods section 2.11.4.1, Table 2.4) ACTB primers and probes (Group A) or the 
primers and probes provided by PrimerDesign (Methods section 2.11.4.1 and Table 
2.6) (Group B). The expression profiles obtained for ACTB  were visually compared. 
Only samples belonging to one subject were used, as inter-individual differences were 
not expected to emerge in this experiment, and thus the kits would not need to be 
evaluated for this. The samples from the subject with the lowest RIN (7.0) were used.
6.2.5 Samples used for RT-QPCR tests
Twenty-nine RNA samples belonging to three female (AF0031, AF0032, and 
AF0035) PER3 VNTR heterozygous volunteers (two volunteers provided 10 samples, 
one volunteer provided 9 samples) were selected. All samples were collected during 
CR following the 7 cycles of extended sleep opportunity (Methods section 2.4, 2.5.2,
2.7, 2.8). Although the full CR was 39-40 h long, the blood samples were collected 
during an approximate 27-h period within the CR. The integrity of RNA samples was 
determined using the Agilent Bioanalyser as described in section Methods section 2.9. 
The average RINs of RNA samples for subjects AF0031, AF0032, and AF0035, were
7.8, 8.0, and 7.0, respectively.
6.3 Results
6.3.1 Identification and evaluation of stably expressed genes (Group A) 
from microarray data
Our microarray dataset was screened for stably expressed genes following the criteria 
specified in section 6.2.1. A list of 20 stably expressed genes was produced (Table
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6.2) and EEF2 and ACTB  were selected for further analysis. Firstly, ACTB  was 
chosen because it has been shown to be stably expressed in peripheral blood 
leukocytes collected at four time points over the course of a day (Yang et al. 2011). 
As the samples were collected in such a way as to encompass the rise in melatonin 
levels towards the end of the day, this result suggests that the expression o f ACTB is 
not under the circadian influence in leukocytes. The ACTB gene is also included in the 
commercially available geNorm Reference gene Selection kit which was used in our 
experiments. This provided an opportunity for a direct comparison between the two 
protocols. ACTB was also not affected by sleep deprivation in whole blood 
preparations in rats (Lee et al. 2009). Secondly, a gene encoding a translation factor 
was chosen as they are abundantly and ubiquitously expressed. The top ranking 
translation factor and second ranking probe in terms of stability from microarray data 
analysis was EEF2.
Gene symbol Gene product Agilent probe
C l lo r f l l chromosome 11 open reading frame 21 A_23_P98671
EEF2 eukaryotic translation elongation factor 2 A_24_P87763
TRMT112 tRNA methyltransferase 11-2 homolog A_23_P12992
UQCRFS1 ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide A_23_P153586
DCAF8 DDB1 and CUL4 associated factor 8 A_24_P76725
ENST00000453392 QARS, glutaminyl-tRNA synthetase A_23_P146736
A_32_P226858 unidentified A_32_P226858
FASTK Fas-activated serine/threonine kinase A_23_P502930
POLR2G polymerase (RNA) II (DNA directed) polypeptide G A_23_P36147
PTDSS1 phosphatidylserine synthase 1 A_23_P168868
ACTB beta actin A_24_P226554
NDUFV1 NADH dehydrogenase (ubiquinone) flavoprotein 1 A_23_P127353
EDF1 endothelial differentiation-related factor 1 A_23_P60376
annexin A2 A_23_P146644
FBLN7 fibulin 7 A_23_P102462
NBPF3 neuroblastoma breakpoint family, member 3 A_23_P103454
KLHL12 kelch-like 12 (Drosophila) A_32_P98534
FAM134A family with sequence similarity 134, member A (C2orfl7) A_23_P108522
CMTM7 CKLF-like MARVEL transmembrane domain containing 7 A_23_P256413
PABPN1 poly(A) binding protein, nuclear 1 A_32_P35311
Table 6.2 Stably expressed genes from microarray data.
Genes are ranked in order o f stability, using the criteria specified in Table 6.1.
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R T-Q PC R  w as perform ed on 29 RNA sam ples (sam ples described in section 6.2.5) as 
described in section 6.2.1. E xpression profiles A C T B  and EEF2  obtained across all 
tim e points during the CR for each individual subject w ere com pared (Figure 6.1). 
The expression levels o f  A C TB  w ere low er than those o f  EEF2  in all three subjects. 
The CV o f  each expression profile w as com puted (Table 6.3). The CV  values w ere 
com parable betw een the two reference genes.
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Figure 6.1 Comparison of E EF2  (o) 2mA A C TB  ( • )  expression levels (copy number).
Shown for all three selected subjects (A F0031, A F0032 and A F0035), across all tim e points, assessed 
in duplicates.
ACTB  expression levels w ere low er than those o f  EEF2 in all subjects.
Subject code E EF2  expression (CV) AC TB  expression (CV)
AF0031 0.152 0.157
A F0032 0.214 0.241
A F0035 0.291 0.284
M ean 0.219 0.227
Table 6.3 Coefficients of variation for E EF2  and AC TB  expression profiles.
Shown for each subject (A F0031, A F0032 and A F0035) and mean value across all three subjects. 
The CV levels w ere com parable betw een the two reference genes.
6.3.2 geN orm  an d  N o rm F in d e r analysis o f genes fro m  G ro u p  B
The geN orm  Reference gene Selection kit w as used to detect expression levels o f  12 
pre-selected reference genes (EIF4A2, YWHAZ, RPL13A, ACTB, GAPDH, CYC1,
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ATP5B, 18S, UBC, TOP, SDHA, and B 2 M - group B) as described in section 6.2.2 in 
the sam e 29 R N A  sam ples. Stability index M  w as calculated using the geN orm  
softw are and the results are shown in Figure 6.2 below.
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Figure 6.2 Average expression stability {M) of remaining reference genes (Group B).
Genes are ranked in order o f  stability according to the M  index (above each bar). D ashed line show s the 
M =  0.5 cut o ff  value.
EIF4A2, YWHAZ, RPL13A, ACTB, GAPDH, CYC1, and ATP5B  w ere stably expressed genes in w hole 
blood RNA  sam ples; B 2 M and TOPI w ere om itted from the list due to poor stability.
The cu t-o ff for stably expressed genes according to the authors o f  the geN orm  
algorithm  is M  < 0.5 (Hellem ans, et al. 2007). EIF4A2, YWHAZ, RPL13A, AC TB, 
GAPDH, CYC1, and A T P 5B  w ere the m ost stably expressed genes in G roup B as 
determ ined by the geN orm  algorithm . Because the softw are could only plot 10 genes 
at a tim e, the tw o least stable genes, B 2 M  and T O P I, w ere excluded from  the analysis 
using the sam e M  index criteria.
N orm Finder softw are w as used to assess gene expression stability using the RT- 
QPCR data obtained by the geN orm  kit. G enes w ere ranked in order o f  stability  
(Table 6.4). As the Stability value is a level o f  expression variance, its range depends 
on the gene expression values entered. Therefore, a cu t-o ff cannot be specified. The
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top seven most stably expressed genes according to the NormFinder algorithm were 
CYC1, RPL13A, YWHAZ, ACTB, ATP5B, EIF4A2, and GAPDH. This cut-off was 
chosen because seven genes were also identified in the geNorm analysis and because 
the range of residual genes is almost twice that of the range of the selected genes 
(0.0057 -  0.0096 for selected genes, and 0.123 -  0.0188 for residual genes).
Gene Symbol Stability Value
CYC1 0.0057
RPL13A 0.0059
YWHAZ 0.0063
ACTB 0.0078
ATP5B 0.0088
EIF4A2 0.0092
GAPDH 0.0096
SDHA 0.0123
B2M 0.0124
TOPI 0.0132
UBC 0.0162
Table 6.4 Ranked list o f stably expressed genes (NormFinder).
Genes were ranked in order o f  decreasing stability according to the Stability Value as calculated by 
NormFinder.
Most stably expressed genes in whole blood RNA were CYC1, RPL13A, YWHAZ, ACTB, ATP5B, 
EIF4A2 and GAPDH.
6.3.3 Expression profiles of genes from Group B
To more accurately investigate the expression profiles and expression levels o f the 12 
potential reference genes their expression levels were plotted for each subject 
separately across all time points (Figure 6.3). The level of expression of all reference 
genes was relatively invariable across all time points. However, the genes displayed a 
very wide range of expression levels (low Ct represents high expression level).
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Figure 6.3 Comparison of expression levels (Cycle threshold) of all 12 reference genes (Group B).
M ean Ct w as calculated from duplicates for each tim e point for each subject (A F0031, A F0032 and 
AF0035).
Expression levels w ere relatively invariable across all tim e points in all genes.
Tn order to be able to com pare the expression profiles am ong the reference genes, the 
expression level o f  each reference gene w as norm alised to its respective m ean (A Ct = 
Ct(TPx) -  Ct(mean)) and transform ed from  exponential to linear form  (2"ACt) (Figure 6.4). 
The resulting expression profiles o f  the 12 genes fo llow ed a com m on pattern o f  
expression across the tim e points in each subject, although the respective profiles 
differed betw een subjects. The m ean ± 1 SD w as chosen as the cu t-o ff interval and 
expression values outside o f  this interval w ere considered outliers. The expression 
profile o f  TO P I did not fo llow  the established pattern w ithin all three subjects and 
several expression values w ere outside the selected interval. S im ilarly, SD H A  and 
f?2M  did not fully follow  the established fluctuations in subject AF0031 and A F0035, 
respectively.
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Figure 6.4 Comparison of linear expression levels (2'ACt) of all 12 reference genes (Group B).
The mean Ct w as calculated from duplicates for each tim e point, for each subject (A F0031, A F0032 
and AF0035). Ct values w ere norm alised to mean expression level o f  each respective gene and 
transform ed to linear form (2 ACt; ACt = C^Px) — Ct(mean)). M ean ± 1 SD expression in each tim e point 
are shown in grey.
TOPI (all subjects), SDHA (subject A F0031) and B2M  (subject A F0035) do not follow  the average 
pattern o f  expression (grey) w ithin respective subjects.
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Coefficients of correlation were computed between the mean expression values of all 
reference genes and each individual reference gene for each subject (Table 6.5). 
ATP5B, GAPDH, SDHA, 18S, RPL13A, ACTB, EIF4A2, YWHAZ, UBC and CYC1 
correlated positively with the mean expression levels of all reference genes in all three 
subjects. TOPI expression levels did not significantly correlate with the mean 
expression profile in subject AF0035, while B2M  significantly correlated only in 
AF0032. The remaining 10 reference genes correlated positively with the mean 
expression profile in all three subjects.
To investigate whether any of the reference genes showed a sleep deprivation- 
dependent change in expression across sampling time, expression levels of each gene 
were normalised to the expression level of their respective first time point (A Ct = 
Ct(TPx) -  Ct(TPi)) (Figure 6.5). The expression profiles revealed that none of the genes 
tested were affected by sleep deprivation, as none of the expression profiles were 
markedly up- or downregulated.
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Reference gene AF0031 AF0032 AF0035 Mean (all subjects)
ATP5B r 0.91 0.96 0.95 0.94
P 0.0006 <0.0001 <0.0001
GAPDH r 0.90 0.94 0.91 0.91
P 0.0011 <0.0001 0.0003
SDHA r 0.87 0.99 0.91 0.92
P 0.0021 <0.0001 0.0003
18S r 0.87 0.87 0.95 0.90
P 0.0021 0.0011 <0.0001
RPL13A r 0.90 0.84 0.86 0.87
P 0.001 0.0025 0.0013
ACTB r 0.86 0.84 0.95 0.88
P 0.0031 0.0025 <0.0001
E1F4A2 r 0.83 0.94 0.86 0.88
P 0.0056 <0.0001 0.0015
YWHAZ r 0.87 0.94 0.81 0.87
P 0.0025 <0.0001 0.0049
UBC r 0.75 0.89 0.90 0.85
P 0.0211 0.0006 0.0003
CYC1 r 0.75 0.83 0.89 0.82
P 0.021 0.0028 0.0005
B2M r 0.05 0.94 0.47 0.49
P (0.8957) <0.0001 (0.176)
TOPI r 0.75 0.84 -0.31 0.41
P 0.0208 0.0025 (0.3847)
Table 6.5 Coefficients of correlation between mean expression profiles of all reference genes and 
each individual reference gene.
Shown for each subject (AF0031, AF0032 and AF0035) and the mean r across all subjects were 
computed for each reference gene, r = Pearson’s coefficient o f  correlation; p = the significance level o f  
the correlation, p < 0.05 was considered significant.
TOPI expression levels did not significantly correlate with the mean expression profile in subject 
AF0035, while B2Msignificantly correlated only in AF0032.
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Figure 6.5 Effect of sleep deprivation on gene expression (2"ACt) of all 12 reference genes (Group 
B).
The mean Ct w as calculated from duplicates for each tim e point for each subject. Ct values were 
norm alised to first tim e point (A Ct = Ct(TPx) -  Ct(TPi)) and transform ed to linear form (2"ACt). M ean 
across all subjects w as calculated.
N one o f  the genes tested show ed an effect o f  sleep deprivation across the sam pling period.
6.3.4 Evaluation of compatibility between the two RT-QPCR kits
R T-Q PC R  w as carried out as described in section 6.2.4. Only sam ples belonging to 
subject AF0035 w ere used. A C TB  expression profiles obtained w ere plotted in F igure 
6.6. Indicated in the figure are those profiles from  cD NA m ade follow ing the 
P rim erD esign protocol w hile triangles indicate that the in-house protocol w as used, 
together w ith profiles obtained by A C T B  from  G roup A and profiles from  probes from  
Group B.
Sim ilar profiles in Ct values w ere obtained regardless o f  the com bination o f  protocols 
used. The sim ilar pattern o f  expression obtained by both kits (dow n in TP 2 and up in 
TP 9) is due to the fact that m RN A  w as diluted and the sam e stock dilution w as used 
for cD N A synthesis w ith both kits.
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Figure 6.6 Comparison of ACTB expression profiles obtained by using different RT-QPCR kits.
The in-house (triangles) and Prim erD esign (PD) (circles) protocols w ere used to synthesise cD N A  and 
ACTB  prim ers and probes from Group A (open) and Group B (filled sym bols) w ere com pared in 
subject AF0035 across all tim e points.
Sim ilar expression profiles w ere obtained regardless o f  kit or probe provider.
6.4 D iscussion
The literature on recom m ended reference genes to be used w hen assessing gene 
expression profiles in leukocytes is not consistent. A lthough m any authors have tried 
to identify the perfect reference gene by extensive screening o f  genes and tissues, 
m ost published findings are contradictory and inconsistent. Few  authors have 
collected a series o f  sam ples across tim e and none, to m y know ledge, have attem pted 
to identify stably expressed genes over a 40-h CR.
6.4.1 Id en tify ing  an d  evalua ting  stab ly  expressed  genes (G ro u p  A) from  
m ic ro a rra y  d a ta
From  a list o f  stably expressed genes as determ ined by our m icroarray experim ent 
described in M ethods Section 6.2.1, two genes w ere selected (from G roup A) and 
tested further. F irstly, A C TB  was chosen as it is a com m only used reference gene and 
has been tested extensively in blood and other tissue. A C T B  has been show n to be 
stably expressed in m onocytes (Piehler et al. 2010), as well as being non-responsive
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to sleep deprivation in whole blood samples in rats (Lee et al. 2009). When blood 
samples were collected in such a way as to encompass the rise in melatonin levels in 
the evening, ACTB was stably expressed in peripheral blood leukocytes across all 
sampling times (Yang et al. 2011). This result suggests that the expression o f ACTB  is 
not under circadian influence. Because samples used in our further experiments were 
from sleep-deprived subjects and collected over a 40-h period, non-responsiveness to 
sleep deprivation and circadian stability were important considerations when choosing 
a reference gene. The geNorm kit contained 12 reference genes and ACTB was the 
only gene available in the kit and that was also in our list of stably expressed genes. 
This way, a comparison between the two protocols and kits could also be made. As 
both geNorm and in-house kits and protocols were to be used in subsequent 
experiments, compatibility between the two had to be assessed.
Secondly, the gene for a translation factor was chosen as they are abundantly and 
ubiquitously expressed. The top ranking translation factor and indeed the top ranking 
probe in terms of stability from the microarray data-derived list was EEF2. EEF2 
codes for translation factor EEF2 (eukaryotic translation elongation factor 2). It 
catalyses the translocation of the newly emerging peptide from the A-site to the P-site 
o f the ribosome (Nygard and Nilsson 1990).
Other reference genes identified to be stably expressed in whole blood or leukocytes, 
such as PPIB (Pachot et al. 2004), YWHAZ (Vandesompele et al. 2002), PGK1 
(Falkenberg et al. 2011), HuPO (Dheda et al. 2004), TRAP1 (heat shock protein 75), 
FPGS (folylpolyglutamate synthase), or DECR1 (2,4-dienoyl CoA reductase 1) 
(Stamova et al. 2009) were not found to be stably expressed in our microarray data 
set. ACTB and EEF2 were therefore chosen for further validation as potential internal 
control genes. Primers and probes for RT-QPCR were designed to most accurately 
target the same region of the exon that is represented by the respective Agilent 
microarray probes.
All further validation of genes was performed on 29 RNA samples from three 
heterozygous PERS subjects, collected during CR following extended sleep
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opportunity. This condition was chosen over the sleep restriction condition as it more 
closely resembled natural sleep length. The expression levels of ACTB  were 
consistently lower than those of EEF2, which was to be expected as EEF2 codes for a 
key translation factor and is therefore more abundantly expressed (Figure 6.1). The 
expression profile of EEF2 in subject AF0032 seemed to be more variable than in 
AF0031 and AF0035. The expression of EEF2 is influenced by Interferon a  (INT-a) 
(Hadj-Slimane, et al. 2004). INT-a is a cytokine produced in response to viral 
infections predominantly by B lymphocytes (Nyman, et al. 1998). Although our 
volunteers were healthy at the time of the study it is possible that subject AF0032 was 
recovering from a cold. The variation seen in this subject cannot be due to poor RNA 
quality as the RIN for samples from this subject were the highest among the three 
subjects tested (8.0). The CVs of EEF2 and ACTB expression profiles were of 
comparable value (Table 6.3). This suggests that EEF2 and ACTB  are o f comparable 
stability.
6.4.2 geNorm and NormFinder analysis of genes from Group B
The following genes, EIF4A2, YWHAZ, RPL13A, ACTB, GAPDH, CYC1, and ATP5B  
were all identified as stably expressed reference genes by the geNorm algorithm and 
displayed an M  index of less than 0.5, as shown in Figure 6.2. The range of M  indices 
for our top 10 genes span from 0.38 to 0.64. However, when this was compared to 
other published literature, where geNorm was used to identify reference genes in PB 
leukocytes, the M  indices for the four genes selected as most suitable internal control 
genes ranged from 0.54 to 0.67 (Stamova et al. 2009) . Compared to these results, all 
our 10 genes tested in geNorm could be considered valid reference genes. In our data, 
the M  indices were lower and the range was narrower compared to those in the study 
by Stamova (2009) .
The NormFinder software was also employed to assess expression stability of the 12 
genes assayed with the geNorm kit. Unlike the geNorm software, NormFinder could 
operate with all genes at the same time, as it is an add-in to be used with MS Excel. 
Stability values were calculated for each gene and genes were ranked according to 
their stability (Table 6.4). As the Stability value is a measure of variance, the actual
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numbers obtained in the Stability Values column depend on the expression data 
entered in to the software. A cut-off value can, therefore, not be predetermined. After 
comparing the Stability values of all genes, it was decided, that selecting the top seven 
genes would present a rational cut-off in this case, as the range o f variance between 
the top seven and the remaining genes differed by almost two-fold.
The top seven most stably expressed genes, as ranked by NormFinder, were CYC1, 
RPL13A, YWHAZ, ACTB, ATP5B, EIF4A2, and GAPDH, while the least stably 
expressed genes were SDH A, B2M, TOPI, UBC, and 18S. These results are consistent 
with those obtained by geNorm analysis. However, the order within the most and least 
stably expressed genes was different. The reason for different ranking of genes is 
probably due to the different algorithms used to assess expression stability. While 
geNorm calculates the average pairwise variation o f a gene with all other control 
genes, NormFinder uses a model-based approach, which estimates the intra- and 
intergroup variation.
YWHAZ and EIF4A2 were the two most stably expressed genes in relation to the 
remaining genes tested (Figure 6.2), as determined by the geNorm analysis. YWHAZ 
was also found to be one of the most stably expressed genes in leukocytes 
(Vandesompele et al. 2002) when using the same algorithm to assess stability, and 
ranked 3rd in our NormFinder analysis. YWHAZ has been shown to be least stably 
expressed in whole blood preparations as determined by geNorm and NormFinder 
analysis (Falkenberg et al. 2011) show. The second member o f the most stably 
expressed pair has been shown to be UBC (Vandesompele et al. 2002) , while in our 
analysis UBC ranked 9th when analysed by geNorm and 11th when NormFinder 
analysis was used. Their 3rd ranking gene, B2M, performed so poorly as a reference 
gene in our experiment that it was either excluded from geNorm analysis or ranked 9th 
when assessed by NormFinder. SDHA performed poorly in both o f our analyses 
which confirms the results obtained by Vandesompele et al (2002) who show that out 
of 10 genes tested, SDHA ranked seventh. They also found ACTB to score the lowest 
in leukocytes, while our results show ACTB to be stably expressed (fourth ranking in 
both analyses).
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Perhaps some of the inconsistencies of results within the same tissue can be explained 
by considering the way the RNA samples were collected in both studies. While single 
blood samples were collected at random times of the day from 13 volunteers in 
Vandesompele’s study, (2002), the collection of samples in our experiment was a very 
tightly controlled time-series and spanning over 27 h. Firstly, the habitual sleep-wake 
schedule of volunteers was recorded and the volunteers adhered to the habitual sleep 
wake schedule one week prior to the study. Secondly, the volunteers resided in a 
controlled environment for seven days prior to sample collection where their sleep, 
food intake and light levels were controlled. Thirdly, the collection of samples was 
timed to individual’s circadian phase as assessed by the DLMO. Fourthly, 10 samples 
were collected across a 27 h CR where the posture, light and food intake of volunteers 
were controlled. In this way, a time-series o f samples was obtained and the expression 
profiles of circadian and non-circadian genes could be assessed, as well as genes that 
show effect o f sleep deprivation. Assessing expression stability on such a dataset is 
much more stringent compared to selecting a single time point in which to perform 
the experiment. In a time-series a gene must show stable expression in most if not all 
time points. This way only genes showing truly invariant expression over time will be 
identified as stable. Perhaps the genes identified as stably expressed by other groups 
were only stable at time points they tested, or perhaps some of the genes tested by us 
were affected by the sleep deprivation protocol and the discrepancies between 
reported results and our findings are due to the manipulation protocol.
The method of data collection used in our study was very stringent and thus far 
represents the best-controlled study from which to determine appropriate reference 
genes for analysis of leukocyte RNA.
6.4.3 Expression profiles of genes from Group B
In order to take advantage of full expression profiles of the 12 potential reference 
genes (Group B) and to visually inspect them, expression levels were plotted for each 
subject separately across all time points (Figure 6.3). All reference genes displayed 
relatively constant expression levels across the sampling period although the levels 
varied greatly between genes.
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Expression profiles of the 12 potential reference genes were normalised to the mean 
expression level of each respective gene and transformed to linear form, to make them 
comparable amongst each other (Figure 6.4). All genes showed a common fluctuation 
in expression as a consequence of variable concentrations of starting mRNA, as 
expected. A visual inspection revealed that TOPI did not fit the average fluctuation 
trend in all three subjects. SDHA is an outlier in subject AF0031 and B2M  in subject 
AF0035. Correlation analysis found that B2M  and TOPI expression levels did not 
significantly correlate with the mean expression profile in all three subjects. While the 
expression of B2M  only significantly correlated in subject AF0032, expression levels 
of TOPI were found to correlate significantly in subjects AF0031 and AF0032 (Table 
6.5).
By inspecting the expression profiles it became evident why TOPI, SDHA, and B2M  
scored so poorly in the geNorm and NormFinder analysis. Although SDHA and B2M  
only show outliers in one subject each, the fact that they are not stably expressed in all 
subjects makes them unsuitable for use as internal controls. UBC and 18S also scored 
very poorly in geNorm but the reason for this was not apparent when the expression 
profiles were examined. The correlation analysis confirmed that TOPI and B2M were 
indeed unstably expressed and therefore unsuitable for use as reference genes. 
However, SDHA was stably expressed in all three subjects, so the reason for scoring 
poorly in geNorm and NormFinder analysis is not clear.
The promoter region of TOPI contains two E-box elements to which the 
BMAL1/CLOCK heterodimer might bind, as well as a D-box element capable of 
binding DBF (albumin D-binding protein) (Yang, et al. 2009). The BMAL1/CLOCK 
complex is one of the key elements regulating circadian rhythmicity in the SCN 
(Shearman, et al. 2000), while DBF modulates circadian and homeostatic aspects of 
sleep regulation (Franken, et al. 2000). TOPI has been shown to be expressed in a 
circadian fashion in an embryonic fibroblast cell line (NIH3T3 cells) (Yang et al. 
2011) . It is, therefore, not surprising that TOPI was least stably expressed in our 
time-series analysis, which was aimed at identifying circadian and non-circadian
160
genes. However, TOPI does not show a circadian profile in gene expression in our 
results.
SDHA codes for one o f the subunits (flavoprotein) in the succinate dehydrogenase 
complex in the inner mitochondrial membrane (Hirawake, et al. 1994). The dopamine 
D2 receptor has been shown to downregulate expression levels o f SDHA and SDHB in 
striatal cultures in a dose-dependent manner (Benchoua, et al. 2008). REM sleep 
deprivation has been shown to result in increased density o f dopamine D2 receptors in 
the rat brain (Brock, et al. 1995; Nunes, et al. 1994). Dopamine D2 receptors have 
also been shown to be involved in the maintenance of wakefulness (Qu et al. 2010). 
Perhaps the change in dopamine D2 receptor numbers could also have an effect on 
SDHA expression levels in the blood, however we have shown that D2 receptors were 
not expressed in peripheral blood (see section 4.5.1.1).
P2M  codes for a protein found in association with the MHC in all nucleated cells in 
the body (Momoi, et al. 1995). It is involved in presentation of peptide antigens to the 
immune system. B2M  is a housekeeping gene, which is stably expressed in many 
different types o f tissue. Its expression levels have been shown to change in response 
to certain illnesses; B2M  is therefore a marker o f multiple myeloma (Garewal, et al. 
1984), acute leukaemia and malignant lymphoma (Hansen, et al. 1992). The variation 
in expression seen in our samples was therefore unexpected.
Although other authors have used SD to illustrate variation between genes, this 
method is not appropriate for time-series experiments. Because the expression levels 
o f tested reference genes have not been normalised, a common fluctuation in 
expression values is expected across time. This is due to different amounts of starting 
mRNA being used for cDNA synthesis. Because the same cDNA stock was used for 
all genes from Group B, the fluctuation in expression levels is expected to be similar 
for all genes. Therefore, variability in expression calculated as SD cannot be used as a 
measure of expression instability. For example, a gene showing a flat expression 
profile in a non-normalised time-series experiment, while all other genes follow a
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common pattern of fluctuation due to variable amounts of starting material, would not 
be considered stably expressed but would nonetheless show a very low SD.
Similarly, box plots showing the mean and range of expression for a particular gene 
would not be useful here. Some genes will display a constantly higher expression than 
the mean across all time points while others will be expressed at a lower level than the 
mean. In a box plot presentation these values would be shown furthest from the mean, 
suggesting these genes were not stably expressed and should be discarded. However, 
a consistently high or low expression does not render the levels o f these transcripts 
unstable.
Expression profiles of genes in subject AF0035 displayed much more variance and 
the outliers were greatest in this subject. This could be due to the quality of mRNA 
used in cDNA synthesis. The RIN, used to quantify RNA quality, was lowest for 
subject AF0035 (7.0), although still within limits recommended by the manufacturers. 
Although a direct correlation between RIN and gene expression cannot be made based 
on such a small sample size, it is an observation worth noting.
To examine whether any of the genes were affected by sleep deprivation, expression 
levels for each gene were normalised to the value of their respective first time point 
(Figure 6.5). A visual inspection revealed that none of the genes tested were affected 
by sleep deprivation. A common fluctuation in expression values across sampling 
time was expected but no additional variation was detected.
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When taking all above in to consideration we conclude that EEIF4A, YWHAZ, 
RPL13A, ACTB, GAPDH, CYC, and ATP5B could all be confidently used as internal 
references. From these seven candidate genes, ACTB  was selected for use as a 
reference gene in all further RT-QPCR work. ACTB was chosen because:
1. It was found to be stably expressed in our microarray dataset
2. geNorm analysis showed ACTB  to be one o f the stably expressed genes
3. NormFinder analysis showed ACTB  to be one of the stably expressed genes
4. ACTB  did not show sleep deprivation effects across sampling time
5. It is an established reference gene
6. ACTB  has been shown to be most stably expressed in PB leukocytes when 
circadian factors (such as changing melatonin levels) were taken into 
consideration (Yang et al. 2011)
7. ACTB  was shown not to be affected by sleep deprivation in rats (Lee et al. 
2009)
Both primers and probes for detecting ACTB (either designed by us -  Group A or by 
PrimerDesign -  Group B) detected a very similar region within the same exon. 
Primers and probes designed by PrimerDesign were selected for use in subsequent 
RT-QPCR experiments.
PPIB (Pachot et al. 2004) and HuPO  (Dheda et al. 2004) have both been shown to be 
a superior reference genes compared to ACTB  in PB leukocytes and whole blood 
respectively. However, the range of Q  values in Pachot et al (2004) samples were 
very variable compared to our results. This makes it difficult to adopt their findings. 
Dheda et al (2004) collected samples during a single sampling session and therefore 
their findings are not necessarily expected to match those of our time-series 
experiment.
Although multiple reference genes are recommended to be used in RT-QPCR 
analysis, it has been shown that when a suitable stable reference gene is selected,
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multiple internal controls are not needed (Falkenberg et al. 2011) . Also, the scope of 
our experiment does not permit for use of two or more internal controls.
6.4.4 Evaluation o f compatibility between RT-QPCR kits
Two different kits and protocols were used to obtain the results described in this 
chapter; genes from Group A were assayed using the in-house protocol while the 
PrimerDesign protocol was used for genes from Group B. The primers and probes 
were designed either by us and manufactured by Sigma (for genes in Group A) or 
they were designed and manufactured by PrimerDesign (for genes in Group B). For 
the QPCR validation of microarray data (not presented in this thesis), primers and 
probes were designed either by us or by PrimerDesign. A validation of compatibility 
between the different approaches therefore needed to be tested.
In Figure 6.6, the expression profiles for ACTB from group A and group B were 
plotted for subject AF0035, using either the in-house or PrimerDesign protocol. The 
expression levels of ACTB obtained using the PrimerDesign protocol were lower than 
those obtained using the in-house protocol as only 0.5 ng of template RNA was used 
compared to 2.5 ng in the in-house protocol for cDNA synthesis. All four 
combinations of kits yielded a similar expression profile for ACTB. However, to 
ensure internal consistency of results the cDNA would need to be synthesized using 
the same kit and at the same time for all samples; the same stock of cDNA must be 
used for assessing expression o f all genes and any internal controls.
6.5 Conclusion
It was concluded that ACTB  was the reference gene of choice and will be used in 
subsequent RT-QPCR analysis. ACTB was selected as it was stably expressed in our 
microarray dataset, showed stable expression when analysed using the geNorm and 
NormFinder algorithm, as well as when profiles were visually inspected. ACTB was 
also stably expressed in time series experiments when circadian factors were 
considered (Yang et al. 2011) and was not affected by sleep deprivation (Lee et al.
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2009). Commercially available primers and probes from PrimerDesign (as in group B) 
were chosen for subsequent RT-QPCR work as they were available free of charge.
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7 Discussion
This study investigated the effect of sleep restriction and sleep deprivation on selected 
clock, sleep, and sleep-deprivation related genes, as well as the effect of the PER3 
VNTR polymorphism on global gene expression. The relationship between clock 
genes and entrained habitual sleep and wake times was also examined, dependent and 
independent of the PER3 VNTR genotype.
It was hypothesised that the PER3 VNTR polymorphism and sleep deprivation will 
affect human whole blood gene expression.
7.1 Effect of sleep deprivation on gene expression
Self-inflicted loss of sleep in the industrialised world has been reported to have 
reached epidemic proportions, and the consequences are manifold (Quan 2006). 
Besides endangering the society via sleep deprived personnel, such as aircraft pilots, 
drivers and medical professionals carrying out demanding and high risk tasks, lack of 
sleep has been shown to have grave consequences on individuals’ health outcomes. 
Sleep deprivation has been shown to be linked to insulin resistance and diabetes 
mellitus (Spiegel, et al. 2005), obesity (Singh, et al. 2005), increased mortality 
(Cappuccio, et al. 2010), altered immune response (Bom et al. 1997; Irwin et al. 
1996), cardiovascular disease (Sabanayagam and Shankar 2010; van Leeuwen et al. 
2009), and cancer (Thompson, et al. 2011).
Consequences of sleep loss in rodents (Cirelli, et al. 2006; Cirelli and Tononi 1998) 
and flies (Cirelli and Bushey 2008) have been studied extensively in the brain and 
other tissues. In these studies, global gene expression was compared between different 
behavioural states at one or two selected time points over the 24-h cycle. These 
studies have provided insight into the function of sleep as well as details on the 
distinction between molecular pathways involved in wakefulness, sleep and sleep 
deprivation. Although this approach has identified most of the known genes involved
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or affected by sleep loss, the complete expression profiles of these genes have not 
been examined. It might, therefore, be difficult to draw conclusions based on data 
collected over such a limited time span.
Using peripheral blood samples similar studies in humans have only examined the 
expression of clock genes (Ackermann et al. 2009; Archer et al. 2008; Boivin et al. 
2003; James et al. 2007; Kusanagi et al. 2008; Teboul et al. 2005), but a wider range 
of genes has not been looked at, and thus the consequences of sleep on the wider 
transcriptome have not been studied in humans. A major reason for this is likely the 
high costs and highly demanding protocols (for the volunteers and the researchers) 
involved in human studies where external factors have to be controlled and volunteers 
are asked to adjust their sleep-wake regime to specific times, or lack sleep completely. 
Similarly, studies in human volunteers have mostly (but not exclusively) examined a 
few time points in the 24-h cycle and extrapolated data, but have not examined full 
expression profiles of either clock or sleep-deprivation-related genes. Additonally, 
whilst the relevance of leukocyte gene expression profiles for immune function is 
obvious, it may not be generally appreciated that the blood transcriptome profile has a 
much wider potential relevance.
In this study, the effect o f acute lack of sleep (40 h CR) on temporal expression of 
genes involved in neuronal plasticity, immune response, cellular stress response, 
energy metabolism, genes previously shown to be involved in sleep deprivation 
response, and clock genes were examined.
Although lack of sleep has been associated with an increased immune response, we 
show that not all inflammatory markers follow this trend. We found that only TNFa 
expression was elevated over the course of acute sleep deprivation, while CRP, IFNy 
and IL6 expression were not affected. IL lfi expression followed a circadian pattern 
indicating some aspects of the immune system to be under circadian control. The 
expression levels of IL lp  were, however, elevated towards the end of CR, compared 
to initial values. NFkB  was also upregulated (Irwin et al. 2008) as a function o f sleep 
deprivation, as has been shown previously. Most of the examined genes involved in
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cellular stress response and metabolism were only upregulated during wakefulness, 
but their expression was attenuated when wakefulness was prolonged into sleep 
deprivation.
Additionally, we show that HOMER1 and NIPSNAP1 were both downregulated 
during sleep deprivation in blood, although studies in rodent brain have shown them 
to have opposing expression profiles (Mackiewicz et al. 2008; Maret et al. 2007). 
Based on published literature we postulate both might have a role in Ca2+ signalling in 
the brain as well as in leukocytes.
Most of the clock genes we selected and examined displayed a circadian variation is 
expression across the sampling time. No effect o f SD was thus observed. However, 
DEC1 and BMAL2 were not expressed in blood cells in our study, which was unusual, 
as they have been assessed in peripheral leukocytes in other studies (Ding et al. 2011; 
Miyazaki et al. 2010). Because in our study the expression was examined under SD 
conditions, it is perhaps plausible, that the lack of expression, as found in our study, 
can be ascribed to the effect o f SD.
7.2 Effect of circadian regulation on entrained sleep-wake timings
It has been shown extensively that the preferred timing o f sleep varies among 
individuals (Dijk et al. 2000; Duffy et al. 2001; Groeger et al. 2004; Roenneberg et al. 
2003). So much so, that ‘chronotype’ has been established as a measure of 
‘momingness’ and ‘eveningness’, and individuals can be segregated into morning 
(early) and evening (late) types. Sleep and its timing are regulated by the circadian 
and the homeostatic processes, as already discussed in the Introduction section 1.1.4.
The role o f clock genes in circadian rhythm generation has been shown by 
constructing mouse models lacking functional clock genes (DeBruyne et al. 2007a; 
Gekakis et al. 1998; Liu, et al. 2008; van der Horst et al. 1999; Zheng, et al. 2001). 
These mice had altered period length in constant conditions elucidating the 
importance of the circadian oscillator in rhythm generation. The circadian system has
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been shown to regulate rhythmicity of many physiological processes (such as 
metabolism (Mazzoccoli, et al. 2012), cardiovascular function (Portaluppi, et al. 
2012), and endocrine function (Prasai, et al. 2011)) as well as sleep and wakefulness 
(Beersma 1998; Borbely 1982; Easton et al. 2004; Hida et al. 2012). Compared to 
mouse models, the tools for studying gene function in humans is limited to association 
studies and naturally occurring mutations and polymorphisms.
When the correlation between clock gene expression (circadian process) and sleep 
wake-timing was examined, the phase of REV-ERBfi, and also REV-ERBa expression 
showed the strongest correlations with sleep-wake parameters. It has recently been 
demonstrated that REV-ERBa and REV-ERBfi play a significant role in circadian 
rhythmicity generation, as a double REV-ERB KO displayed perturbations in 
rhythmicity of gene expression in the liver (Cho et al. 2012). Besides this, the authors 
o f this article also indicate the importance of the interaction between REV-ERBs and 
BMAL1 in regulating clock and clock output genes, and suggest that BMAL1 might 
control one loop while REV-ERB might control another loop of the molecular clock, 
and in this way regulate behavioural and metabolic physiology. In the study described 
in this thesis, we have found no correlation between BMAL1 phase of expression and 
the timing of sleep and wakefulness, which is strongly in contrast to the 
aforementioned reports. However, we did identify a potentially important association 
between the REV-ERB paralogue expression profiles and sleep-wake behaviour. This, 
as summarised by Cho et al, is more reminiscent of a pacemaker role, rather than a 
stabiliser of rhythm, as has been suggested until now.
Additionally, DEC2, CSNK1D, and TIMELESS phase of expression showed 
prominent associations with reported bed times. PERI amplitude of expression related 
to entrained bed times, while PER2 amplitudes were related to wake times.
A mutation in DEC2 has been shown to result in shorter sleep requirements in humans 
and has been postulated to regulate sleep length in mammals (He et al. 2009). In our 
study, no correlation between DEC2 expression (neither phase nor amplitude) and the 
amount of sleep obtained per night has been found. However, a correlation between
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DEC2 expression amplitude and sleep latency emerged (in two questionnaires out of 
four assessing sleep latency) indicating a possible connection between DEC2 
expression and sleep homeostasis. A link between altered homeostasis and DEC2 has 
already been proposed previously (He et al. 2009), however our study has shown that 
high DEC2 expression associates with lower homeostatic sleep pressure, which is in 
contrast to the findings reported by He et al. (2009).
The role of TIMELESS in mammalian clocks has been questioned (Sangoram et al. 
1998; Zylka et al. 1998a), however, here we report, that TIMELESS is rhythmically 
expressed in blood cells. Moreover, in our study the phase of expression o f the 
TIMELESS gene was shown to correlate with the timing of entrained bedtime. These 
findings suggest that TIMELESS might, nevertheless, have a role in the human 
circadian system.
This study has shown that earlier and high amplitude of CSNK1D expression 
associated with an earlier bedtime. As CSNK1D plays a role in PER phosphorylation 
leading to its degradation, the earlier peak in CSNK1D expression most likely 
resulted in a faster and/or earlier degradation of PER proteins leading to a hastening 
of the clock, possibly resulting in earlier bedtimes. Surprisingly though, the 
correlation between PER gene expression and sleep-wake timings was not as 
pronounced, suggesting that the proposed mechanism might happen at the protein 
rather than expression level. However, protein abundance or even enzymatic activity 
can not be speculated on based on mRNA expression profiles. Additional work would 
therefore need to be carried out in order to study this mechanism.
An alternative explanation would also be that the sleep-wake timings are under the 
control o f a different mechanism, and it is the sleep-wake behaviour which influences 
the expression o f clock genes and plays a role in shaping the gene expression profiles 
which we have observed. Similarly, the expression of some clock genes in mouse 
cortex has been found to be increased after SD, and Per2 expression remained high 
even after recovery sleep (Franken, et al. 2007). Therefore the behavioural state can 
influence the expression of clock genes. Additionally, a third unidentified mechanism
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might be involved, which controls both, circadian gene expression and sleep-wake 
behaviour. These possibilities have not been ruled out by our protocols, and remain 
possible explanation for the observed findings.
7.3 Effect of the homeostatic component on expression of selected 
genes
To study the role of the homeostatic component of sleep regulation on gene 
expression, a SR compared to SE paradigm was used in a cross-over design. In one 
leg of the study volunteers were given 10 h sleep opportunity (SE) lowering their 
homeostatic sleep propensity, and in the other leg their sleep opportunity was 
restricted to only 6 h (SR) for 7 dark-light cycles prior to undergoing CR, thus 
elevating their propensity to fall asleep. Gene expression during CR o f selected genes 
was compared between the two conditions.
Clock genes have been shown to be linked to the homeostatic regulation of sleep. 
Deletions in some clock genes in mice {Clock (Naylor, et al. 2000), Cryl and Cryl 
(Wisor et al. 2002), Perl and P erl (Shiromani, et al. 2004), Em ail (Laposky et al. 
2005), and N pasl (Franken, et al. 2006)) led to changes in sleep time and structure, 
fragmentation of sleep, and an altered response to sleep deprivation. When we 
examined the effect of increased homeostatic pressure on circadian clock genes, by 
restricting sleep opportunity (SR) prior to CR, the expression levels o f clock genes 
were generally lower and the oscillations dampened, compared to when homeostatic 
sleep pressure was not increased (SE).
Genes involved in cellular stress response and metabolism were more abundantly 
expressed after sleep was restricted during nights prior to the CR. The literature 
suggests that the effects of total sleep deprivation diminish after 1-2 recovery nights 
of sleep, while chronic sleep restriction effects are longer lasting (reviewed in Balkin, 
et al. 2008). According to our findings, it seems that chronic sleep restriction over 7 
days thus has a more profound or compounded effect on physiological processes in 
the body than acute lack of sleep over 40 h. In our study, the SR and SE conditions
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represented a method for manipulating the homeostatic process of sleep regulation. As 
most sleep and sleep-deprivation-related genes were shown to be expressed at a 
higher level following SR, it was concluded that the elevated homeostatic pressure 
may play a role. However, the question of what changes occur during chronic 
compared to acute sleep loss, or what accumulates during chronic sleep restriction 
remains unanswered.
7.4 Effect of PER3 VNTR polymorphism on expression of clock 
genes and global gene expression
As briefly mentioned above, effects of clock genes on sleep can also be studied by 
identifying naturally occurring variations in genes such as polymorphisms and 
mutations and exploring the phenotypic effect o f these. A VNTR polymorphism in the 
coding region of the PER3 gene has been shown to associate with diurnal preference, 
as well as a number of other parameters, as already described in the introduction 
section 1.3.1.2. Firstly, the effect of PER34/4 and PER35/5 genotype on the relationship 
between clock gene expression (phase and amplitude) and entrained sleep-wake 
timing was examined, and then genes which were found to be differentially expressed 
between the two homozygous PER3 VNTR genotypes were identified and examined.
A similar study comparing correlations between the two homozygous PER3 
genotypes has already been conducted on BMAL1, PER2 and PER3 genes (Archer et 
al. 2008), but in this thesis the list o f examined clock genes was considerably 
expanded. The phase o f expression of examined clock genes correlated with the 
assessed sleep-wake timings, the correlation was mostly significant in PER34/4 but not 
in PER35/5 homozygotes, which is in contrast to previous findings (Archer et al.
2008). A relationship between REV-ERBa and REV-ERBfi phase o f expression, and 
many sleep-wake timings was found to be significant in PER34/4 homozygotes 
compared to PER35/S (Figure 1.17). By contrast, the correlations between REV-ERBa 
expression amplitude and sleep-wake timings were only significant in PER3S/5 
homozygotes (Figure 1.18). This suggests that these two genes do not only play an 
important role in the circadian regulation of sleep, as mentioned above, but may also 
contribute to the many phenotypic differences observed between the two homozygous 
PER3 VNTR genotypes, thus possibly identifying a novel role for REV-ERBa and
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REV-ERB^ genes in regulation of sleep and sleep homeostasis. Besides REV-ERBa 
and REV-ERBfi, we show that CSNK1D and TIMELESS phase of expression also 
plays a role in determining bedtimes and wake times, although the role of TIMELESS 
in influencing bedtimes is significant in PER35/5 homozygotes. Although PER3 
expression amplitude and phase also show significant correlations with reported 
sleep-wake timings, the number of individuals providing data was too low, making 
these results unreliable. These results thus represent additional evidence for a role of 
clock genes in sleep homeostasis, in particular REV-ERBa and REV-ERB/3.
The PER3 VNTR polymorphism has been shown to have varying phenotypic 
manifestations in humans (sleep timing, mood disorders, cardiovascular, vulnerability, 
cancer, immune function), as described in section 1.3.1.2. The collected expression 
data (44,000 probes per time point) were therefore explored in order to examine 
whether the two PER3 VNTR homozygous genotypes displayed differences at the 
level o f gene expression, and whether any of the observed phenotypic trait differences 
could be attributed to differential expression of specific genes. Using two different 
approaches, we identified many genes differentially expressed between the two 
genotypes. Our findings suggest the cellular-mediated and humoral immune functions 
to be more active in PER35/5, while phagocytosis and antigen-presentation are more 
pronounced in PER34/4 homozygotes.
Phosphorylation and dephosphorylation is one of the key post-transcriptional 
modifications, which plays a major role in setting the period of the circadian feed­
back loop. Four phosphatases were expressed at a higher level in PER35/5> compared 
to PER34/4 homozygotes. Additionally, PERI and one PER2 probe were differentially 
expressed between the two genotypes, but due to the abundance of probes targeting 
these two genes the significance could have arisen by chance alone. Additionally, 
transcripts for the four kinases CAMK, PI3K, MAPK, and MAPKIP were also 
differentially expressed between the two homozygous genotypes, which have been 
shown to be involved in phosphorylation of clock proteins (Weber et al. 2006; Yagita 
et al. 2009) and thus possibly involved in circadian clock regulation.
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Three of the identified differentially expressed phosphatases (PP2A, PP2B and PP1) 
have been shown to hyperphsphorylate tau, a protein previously shown to play a role 
in pathogenic neurodegeneration, such as Alzheimer’s disease, Down’s syndrome and 
dementia, as well as reversible downregulation of neuronal activity, such as that seen 
during hypothermia, anaesthesia, or hibernation (Arendt et al. 2003; Gong et al. 1995; 
Planel et al. 2007; Weingarten et al. 1975). These findings suggest the possibility that 
these enzymes may be differentially regulated between the two PER3 homozygous 
genotypes in neural tissue as well.
Additionally, differentially expressed PI3K  and PP2A involved in PI3K-AKT and 
PP2A-AKT signalling pathways, respectively, have been shown to mediate the effects 
o f BDNF and serotonin, and dopamine, respectively (Andjelkovic et al. 1996; 
Johnson-Farley et al. 2006). Both signalling pathways regulate GSK3 
phosphorylation, which in turn has been shown to play a role in mood disorders, as 
well as the molecular clock, and could influence period length. The two homozygous 
PER3 VNTR genotypes have also been shown to differ in their association with mood 
disorders; the PER35/5 homozygotes have been shown to be prone to an earlier onset 
of bipolar disorder (Benedetti et al. 2008), while the PER34/4 homozygotes have been 
shown to be at an increased risk of post partum  depressive disorder and bipolar 
disorder onset (Dallaspezia et al. 2011).
Genes involved in cerebellar cell layer differentiation (TMEM176B and RORA) 
(Hamilton et al. 1996; Maeda et al. 2006), as well as a gene shown in rat to play a role 
in depression (TMEM176A) (Blaveri et al. 2010) were also identified as differentially 
expressed between the two homozygous genotypes in our study. These findings may 
point to differences found in depression susceptibility between the two genotypes.
Taken together, the differentially expressed genes were shown to be involved in 
immune function, phosphorylation/dephosphorylation, chronotype determination, and 
neurophysiology, suggesting that the PER34/4 and PER35/5 homozygotes may differ in 
this regard.
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7.5 Identification of a reference gene for RT-QPCR in circadian 
studies
The literature on the use of reference genes in RT-QPCR experiments is vast and 
varied. However, time-series and circadian variation in studied and/or reference genes 
has rarely been taken into account when selecting appropriate internal controls. Our 
own microarray data were, therefore, analysed to identify stably expressed genes. 
Selected genes from this list, as well as 12 known reference genes (from geNorm kit) 
were tested on a subset of our samples to analyse the stability of these genes and their 
appropriateness for our study. ACTB  has been confirmed as the reference gene of 
choice as it was found to be stably expressed in our microarray dataset, and was 
identified as one of stably expressed genes by geNorm and NormFinder analysis. 
ACTB  is an established reference gene and has already been shown to be stably 
expressed in blood cells when samples were collected across the circadian cycle 
(Yang et al. 2011), and has shown no variation in response to SD in rats (Lee et al.
2009), or humans (this study).
7.6 Conclusion
This work has shown that a relationship exists between entrained sleep-wake timing 
and gene expression of several clock genes and that this relationship is affected by the 
PER3 VNTR genotype. It was also shown that sleep loss affects certain sleep and 
sleep-deprivation related genes but not all. Global gene expression in peripheral blood 
has also been shown to differ between homozygous PER3 VNTR genotypes. Based 
on these findings the hypothesis has been accepted.
7.7 Limitations of the study and future work
Firstly, the tissue used for all the expression analyses carried out in the study at hand 
was whole blood, which is composed of several cell types. Although the expression 
profile of PERI has been shown to be the same in both mononuclear and polynuclear 
cells (Kusanagi et al. 2004), and that the amount o f sleep obtained per night does not 
have any effect on the number of leukocytes (Adachi et al. 2010), the relative 
proportions o f the different cell types have been shown to be influenced by sleep
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deprivation (Ozturk, et al. 1999). In order to obtain a more accurate picture of gene 
expression, the variation in cell numbers should also have been assessed and 
considered while studying variation of gene expression over time. Another interesting 
approach would be to analyse the protein levels for some of the genes identified in the 
present study. For this, additional blood samples would have to have been collected at 
every time point and, using the ‘buffy coaf technique, leukocytes would have to have 
been extracted. These would then be used for protein analysis. Similarly, additional 
blood samples during baseline and/or recovery sleep would have been interesting to 
analyse, especially when studying the PERS VNTR genotype differences. This would 
enable us to study the potential difference in rate and mechanisms of recovery from 
sleep deprivation between the two homozygous PER3 genotypes. However, for these 
additional parameters to be analysed, additional blood samples would have to be 
drawn during the study and at every time point, thus breaching the allowed limits of 
blood volume being taken from human volunteers within 3 months.
Secondly, the laboratory sessions of the study took place over a period o f several 
months and seasons (spring 2009 -  spring 2010). The photoperiod changes over 
seasons, and that affects the expression of genes as well as mood, sleep and wake 
times, and possibly other factors. Because of this the morning and evening oscillator 
could have influenced the data. The data could, o f course, not be split by season of 
data collection, as that would result in lack of power. On the other hand all the data 
could not have been collected in a shorter time, as the capabilities of the facilities, 
staff and researchers were limited.
Thirdly, additional analysis using the data already collected could be performed in the 
future. In this study we have computed and studied correlations between clock gene 
expression and assessed sleep-wake timings, as well as analysed the correlations for 
each PER3 genotype separately. Additionally, the correlations in each PER3 genotype 
could also be grouped by condition, and the interaction genotype x condition could be 
studied. Besides this, we have also collected a wealth of data (questionnaires listed in 
Appendix C) on other aspects of volunteers’ health, habits and personality.
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Correlations between these data and clock genes, and possibly other genes expressed 
in a circadian manner, could also be analysed in the future.
Finally, it would be interesting to study some of the mechanisms and interactions 
which our results have highlighted, and which we have suggested in the discussion, 
using cell culture. We have, in fact, collected fibroblast biopsies from study 
volunteers undergoing a FD protocol at baseline and half way through the FD, in a 
study carried out in parallel to this one. The biopsies were collected from all 
volunteers timed to their habitual sleep-wake timing. These cells are readily available 
to be used in our laboratory. Alternatively or additionally a blood cell line could also 
be used.
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Appendix A: Volunteer Information Document
INFORMATION PROTECTED BY THE PRIVACY ACT OF 1974
Volunteer Information and Informed Consent Document
For
Cognitive vulnerability following extended wakefulness in defined genotypes: 
Effects of sleep duration on sustained attention, executive function, and
novel biomarkers
Surrey Sleep Research Centre, University of Surrey, Guildford
Principal Investigator: Prof. Derk-Jan Dijk, Surrey Sleep Research Centre,
University of Surrey, Guildford,UK 
Email: D.j.Dijk@surrey.ac.uk
Associate Investigators: Dr Simon Archer, University of Surrey, Guildford, UK
Email: Simon.Archer@surrey.ac.uk
Dr Malcolm von Schantz, University of Surrey, 
Guildford, UK
Email: M.von.Schantz@surrey.ac.uk
Prof Colin Smith, University of Surrey, Guildford, UK 
Email: C.Smith@surrey.ac.uk
Prof John Groeger, University of Surrey, Guildford, UK 
Email: J.Groeger@surrey.ac.uk
Dr Andrzej M Kierzek, University of Surrey, Guildford,
UK
Email: A.Kierzek@surrey.ac.uk
1. Nature and purpose: You have been offered the opportunity to participate in the 
research study “Cognitive vulnerability following extended wakefulness in defined 
genotypes: Effects of sleep duration on sustained attention, executive function, and 
novel biomarkers” . Funding for this research study is provided by the US Air Force 
Office of Scientific Research. Your participation will occur at the Surrey Sleep 
Research Centre, University of Surrey, Guildford, UK.
The purpose of this research is to evaluate, how the cycles of sleep and wakefulness 
are regulated by biological clocks. These clocks are influenced by a set o f genes 
which are called clock genes. We discovered that an alteration in one of the clock 
genes, the gene PERS, leads to changes in the structure of sleep and cognitive 
performance during wakefulness. How this alteration in PER3 interacts with the
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mechanism involved in the regulation of sleep and biological rhythms is not yet 
known. In particular it is not known how extending your sleep period to 10 hours per 
day and restricting your sleep period to 6 hours per day will affect sleep and 
performance differently in people who carry different versions of the PER3 gene.
The aim of this research study is to investigate how alterations in the clock gene 
PER3 affects sleep and performance and the rhythms of hormones and other factors in 
your blood including the rhythms in the expression o f genes in white blood cells. This 
research study has been reviewed by an independent Ethics Committee which has no 
objections to it taking place. The research study consists of two parts and dependent 
on the outcome of Part One, we may or may not ask you to participate in Part Two. 
Participation in the entire duration of the experiment even when we ask you to 
participate in part two cannot be guaranteed.
Here is some information to help you decide whether or not to take part. Please take 
time to read it carefully. If  there is anything you do not understand, or if you would 
like more information, please ask us. Participation in the research study is voluntary, 
and you can withdraw your consent at any time and for any reason. You should 
volunteer only if you have the time to complete the whole study. Thank you for 
reading this information, and thank you again if you decide to take part. We will give 
you a copy of this form to take away with you.
If  you decide to participate in the research study, you will be required to undergo a 
screening process which will involve the completion of questionnaires about your 
general health and sleep habits. We will also obtain written consent from you and we 
will inform your General Practitioner (GP) that you are participating in this research 
study.
P a rt 1: A total of approximately 750 people will take part in this section. In order to 
take part in this section of the study we need to collect information on your sleep and 
health. For this we will ask you to complete a number of questionnaires but only after 
we have explained the study to you, provided you with a tour of the Clinical Research 
Centre and obtained your written informed consent. One of the investigators or a post­
doctoral research officer associated with the project will explain the research study to 
you and answer any questions you may have. This will take place in a private room 
and is estimated to take 60-90 minutes. We also need to analyze the structure o f your 
PER3 clock gene. For this we will use the buccal swab technique to collect cells that 
will be used for the analysis of the clock gene. We will stroke the inside of your cheek 
with a swab. This does not hurt but cells from the inner cheek will stick to the cotton 
swab. The total duration o f the visit will be less than 5 hours. If  you are not selected 
and you agreed to participate in future studies, we may contact you to participate in 
another study corresponding to your profiles.
If you satisfy the following inclusion and exclusion criteria you may be able to take 
part in the study. You can choose not to participate and will not lose any benefits to 
which you are otherwise entitled.
Inclusion and exclusion criteria:
• Be aged 20-35 years
• Be a non-smoker
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• Not consume more than 5 cups of caffeinated beverages (e.g. coffee/tea/coke) 
per day
• Not consume more than 14 units of alcohol per week (1 unit is equivalent to V2  
pint beer or 1 small glass of wine)
• Have a body mass index between 20 and 33 if you are a man and 18.5 and 33 
if you are a woman.
• Not be taking any medication (except non-steroid skin creams or mild pain 
killers)
• Not have had a recent acute or chronic illness
• Not have any sleep disorders
• Not be pregnant (women only)
• Not have been a shift worker or traveled across more than one time zone in the 
past two months
In addition to these criteria, in order to participate in part 2 of this study you must: not 
have donated blood in the past six weeks
If  you are a woman you must be at least six months post-partum, not breast feeding, 
not pregnant and not planning a pregnancy in the immediate future.
There may be other reasons why you may not be able to participate in this study. The 
study doctor or staff will discuss these with you.
P a rt 2: In this part of the investigation we will first record your rest-activity/sleep- 
wake patterns for two weeks, while you go about your normal schedule. You will then 
come to the laboratory for a medical screen. If you are eligible and available you then 
will stay in the laboratory for two periods of 11 days, separated by at least one week. 
During this period you will undergo intensive physiological investigations, including 
sleep recordings and measurements o f performances, hormones and expression of 
genes in white blood cells. A total of approximately 36 subjects will be enrolled in 
this study.
Experim ental procedures (P art 1 and 2):
P a rt 1: You will be asked to complete a series of questionnaires regarding your 
general health and sleep. You will also ask to provide a buccal swab for DNA 
analysis. Upon outcome of this test, then you will be asked to participate in part 2 of 
the study. Not more than 36 volunteers will complete part 2.
P a rt 2: 
Pre-study:
Two weeks prior to the beginning of the study you will be asked to complete a sleep 
diary and wear an actiwatch (see below). For the first week you will be asked to 
maintain your normal sleep/wake schedule and in the second week we will ask you to 
stick to specific bed and wake times that are close to your normal average bed and 
wake time. Any participant who deviates from the requested sleep schedule for more 
than 30 minutes more than twice in the week prior to the experiment will not be 
allowed to start the laboratory part of the study. It maybe that the laboratory study can
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be rescheduled after the rest-activity monitoring is repeated and compliance is 
achieved, but this cannot be guaranteed.
You will be asked to avoid prescription or non-prescription drugs, over-the-counter 
drugs, recreational/street drugs, and other foreign substances during the last three 
weeks before entering the study, and compliance will be verified upon admission with 
a urine toxicology screen.
For three days prior to the study you will also be asked to refrain from carrying out 
any strenuous exercise, drinking alcohol or caffeine-containing drinks, or from taking 
any medication, food supplements, etc. during the pre-laboratory segment o f the 
study.
Upon admission to the Clinical Research Centre you will undergo a medical exam 
during which we will do blood tests, a pregnancy test if relevant, and also test for 
drugs of abuse and alcohol.
In-laboratory  study:
You will be living in the Clinical Research Center for 11 consecutive days on two 
occasions. You will be sleeping in a windowless bedroom. On both occasions, you 
will be scheduled to two baseline sleep-wake cycles (8h:16h) the timing o f which will 
be determined by your sleep habits. These two baseline sleep episodes will be 
followed by either seven consecutive sleep-restricted wake cycles (6h:18h), or seven 
consecutive sleep-extended wake cycles (10h:14h). During the waking episodes you 
will stay inside the Clinical Research Centre. You will be asked to complete 
computerized performance test every 2 hours. The performance test battery takes 
approximately 40 minutes.
Following both sleep restriction and sleep extension, you will undergo simulated 
extended duty hours, i.e. stay awake in constant routine condition for approximately 
40-h during which workload, sustained attention, and executive function will be 
closely monitored.
After waking up in the morning after the sleep restriction or sleep extension you will 
stay in bed and the nurse will insert a thin plastic tube (catheter or cannula) in a vein. 
During the approximately 40-h period you will remain in a constant semi-recumbent 
position and be given hourly snacks and drinks. You will also be asked to conduct 
performance tests every two hours and blood samples will be taken every hour for a 
30 h period using the catheter. After the constant routine there will be a 12-h recovery 
sleep episode and you will be free to leave the laboratory after this has been 
completed.
There will be no follow-up visits.
M easurem ents to be taken:
Actiwatches: you will be asked to wear an Actiwatch L® (Cambridge 
Neurotechnology, UK) throughout your participation in the study including the period 
in between the two 11 day sessions. Actiwatches are compact, unobtrusive, light­
weight, wrist-worn devices (27 x 26 x 9 mm, 16 g) used for measuring activity and
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light exposure in chronobiological and sleep research. You will be given written 
instructions to wear the watch continuously except when bathing/showering.
Sleep diary: you will also be required to keep a sleep diary covering the period of 
your participation. You will be asked to estimate the duration, timing and quality of 
all sleep periods.
Brain waves and other variables: Your brain waves, in the form of an 
electroencephalogram (EEG) and eye movements or electrooculogram (EOG), and 
Electrocardigram (ECG) will be monitored during all sleep episodes while you are in 
the laboratory and during wake episodes as well. This will be achieved by placing 
electrodes on your scalp and a few centimetres from your eyes.
Heart Rate: Heart rate will be monitored continuously while you are in the laboratory 
by two electrodes placed on the chest.
“Elasticity” o f your major arteries will be assessed using a special type of ultrasound 
scan connected to a computer system. A probe will be placed over your radial (wrist), 
carotid (neck) and femoral (groin) arteries by a trained operator. In addition to this we 
will also measure your blood pressure and perform an Electrocardiogram trace which 
will involve attaching stickers and electrodes to your shoulders and chest. The whole 
procedure should take no more than 30 minutes.
Chin muscle tone: Movement in chin muscles will be recorded during the sleep 
episodes in the laboratory, by placing two electrodes on your chin.
Blood sampling: We will collect no blood during phase 1. We will collect one blood 
sample prior to enrolment in phase 2 for screening purposes. Blood sampling will also 
take place once an hour during a 30 h period in constant routine in order to measure 
rhythms of clock genes, a large number of hormones, including melatonin and other 
variables that will provide information about the timing o f your body clock. The total 
volume of blood collected will be 485 ml (less than one pint).
Performance Test Sessions: While in the laboratory you will be asked to complete a 
battery of psychomotor tests, lasting approximately 40 minutes, every two hours 
during all wakefulness periods.
We will also assess your hunger and appetite throughout the laboratory part o f the 
protocol. Your blood pressure and pulse will be taken repeatedly.
Rating scales/questionnaires: The Karolinska Sleepiness Scale (KSS): asks about 
sleepiness in the immediately preceding period and has been validated with respect to 
objective measures of sleepiness. The Survey of British Sleep questionnaire will be 
used to assess sleep duration and quality, demographic and ethnicity data. Epworth 
sleepiness scale (ESS): measures to what extent people feel drowsy or sleepy during 
the day. The Home-Ostberg questionnaire (HO) determines your preferred timing of 
sleep and waking activities, i.e. are you a morning or evening person. The Pittsburgh 
Sleep Quality Index (PSQI) questionnaire quantifies sleep quality and sleep problems 
during the past month. Positive and Negative Affect Scale (PANAS): a short scale (20 
items -yes/no) measuring the current level of well-being by asking questions
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pertaining to people’s level of arousal, activity, anxiety, mood states, this instrument 
includes two sub-scales (positive mood statement, and negative mood statements). 
The Big-Five questionnaire: determines the personality parameters as emotion, 
imagination, agreeableness, conscientiousness and extraversion. Insomnia Severity 
Scale contains questions about your sleep and how it impacts your waking activity 
and SF36 is a standard set o f questions about quality of life. We will also ask you to 
do Verbal reasoning task and complete IQ test (RAVENS).
G eneral inform ation
Once you have been screened and accepted into the study, if you live locally you will 
be transported to the unit and home again by taxi. If  you do not live locally, you will 
be transported to and from the nearby train or bus station and will be reimbursed for 
all public transport costs as agreed with you during screening.
Standard meals (e.g. lasagne, shepherds pie,) and decaffeinated tea / coffee will be 
provided whilst you are resident at the unit. No food is to be consumed other than the 
food which is provided for you by the unit at the allocated times. You are expected to 
eat the standard meals provided to you, and you will not be provided with any special 
dietary requirements you may have (e.g. vegetarian).
The CRC has a non-smoking policy is strictly adhered to.
3. Discomfort and risks: The risks associated with this study are currently
considered minimal but the protocol and procedures may cause risks to the subjects 
which can currently not be foreseen.
You will probably feel quite sleepy during some segments of the study. You will be 
asked to remain awake during the entirety of the scheduled wake times and you will 
be monitored to assure that you are awake during those times.
A risk associated with lying in bed for 4Oh, is the possibility of deep vein thrombosis 
developing, which may be increased in women using oral contraception. Other risks 
associated with remaining in bed for 40h are fainting and feeling dizzy or light­
headed on getting out of bed.
You will be asked to regularly move your legs throughout the 4Oh of wakefulness, to 
minimise the risk of deep vein thrombosis. Two nurses will aid you when you get out 
of bed, to minimise the risk o f fainting.
The intravenous thin plastic tube (catheter) will be inserted into a peripheral (arm) 
vein by a qualified person (e.g. nurse, paramedic, medical practitioner or 
phlebotomist) experienced in cannulation. Blood will be collected by an appropriately 
trained nurse and aseptic techniques will be used. A nurse or medical practitioner will 
be on call to the supervising staff in case any problems occur during collection of 
blood.
The blood sampling system to be used in this study has been used in previously 
studies without any major complications.
There may be some discomfort or bruising on initial insertion of the catheter into the 
vein, but wearing the catheter should not be painful. There is a rare chance of a small
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blood clot developing or local infection around the area where the catheter is inserted, 
or in very rare case the possibility of embolism, phlebitis, or destruction of 
neighboring tissue. Occasionally, there is a black or blue mark, which may last for a 
couple of weeks; and, rarely, a small scar at the site where the catheter is inserted. 
Rarely, mild discomfort may occur from the tube in the vein. If  this should occur, we 
will either reposition it or remove it completely and only with your permission would 
we reinsert it. To help keep the venepuncture site clean, we may ask permission to 
shave the forearm hair of the participant prior to insertion of the catheter. There is a 
possibility that the volunteer may faint during or after the IV (intra-venous) insertion 
procedure. A minor skin rash or reaction to the tape used to hold the catheter in 
position may develop.
The amount of blood drawn during this research study should not significantly alter 
blood volume.
The tape and special paste used to attach the EEG electrodes may cause some minor 
discomfort, and the glue used to hold the electrodes to the scale may leave a flaky 
residue for a few days. If  this occurs we will move the electrodes to an unaffected 
area and treat the affected area with cream.
In addition to this information Consent Document you will be given a (non-scientiflc) 
verbal explanation of the study procedures and its significance. You will be shown all 
the questionnaires, and the tests and equipment to be used will be demonstrated. The 
payment procedure will be explained and you will be told that should you agree to 
participate, you will be free to withdraw from the study at any time.
All the tests and questionnaires we will ask you to complete have been used in 
previous studies.
Throughout the research study at least one investigator will either be present in the 
building or on call. One nurse will be on site at all times.
Should you experience any discomfort during the test sessions or you become unwell, 
you are asked to report it to the member of staff supervising the study. A medical 
supervisor will be on call to the investigators should an adverse event occur.
If  you became ill soon after leaving our unit, you should contact us immediately on 
the numbers provided on the emergency contact card. Your rights at law to claim 
compensation where you can prove negligence are not affected.
Every effort will be made to ensure you are not excessively sleepy when you are 
discharged.
4. Precautions for female subjects or subjects who are  or may become pregnan t 
during the course of this study: A1 women will undergo a pregnancy test prior to 
admission and pregnant women will not be eligible to participate.
5. Benefits: You are not expected to benefit directly from participation in this 
research study but others may because this research could lead to a better 
understanding of sleep disorders and the mechanisms underlying aspects of mental 
performance associated with sleep loss.
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6. Compensation:
All volunteers will be reimbursed for reasonable out of pocket expenses, e.g. bus 
fares, etc. For the completion of the initial characterization, including the genotyping 
and questionnaires, each volunteer will receive £10.
In part 2, volunteers who complete the 2 week period o f activity monitoring and 
completion of daily sleep diaries will receive £100. Those who complete the entire 
study, including the two 11-day laboratory studies will receive a total o f £3000. 
Should you withdraw from the study, payment will be made to you on a pro rata basis 
at the discretion o f the principal investigator.
Please note that if  you have been withdrawn from the study for any positive results on 
urine drugs of abuse at any time, you will not receive any of the study payment.
This payment, depending on your circumstances, may be liable to income tax. Please 
note that non-compliance with any of the procedures or tests/measurements under 
investigation may result in a decrease o f the inconvenience allowance. You can 
withdraw from the study at any time and will not lose any benefits to which you are 
otherwise entitled.
You will not incur any additional costs as a participant in this research study.
7. Alternatives: There are no alternative procedures but to withdraw from the
research study. You are free to do so at any time and you will be under no obligation 
to give the reason for withdrawal or to attend again for any experimentation.
8. Entitlem ents and confidentiality:
No findings from this research study that could identify you will be published. By 
using a code for each participant rather than your name, your anonymity is assured. 
All information will be collected and stored in accordance to the Data Protection 
legislation (1998).
Storage and disposition of samples: The blood and buccal samples and extracted 
DNA as well as other variables collected in this study will be stored. We will ask you 
to give consent for using these samples for the research described in this document 
and ask you for separate consent for these samples to be used for other research in the 
area o f sleep, rhythms and cognition. This other research can, however, only be 
conducted with approval of an Ethics committee. We will not perform tests of known 
clinical value for diagnosing or predicting disease on samples that can be linked to 
you individually without your consent specifically for these tests. If  you do not give 
consent for use of your samples in other research then the sample will be destroyed 
three years after completion of the study, otherwise it will be kept indefinitely
Any information and results will be treated as highly confidential. The Wright Site 
Institutional Review Board, HeadQuarters US Air Force, Biomedical Research 
Regulatory Division (HQ USAF /SGRC), and the Office o f the Director o f Defence 
Research and Engineering (DDR&E) will have access to the coded data. If  the results
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are published in scientific journals or in any other fashion, it will be made in a way 
that fully protects your privacy. We will not use the data for any other purpose 
without your full consent.
You must not take part in too many studies because it is not good for you. So, we and 
other units like ours in the UK keep a database o f healthy volunteers and when they 
take part in studies. We will enter into the database:
• your National Insurance (NI) number (if you are a UK citizen); or
• your passport number and country of origin (if you are not a UK citizen);
Only staff at the CRC and other medical research units can use the database. We may 
call other units, or they may call us, to check your details. We will keep your details 
for at least 2 years. If  we need to contact you about the study after you have finished 
it, but we cannot because you have moved or lost contact with your GP , we might be 
able to trace you through the information in the database.
If  significant new findings develop during the course o f the research study which may 
affect your willingness to participate, you will be informed.
If  an unanticipated event (medical misadventure) occurs during your participation in 
this research study, you will be informed. If you are not competent at the time to 
understand the nature of the event, such information will be brought to the attention of 
your next of kin.
Next of kin details:
Name________________________________________  Phone ( ) ______________
The decision to participate in this research is completely voluntary on your part. No 
one may coerce or intimidate you into participating in this program. You are 
participating because you want to. Professor Derk-Jan Dijk, or an associate, has 
adequately answered any and all questions you have about this study, your 
participation, and the procedures involved. Professor Derk-Jan Dijk can be reached at 
(01783) 682503. Professor Derk-Jan Dijk, or an associate will be available to answer 
any questions concerning procedures throughout this study. If significant new 
findings develop during the course of this research, which may relate to your decision 
to continue participation, you will be informed. You will be free to withdraw from 
the study at any time and you will be under no obligation to give the reason for 
withdrawal or to attend again for any experimentation. You may be withdrawn from 
the study by the principal investigator or by the medical supervisor without reason, or 
if you deliberately and persistently fail to comply with the study protocol. If  you have 
any questions or concerns about your participation in this study or your rights as a 
research subject, please contact Dr Daryl Bendel at 01483 689797.
We will ask whether you are willing to be contacted again for participation in future 
studies.
If  you have any questions or would like to be informed about the aggregate research 
findings, please do not hesitate to contact the researchers. In the first instance, contact:
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Dr. Nayantara Santhi 
University of Surrey,
Guildford GU2 7XH
Phone: 01483 68 6749 
Email: n.santhi@surrey.ac.uk
Or:
Professor Derk-Jan Dijk
Surrey Sleep Research Centre, Faculty of Health and Medical Sciences, 
University of Surrey,
Guildford GU2 7XH 
Phone: 01483 68 9341 
Email: d.j.dijk@surrey.ac.uk
Appendix B: Informed consent
Name of volunteer 
Identification code.
Research Study: Cognitive vulnerability following extended wakefulness in defined
genotypes: Effects o f sleep duration on sustained attention, executive function, 
and novel biomarkers
Institution: Surrey Sleep Research Centre, University of Surrey, Guildford
Investigators: Prof. Derk-Jan Dijk, Dr Simon Archer, Dr Malcolm von
Schantz,
Prof Colin Smith, Prof John Groeger, Dr Andrzej Kierzek
To indicate that you have read and understood 
each o f the statements, please initial the boxes
I have read the information sheet provided. I have been given a full explanation by the 
scientific investigators of the nature, purpose and the likely duration o f the research 
study, and what I will be expected to do. I have been given the opportunity to question 
the investigators on all aspects of the study, and have understood the information 
given as a result.
I agree to comply with any instruction given to me during the research study and to 
co-operate fully with the investigators and other staff, informing them immediately of 
any problems that may rise.
I understand that all documentation about a volunteer is held in the strictest 
confidence and must comply with the Data Protection Act (1998).
I understand that I am free to withdraw from the research study at any time without 
needing to justify my decision and without prejudice. I understand that such a 
decision will in no way affect my employment.
I acknowledge that on completion of the entire research study (the initial 
characterisation, 2 week period of activity monitoring and completion o f daily sleep 
diaries, and the two period of 11 day laboratory study I will receive £3000. If  I 
withdraw from the research study, payment will be made to me on a pro rata basis. If  
I only complete the first part o f the research study (the genotyping and questionnaires)
215
I will receive £10. If  I only complete the 2 week period of activity monitoring and 
completion of daily sleep diaries I will receive £100. If  I am not selected for the 
research study I will only be reimbursed for out of pocket expenses
I understand that the University of Surrey holds insurance, which covers claims for 
injury or deterioration in health, which arise directly from participation in clinical 
trials but that it applies only in those situations where the University can be shown to 
be legally liable.
I understand that I will be asked to sign two copies of the consent form and that I will 
keep one of the copies.
I confirm that I have read and understood the above and freely consent to participate 
in the research study: Cognitive vulnerability following extended wakefulness in 
defined genotypes: Effects o f sleep duration on sustained attention, executive 
function, and novel biomarkers.
I agree to comply with the instructions imposed by this research study.
I agree that you contact me to participate in future studies and I understand that I will 
be asked to give written informed consent separately for each study?
Tick only one of the following two statem ents
I agree that my DNA data and other samples are stored and used for other research in 
the area of sleep, circadian rhythms and cognition, provided that an Ethics committee 
has given its approval
I do not give permission to use my DNA and others samples for other research;
Information on any aspect o f this study can be obtained by contacting Prof Derk-Jan 
Dijk on 01483 689341.
Name of volunteer:  USE BLOCK CAPITALS
Address of volunteer:.............................................................
Telephone of volunteer:............................................................
M obile:........................................
E-mail address of volunteer:.................................................................
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Signature of volunteer:..........................................................
Date..............................
Name of witness (could be part of the research team):......
USE BLOCK CAPITALS
Signature of witness (could be part of the research team): 
Date.........................
Privacy Act Statement
Authority: We are requesting disclosure o f personal information, to include your National Insurance 
Number. Researchers are authorized to collect personal information (including National Insurance 
number) on research subjects under the Data Protection legislation (1998)
Purpose: It is possible that latent risks or injuries inherent in this experiment will not be discovered 
until some time in the future. The purpose o f  collecting this information is to aid researchers in 
locating you at a future date if  further disclosures are appropriate.
Disclosure: Disclosure o f  the requested information is voluntary. No adverse action whatsoever will 
be taken against you, and no privilege will be denied you based on the fact you do not disclose this 
information. However, your participation in this study may be impacted by a refusal to provide this 
information.
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Appendix C: List of questionnaires administered during screening
1. Medical questionnaire
2. Epworth sleepiness scale
3. Pittsburgh sleep quality index
4. Big-five questionnaire
5. Positive & negative affect scale
6. The insomnia severity index
7. Home-Ostberg questionnaire
8. The Munich chronotype questionnaire
9. SF36 health survey
10. Survey of british sleep
11. Karolinska sleep diary
12. Dutch eating behaviour questionnaire
13. General health questionnaire
14. Behavioural inhibition /behavioural approach systems
15. IQ (Ravens)
16. Verbal reasoning task
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Medical Questionnaire 
Appendix D: Questionnaires examined for the purpose of this thesis
MEDICAL QUESTIONNAIRE
Date of birth (DD/MM/YY): .......... / ........... / ...........
Age: ........................
Sex: Male /  Female
Weight:   Height: .............................
BMI: .............................. (official use only)
1. Have you ever been told that you have high blood pressure? YES / NO
If YES, give details.............................................................................................................
Have you had any history of heart trouble? Y E S /N O
If YES, give details..................................................................
Have you a family history of heart disease/stroke? Y E S /N O
If YES, give details............................................................
4. Have you ever been told by a doctor that you have asthma? YES / NO
5. Do you suffer from a wheezy chest? YES / NO
6. Do you ever have pains in your heart and chest? YES / NO
7. Do you ever feel faint or have spells of dizziness? YES / NO
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8. Has a doctor told you that you have a bone or joint YES / NO
problem which could be made worse by exercise?
9. Have you been in hospital at all in the last 2 years? YES / NO
If YES, give details............................................................................................................
10. Have you had any operations or major illness in the last 6 months? 
If  YES, give details.....................................................................................
Y E S /N O
11. Are you undergoing treatment or having any regular medication 
at the moment?
Y E S /N O
If YES, give details.....................................................................................
12. Are you taking any pills or any other medicines, including inhalers, for any o f the 
following:
- heart trouble, angina? Y E S /N O
chest pains or blood pressure? Y E S /N O
asthma or other chest diseases? Y E S /N O
contraceptives {women only) Y E S /N O
or for anything else? Y E S /N O
If YES, give details...............................................................................
13. Do you have any physical disabilities of any kind? Y E S /N O
If YES, give details.....................................................................................
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14. Have you ever suffered any complications from previous trials YES / NO
or treatment?
If YES, give details............................................ ................................................................
15. Do you suffer from any allergies?
If  YES, give details..................................................................
Y E S /N O
16. Have you ever had an adverse reaction to a medicine or a food? Y E S /N O
If YTS, give details............................................................
17. What is your average weekly intake of alcohol? ......................... .. units per week
(One unit is half a pint beer /  one glass of wine / one measure of spirits)
18. Has there been a time when you regularly consumed more than Y E S /N O
14 units of alcohol per week?
If  YES, give details...............................................................
19. Have you, or a member of your family, ever been told by a Y E S /N O
doctor that you had epilepsy problems?
If  YES, give details.................................................................
20. Have you recently been checked for glaucoma by an optician? YES / NO
If YES, have you been diagnosed with glaucoma? YES / NO
221
Medical Questionnaire
21. Have you ever been diagnosed with mental problem such as 
clinical depression?
Y E S /N O
22. How many hours do you sleep per night on average? hours
23. Have you done any shift work in the past year? Y E S /N O
24. Have you travelled across more than one time zone in the 
past 2 months?
Y E S /N O
25. Women only: Do you have regular menstrual cycles? Y E S /N O
(ranging in length from 26-35 days with a maximum of three days variation 
month-to-month)
To the best of my knowledge I have given true and complete information. I agree to 
my GP being informed, and for the investigators to contact my GP for past medical 
history, when deemed essential. If  a significant abnormality is discovered in the 
course of the study I understand that the Medical Supervisor will discuss this with me 
before corresponding with my GP.
Name and address o f GP: Home Address o f Participant:
Participant's Signature:........................................  Date:
Participant’s name: (please print)
2 2 2
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PITTSBURGH SLEEP QUALITY INDEX (PSQI)
Instructions:
Instructions:
The following questions relate to your usual sleep habits during the past month only. 
Your answers should indicate the most accurate reply for the majority of days and 
nights in the past month. Please answer all the questions.
1. During the past month, when have you usually gone to bed at night?
Usual bed tim e :............................................................................
2. During the past month, how long (in minutes) has it usually take you to fall asleep 
each night?
Number of m inutes:............................................................................
3. During the past month, when have you usually got up in the morning?
Usual getting up tim e:............................................................................
4. During the past month, how many hours of actual sleep did you get at night? (This 
may be different from the number of hours spent in bed.)
Hours of sleep per n igh t:............................................................................
For each of the remaining questions, check the one best response. Please answer all 
questions
5. During the past month, how often have you had trouble sleeping because you......
a) Cannot get to sleep within 30 minutes
Not during the Less than Once or twice Three or more
past month ....... once a week ....... a week   times a week ...
b) Wake up in the middle of the night or early morning
Not during the Less than Once or twice Three or more
past month ......  once a week ......  a week   times a week ...
223
Medical Questionnaire
c) Have to get up to use the bathroom
Not during the Less than Once or twice Three or more
past month . once a week ..............  a week   times a week ...
d) Cannot breathe comfortably
Not during the Less than Once or twice Three or more
past month .........  once a week . a week   times a week
e) Cough or snore loudly
Not during the Less than Once or twice Three or more
past month .........  once a week . a week   times a week ....
f) Feel too cold
Not during the Less than Once or twice Three or more
past month .........  once a week . a week   times a week ....
g) Feel too hot
Not during the Less than Once or twice Three or more
past month .........  once a week . a week   times a week
h) Had bad dreams
Not during the Less than Once or twice Three or more
past month .........  once a week . a week   times a week
i) Have pain
Not during the Less than Once or twice Three or more
past month .........  once a week . a week   times a week ....
j) Other reason(s), please describe
How often during the past month have you had trouble sleeping because of this?
Not during the Less than Once or twice Three or more
past month ........  once a week . a week   times a week
Medical Questionnaire
6. During the past month, how would you rate your sleep quality overall?
Very g o o d   Fairly g ood   Fairly b a d   Very b a d ..........
7. During the past month, how often have you taken medicine (prescribed or “over 
the counter”) to help you sleep?
Not during the Less than Once or twice Three or more
past month ....... once a week ....... a week   times a week ...
8. During the past month, how often have you had trouble staying awake while 
driving, eating meals, or engaging in social activity?
Not during the Less than Once or twice Three or more
past month ....... once a week ....... a week   times a week ...
9. During the past month, how much of a problem has it been for you to show 
enthusiasm to get things done?
No problem at Only a very Somewhat o f A very big
all ....... slight problem   a problem ....... problem
10. Do you have a bed partner or roommate?
Partner in same
No bed partner Partner/roomma room, but not Partner in
or roommate? ....... te in other ro o m   same bed ....... same bed ....
If you have a roommate or bed partner, ask him/her how often in the past 
month you have had)...
a) Loud snoring
Not during the Less than Once or twice Three or more
past month ....... once a week ....... a week   times a week ....
b) Long pauses between breaths while asleep
Not during the Less than Once or twice Three or more
past month ......  once a week ......  a week   times a week ....
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c) Legs twitching or jerking while you sleep
Not during the Less than Once or twice Three or more
past month ....... once a week ....... a week   times a week
d) Episodes of disorientation or confusion during sleep?
Not during the Less than Once or twice Three or more
past month ....... once a week ....... a week   times a week
e) Other restlessness while you sleep; please describe
Not during the Less than Once or twice Three or more
past month . once a week ..............  a week   times a week
2 2 6
Medical Questionnaire
HORNE-ÔSTBERG QUESTIONNAIRE
Instructions:
1. Please read each question very carefully before answering.
2. Answer ALL questions.
3. Answer questions in numerical order.
4. Each question should be answered independently of others. DO NOT go back and 
check your answers.
5. All questions have a selection of answers. For each question place a cross 
alongside ONE answer only. Some questions have a scale instead o f a selection of 
answers. Place a cross at the appropriate point along the scale.
1. Considering only your own “feeling best” rhythm, at what time would you get up 
if you were entirely free to plan your day?
- L ' -  J I l- t ., l I l L,n„ l , I l I l . f  l f j _f j I l I I  I l I l
5am 6 7 8 9 10 11 12
2. Considering only your "feeling best" rhythm, at what time would you go to bed if  
you were entirely free to plan your own evening?
W-'1 i1111 '■11L111L111L11 i1111
3. If  there is a specific time at which you have to Not at all dependent
get up in the morning, to what extent are you Fairly dependent
dependent on being woken up by an alarm Very dependent
dock? Slightly dependent
2 2 7
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4. Assuming adequate environmental conditions, 
how easy do you find getting up in the 
morning?
5. How alert do you feel during the first half 
hour after having woken in the mornings?
6. How is your appetite during the first half-hour 
after having woken in the mornings?
7. During the first half-hour after having woken 
in the morning, how tired do you feel?
8. When you have no commitments the next day, 
at what time do you go to bed compared to 
your usual bedtime?
Not at all easy 
Not very easy 
Fairly easy 
Very easy
Not at all alert 
Slightly alert 
Fairly alert 
Very alert
Very poor 
Fairly poor 
Fairly good 
Very good
Very tired 
Fairly tired 
Fairly refreshed 
Very refreshed
Seldom or never later 
Less than one hour later 
1-2 hours later 
More than 2 hours later
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9. You have decided to engage in some physical 
exercise. A friend suggests that you do this 1 
hr twice a week and the best time for him is 
between 7.00-8.00AM. Bearing in mind 
nothing else but your own "feeling best"
Would be in good form 
Would be in reasonable 
form
Would find it difficult 
Would find it very
rhythm how do you think you would perform? difficult
Neither
agree
Disagree Disagree nor Agree Agree 
strongly a little disagree a little strongly
10. At what time in the evening do you feel tired and as a result in need o f sleep?
L l.j . i I j -1 ? I i ,i. i 1 » i t I
8pm 9 io ii  i2
i—1 i 1 r_l i_J ;
lam
11. You wish to be at your peak performance for 
a test which you know is going to be mentally 
exhausting and lasting for two hours. You are 
entirely free to plan your day and considering 
only your own "feeling best" rhythm which 
ONE of the 4 testing times would you 
choose?
8.00-10.00AM
11.00 AM-1.00PM
3.00-5.00PM
7.00-9.00PM
12. If  you went to bed at 11.00PM at what level 
of tiredness would you be ?
Not at all tired 
A little tired 
Fairly tired 
Very tired
2 2 9
Medical Questionnaire
13. For some reason you have gone to bed several 
hours later than usual, but there is no need to 
get up at any particular time the next morning. 
Which ONE of the following events are you 
most likely to experience?
Will wake at usual time 
and NOT go back sleep 
Will wake at usual time 
and doze thereafter 
Will wake up at usual 
time but fall asleep again 
Will NOT wake up until 
later than usual
14. One night you have to remain awake between 
4.00-6.00AM in order to carry out a night 
watch.You have no commitments the next 
day. Which ONE of the following alternatives 
will suit you best?
Would NOT go to bed 
until watch was over 
Would take a nap before 
and sleep after 
Would take a good sleep 
and nap after 
Would take ALL sleep 
before watch
15. You have to do 2 hours o f hard physical work. 8.00-10.00AM
You are entirely free to plan your day and 
considering only your own "feeling best" 
rhythm which ONE of the following times 
would you choose?
11.00AM-1.00PM
3.00-5.00PM
7.00-9.00PM
16. You have decided to engage in hard physical 
exercise. A friend suggests that you do this 
for one hour twice a week and the best time 
for him is between 10.00-11.00PM. Bearing 
in mind nothing else but your own "feeling 
best" rhythm how well do you think you 
would perform ?
Would be in good form 
Would be in reasonable 
form
Would find it difficult 
Would find it very 
difficult
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17. Suppose that you can choose your own work hours. Assume that you work a 
FIVE-hour day (including breaks) and that your job was interesting and paid by 
results. Which FIVE CONSECUTIVE HOURS would you select?
12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 
MIDNIGHT NOON MIDNIGHT
18. At what time of the day do you think that you reach you "feeling best" peak?
12 1 2 3 4 5 6 7  8 9 10 11 12 1 2 3 4 5 6 7  8 9 10 11 12 
MIDNIGHT NOON MIDNIGHT
19. One hears about "morning" and "evening" 
types o f people. Which one of these types do 
you consider yourself to be?
Definitely "morning" type 
Rather more a "morning" 
than an "evening" type 
Rather more an "evening" 
than a "morning" type 
Definitely an "evening" 
type
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TH E M UNICH CHRONOTYPE QUESTIONNAIRE
The following data are essential for the analysis o f your chronotype to be 
comprehensive.
Birth date (YY/MM /DD):.......... / ........... / ...........
Gender: Male / Female
Place of birth:  ....................................................
Height:  cm
Weight: ..................... kg
Im portan t: In the following sections, please give your answers as they hold true in 
your present-time situation. For changing conditions (for example, beginning
o f work), please choose the most frequent or approximate values.
On w orkdays (dont’fi l l  out i f  you are retired)
I have to get up at 
I need
I regularly wake up
From. 
At around.
On nights before workdays, I go to bed a t .
... and it then takes m e . 
If  I get the chance, I like to take a siesta/nap...
correct 
not correct
.. o’clock 
.. min to wake up
.. min before the alarm / with the alarm 
(please delete one)
• o'clock, I am fully awake
. o'clock, I have an energy dip
.o'clock...
. min to fall asleep
I then sleep fo r .......................min
I would feel terrible afterwards
2 3 2
On free days (please only judge normal free days, i.e., without parties etc.)...
My dream would be to sleep until
I normally wake up at
I f  I wake up at around the normal (workday) alarm time, I tiy to get back to sleep
Correct /  Not correct
I f  I get back to sleep, I sleep for another
I n eed ..
F ro m ,
At around
On nights before free days, I go to bed at
... and it then takes me
If  I get the chance, I like to take a siesta/nap...
correct I then sleep f o r ..................... min
not correct I would feel terrible afterwards
Once I am in bed, I would like to read for
... but generally fall asleep after no more than ........min
I prefer to sleep in a completely dark room Correct /  Not correct
I wake up more easily when morning light shines into my room Correct /  Not correct
How long per day do you spend on average outside ( really outside) exposed to day light?
On work days: .................h r s .................. min
On free days: .................h r s .................. min
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Self assessment
After you have answered the preceding questions, you should have a feeling of the 
chronotype you belong to. If, for example, you like (and manage) to sleep quite a bit 
longer on free days than on workdays, or if  you cannot get out of bed on Monday 
mornings, even without a Sunday-night party, then you are more likely a late type. If, 
however, you regularly wake up and feel fresh right from the moment you jump out 
o f bed, and if  you would go to bed early rather than to an evening concert, then you 
are more an early type. In the following questions, please characterize yourself and 
your family members in terms of early/late types.
Extreme Moderate Slight 
early early early Normal
type type type Type type
Slight Moderate Extreme  
late late late 
type
I am ...
As a child, I w as.. .  
As a teenager, I
w as... 1
In case you are older than 65: in the middle o f my life, I w as...
0 1 2  3
My parents are/were...
M other... 0 1 2  3
Father... 0 1 2  3
M y siblings are/were... (please underline Brother or Sister)
Brother/Sister 0 1
Brother/Sister 0 1
Brother/Sister 0 1
Brother/Sister 0 1
Brother/Sister 0 1
Brother/Sister 0 1
Brother/Sister 0 1
2
2
2
2
2
2
2
3
3
3
3
3
3
3
M y partner (girl/boy friend, spouse, significant other) is/was...
0 1 2  3
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
type
6
6
6
6
6
6
6
6
6
6
6
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SURVEY OF BRITISH  SLEEP
Instructions:
Please think about the sleep that you have had over the last week. In these questions 
we use the terms ‘work day’ and weekend -  if you do not work, then please think of 
‘work day’ as Monday to Friday. Similarly, if  you work at weekends and have time 
off during the week, then a ‘work day’ is any day that you were at work and a 
‘weekend’ is any day that you were not at work.
la. On average, over the last seven days, how much sleep IN BED would you say you 
had per day? (PLEASE INDICATE THE APPROXIMATE NUMBER OF 
HOURS AND MINUTES -  IF YOU ARE NOT SURE PLEASE GIVE ME 
YOUR BEST ESTIMATE)
....................................hours ......................................... mins
lb. And were there some days of the week where you slept for a different amount? 
Yes / No
If YES, please specify the day(s) of the week and the amount of sleep below:
Day of the week A m ount of sleep
1c. Please indicate approximately how much sleep you had on each day of the week 
in the last seven days.
....................................hours  mins
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2a. Approximately how much sleep did you get in the last seven days, if  any, that was 
NOT IN BED, on a typical W ORKDAY?
....................................hours  mins 4
2b. Approximately how much sleep did you get in the last seven days, if any, that was 
NOT IN BED, on a typical WEEKEND (non-working) day?
.................................. hours ..................................... mins
3 a. Over the last seven days, what would you say is the average time that you went to 
bed?
.................................. : ..................................... AM / PM
3b. And were there some days in the last week that you went to bed at a different 
time?
Yes / No
If  YES, please specify the day(s) o f the week and bedtime below:
Day of the week Bedtime
3c. Please indicate approximately what time you went to bed each night (or day) on 
each of the last seven days.
.................................. :  AM / PM
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4a. On average, over the last week when did you typically get out o f bed?
.................................. : ....................................AM / PM
4b. And were there some days o f the week when you got out o f bed at a different 
time?
Yes / No
If  YES, please specify the day(s) o f the week and bedtime below:
Day of the week Bedtime
4c. Please indicate approximately what time you got out of bed each day on each of 
the last seven days.
AM / PM
5. How would you describe the overall quality of your sleep over the last seven 
days...?
Very Very
good Good Fair Poor poor
...before getting up for a 1 2 3 4 5
typical working day
...before atypical weekend 1 2 3 4 5
or non-working day
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6. How often, if  at all, would you say that you woke feeling rested and refreshed 
over the last seven days...?
Never Seldom Sometimes Often Always 
...before getting up for a 1 2 3 4 5
typical working day
...before atypical weekend 1 2 3 4 5
or non-working day
7. How would you describe the way in which your sleep over the last seven days has 
affected your energy levels/ amount of effort required in the following areas of 
your life?
Very Very
Negative Negative No effect Positive Positive N/A
Your Work 1 2 3 4 5 N/A
Your Home/Family life 1 2 3 4 5 N/A
Leisure Time 1 2 3 4 5 N/A
8. How would you describe the way in which your sleep over the last seven days
affected how things went generally in the following areas of your life?
Very Very
Negative Negative No effect Positive Positive N/A
Your Work 1 2 3 4 5 N/A
Your Home/Family life 1 2 3 4 5 N/A
Leisure Time 1 2 3 4 5 N/A
2 3 8
9. How would you describe the way in which your sleep over the last seven days 
affected your general levels of satisfaction and enjoyment in the following areas 
o f your life?
Very Very
Negative Negative No effect Positive Positive N/A
Your Work 1 2 3 4 5 N/A
Your Home/Family life 1 2 3 4 5 N/A
Leisure Time 1 2 3 4 5 N/A
10. Thinking about the last seven days, to what extent, would you say that you were 
able to ‘switch o ff  and not think about work issues during a working day 
evening?
Completely Completely
unable to able to
switch off switch off
1 2 3 4 5 6 7
11. And over the last seven days, approximately how often have you experienced any
of the following?
a) Difficulty in getting Not at all 1-3 nights 4+ nights Don’t know/can’t recall
to sleep?
b) Difficulty staying Not at all 1-3 nights 4+ nights Don’t know/can’t recall
asleep?
c) Difficulty in Not at all 1-3 nights 4+ nights Don’t know/can’t recall
waking on time?
d) Difficulty getting Not at all 1-3 nights 4+ nights Don’t know/can’t recall
enough sleep?
2 3 9
12. Have you ever had any sleep problems? YES / NO
If YES, thinking about any sleep problems that you may have, which o f the 
following would you say are the main causes of these problems? (You can check 
more than one boxes.)
a) Noise 0
b) Light D
c) Temperature D
d) Shift work/too tired/too busy to sleep D
e) Illness or discomfort D
f) Medication/Side effect o f medicine 0
g) Worry about/ thinking about work issues 0
h) Worry about/thinking about non-work issues D
i) Needing to go to the toilet 0
j) Having to do something for example having to D
look after a child or pet 
k) Pre-bed activities for example exercise 0
1) Behaviour of bed partners for example snoring D
or going to bed at a different time 
m) Other reason 0
Please specify:........................................................
n) Don’t know 0
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13. Some people have said that the following remedies or activities can help their 
sleep problems. Which, if  any, do you ever use for your own sleep problems? 
(You can check m ore than one boxes.)
a) Over the counter products (e.g Sleepeaze, Kalms, □
Nytol, Valerian etc.)
b) Paracetamol □
c) Antihistamines □
d) Melatonin □
e) Homeopathic remedies □
f) Herbal teas □
g) Lavender pillows □
h) Relaxation tapes or therapies □
i) Listen to music/radio/ watch TV □
j) Drink alcohol □
k) Hot or cold non-alcoholic drink □
1) Food □
m) Read □
n) Prescribed medications □
o) Have sex □
p) Get up and return to bed later □
q) Have a bath or shower □
r) Exercise □
s) Others □
Please specify:...............................................................
t) Do nothing □
u) Don’t know/can’t recall □
14. Does your job involve shift or night work? Yes / No
15. On which days over the last week did you (go to) work or attend/college etc.? 
(You can circle m ore than one days.)
Monday Tuesday Wednesday Thursday Friday Saturday Sunday
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16. Demographics (Please check the option that suits you the best.)
a) Sex/Household status:
Male Housewife □
Female Housewife □
b) Status:
Male Head o f Household □
Not Head o f Household □
c) Age:  y ears .......
Working status:
Employee Full Time □
Self Employed Full Time □
Still at School □
Retired □
Unemployed and seeking work □
TV Region:
Tyne Tees (North East) □
Yorkshire □
Harlech (Wales and West) □
Carlton, LWT (London) □
West Country TV (South West) □
Social Group:
A □  B □  Cl □
Male non Housewife □  
Female non Housewife □
Female Head of Household □
months
Employee Part Time □
Self Employed Part Time □
In full time Higher Education □
Not able to work □
Not working for other reason □
Granada (Lancashire) □
Central (Midlands) □
Anglia (East Anglia) □
Meridian (South, South East) □
C2 □  D □  E D
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g) Marital Status:
Married □
Single □
Separated □
h) Partner’s Working Status:
Employee Full Time □
Self Employed Full Time □
Still at School □
Retired □
Unemployed and seeking work □
i) Number aged 15+ in household:
1 □
3 □
5 or more □
Living with partner □  
Widowed □
Divorced □
Employee Part Time □
Self Employed Part Time □
In full time Higher Education □
Not able to work □
Not working for other reason □
□
□
j) Children in household:
YES / NO (please go to question m)
k) Number of children in household (under 15):
I D  2 D
3 D  4 D
5 or more 0
1) Actual age of children:
Age
Child #1  years
Child #2  years
Child #3  years
243
m) Gross Household Income:
Under £2,500 D £2,5OO-£4,499 □
£4,500-£6,499 □ £6,500-£7,499 □
£7,500-£9,499 D £9,500-£ll,499 □
£11,500-£13,499 □ £13,500-£15,499 □
£15,500-£17,499 D £17,500-£19,999 □
£2O,OOO-£24,999 D £25,000-£34,999 □
£35,000-£49,999 □ £50,000+ D
Prefer not to answer □
n) Ethnie Group:
White □ Black — Caribbean D
Black -  African □ Black -  Other D
Indian □ Pakistani D
Bangladeshi □ Chinese □
Other Asian □ Other group □
Prefer not to answer □
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KAROLINSKA SLEEP DIARY
Instructions:
Please refer to your last overnight sleep episode, i.e. not a daytime nap, when 
answering the following questions. Please indicate whether the time is am or pm.
What time did you go to bed? AM/PM
What time did you try starting to sleep at? AM/PM
How long did it take you to fall asleep? (min)
How many times did you wake up?
How long were you awake for? (min) Please estimate 
the time and duration of each night awakening.
What time did you wake up? AM/PM
What time did you get up? AM/PM
Did your alarm clock wake you up?
Did you do any strenuous activity during the last 24 
hours (if yes, please specify)
How would you rate you rate your quality of sleep?
Best sleep Worst sleep
ever ever
1 2 3 4 5 6 7 8  9
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Appendix G: PER3 genotype-dependent correlations between phase 
of clock gene expression maxima and entrained timing of sleep and 
wakefulness
N um ber o f  individuals contributing data fo r com puting the correlations for each gene 
is show n in the top  tw o row s (N)
Top num ber — z-transform ed correlation coefficient
B ottom  num ber -  significance (p)
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N (PER34'4) 1 8 8 4 8 7 6 5 5 6 6 6
N (PER35'5) 5 7 4 6 7 7 7 6 4 7 6 7
Sleep per night
MQ Sleep per night {PER34/4) 0.10 0.28 -0.45 -0.34 0.62 0.56 0.55 0.66 0.00 -0.53 0.24 0.61
0.84 0.51 0.27 0.72 0.10 0.20 0.28 0.26 1.00 0.31 0.67 0.22
MQ Sleep per night (PER35'5) 0.05 -0.24 -0.56 -0.53 0.08 0.38 0.33 0.29 -0.13 -0.51 0.01 -0.17
0.94 0.63 0.52 0.31 0.87 0.42 0.49 0.61 0.90 0.26 0.99 0.73
PSQI Actual sleep hours (PER34/4) -0.40 0.29 0.55 0.84 0.07 0.38 0.44 0.27 0.09 -0.18 0.39 0.38
0.40 0.50 0.17 0.23 0.88 0.42 0.42 0.70 0.90 0.75 0.47 0.49
PSQI Actual sleep hours (PER35/s) -0.10 -0.57 -0.74 -0.92 -0.64 -0.23 -0.34 0.22 -0.73 -0.50 -0.16 0.00
0.88 0.19 0.34 0.01 0.13 0.64 0.48 0.70 0.35 0.27 0.77 0.99
PSQI Time in bed (PER34/4) 0.23 0.17 0.55 0.77 0.36 0.14 0.75 0.87 0.05 -0.46 0.00 0.09
0.64 0.71 0.17 0.31 0.40 0.78 0.09 0.06 0.94 0.39 1.00 0.87
PSQI Time in bed {PER35'5) 0.20 -0.71 -0.66 -0.23 -0.27 0.11 -0.13 0.18 -0.79 -0.20 0.24 -0.38
0.77 0.08 0.43 0.69 0.58 0.83 0.80 0.76 0.28 0.68 0.67 0.43
BSS Actual sleep hours (PER34/4) -0.42 0.37 0.32 0.46 0.18 0.29 0.59 0.18 0.52 -0.09 0.25 0.51
0.37 0.38 0.45 0.62 0.68 0.56 0.24 0.79 0.42 0.88 0.65 0.33
BSS Actual sleep hours (PER35'5) -0.35 -0.38 -0.28 0.05 0.03 0.31 0.41 0.06 0.22 -0.63 -0.07 -0.12
0.61 0.42 0.77 0.93 0.95 0.52 0.39 0.92 0.83 0.14 0.90 0.81
Bedtime
PSQI Bedtime (PER34'4) 0.58 0.75 -0.22 0.04 0.84 0.81 0.52 0.91 0.23 0.17 -0.25 0.51
0.18 0.03 0.62 0.97 0.01 0.02 0.32 0.03 0.74 0.77 0.66 0.33
PSQI Bedtime (PER35/5) -0.67 0.45 0.17 0.35 0.48 0.63 0.54 0.01 0.90 -0.12 -0.11 0.66
0.25 0.33 0.86 0.53 0.29 0.13 0.23 0.99 0.15 0.81 0.85 0.11
BSS Avg bedtime (PER34/4) 0.66 0.77 -0.17 -0.06 0.81 0.81 0.38 0.86 -0.02 0.26 -0.33 0.33
0.11 0.02 0.71 0.95 0.01 0.02 0.49 0.07 0.98 0.64 0.55 0.55
BSS Avg bedtime (PER35'5) -0.72 0.45 0.26 0.07 0.36 0.45 0.37 -0.01 0.76 -0.09 -0.22 0.75
0.20 0.33 0.79 0.91 0.46 0.33 0.43 0.99 0.32 0.85 0.70 0.05
MCQ Work bedtime (PER34/4) 0.42 0.74 -0.23 0.10 0.88 0.85 0.62 0.83 0.39 -0.02 -0.09 0.56
0.36 0.03 0.61 0.92 0.00 0.01 0.21 0.10 0.56 0.98 0.88 0.27
MCQ Work bedtime (PER35'5) -0.74 0.57 -0.42 0.19 0.42 0.62 0.63 0.26 0.79 0.03 0.03 0.61
0.18 0.20 0.66 0.73 0.37 0.14 0.13 0.65 0.28 0.95 0.96 0.16
MCQ Free bedtime {PER34'4) 0.58 0.59 -0.12 -0.36 0.61 0.44 0.61 0.77 -0.01 -0.27 -0.41 0.26
0.18 0.13 0.79 0.70 0.11 0.35 0.22 0.15 0.99 0.63 0.45 0.64
MCQ Free bedtime (PER35'5) -0.80 -0.21 0.88 0.58 0.25 0.28 0.29 0.13 0.82 -0.54 -0.23 0.35
0.12 0.67 0.16 0.25 0.61 0.56 0.55 0.82 0.24 0.23 0.69 0.46
KSD Bedtime (PER34'4) 0.84 0.27 -0.20 -0.12 0.62 0.45 0.35 0.96 -0.09 0.00 -0.36 0.43
0.01 0.53 0.64 0.90 0.10 0.33 0.52 0.01 0.89 0.99 0.51 0.43
KSD Bedtime (PER3S/S) -0.78 0.13 -0.14 0.00 0.40 0.50 0.50 0.17 0.99 -0.20 -0.23 0.77
0.14 0.80 0.89 0.99 0.40 0.27 0.28 0.77 0.01 0.68 0.69 0.04
KSD Try start to sleep (PER34'4) 0.82 0.33 -0.12 0.09 0.73 0.52 0.38 0.92 -0.03 0.01 -0.22 0.54
0.02 0.45 0.78 0.93 0.04 0.25 0.48 0.02 0.97 0.98 0.70 0.30
KSD Try start to sleep (PER35/S) -0.84 0.23 -0.41 -0.14 0.20 0.36 0.37 0.12 0.10 -0.06 -0.07 0.85
0.09 0.63 0.66 0.81 0.68 0.46 0.43 0.83 0.92 0.91 0.91 0.01
HO Go to bed (PER34'4) 0.49 0.62 -0.23 -0.21 0.72 0.69 0.70 0.93 0.56 0.03 -0.08 0.51
0.28 0.11 0.61 0.83 0.04 0.09 0.13 0.02 0.37 0.96 0.89 0.33
HO Go to bed (PER3S/S) -0.66 0.49 0.88 0.49 0.43 0.46 0.44 0.11 0.97 0.00 -0.24 0.38
2 5 2
HÔ Need of sleep
0.26 0.29 0.17 0.36 0.36 0.32 0.34 0.85 0.04 1.00 0.67 0.43
(PER34/4) 0.61 0.61 0.05 -0.33 0.88 0.41 0.75 0.83 0.58 0.34 0.05 0.55
HO Need of sleep (PER3!/5)
0.16 0.11 0.92 0.74 0.00 0.38 0.09 0.09 0.35 0.54 0.94 0.28
-0.74 0.36 -0.40 -0.01 0.35 0.28 0.28 0.04 0.89 -0.02 -0.11 0.72
0.18 0.45 0.67 0.98 0.46 0.57 0.57 0.94 0.15 0.97 0.84 0.07
Wake time
PSQI Getup time (PER34'4) 0.53 0.67 0.03 0.54 0.94 0.71 0.63 0.91 0.44 -0.46 -0.19 0.80
(PER35,s)
0.24 0.07 0.94 0.55 0.00 0.08 0.20 0.03 0.51 0.39 0.73 0.06
PSQI Getup time -0.91 -0.34 -0.37 0.33 0.31 0.71 0.48 0.17 0.80 -0.33 0.14 0.39
(PER34'4)
0.03 0.48 0.70 0.55 0.53 0.07 0.30 0.76 0.28 0.49 0.80 0.41
BSS Avg getup time 0.60 0.65 0.13 0.70 0.92 0.72 0.63 0.95 0.54 -0.50 -0.32 0.93
(PER3S/S)
0.17 0.08 0.78 0.39 0.00 0.07 0.20 0.01 0.40 0.34 0.57 0.00
BSS Avg getup time -0.96 -0.38 -0.49 0.15 0.18 0.62 0.40 0.17 0.25 -0.33 0.12 0.54
0.01 0.43 0.59 0.79 0.72 0.15 0.40 0.77 0.80 0.49 0.84 0.23
MCQ Work wakeup (PER34'4) -0.41 -0.31 -0.30 -0.51 -0.12 0.14 0.48 -0.46 0.42 -0.38 0.88 0.05
(PER35/S)
0.38 0.47 0.48 0.57 0.79 0.77 0.36 0.48 0.53 0.48 0.02 0.92
MCQ Work wakeup -0.71 0.16 0.42 -0.27 -0.20 0.03 0.07 -0.11 -0.56 0.35 0.25 0.63
(PER34'4)
0.21 0.75 0.66 0.63 0.68 0.94 0.89 0.85 0.53 0.47 0.66 0.14
MCQ Work getup time 0.34 0.69 -0.01 0.52 0.93 0.76 0.76 0.79 0.89 -0.22 0.01 0.42
0.49 0.06 0.98 0.57 0.00 0.05 0.08 0.13 0.04 0.70 0.99 0.43
MCQ Work getup time (PER35,S) -0.75 -0.03 -0.24 0.00 0.28 0.61 0.45 -0.03 -0.10 -0.13 0.14 0.59
{PER3i/4)
0.17 0.95 0.81 1.00 0.56 0.16 0.34 0.96 0.92 0.79 0.81 0.18
MCQ Free wakeup time -0.04 0.54 0.33 0.28 0.57 0.39 0.91 0.34 0.50 -0.30 0.02 0.89
0.94 0.18 0.44 0.77 0.14 0.41 0.01 0.61 0.44 0.59 0.97 0.01
MCQ Free wakeup time (PER3S/S) -0.73 -0.27 -0.73 0.15 0.51 0.80 0.51 0.40 0.94 -0.37 0.05 0.17
0.19 0.57 0.35 0.79 0.27 0.03 0.26 0.47 0.08 0.44 0.93 0.74
KSD Getup time (PER34'4) 0.75 0.17 0.03 0.23 0.64 0.19 0.41 0.94 -0.79 -0.57 -0.14 0.21
(PER35/5)
0.05 0.69 0.94 0.82 0.09 0.70 0.45 0.02 0.13 0.27 0.80 0.71
KSD Getup time -0.29 0.06 -0.21 0.02 0.31 -0.09 0.15 0.07 0.50 0.05 -0.09 -0.32
HO Getup time
0.67 0.91 0.83 0.98 0.52 0.86 0.76 0.91 0.58 0.91 0.88 0.51
0.34 0.29 -0.13 0.38 0.80 0.56 0.74 0.86 0.90 -0.87 0.09 0.78
0.47 0.50 0.77 0.69 0.01 0.21 0.10 0.06 0.04 0.02 0.88 0.07
HO Getup time (PER35/s) -0.31 -0.07 0.20 0.75 0.91 0.89 0.78 0.32 0.85 -0.40 0.06 0.06
0.65 0.90 0.84 0.09 0.00 0.00 0.04 0.57 0.21 0.40 0.92 0.91
Sleep latency
PSQI Sleep latency min (PER34/4) 0.37 -0.58 0.29 0.71 0.25 -0.47 0.83 0.43 0.53 -0.85 -0.36 0.13
0.43 0.14 0.51 0.37 0.57 0.31 0.04 0.51 0.40 0.03 0.51 0.83
PSQI Sleep latency min (PER35/s) -0.73 -0.29 -0.07 0.28 0.27 0.66 0.60 0.08 -0.03 -0.02 0.44 0.59
0.19 0.55 0.95 0.61 0.58 0.11 0.16 0.88 0.98 0.98 0.42 0.18
MCQ Work sleep latency (PER34'4) 0.35 -0.49 0.57 0.80 0.26 -0.34 0.81 0.51 0.50 -0.76 -0.48 0.43
0.46 0.23 0.14 0.27 0.55 0.48 0.05 0.42 0.43 0.08 0.37 0.42
MCQ Work sleep latency (PER35/5) -0.43 -0.37 -0.09 0.08 0.02 0.68 0.65 0.12 -0.47 0.41 0.81 0.37
0.51 0.44 0.93 0.89 0.97 0.09 0.12 0.84 0.61 0.39 0.05 0.43
MCQ Free sleep latency (PER344) 0.19 -0.33 0.86 0.77 0.21 -0.21 0.83 0.44 0.55 -0.19 -0.32 0.60
0.69 0.44 0.00 0.30 0.63 0.67 0.04 0.50 0.38 0.74 0.57 0.23
MCQ Free sleep latency {PER35/s) -0.56 -0.13 -0.03 0.24 0.26 0.66 0.62 -0.07 -0.25 0.21 0.57 0.55
0.37 0.80 0.98 0.68 0.60 0.11 0.15 0.90 0.80 0.66 0.27 0.22
KSD Sleep latency {PER34'4) 0.28 -0.31 0.31 0.48 0.43 -0.35 0.81 0.44 0.56 -0.90 -0.37 0.17
0.56 0.48 0.47 0.61 0.31 0.46 0.05 0.51 0.37 0.01 0.50 0.76
KSD Sleep latency (PER35/1) -0.42 -0.08 0.05 0.42 0.43 0.76 0.68 -0.13 0.08 0.26 0.61 0.36
0.53 0.87 0.96 0.44 0.35 0.05 0.10 0.82 0.94 0.59 0.22 0.45
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Appendix H: PER3 genotype-dependent correlations between 
amplitude of clock gene expression and entrained timing of sleep and 
wakefulness
Number of individuals contributing data for computing the correlations for each gene 
is shown in the top two rows (N) 
Top number -  z-transformed correlation coefficient 
Bottom number -  significance (p)
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N (PER34'4) 7 8 8 4 8 1 6 5 5 6 6 6
N (PER]5'5) 5 7 4 6 7 7 7 6 4 7 6 7
Sleep per night
MQ Sleep per night (PER]4'4) -0.35 0.37 0.03 -0.19 0.30 0.09 0.67 0.06 -0.92 0.20 0.51 0.12
0.47 0.39 0.94 0.85 0.49 0.86 0.16 0.93 0.02 0.72 0.33 0.83
MQ Sleep per night (PER]5'5) -0.15 0.27 0.56 0.45 0.44 0.24 0.26 0.04 0.83 -0.38 0.53 -0.67
0.83 0.58 0.52 0.40 0.35 0.62 0.59 0.95 0.23 0.43 0.30 0.11
PSQI Actual sleep hours (PER]4'4) -0.65 -0.08 0.50 0.13 0.26 -0.41 -0.10 -0.74 0.85 -0.63 0.19 0.15
0.12 0.85 0.22 0.89 0.55 0.38 0.86 0.18 0.07 0.20 0.74 0.80
PSQI Actual sleep hours (PER]5'5) -0.29 -0.01 0.59 0.42 0.57 0.00 0.14 -0.36 0.28 -0.12 0.07 -0.32
0.68 0.99 0.50 0.44 0.20 1.00 0.77 0.51 0.78 0.81 0.90 0.50
PSQI Time in bed (PER]4'4) -0.28 0.42 0.54 0.20 0.21 0.08 0.60 -0.51 0.96 -0.39 0.13 0.12
0.56 0.32 0.18 0.84 0.63 0.87 0.23 0.43 0.01 0.47 0.82 0.84
PSQI Time in bed (PER]5'5) -0.23 0.12 0.63 0.00 0.75 0.04 0.33 -0.09 -0.80 0.08 0.37 -0.31
0.74 0.81 0.45 1.00 0.05 0.93 0.49 0.87 0.27 0.87 0.51 0.52
BSS Actual sleep hours (PER]4'4) -0.79 -0.24 -0.39 -0.09 0.17 -0.33 -0.36 -0.88 0.24 -0.51 -0.13 -0.48
0.03 0.58 0.36 0.92 0.71 0.50 0.52 0.05 0.73 0.33 0.81 0.36
BSS Actual sleep hours (PER]5'5) -0.60 -0.07 0.29 0.20 0.23 0.24 -0.04 -0.21 0.88 -0.30 0.34 -0.75
0.33 0.89 0.77 0.73 0.64 0.63 0.94 0.71 0.17 0.54 0.54 0.05
Bedtime
PSQI Bedtime (PER]4'4) -0.18 -0.10 -0.55 -0.88 0.12 0.33 0.40 -0.23 -0.95 0.55 -0.01 -0.23
0.71 0.83 0.17 0.17 0.78 0.49 0.47 0.74 0.01 0.28 0.99 0.68
PSQI Bedtime (PER]5'5) -0.33 0.14 -0.29 -0.66 -0.92 -0.28 -0.56 0.07 0.40 -0.27 0.31 -0.43
0.63 0.78 0.76 0.17 0.00 0.56 0.21 0.91 0.67 0.58 0.57 0.35
BSS Avg bedtime (PER]4'4) -0.05 -0.15 -0.62 -0.87 0.05 0.31 0.66 -0.06 -0.99 0.47 0.05 -0.20
0.91 0.74 0.10 0.18 0.90 0.53 0.17 0.93 0.00 0.37 0.93 0.72
BSS Avg bedtime (PER]5'5) -0.36 0.12 -0.45 -0.48 -0.96 -0.39 -0.58 0.03 0.45 -0.35 0.09 -0.33
0.59 0.81 0.63 0.36 0.00 0.41 0.19 0.96 0.63 0.47 0.88 0.50
MCQ Work bedtime (PER]4'4) -0.32 -0.05 -0.53 -0.83 0.25 0.23 0.36 -0.27 -0.87 0.60 0.06 -0.15
0.50 0.91 0.18 0.23 0.57 0.63 0.51 0.69 0.06 0.23 0.92 0.79
MCQ Work bedtime -0.36 0.46 0.44 -0.40 -0.80 -0.26 -0.40 0.08 0.80 -0.28 0.68 -0.47
0.59 0.32 0.63 0.46 0.03 0.59 0.40 0.88 0.27 0.56 0.15 0.31
MCQ Free bedtime (PER]4'4) -0.13 -0.03 -0.59 -0.70 -0.12 0.10 0.51 -0.59 -0.69 0.66 -0.18 -0.45
0.80 0.95 0.13 0.38 0.78 0.83 0.33 0.34 0.23 0.17 0.75 0.40
MCQ Free bedtime (PER]5'5) -0.74 -0.66 -0.79 -0.45 -0.84 -0.41 -0.67 -0.50 0.00 -0.25 -0.75 -0.29
0.18 0.12 0.29 0.40 0.02 0.38 0.10 0.35 1.00 0.61 0.09 0.55
KSD Bedtime (PER]4'4) 0.29 -0.04 -0.56 -0.85 0.04 0.61 0.74 -0.13 -0.98 0.69 0.01 -0.39
0.55 0.94 0.15 0.21 0.94 0.16 0.10 0.86 0.00 0.14 0.99 0.48
KSD Bedtime (PER]5'5) -0.49 0.31 -0.05 -0.40 -0.94 -0.51 -0.39 0.03 0.49 -0.52 0.12 -0.49
0.45 0.52 0.96 0.46 0.00 0.26 0.41 0.95 0.59 0.24 0.84 0.29
KSD Try start to sleep (PER]4'4) 0.23 0.00 -0.51 -0.92 0.17 0.60 0.69 -0.07 -0.95 0.66 0.13 -0.33
0.63 1.00 0.20 0.11 0.69 0.17 0.14 0.92 0.01 0.17 0.82 0.55
KSD Try start to sleep (PER]5'5) -0.48 0.42 0.21 -0.31 -0.92 -0.54 -0.43 0.03 -0.04 -0.37 0.14 -0.32
0.46 0.38 0.83 0.59 0.00 0.23 0.36 0.96 0.97 0.44 0.81 0.51
HO Go to bed (PER]4'4) -0.24 0.06 -0.50 -0.77 0.06 0.53 0.37 -0.35 -0.83 0.60 -0.07 -0.40
0.62 0.89 0.22 0.30 0.90 0.24 0.50 0.60 0.09 0.23 0.91 0.46
HO Go to bed (PER]5'5) -0.42 -0.55 -0.76 -0.32 -0.88 -0.19 -0.71 -0.24 0.32 -0.08 -0.41 -0.24
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0.53 0.22 0.32 0.56 0.01 0.70 0.08 0.67 0.74 0.87 0.45 0.62
HO Need of sleep (PER3m ) -0.02 0.32 -0.51 -0.64 0.26 0.68 0.49 -0.26 -0.63 0.39 0.17 -0.21
0.97 0.46 0.21 0.45 0.55 0.10 0.35 0.71 0.30 0.48 0.77 0.71
HO Need of sleep (PER3s/5) -0.42 0.48 0.45 -0.30 -0.90 -0.47 -0.26 0.22 -0.01 -0.37 -0.25 -0.17
0.53 0.30 0.63 0.59 0.00 0.30 0.59 0.70 0.99 0.44 0.65 0.74
Wake time
PSQI Getup time (PER34'4) -0.23 0.09 -0.30 -0.96 0.21 0.30 0.49 -0.30 -0.63 0.35 , 0.03 -0.24
0.63 0.83 0.49 0.05 0.64 0.54 0.35 0.66 0.29 0.53 0.96 0.67
PSQI Getup time {PER35'5) -0.75 0.24 0.30 -0.82 -0.37 -0.24 -0.32 -0.02 -0.03 -0.19 0.64 -0.70
0.16 0.63 0.76 0.04 0.43 0.62 0.51 0.97 0.98 0.70 0.19 0.08
BSS Avg getup time (PER34'4) -0.16 0.11 -0.20 -0.92 0.17 0.37 0.60 -0.27 -0.70 0.36 -0.07 -0.03
0.74 0.81 0.65 0.11 0.70 0.43 0.23 0.70 0.22 0.52 0.90 0.96
BSS Avg getup time (PER35'5) -0.74 0.31 0.39 -0.72 -0.46 -0.33 -0.35 -0.04 -0.04 -0.19 0.63 -0.65
0.18 0.52 0.68 0.12 0.32 0.50 0.47 0.94 0.97 0.70 0.20 0.12
MCQ Work wakeup (PER34'4) -0.06 0.54 0.11 0.83 0.59 0.47 0.39 0.43 0.11 0.35 0.58 0.57
0.90 0.17 0.80 0.23 0.13 0.30 0.47 0.52 0.88 0.53 0.25 0.26
MCQ Work wakeup (PER35/s) -0.27 -0.05 -0.44 -0.05 -0.72 -0.19 -0.37 -0.21 -0.20 -0.41 -0.15 0.25
0.70 0.92 0.63 0.93 0.07 0.69 0.44 0.71 0.84 0.38 0.79 0.60
MCQ Work getup time (PER34/4) -0.38 0.21 -0.21 -0.97 0.24 0.26 0.23 -0.31 -0.39 0.19 0.01 -0.11
0.42 0.64 0.64 0.03 0.59 0.59 0.69 0.65 0.56 0.74 0.98 0.85
MCQ Work getup time (PER35/s) -0.35 0.30 0.09 -0.74 -0.66 -0.18 -0.38 0.05 0.04 -0.56 0.67 -0.45
0.60 0.53 0.93 0.10 0.11 0.71 0.43 0.94 0.97 0.20 0.16 0.33
MCQ Free wakeup time (PER34/4) -0.49 0.39 -0.39 0.07 0.31 0.14 0.16 -0.75 -0.01 -0.12 -0.21 0.39
0.28 0.36 0.36 0.94 0.47 0.78 0.78 0.17 0.99 0.83 0.71 0.48
MCQ Free wakeup time (PER3S,S) -0.81 0.65 0.80 -0.38 -0.06 -0.40 0.47 0.47 0.13 -0.51 0.39 -0.91
0.11 0.12 0.28 0.48 0.90 0.39 0.31 0.37 0.90 0.26 0.48 0.00
KSD Getup time (PER344) 0.19 0.29 -0.05 -0.47 0.06 0.60 0.80 -0.13 0.15 0.54 0.18 -0.59
0.71 0.51 0.91 0.61 0.89 0.16 0.06 0.86 0.83 0.30 0.75 0.24
KSD Getup time (PER35'5) -0.71 0.10 0.41 0.37 0.27 0.09 0.53 0.47 0.12 0.33 -0.46 -0.01
0.21 0.85 0.66 0.50 0.58 0.86 0.24 0.38 0.90 0.49 0.39 0.99
HO Getup time {PER34'4) -0.31 0.40 0.01 -0.68 0.27 0.34 0.62 -0.31 -0.27 0.47 0.17 -0.37
0.52 0.34 0.98 0.41 0.54 0.47 0.20 0.65 0.69 0.38 0.77 0.50
HO Getup time (PER35/3) -0.36 0.06 -0.14 -0.72 -0.54 -0.23 -0.13 0.22 0.00 -0.63 0.18 -0.66
0.60 0.90 0.89 0.11 0.23 0.64 0.79 0.70 1.00 0.13 0.76 0.11
Sleep latency
PSQI Sleep latency min (PER34'4) 0.21 0.62 0.73 0.17 -0.12 0.47 -0.15 -0.94 0.72 0.52 -0.71 0.15
0.67 0.11 0.04 0.86 0.78 0.30 0.79 0.01 0.20 0.32 0.13 0.80
PSQI Sleep latency min (PER35'5) -0.51 0.09 -0.08 -0.89 -0.70 -0.43 -0.52 -0.10 -0.91 -0.23 0.65 -0.47
0.43 0.86 0.93 0.01 0.08 0.36 0.24 0.86 0.13 0.63 0.18 0.31
MCQ Work sleep latency {PER34/4) 0.18 0.53 0.64 0.15 -0.11 0.51 -0.12 -0.96 0.73 0.44 -0.80 0.15
0.72 0.19 0.09 0.88 0.81 0.26 0.83 0.00 0.18 0.41 0.06 0.79
MCQ Work sleep latency (PER35'5) -0.26 0.07 -0.05 -0.75 -0.32 -0.43 -0.50 -0.12 -0.96 0.03 0.81 -0.16
0.71 0.90 0.96 0.09 0.51 0.36 0.27 0.83 0.06 0.96 0.05 0.75
MCQ Free sleep latency (PER34/4) 0.06 0.31 0.36 0.28 0.03 0.53 -0.17 -0.98 0.71 0.07 -0.74 0.11
0.91 0.47 0.40 0.78 0.95 0.24 0.77 0.00 0.21 0.91 0.10 0.85
MCQ Free sleep latency {PER3s/5) -0.28 0.12 -0.12 -0.86 -0.66 -0.33 -0.52 0.00 -0.94 -0.14 0.73 -0.28
0.68 0.81 0.90 0.03 0.11 0.50 0.25 1.00 0.08 0.78 0.10 0.56
KSD Sleep latency {PER34'4) 0.00 0.73 0.46 0.36 -0.29 0.32 -0.11 -0.90 0.37 0.60 -0.68 0.17
0.99 0.04 0.27 0.71 0.51 0.50 0.85 0.03 0.58 0.24 0.15 0.76
KSD Sleep latency {PER3S/5) -0.22 0.09 -0.15 -0.94 -0.56 -0.24 -0.48 0.09 -0.85 -0.08 0.73 -0.29
0.76 0.86 0.88 0.00 0.20 0.63 0.30 0.88 0.21 0.87 0.11 0.56
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Appendix I: Differentially expressed genes (identified by ANOVA) 
between the PER34/4 and PER3S/5 homozygotes following sleep 
extension condition
Genes are ranked in order of significance (p)
Gene name Agilent probe name Fold change 
(PER34/4/PER35/s)
p-value
NPDC1 A 23 P146572 -0.67 4.01 xlO"16
CDK5RAP2 A 23 P83110 -0.24 2.17x10'"
AF063695 A 24 P465799 -0.89 2.70x10'"
MPP7 A_23_P384663 0.30 3.77x1 O'09
A 24 P298029 A 24 P298029 -0.24 2.83 xlO'08
ST13 A 23 P68949 0.31 2.42x1 O'07
LEPROT A 23 P I 126 0.24 5.04 xlO'07
FCN2 A 23 P501732 -0.24 8.31 xlO'07
AMD1 A 23 P214121 0.22 1.65x1 O'06
SDHD A 23 P138967 0.14 3.16 xlO'06
A 24 P868905 A 24 P868905 -0.54 4.95 xlO'06
SORD A_32 P89691 0.25 6.92 xlO"06
CACNG6 A 23 P501933 0.42 2.44x1 O'05
HERC6 A 23 P250353 -0.20 3.18 xlO'05
A 24 P534290 A 24 P534290 -0.29 3.64x1 O'05
,4 24 # 7 4 4 3 7 A 24 P578437 -0.32 4.57x1 O'05
HGD A 23 P250164 0.24 4.78 xlO'05
NGFRAP1 A 23 P45524 0.22 1.13 xlO'04
A 24 PI6071 A 24 P16071 -0.41 1.23 xlO'04
v4J%%)7472 A 32 P72611 -0.13 1.77x1 O'04
GMPPA A 24 P396800 -0.16 2.04x1 O'04
SORD A 23 P77103 0.20 3.07 xlO'04
LGALS9 A 23 P I 16557 0.24 3.76 xlO'04
HLA-DQB1 A 23 P8108 -0.20 0.001
REV1 A 24 P256325 0.12 0.001
NOXA1 A_23 P254353 0.15 0.002
PRKAB2 A 23 P350704 0.13 0.002
B3GALNT2 A 23 P334751 0.19 0.002
LIMS3 A 23 P365685 0.19 0.003
JUN A 23 P201538 -0.15 0.003
SNTB1 A 23 P386030 0.16 0.004
IFI6 A 23 P201459 0.24 0.004
A 23 P3083 A 23 P3083 -0.20 0.004
HLA-DRB4 A 24 P370472 -0.23 0.004
DEXI A 32 P164971 -0.19 0.005
A 24 P7040 A 24 P7040 -0.16 0.005
CLDN5 A 23 P6321 -0.20 0.005
IRF7 A 24 P378019 -0.14 0.006
C77or/59 A 23 P152955 -0.10 0.006
ATP6AP2 A_23_P11353 0.10 0.007
SERPING1 A 23 P139123 -0.31 0.009
ICAM1 A 23 P153320 -0.11 0.010
GNG11 A 23 P111701 0.20 0.013
IGF2BP3 A 23 P19987 0.13 0.013
ZMAT5 A_23_P132248 -0.11 0.016
A 24 P400690 A 24 P400690 0.13 0.018
A 32 P194704 A 32 P I94704 -0.14 0.018
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PDP1 A_23_P 123336 3 j 3  0022
BMF A_23_P379649 -0.09 0 033
Œ ^ 7 A_24_P418294 0.09 0 036
Sep-07 A_23_P8482 0.06 0 041
LOC646791 A_24_P392690 0.14 0 047
BQ674642_____________ A 24 P903460___________-0J4 ________________  0 049
Appendix J: Differentially expressed genes (identified by ANOVA) 
between the PER34/4 and PER3S/5 homozygotes following sleep 
restriction condition
Genes are ranked in order of significance (p)
Gene name Agilent probe name Fold change 
(PER34/4/PER355)
p-value
A 24 P400690 A 24 P400690 0.57 5.70E'13
CLDN5 A_23 P6321 -0.56 2.09E'12
TUBA 1C A 24 P188071 -0.28 7.3 I F 11
EEF1A2 A_23_P256033 0.52 3 .97F 09
HEX1M2 A 23 P377214 -0.30 4.55E"09
A 23 P3083 A 23 P3083 -0.49 4 .8 9 F 09
NPDC1 A_23 P146572 -0.40 9 .43F 09
A 32 P194704 A_32 P I94704 -0.39 1.07E'08
AASDHPPT A 24 P I84230 -0.20 1.23F08
LGALS9 A 23 P I16557 0.46 1.43E"08
HYAL2 A 23 P57927 0.24 1.79F08
C16orf7 A 23 P I29476 0.31 3 .55F 08
C17orf59 A 23 P I52955 -0.26 4.6 I F 08
PDP1 A 23 P123336 -0.21 1.09F07
GPR84 A_23_P25155 0.30 1.72E'07
SEPN1 A 23 P370625 0.26 2 .78F 07
GPD1 A 23 P204736 0.27 4 .2 8 F 07
NOXA1 A_23_P254353 0.28 4 .50F 07
BLOC1S1 A 23 P53298 0.29 8.72F 07
JUN A_23_P201538 -0.25 2 .72F 06
Sep-07 A 23 P8482 -0.13 4 .14F 06
TBC1D24 A 23 P391637 -0.23 4 .5 2 F 06
SLC10A3 A 23 P366254 -0.15 9.1 I F 06
Sep-13 A 24 P855187 -0.17 9.13E'06
AP3B1 A_32 P47510 -0.21 1.25F05
CDK9 A_23_P169470 -0.15 1.33F05
IF1TM1 A 23 P72737 0.23 1.60F 05
ARID5A A 23 P143016 0.16 1.80F05
ENST00000308076 A 24 P178963 0.25 5 .18F 05
TBC1D13 A 23 P94660 -0.14 6 .97F 05
,4 24 f 722472 A 24 P722473 -0.22 7.3 8 F 05
APBB3 A_23 P I10445 0.16 8.34F 05
SC02 A_23 P132388 0.22 l.OOF04
AF063695 A 24 P465799 -0.42 1.40F 04
#6674642 A 24 P903460 0.27 1.43F04
Sep-07 A 24 P291973 -0.14 1.93F04
ITGB1 A 23 P104193 -0.17 2 .43F 04
UNC93B1 A_23_P98167 0.19 3 .18F 04
TYMP A_23 P91802 0.24 4 .53F 04
TRIB3 A 23 P210690 -0.17 4 .8 7 F 04
IFI6 A_23_P201459 0.39 0.001
LIMS3 A_23_P365685 -0.23 0.001
DRAP1 A_24_P107277 0.20 0.001
TERF1 A 24 P50458 -0.12 0.001
SLC45A3 A_24_P208345 -0.31 0.001
ARL6IP1 A 24 P356218 -0.11 0.001
PCTK1 A 24 P233663 0.17 0.001
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CST3 A 24 P216294 0.18 0.003
AK026351 A 32 P I42991 -0.09 0.004
SLPI A_24 P I90472 0.34 0.004
PTPLAD1 A 23 P99927 -0.13 0.004
KPTN A 23 P67391 0.18 0.005
A 24 P7040 A 24 P7040 0.17 0.009
ZMAT5 A 23 P132248 0.13 0.010
CEP97 A 24 P418294 -0.14 0.010
HERC5 A 23 P110196 0.33 0.010
CAMK1 A 23 P121215 0.13 0.014
GNG11 A 23 P111701 -0.18 0.016
0AS3 A_23_P47955 0.28 0.017
GRAP2 A 24 P408449 -0.12 0.017
CBX1 A_23_P107507 -0.14 0.018
A 24 P450493 A 24 P450493 -0.12 0.018
A 32 P72611 0.09 0.022
RAB4B A 23 P16116 0.11 0.024
MAE A 23 P397376 -0.10 0.026
A 24 P561165 A 24 P561165 0.30 0.026
ST13 A_23_P68949 0.11 0.028
SIGLEC1 A 23 P17481 0.26 0.041
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Appendix K: Differentially expressed genes (identified by model 
fitting) between the PER34/4 and PER35/S homozygotes following sleep 
extension
Genes are ranked in order of gap between 95% confidence intervals (absolute values)
Gene name Agilent probe name Fold change 
(PER34/4/PER355)
Gap between 95% 
con fidence intervals
TMEM176A A 23 P252082 2.291 1.604
TMEM176B A 23 P157007 2.409 1.523
BP418551 A 32 P117185 -2.292 0.910
GSTM5 A 24 P212021 -1.643 0.638
BP418551 A 24 P703642 -1.172 0.521
MEG3 A 24 P272993 -1.341 0.498
AJ697910 A 32 P76137 -1.281 0.475
ENST00000390271 A 24 P I6004 -1.241 0.444
MAGED4B A 23 P159907 -0.865 0.432
NAT12 A 24 P66679 0.027 -0.418
MXRA7 A_32_P161681 -0.275 -0.414
KLRC2 A 23_P22232 -1.019 0.404
PAK2 A 23 P327307 -0.884 0.389
S&O A 23 P I 14134 0.357 -0.378
DSC1 A 23 P38696 1.106 0.356
A 24 P365129 A 24 P365129 -0.379 -0.354
HRASLS2 A 24 P364263 -1.028 0.352
HSD11B1 A 23 P63209 -1.066 0.337
NFYB A 24 P49731 -0.275 -0.319
LOC100131176 A 32 P138396 -0.244 -0.314
ZNF107 A 23 P45087 -0.133 -0.313
BOD1L A 24 P931476 1.056 0.304
BC039457 A 24 P368023 -0.227 -0.301
SS18L1 A 23 P423926 -0.077 -0.295
IL6 CPID 233 -0.438 -0.290
ZNF286A A 23 P89327 -0.140 -0.282
TMEM231 A 23 P359497 -0.122 -0.271
A 23 PI 59163 A 23 P159163 -0.793 0.257
BHLHE41 A 23 P139500 -0.790 0.256
REEP3 A 23 P423543 -0.229 -0.256
TRIM5 9 A 23 P407718 -0.149 -0.255
A 24 P357847 -0.825 0.252
ITGA1 A 23 P256334 -0.676 0.252
TMEM220 A 24 P I 16700 0.040 -0.252
A 24 P323298 A 24 P323298 -0.699 0.251
MPP3 A 23 P141346 -0.413 -0.246
1GLL1 A 24 P239076 -0.892 0.242
A_24_P324644 A 24 P324644 -0.316 -0.241
AF343666 A 24 P395415 -0.714 0.238
U21252 A 24_P608268 -0.705 0.238
AF063695 A 24 P465799 -1.036 0.235
TSPYL1 A 24 P I79277 -0.754 0.232
EBI3 A 23 P I 19478 -0.693 0.230
32 P662P7 A 32 P66297 -0.212 -0.230
CW3&&02 A 24 P467449 -0.060 -0.230
FA2H A 23P 49448 -0.715 0.229
Z O C W 22# A 23 P58869 -0.677 0.229
260
A 32 P15829 A 32 P15829 -0.263 -0.229
EF178107 A 32 P51988 -0.664 0.228
PARP3 A 24 P402779 -0.162 -0.226
A 23 P84791 A 23 P84791 -0.895 0.222
23 f 72232 A 23 P72252 -0.834 0.221
MX&47 A 24 P925062 -0.361 -0.213
ZNF791 A 24 P382401 -0.096 -0.213
GSTM1 A 23 P I 15407 -0.827 0.213
A 32 P207151 A 32 P207151 -0.321 -0.213
A 32 P124833 A 32 P124833 -0.613 0.212
J37M 2 A 24 P519504 -1.000 0.212
DENND5B A_23_P366559 -0.595 0.212
TWF1 A 24 P I78273 -0.090 -0.207
ZBTB32 A 23 P131024 -0.581 0.206
CASP2 A_24 P269398 0.077 -0.204
Cllorf39 A 32 P203559 0.749 0.203
KLRD1 A 23 P204208 -0.195 -0.200
TAS2R20 A 23 P382794 -0.905 0.200
CROCCL1 A 23 P126486 -0.165 -0.198
RAS1P1 A_23 PI 19353 -1.037 0.198
HPX-2 A 24 P911288 0.733 -0.197
F2RL1 A 23 P58835 0.257 -0.195
A 32 P61415 A 32 P61415 0.329 -0.194
LOC387895 A 32 P35047 -0.688 0.193
MTOR A 23 P34606 0.010 -0.192
24 f9377J& A 24 P937158 0.155 -0.191
G ATM A 23 P129064 -0.557 -0.185
AF103312 A 24 P604784 -0.769 0.185
EPS8L2 A_23 P 147822 -0.199 -0.178
CAND2 A 23 P250102 -0.251 -0.174
IL6 CPID 231 -0.447 -0.172
A 24 P I40204 -0.404 0.172
CDRT4 A 24 P262321 -0.413 -0.172
ACVR2B A_32_P134209 -0.281 -0.168
KLHL21 A 23 P201478 0.049 -0.167
F0LR1 A 23 P53176 0.201 -0.167
A 32 P40145 A 32 P40145 0.351 -0.166
AW015426 A_32_P221096 0.127 -0.163
A 24 P213073 A 24 P213073 -0.125 -0.161
AG PS A 24 P902100 -0.196 -0.159
ABHD11 A 23 P8558 0.336 0.157
AP4S1 A 24 P12281 -0.081 -0.156
MGC29506 A 23 P84596 -0.662 0.156
SLC8A1 A 24 P913900 0.123 -0.154
PER2 CPID 5 0.251 -0.154
MGC3P3&4 A 32 P I11996 0.942 0.153
ANKRD20A2 A 24 P64241 -0.398 -0.151
KLRC4 A 23 P218058 -0.176 -0.147
CU675050 A 32 P92922 0.289 -0.146
BC035371 A 24 P376422 0.381 0.145
FU34077 A 23 P35656 -0.151 -0.145
GRAPE A 24 P299355 -0.645 0.142
PPP2R2B A 23 P213620 -0.070 -0.141
C0X11 A 24 P73943 -0.255 -0.140
SMYD4 A 24 P307175 -0.101 -0.137
ZNF107 A 24 P154914 -0.147 -0.136
A_24 P860662 -0.474 -0.135
TFAM A 24 P I34727 -0.769 0.133
LOC338620 A 23 P97780 -0.278 -0.132
C3orf51 A 23 P I8053 0.333 -0.131
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TLR6 A_23_P256561 -0.451 0.130
AGFG2 A 23 P311640 -0.095 -0.130
EPHA4 A 24 P274219 -0.321 0.128
0DF2L A 23 P328298 -0.181 -0.127
RAB11FIP5 A 23 P415006 -0.442 0.127
MANEAL A 23 P391228 -0.205 -0.125
CAPN10 A 23 P305550 0.153 -0.125
A 23 P21393 A 23 P21393 -0.567 -0.124
POU2AF1 A_23 P312920 -0.497 0.124
ZNF37B A 32 P48043 -0.150 -0.121
WC100132167 A 24 P419103 -0.272 -0.121
TTC31 A_23 P39813 0.094 -0.121
AY505570 A 24 P101226 -0.685 0.121
Clorj91 A 24 P285378 0.118 -0.120
CF552909 A 23 P161706 -0.462 -0.119
HP A_23_P206760 0.780 0.119
BC035091 A_24_P576219 -0.391 -0.118
ACSM2B A_23_P66328 0.333 -0.118
AL390143 A 24 P466102 0.285 -0.117
TXLNB A 23 P434398 -0.391 -0.117
RALGPS2 A 24 P I73746 -0.422 0.117
BX392861 A 32 P153469 0.287 -0.117
A 24 P161494 A 24 P161494 -1.265 0.113
SYT11 A 24 P139899 -0.129 -0.110
A 24 P837537 -0.523 0.109
HMGN1 A 32 P22257 0.090 -0.104
PDCD5 A 24 P339611 -0.119 -0.104
FREQ A 23 P217049 0.649 -0.104
TUG1 A 24 P382724 0.114 -0.103
AK056664 A 24 P239309 -0.270 -0.103
KLF8 A 24 P937159 -0.388 -0.103
TPBG A 23 P59261 -0.452 -0.102
CCR6 A 24 P234921 -0.325 -0.101
TBL1XR1 A 23 P212554 0.093 -0.101
SAR1B A_24_P916845 0.143 -0.100
RPS2 A 23 P106708 -0.117 -0.099
COQIOA A_23_P354798 -0.141 -0.099
BSPRY A_24 P I80849 0.271 -0.097
ENST00000450815 A 23 P109677 -0.303 0.097
BLK A 23 P31725 -0.484 0.097
GEN1 A 24 P177585 -0.280 -0.095
GAL3ST4 A 23 P31240 0.149 -0.095
A 32 P207420 A_32_P207420 0.250 -0.092
CCDC65 A 23 P47904 -0.229 -0.091
A 24 P307443 A 24 P307443 -0.377 -0.091
BLNK A 24 P64344 -0.435 0.090
A 32 P58401 A_32_P58401 0.164 -0.090
EPPK1 AJ24 P357169 0.263 -0.089
PPP2R1B A 24 P I07291 -0.143 -0.088
EOMES A_24 P97374 -0.222 -0.088
NOP56 A 24 P101402 -0.110 -0.088
FAM98A A_23 P313728 -0.139 -0.088
ZIM2 A 23 P78479 0.541 -0.087
QDPR A 23 P167212 -0.230 -0.085
IL6 CPID 234 -0.555 -0.084
PLAC9 A 23 P86461 -0.417 -0.082
A 32 P36005 A_32_P36005 0.428 0.081
^  24 f2244&S A 24 P324488 -0.137 -0.079
KLC2 A 24 P227211 0.355 -0.079
LOC388796 A 24 P860703 -0.385 0.078
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PRR4
ABHD15
PPM
MY06
GREM2
GALT
COPG2
SETBP1
REG4
NINL
Cl lorf2 4
LOC441245
ZNF121
A_32_P186865
PERP
DOK7
SERPINF1
TNFRSF17
LOC651250
CDK5RAP2
ENST00000444996
A_24_P169645
LOC644617
ZNF616
A_24_P901084
ALMS1P
A_24_P409661
CD40LG
OSBPL3
LOCI 00133131
KRTAP4-11
LOC100130729
A_32_P57717
C10orf75
FLJ34077
DTNB
A_24_P341489
CALML4
AK097965
FKSG43
FAM182A
A_23_P28397
PIK3R1
BC034827
ZNF224
MY01D
TCEAL4
A_32JP230326
IP6K2
A_24_P392540
PRKD3
FL746111
LOC100287852
A_24_P486503
BC047753
USP45
ZNF845
RAP1GDS1
NPDC1
A_23_P62042
A_23_P363034
A_24_P246943
A_23_P255952
A_24_P40626
A_24_P12865
A_23_P61280
A_32_P32413
A_23_P400310
A_23_P143374
A_23_P12911
A_24_P350514
A_23_P89960
A_32_P186865
A_23_P214950
A_23_P398854
A_23_P100660
A_23_P37736
A_24_P484894
A_23_P83110
A_24_P383130
A_24_P169645
A_24_P170869
A_24_P275984
A_24_P901084
A_23_P435657
A_24_P409661
A_23_P62220
A_24_P599340
A_32_P100771
A_24_P282474
A_23_P4400
A_23_P75355
A_32_P57717
A_32_P199998
A_24JP175589
A_24_P216421
A_24_P341489
A_23_P129188
A_24_P273523
A_23_P33927
A_32_P129120
A_23_P28397
A_24_P29401
A_24_P677471
A_24_P941309
A_23_P389102
A_23_P259166
A_32_P230326
A_23_P301138
A_24_P392540
A_23_P108574
A_24_P489695
A_24_P143543
A_24_P486503
A_24_P889980
A_23_P134008
A_32_P207436
A_32_P85813
A 23 P146572
-0.219
-0.263
-0.289
-0.434
-0.796
-0.117
-0.360
-0.219
0.441
0.544
-0.127
-0.204
-0.244
0.485
-0.338
-0.548
0.408
-0.780
-0.213
-0.146
-0.321
-0.313
-0.117
-0.208
-0.225
-0.459
-0.194
-0.260
-0.339
-0.487
-0.178
0.492
0.273
0.244
0.155
-0.290
-0.403
-0.292
0.416
-0.687
0.184
0.636
-0.646
-0.254
-0.178
-0.337
-0.408
-0.231
0.745
0.140
-0.324
-0.147
0.378
-0.478
-0.281
0.381
-0.303
-0.184
-0.159
-0.495
-0.078
0.077
0.077
-0.077
0.077
-0.076
0.075
-0.073
0.072
-0.072
-0.070
-0.069
-0.069
0.067
-0.066
0.066
0.066
0.065
-0.065
-0.065
-0.065
-0.064
-0.064
-0.062
-0.061
0.060
-0.060
-0.059
0.059
-0.058
-0.057
-0.056
-0.055
-0.055
-0.055
-0.054
0.054
0.054
0.054
-0.054
-0.053
0.053
-0.051
0.051
-0.051
-0.050
0.050
-0.050
-0.049
-0.047
0.047
-0.046
0.045
0.045
-0.044
0.044
0.044
-0.043
-0.041
0.041
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ZNF415 A 23 P89871 -0.674 -0.039
24 f2P&744 A 24 P298744 -0.361 0.038
TNS4 A 23 P207850 -0.263 -0.038
FLAD1 A_32 P318086 -0.148 -0.038
vl 24 f&4J0g A 24 P84508 -0.185 -0.037
CFC1 A 23 P5679 0.446 -0.037
TTC9 A 23 P14508 0.331 0.036
CAMK2N1 A 24 P I 17620 -0.381 0.035
j4%727277 A 24 P323698 -0.513 0.035
GGTA1 A 23 P I12452 0.472 0.035
ZKSG4A% A 23 P168019 -0.288 -0.033
KHK A 23 P5845 -0.349 0.033
TAGS A 23 P2283 0.694 0.033
L043S6 A 24 P161764 -0.570 -0.032
hCG 1811732 A 23 P319640 0.376 -0.032
KEAP1 A 23 P119141 -0.168 -0.031
MTHFD1L A 24 P235049 -0.366 -0.031
22 f  726^46 A 32 P126846 0.222 0.030
C79oy/46 A 23 P350074 0.205 -0.030
10C6447P4 A 32 P12595 0.242 -0.029
PHTF2 A 24 P323944 -0.321 0.029
RPL23AP71 A 24 P333106 -0.302 -0.028
BC033996 A 32 P64324 0.264 -0.026
A 24 P341176 A 24 P341176 -0.202 -0.025
OBSCN A 23 P63128 0.317 0.024
A 24 P417751 A 24 P417751 -0.420 -0.024
GCNT1 A_23_P9232 -0.281 0.023
A 32 P193908 A 32 P193908 0.423 -0.023
A 24 P401013 A 24 P401013 -0.220 -0.022
AF085351 A 32 P I74398 0.159 -0.022
AL833696 A 32 P34926 0.387 0.022
ZNF507 A 23 P208812 -0.271 -0.022
TDRD3 A 32 P187617 -0.237 -0.021
SUPV3L1 A_23_P63847 -0.257 -0.020
DQ926472 A 23 P32793 -0.540 -0.020
LOC643733 A 23 P24507 -0.330 -0.020
A 23 P348349 A 23 P348349 -0.369 0.019
OR4X2 A_24_P349274 0.580 0.018
C0G2 A 23 P402437 0.211 -0.017
COL27A1 A 23 P158096 0.454 0.017
MY06 A 24 P283225 -0.469 0.017
GEN1 A_24_P920968 -0.414 -0.017
HNRNPA1L2 A 24 P32849 -0.386 -0.016
C13orfl A_24_P116233 -0.231 -0.016
ZNF616 A 32 P186921 -0.208 0.015
DHX33 A 24 P364970 -0.229 -0.015
LRRC14 A 23 P134946 -0.218 -0.014
FBX034 A 24 P919493 -0.358 0.014
LOC348751 A 24 P247587 -0.433 -0.013
VASH2 A 23 P I15492 0.322 -0.013
CR620010 A 32 P98966 0.515 0.011
A 32 P67355 A 32 P67355 0.410 0.011
ZSWIM1 A 23 P5974 -0.262 0.010
GSTM4 A 24 P396662 -0.673 0.010
ClorJ212 A 23 P314666 -0.160 -0.010
A 24 P920070 A 24 P920070 0.518 0.010
HSD17B1 A 23 P387374 -0.200 0.010
PRDM6 A 32 P222684 0.325 -0.010
MAF A 24 P256219 -0.403 -0.009
EPHA4 A 23 P I19899 -0.241 -0.009
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ZBTB38 A 23 P212025 -0.204 -0.008
SC4MP4 A 24 P333341 -0.226 0.008
FKBP11 A 23 P25121 -0.222 -0.008
A 24 P642306 A 24 P642306 0.707 0.007
CCNDBP1 A 23 P26243 0.242 0.007
MSX2 A 24 P132008 0.595 0.006
,4 A 24 P453544 0.365 -0.006
F0XK2 A 23 P397969 0.345 -0.005
PNMA5 A 23 P352950 0.416 -0.005
v* 24 f27J076 A 24 P375076 -0.269 0.005
JAKMIP1 A 23 PI44274 -0.408 0.004
A 24 PI43785 A 24 P143785 -0.391 -0.004
ZNF259P A 24 P213206 -0.378 -0.003
KIAA1529 A 24 P280706 -0.214 -0.002
NGLY1 A 23 P430051 -0.228 -0.002
CYB561 A 24 P39843 -0.231 0.001
SYPL1 A 24 P141005 -0.185 -0.001
NEK1 A 24_P914599 -0.304 0.001
GPC2 A 23 P251795 0.250 0.001
Clorfl23 A 23 P23017 -0.289 0.0004
A 32 P5417 A 32 P5417 0.971 -0.0002
FBXOIO A 32 P57453 -0.653 0.00001
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Appendix L: Differentially expressed genes (identified by model 
fitting) between the PER34/4 and PER3S/5 homozygotes following sleep 
restriction
Genes are ranked in order of gap between 95% confidence intervals (absolute values)
Gene name Agilent probe name Fold change 
(PER34/4/PER35/s)
Gap between 95% 
confidence intervals
TMEM176A A 23 P252082 2.295 1.556
TMEM176B A 23 P157007 2.442 1.501
BP418551 A 32 P117185 -2.437 0.993
A 23 P 145724 1.691 0.669
57.3202 A 24 P929818 0.279 -0.549
GSTA2 A 23 P214300 0.028 -0.540
BP418551 A 24 P703642 -1.221 0.521
TTC25 A 23 P73150 0.462 -0.480
MAGED4B A 23 P159907 -0.897 0.437
C9orfl30 A 24 P918888 0.621 -0.436
ZBTB41 A 24 P221660 -0.069 -0.419
NAT12 A_24_P66679 -0.055 -0.404
SCGB1A1 A 23 P150583 0.363 -0.393
AK095453 A 32 P50275 0.026 -0.379
C6orfl67 A 32 P208136 -0.033 -0.376
MGC12916 A 24 P522864 0.015 -0.363
MEG3 A 24 P272993 -1.218 0.362
HIST1H1E A 23 P7976 -0.060 -0.346
A 32 P205722 A 32 P205722 0.094 -0.344
DENND1B A 24 P943283 0.002 -0.337
X57802 A 24 P519504 -1.121 0.333
A 23 P72252 A 23 P72252 -0.967 0.332
CLDN5 A_23 P6321 -0.102 -0.330
C6orfl67 A 32 P137926 -0.035 -0.327
A 23 P84791 A 23 P84791 -0.993 0.325
A 24 P941210 0.132 -0.325
WC375010 A 32 P79190 -0.857 0.319
A 32 P194704 A 32 P I94704 -0.051 -0.316
HBZ A 23 P3651 1.280 -0.316
PEAR1 A 24 P323901 0.116 -0.316
DAI 10513 A 32 P156373 -0.019 -0.315
GPR174 A 23 P I1070 -0.041 -0.315
RAS1P1 A 23 P I 19353 -1.181 0.314
OTUD3 A 24 P8575 -0.031 -0.314
MYADM A 24 P134195 0.145 -0.312
OTUD6B A 23 P I11929 -0.036 -0.312
GK5 A 23 P347562 -0.074 -0.311
CCDC144A A_32 P216369 -0.294 -0.310
A 32 P215318 -0.067 -0.306
A 24 P323298 A 24 P323298 -0.756 0.305
PAK2 A 23 P327307 -0.820 0.303
PTER A 23 P323774 -0.005 -0.301
DENND5B A 23 P366559 -0.683 0.299
TRIMS 9 A_23_P407718 -0.101 -0.295
COL19A1 A 23 P375922 -0.310 -0.292
MYBL1 A_24_P308139 -0.044 -0.292
ZNF765 A 32 P84772 -0.071 -0.289
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APOBEC3H
MGAT2
SS18L1
EF178107
DA572835
AF020645
KLRA1
SEL1L3
KLRC2
U21252
SYT11
CEACAM3
ANKRD36
RASGRP1
A_24_P698128
F12
SEPSECS
DID01
STAT4
CCR4
MLLT10
LOC647121
AJ2_P75115
NAT12
STX11
A_23_P3083
TAS2R19
FU40330
SAMD3
A_24_P627415
A_23_P18871
GPAT2
TAS2R45
BLK
LOC100132941
C&*/37
DNAJC21
AF103312
A_32_P67223
MLLT1
ZNF10
CCDC91
PLEKHF1
METT5D1
POU2AF1
/W2_f72477
PDP1
AK054921
CCDC144B
CU679836
A_32_P207151
LAX1
WWOX
RORA
RORA
GM2A
A_32_P66297
M4Æ
A_32_P347617
A_23_P336342
A_23_P65558
A_23_P423926
A_32_P51988
A_24_P478153
A_24_P919358
A_23_P407662
A_23_P426021
A_23_P22232
A_24_P608268
A_23_P12018
A_23JP358244
A_24_P6725
A_23_P124642
A_24_P698128
A_23_P167674
A_23_P167201
A_24_P322611
A_32JP3317
A_23_P305198
A_23_P72989
A_24_P84540
A_24_P511877
A_32_P75115
A_24_P221770
A_23_P156788
A_23_P3083
A_23_P340308
A_24_P341089
A_23_P397937
A_24_P627415
A_23_P18871
A_24_P712271
A_23_P303851
A_23_P31725
A_24_P161853
A_23_P327907
A_24_P177987
A_24_P604784
A_32_P67223
A_24_P151295
A_23_P203829
A_24_P372959
A_24_P194068
A_32_P183495
A_23_P312920
A_32_P72477
A_23_P123336
A_32_P61298
A_24_P75917
A_32_P173582
A_32_P207151
A_23_P438
A_24_P116606
C PID 184
C P ID l 86
A_23_P144872
A_32_P66297
A 24 P363278
- 0.122
0.094
-0.043
-0.105
-0.716
0.150
-0.085
- 0.210
-0.076
- 0.886
-0.758
-0.075
0.028
-0.042
0.009
-0.246
0.272
-0.042
-0.013
-0.057
-0.043
-0.173
0.022
-0.013
0.189
-0.045
0.130
0.182
-0.144
0.089
-0.016
-0.435
-0.172
0.173
-0.090
-0.615
-0.728
-0.293
-0.007
-0.829
-0.092
0.259
-0.103
-0.048
0.516
-0.178
-0.604
-0.069
-0.029
-0.534
-0.439
-0.250
-0.304
-0.006
-0.187
0.053
0.065
-0.147
-0.240
0.154
-0.288
-0.288
-0.286
-0.285
0.283
-0.283
-0.281
-0.280
-0.280
0.280
0.278
-0.276
-0.276
-0.275
-0.274
-0.274
-0.270
-0.269
-0.268
-0.267
-0.267
-0.265
-0.264
-0.264
-0.264
-0.263
-0.262
-0.255
-0.255
-0.254
-0.253
-0.251
-0.249
-0.247
-0.247
0.246
0.245
-0.245
-0.244
0.242
-0.241
-0.241
-0.240
-0.240
-0.239
-0.237
0.236
-0.236
-0.236
-0.233
-0.233
-0.232
-0.232
-0.231
-0.230
-0.230
-0.229
-0.229
-0.229
-0.228
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TWFl A 24 P I78273 -0.086 -0.227
TMEM38B A 24 P278156 -0.009 -0.227
PERI CPID 598 0.421 -0.225
LOC100128398 A 24 P135427 -0.042 -0.225
AK024304 A 32 P874394 -0.140 -0.225
EPC1 A 23 P46725 -0.072 -0.222
REST A 23 P167081 -0.072 -0.220
A 24 P173566 -0.794 0.220
MED9 A 24 P8267 -0.019 -0.219
A 24 P368748 0.284 -0.218
RASGRP4 A 23 P165007 0.101 -0.218
ZFP42 A 23 P395582 -0.302 -0.218
KLRD1 A 23 P204208 -0.197 -0.218
Sep-13 A_24_P855187 0.035 -0.218
KIF3A A 23 P I22027 -0.066 -0.218
UNC5A A 23 P I 10557 0.163 -0.216
PRIM2 A 24 P282237 -0.168 -0.216
PIK3R1 A 23 P144980 -0.115 -0.215
A 24 P195454 A 24 P I95454 -0.044 -0.215
PHF6 A 23 P171385 -0.065 -0.215
KPN A 5 A 23 P I56443 -0.192 -0.215
MBNL2 A 23 P204979 -0.018 -0.213
CRYZL1 A 24 P924836 -0.121 -0.213
EIF4A2 A 32 P110751 -0.108 -0.212
A 24 P409471 A 24 P409471 -0.071 -0.212
MPPED1 A 23 P146855 0.209 -0.210
CD96 A 32 P7502 -0.129 -0.210
XYLT2 A 23 P15582 -0.021 -0.210
ZNF197 A 24 P385148 -0.086 -0.209
ANKRD36B A 24 P135092 -0.083 -0.209
MAK A 23 P214839 0.248 -0.208
PDE4D A 24 P419351 -0.165 -0.208
CREB3L3 A 24 P57207 0.129 -0.207
C77orf%) A 23 P152955 -0.016 -0.206
FCGRT A_23_P55936 0.081 -0.205
A 24 P204727 -0.730 0.205
Æ\H%7 A 23 P86570 -0.149 -0.204
KLRC4 A_23_P218058 -0.127 -0.203
RFC1 A 24 P136807 -0.030 -0.202
NUCKS1 A_24_P216968 -0.091 -0.202
TMEM87A A 24 P65098 -0.062 -0.202
ZBTB38 A 24 P221323 -0.128 -0.201
P0P1 A_23_P94133 -0.013 -0.201
AY505570 A 24 P101226 -0.772 0.201
LOC729088 A 32 P36143 -0.139 -0.201
ATF7IP2 A 24 P341987 -0.104 -0.200
RORA A_23_P26124 0.077 -0.200
C4orf42 A 23 P7083 -0.036 -0.199
C19orf2 A 23 P119418 -0.034 -0.199
HNRNPA3 A 24 P488588 -0.179 -0.198
UBXN2A A 23 P131240 -0.041 -0.196
A 23 P96633 0.335 -0.196
BLMH A 23 P141606 -0.047 -0.195
CTSB A 24 P397928 0.358 -0.194
IPP A 23 P9662 -0.160 -0.190
SEC63 A 24 P192183 -0.012 -0.189
SCARNA17 A 32 P37592 -0.108 -0.189
AK023394 A 32 P66788 -0.122 -0.188
LMBRD2 A 32 P8952 -0.066 -0.188
TRAT1 A 23 P212568 -0.128 -0.188
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ISM1 A_32_P 186731 -0.3 03
AK021463 A_24_P481530 -0.152
ENST00000239730 A_24_P66398 -0.060
PJA1 A_23_P 11244 -0.062
MAPK1IP1L A_24_P107674 -0.084
GUSBL2 A_24_P332739 -0.147
TWJSTNB A_23_P82474 -0.080
CD22 A_24_P254106 -0.638
A_24_P516978 A_24_P516978 -0.095
RBM27 A_23_P92786 -0.026
ZNF468 A_32_P29615 -0.122
RGPD2 A_24_P33197 -0.231
ABHD11 A_23_P8558 0.367
CCDC144A A_24_P332161 -0.429
MAP4K5 A_24_P 16997 0.023
LOC730091 A_32_P224327 -0.673
A_32_P124728 A_32_P 124728 -0.460
A_23_P385771 -0.033
A_24_P528213 A_24_P528213 -0.166
A_32_P145302 A_32_P145302 -0.119
C5/?/ A_23_P29046 -0.105
PTPN4 A_24_P 122940 -0.095
C18orf54 A_23_P3 00797 -0.046
APOBEC2 A_23_P70387 0.469
SYNCR1P A_24_P791515 -0.090
CCDC75 A_24_P358425 -0.197
GCET2 A_24_P 182947 -0.202
A_24_P55225 0.165
AX721128 A_24_P810735 -0.279
C P ID l 85 0.100
ENST00000429401 A_24_P392436 -0.202
A_24_P859859 A_24_P859859 0.323
A_24_P 153576 -0.065
C20orfl35 A_32_P465065 0.385
GUSBP3 A_24_P649357 -0.222
TCF12 A_24_P82142 -0.069
A_23_P98369 -0.358
MOL47 A_24_P925062 -0.435
WC100132790 A_32_P42797 -0.327
A_32_P50264 A_32_P50264 0.226
A_23_P96483 -0.178
A_32_P15829 A_32_P 15829 -0.296
A_23_P255215 -0.110
SUPT16H A_24_P153800 -0.061
AJ519285 A_24_P488083 -0.674
HEXIM2 A_23_P377214 0.094
C15orf40 A_32_P99902 -0.080
ZPPi?2 A_23_P153461 0.128
CROCCL1 A_23_P126486 -0.214
7TC5 A_32_P165330 -0.385
hCG J820661 A_32_P481631 0.392
CCDC144NL A_32_P109214 -0.529
PLAGL1 A_24_P312041 0.069
A_23_P216915 0.335
SEMA3B A_24_P294419 0.135
A_23_P406438 -0.188
ZFR A_24_P311771 -0.066
BCÂ" A_24_P89080 -0.255
ANKRD20A2 A_24_P64241 -0.422
ANKRD32 ____________ A 23 P144684 -0.088
-0.188
-0.187
-0.187
-0.187
-0.187
-0.186
-0.185
0.183
-0.183
-0.182
-0.182
-0.181
0.181
-0.181
-0.180
0.180
-0.180
-0.179
-0.178
-0.178
-0.178
-0.178
-0.178
-0.178
-0.177
-0.177
-0.176
-0.175
-0.175
-0.174
-0.174
-0.174
-0.173
-0.173
-0.172
-0.172
-0.172
-0.171
-0.171
-0.171
-0.170
-0.170
-0.169
-0.169
0.169
-0.168
-0.168
-0.168
-0.168
-0.168
-0.167
-0.167
-0.167
-0.166
-0.165
-0.164
-0.164
-0.164
-0.164
-0.164
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ARSD A 23 P357760 0.415 -0.164
ZNF107 A 24 P154914 -0.135 -0.164
BLNK A 24 P64344 -0.500 0.163
ATMIN A 23 P100133 -0.134 -0.163
PLGLB1 A 23 P359630 -0.439 -0.163
KLHDC5 A 24 P304485 -0.101 -0.162
RPN1 A 23 P132809 -0.221 -0.162
A 24 P349547 A 24 P349547 -0.162 -0.162
CX3CL1 A 24 P381901 0.197 -0.162
PTPN2 A 32 PI445 -0.045 -0.161
PDCD7 A 24 P159181 -0.093 -0.161
LOC387895 A 32 P35047 -0.688 0.161
CWSOf A 24 P284213 -0.202 -0.160
JUN A 23 P201538 -0.140 -0.159
SEMA6C A 23 P138000 0.597 -0.159
BC062753 A 24 P594721 -0.168 -0.159
D0K7 A 23 P398854 -0.614 0.158
BC035371 A 24 P376422 0.398 0.158
UBB A 24 P I 13109 0.169 -0.158
ALG10 A 23 P204333 -0.121 -0.157
RAB11FIP5 A 23 P415006 -0.490 0.157
TFAM A 24 P I34727 -0.819 0.157
NOLIO A 24 P384755 -0.183 -0.157
RSF1 A 23 P395703 -0.063 -0.157
SLC30A7 A 23 P22915 -0.114 -0.157
DQ840829 A 24 P33341 -0.665 0.156
SESN1 A 24 P346339 -0.194 -0.156
CB985069 A 32 P139113 -0.123 -0.156
ZNF318 A 24 P204043 -0.113 -0.156
ZNF605 A 24 P923594 -0.167 -0.155
HLTF A 24 P248251 -0.053 -0.155
UBA6 A 24 P316270 -0.064 -0.155
G0SR1 A 24 P I69462 -0.085 -0.155
DNAJC22 A 32 P407245 0.314 -0.154
Æ RM ga# A 32 P65571 -0.149 -0.153
GPR89B A 24 P887553 -0.089 -0.152
TMED7 A 24 P331727 -0.098 -0.151
A 23 P200252 0.572 0.151
HNRNPA3 A_24_P269895 -0.163 -0.151
CCDC45 A 24 P324814 0.062 -0.150
A 32 P56320 A_32 P56320 -0.188 -0.149
A 23 P11800 -0.240 -0.148
C15orf63 A 23 P I 17683 -0.044 -0.148
SRRM1 A 24 P264192 -0.082 -0.148
UBR1 A 24 P I02203 -0.041 -0.147
STRN3 A 23 P392076 -0.131 -0.147
RGPD5 A 32 P89371 -0.167 -0.147
PLA2G5 A 23 P I03465 0.365 -0.147
PERI CPID 599 0.238 -0.146
AASDHPPT A_24_P184230 -0.040 -0.146
A 32 P27532 A 32 P27532 0.062 -0.145
ZNF841 A 23 P27404 -0.115 -0.145
ABAT A 24 P330684 0.241 -0.144
A 23 P373799 -0.142 -0.144
TRIMS 2 A 23 P58579 -0.017 -0.144
EPHA4 A 24 P274219 -0.345 0.143
A 23 PI 39104 A_23_P139104 0.190 -0.143
CDRT4 A_24 P262321 -0.470 -0.142
A 32 P208200 A 32 P208200 -0.313 -0.142
PPP2R2B A 23 P213620 -0.079 -0.142
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C9orf21 A 24 P I69343 -0.084 -0.141
JMY A 32 P176550 -0.115 -0.140
CCDC123 A 24 P I45229 -0.073 -0.140
Z1M2 A 23 P78479 0.488 -0.140
A 32 P74831 A 32 P74831 0.436 -0.140
SENP1 A 24 P167412 -0.167 -0.140
FLCN A 23 P414308 0.817 -0.140
OXR1 A 24 P163632 -0.147 -0.139
PLBD2 A 23 P10911 0.159 -0.139
RNF216 A 24 P469641 -0.153 -0.138
AK125393 A 32 P30831 -0.319 -0.138
PXK A 24 P 140204 -0.385 0.138
GTPBP2 A 23 P379026 0.107 -0.138
BC092452 A 24 P548415 -0.104 -0.137
A 24 P287526 0.593 -0.137
A 32 P20535 A 32 P20535 0.197 -0.136
KCNMA1 AJ24 P61150 0.392 -0.136
A 24 P350252 A 24 P350252 0.216 -0.135
OR7E156P A 24 P384018 0.113 -0.135
RNF125 A 23 P101141 -0.202 -0.135
A7ŒS-2 A 23 P86587 0.466 -0.135
ADAM28 A 23 P10356 -0.562 0.135
ASPHD1 A 23 P I70667 0.360 -0.135
RALGPS2 A 24 P I73746 -0.451 0.134
A 24 P937765 A 24 P937765 -0.102 -0.134
INADL A 23 P126100 -0.277 -0.134
GNPNAT1 A 24 P943040 -0.134 -0.132
MG AT5 A 23 P I6743 -0.283 -0.132
ENST00000299415 A 32 P62090 0.197 -0.132
PRPF38B A 24 P222844 -0.130 -0.131
UTP14A A 24 P170538 -0.117 -0.131
HSPD1 A 32 P76091 -0.143 -0.131
,4 22 f22J7& A 32 P22578 -0.836 0.131
AF119798 A 24 P15388 -0.676 0.130
FLJ13197 A_23_P30163 -0.176 -0.129
SACO A 23 P42498 0.182 -0.129
PSPC1 A_24_P253233 -0.113 -0.128
A 32 P210723 A 32 P210723 -0.203 -0.128
MFSD2A A_23_P43820 0.198 -0.127
GAD1 A_23_P209578 0.639 -0.127
AK025762 A 32 P213822 -0.110 -0.126
C7&,r/70 A 23 P141717 0.476 -0.125
RPP30 A 23 P138453 -0.080 -0.125
DHRS7B A 23 P141208 0.098 -0.125
CCDC144B A 24 P288915 -0.539 -0.124
C12orf75 A 32 P163089 -0.179 -0.123
ATP10D A 24 P919399 -0.165 -0.123
LOC388796 A 24 P860703 -0.443 0.123
PTPRN A 23 P90722 0.268 -0.123
SFXN5 A 24 P63030 0.153 -0.123
KLHL21 A 23 P201478 0.100 -0.122
BX111592 A 32 P49959 0.565 0.122
A 24 P238525 A 24 P238525 -0.430 -0.122
GPRIN3 A 24 P76649 -0.207 -0.120
EX0SC2 A 23 P216396 -0.131 -0.120
AF090903 A 23 P42063 0.387 -0.119
24 fP24744 A 24 P934744 -0.255 -0.119
AP3S2 A 24 P287691 0.123 -0.118
A 32 PI85398 A 32 P185398 -0.644 0.117
C9orfl 16 A 23 P422115 0.288 -0.116
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APLN A_23_P147755 0.320 -0.116
CHST12 A_23 P310421 -0.110 -0.116
BCOR A 23 P I59741 -0.234 -0.116
RASA4 A_23 P I68449 0.308 -0.115
LOC338620 A 23 P97780 -0.321 -0.114
A 24 P837085 0.170 -0.113
C lo ip l A_24_P285378 0.130 -0.112
ZMYND15 A 23 P89570 0.219 -0.112
MANEA A 24 P I87921 -0.270 -0.112
A 32 P91773 A 32 P91773 0.238 - 0.111
HAUS2 A 23 P129301 -0.101 - 0.111
AKAP11 A 23 P 418477 -0.181 - 0.111
IP07 A_32 P I86226 -0.198 - 0.111
IFT80 A_23 P406013 -0.233 - 0.111
NFKB2 CPID_112 0.161 - 0.111
A 24 P920070 A 24 P920070 0.612 0.111
TTC3 7 A 24 P93353 -0.149 - 0.111
PERP A_23 P214950 -0.317 -0.110
METTL10 A_24 P86868 -0.087 -0.110
HIST2H2AB A 24 P68631 -0.197 -0.109
TAS2R20 A 23 P382794 -0.851 0.109
DCPS A 23 P52738 -0.194 -0.109
PDP2 A 23 P66063 -0.155 -0.108
ABCC2 A_23_P44569 0.233 -0.108
PCDH9 A 24 P187218 -0.694 0.107
ACTR8 A 23 P80694 -0.155 -0.106
PPP1R16A A 23 P157715 -0.105 -0.106
PIGC A 23 P86252 -0.054 -0.106
LIG4 A_24 P415845 -0.605 -0.105
PPAPDC1B A 23 P329971 -0.334 -0.104
ELF1 A_24 P78590 -0.164 -0.103
GTF2IRD2 A 24 P I86497 -0.157 -0.103
BDP1 A_24 P26342 -0.124 -0.103
PPP2R1B A_24_P107291 -0.137 -0.103
SYT11 A 24 P139899 -0.142 -0.103
HK3 A 24 P37962 0.255 -0.102
1LKAP A_23_P142590 -0.108 -0.102
LOCI00131998 A 32 P138557 -0.218 -0.102
A 24 P350017 A_24_P350017 -0.733 -0.101
TUG1 A_24 P382724 0.121 -0.101
S1PR1 A 23 P404481 -0.194 -0.100
A 24 P926450 A 24 P926450 -0.198 -0.099
A 24 P750305 0.263 -0.099
CLIC5 A 23 P416774 -0.220 -0.099
TMEM135 A 24 P I27075 -0.185 -0.098
CTRL A 23 P152199 0.166 -0.098
HP A_23_P206760 0.805 0.097
APBB1 A 23 P1998 0.298 -0.097
PHEX A 23 P I 14084 0.526 0.097
SMYD4 A 24 P307175 -0.148 -0.096
TMED5 A 23 P86002 -0.115 -0.096
GRINA A 24 P179615 0.363 -0.095
LOC729806 A_23 P I58997 -0.179 -0.095
GM2A A_24_P925314 -0.261 -0.095
RPAIN A 23 P66766 -0.166 -0.095
CR616058 A_24 P455060 -0.182 -0.095
A 24 P532730 A 24 P532730 -0.101 -0.094
v4f%7747J A 23 P259763 -0.641 0.094
AL833099 A 24 P287785 -0.120 -0.093
PGLYRP1 A 23 P208747 0.420 -0.093
272
FAM108B1 A 23P 83149 -0.153 -0.093
HNRNPA1L2 A 32 P216426 -0.233 -0.093
C0BLL1 A 24 P915926 -0.482 -0.093
PPHLN1 A 23 P128436 -0.067 -0.093
CLCN3 A 24 P402847 -0.174 -0.093
LOCI 00133050 A 32 P39003 -0.261 -0.093
AK054806 A 24 P680779 -0.646 0.093
A 24 P126902 A 24 P I26902 -0.782 0.093
ENHO A 24 P32560 0.361 -0.092
SRP19 A 24 P388810 -0.167 -0.092
TYW1 A 32 P52206 -0.177 -0.092
FZD1 A 23 P134502 0.754 0.092
FAM98A A 23 P313728 -0.147 -0.091
NOM1 A 23 P322196 -0.144 -0.091
A 23 PI 18135 A 23 P118135 -0.083 -0.091
A 24 P837537 A 24 P837537 -0.527 0.091
EBF1 A 32 P197561 -0.559 0.090
FAM131B A 23 P215718 0.426 -0.090
A 24 P290263 A 24 P290263 -0.176 -0.089
TR1M27 A 24 P I63405 0.121 -0.089
BQ069859 A 24 P697437 -0.128 -0.088
CTSE A 23 P10291 0.369 -0.088
EOMES A 24 P97374 -0.239 -0.088
AK131430 A 23 P72372 -0.340 -0.088
ZNF587 A 24 P408801 -0.319 -0.088
A 23 P254353 0.211 -0.087
SIGLEC10 A 23 P208182 0.317 -0.087
ZNF616 A 24 P275984 -0.192 -0.086
CAMK2N1 A 24 P I 17620 -0.448 0.086
ANKRD20A2 A 32 P168326 -0.615 0.086
FLJ34077 A 23 P35656 -0.216 -0.086
KATNAL1 A 23 P151415 -0.184 -0.086
KIAA0141 A 24 P63563 -0.101 -0.085
EZR A 24 P290481 -0.227 -0.084
KLHL26 A 23 P39375 0.169 -0.082
ODF2L A 23 P328298 -0.237 -0.082
KHK A 23 P5845 -0.394 0.081
AK056664 A 24 P239309 -0.313 -0.081
PBRM1 A 24 P362850 -0.188 -0.081
A 24 P324488 -0.150 -0.079
AF289600 A 24P 922182 -0.167 -0.079
SMPD4 A_24_P268357 -0.144 -0.079
P1K3R1 A 24 P29401 -0.290 0.079
PARP15 A 23 P378555 -0.211 -0.079
FKBP1B A 23 P142631 0.441 -0.078
LOC728411 A 24 P84822 -0.273 -0.078
A 24 P204484 A 24 P204484 -0.233 -0.078
BC033990 A 32 P67414 0.234 -0.078
RNF145 A 23 P167559 -0.210 -0.078
CFDP1 A 23 P89123 -0.137 -0.078
SMG1 A 32 P20120 - 0.111 -0.078
GPX1 A 23 P250671 0.298 -0.077
ZNF37B A 32 P48043 -0.205 -0.076
24 f  &4(%W A 24 P84608 -0.443 -0.076
SFRS13A A 23 P45737 -0.106 -0.076
MAPRE2 A 24 P193911 -0.184 -0.076
0RC5L A 24 P394698 -0.186 -0.075
C16orf93 A 24 P842006 0.117 -0.075
GF0D2 A 23 P3574 0.309 -0.074
RNF5 A 23 P320200 0.216 -0.074
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CU677606 A 32 P219011 0.446 0.073
LRP8 A 23 P200222 -0.196 -0.073
A 24 PI 61068 A 24 P161068 -0.292 -0.073
A 32 P232523 A 32 P232523 -0.314 -0.072
TTC3 A 24 P549553 -0.195 -0.072
SUCLA2 A 24 P181275 -0.430 -0.071
PNMA5 A 23 P352950 0.502 0.071
G0N4L A 24 P212457 -0.247 -0.071
PRR4 A 23 P62042 -0.226 -0.071
G ATM A 23 P129064 -0.704 -0.070
PANK3 A 24 P380330 -0.181 -0.070
A 32 PI 15555 A 32 PI 15555 0.255 -0.070
KIAA1919 A 32 P I97870 -0.204 -0.069
RXRB A_23_P59179 0.245 -0.069
WC651250 A 24 P484894 -0.226 -0.069
LUC7L3 A 24 P920693 -0.148 -0.068
A_24_P899637 -0.170 -0.068
TRPM7 A 24 P50829 -0.205 -0.067
SERPINF1 A 23 P100660 0.429 0.067
A 32 P36005 A 32 P36005 0.427 0.067
A 32 P213930 A 32 P213930 -0.161 -0.066
BM508076 A 32 P4505 0.219 -0.065
TRIT1 A_23 P I2062 -0.230 -0.065
A 32 P73580 A 32 P73580 -0.203 -0.065
GEN1 A 24 P177585 -0.324 -0.065
MANBAL A 23 P131778 0.116 -0.065
SNRPD3 A 23 P132216 -0.164 -0.065
MADCAM1 A 24 P I0731 0.271 -0.065
SMN2 A 24 P126682 -0.348 -0.064
M1CAL3 A 23 P403195 -0.238 -0.064
BQ272125 A 32 P215462 -0.181 -0.064
C7orf27 A 23 P251898 0.210 -0.064
HYAL2 A_23 P57927 0.150 -0.063
BCL11A A 23 P218584 -0.396 0.062
ALMS1P A 23 P435657 -0.486 0.062
AJ2_P93584 A 32 P93584 0.528 0.062
C19orf46 A_23_P350074 0.188 -0.062
NOP56 A_24 P I01402 -0.148 -0.061
TAC3 A 23 P2283 0.706 0.061
24 A 24 P238836 -0.748 0.061
AI791206 A 24 P856722 -0.432 0.061
FREQ A_23 P 217049 0.737 -0.060
A 32 P62211 -0.218 -0.060
ZFR2 A 32 P55462 0.727 0.059
ClSorfl 0 A 23 P141715 0.497 -0.059
SK4YD3 A 23 P51410 -0.141 -0.058
A 24 P486503 A 24 P486503 -0.288 -0.058
FYC01 A 23 P212339 -0.129 -0.058
ENDOG A 23 P83266 0.412 0.058
PKP3 A 23 P95810 0.253 -0.058
NFYA A 23 P501583 -0.126 -0.057
BC034827 A 24 P677471 -0.186 -0.056
RAB4A A 24 P122682 -0.165 -0.056
ADSSL1 A 23 P76823 0.241 -0.056
ATXN3 A 23 PI 17635 -0.163 -0.056
IKZF3 A 23 P376060 -0.249 -0.055
USP45 A 23 P134008 -0.329 0.054
RBMX A 24 P824592 -0.329 -0.054
KEAP1 A 23 P119141 -0.156 -0.053
QRICH1 A 23 P45106 -0.189 -0.053
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SFXN4 A 23 P75149 0.293 -0.053
Clorfl 75 A 23 P I60226 0.322 -0.053
RC3H2 A 24 P128085 -0.177 -0.053
32 f  7 72724 A 32 P I78724 -0.514 0.053
GALT A 24 P I2865 -0.151 -0.052
CACNA1F A 23 P148327 0.272 -0.052
A 24 PI69645 A 24 P169645 -0.347 -0.052
RPL14 A 32 P81149 -0.281 -0.052
A 24 P733083 A 24 P733083 -0.164 -0.051
A 32 P137819 A 32 P137819 -0.469 0.051
SLC30A4 A 32 P21255 -0.270 -0.051
AKTIP A 32 P224840 -0.224 -0.051
BC014971 A 23 P140884 0.901 -0.051
24 f 347429 A 24 P341489 -0.302 0.050
EPHA4 A_23_P119899 -0.299 0.050
MRPL42P5 A 23 P398491 -0.608 0.047
A 32 PI4737 A 32 P14737 0.336 -0.047
GEN1 A 24 P920968 -0.404 -0.047
CR592318 A 24 P611903 -0.364 -0.047
A 24 P850069 A 24 P850069 0.364 -0.046
PHTF2 A 24 P323944 -0.353 0.046
SYDE1 A 23 P101796 0.408 -0.046
ABHD15 A 23 P363034 -0.230 0.045
TCEAL4 A 23 P259166 -0.249 -0.045
KLF8 A 24 P937159 -0.540 0.044
RNF5 A 23 P8095 0.178 -0.044
CCDC65 A 23 P47904 -0.287 -0.044
LARS A 23 P218965 -0.213 -0.044
PRKD3 A 23 P108574 -0.157 -0.044
NUSAP1 A 24 P416079 0.585 0.044
TOLLIP A 23 P75903 0.410 -0.043
TMPRSS13 A 23 P435477 0.431 -0.042
A 32 P231265 A 32 P231265 -0.295 -0.042
CENPB A_23_P257905 0.206 -0.042
MXD3 A 23 P124559 0.236 -0.041
CA314936 A 32 P140228 -0.224 -0.040
GALNT10 A 23 P7706 -0.207 -0.040
BSPRY A 24 P I80849 0.315 -0.040
Z7VF245 A_32_P207436 -0.200 -0.040
KCNA2 A 23 P137923 0.355 0.040
A 32 PI80078 A 32 P180078 0.425 0.040
TARP A 23 P59543 -0.378 -0.040
C7C2720J2 A 24 P933173 -0.449 -0.039
C73or/57 A 32 P98975 -0.276 -0.039
PKMYT1 A 23 P398515 0.382 -0.039
A 32 P76865 A 32 P76865 0.349 -0.038
ACVR2B A 32 P I34209 -0.380 -0.038
CCDC55 A 24 P382130 -0.244 -0.038
REST A 24 P299507 -0.299 -0.038
LOCI52719 A 24 P919733 -0.182 -0.038
CASP8 A 24 P I48499 -0.190 -0.037
AF130099 A 32 PI29772 0.303 -0.037
A 32 PI 46169 A 32 P146169 0.322 -0.037
SWAP70 A 24 P359165 -0.352 -0.037
SERF2 A 23 P I06299 0.317 -0.036
A 24 P642306 A 24 P642306 0.695 0.036
GGT5 A 24_P297182 0.454 0.036
NGLY1 A 23 P430051 -0.263 0.035
SCAMP4 A 24 P333341 -0.263 0.035
A 24 P901084 A 24 P901084 -0.261 -0.034
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F0XRED2 A 24 P147765 0.325 0.034
SLC12A3 A 23 P77653 0.485 -0.034
HNRNPCL1 A 24 P767422 -0.348 0.034
A 23 P216900 0.418 -0.034
P2RY8 A 24 P340128 -0.195 -0.032
ZBTB38 A 23 P212025 -0.193 -0.032
FCAMR A 23 P201510 0.361 -0.032
AF086054 A 32 P I 15475 -0.229 -0.032
FKSG43 A 23 P33927 0.214 -0.031
MCART2 A 32 P I77267 -0.181 -0.029
FBXOIO A 32 P57453 -0.713 0.028
SMYD4 A 24 P359145 -0.207 -0.028
CALM1 A 23 P163178 -0.205 -0.028
A 32 P186865 A 32 P186865 0.375 -0.028
IGFBP3 A_23_P215634 -0.554 0.028
AK091034 A 24 P183963 -0.337 0.028
FBX034 A 24 P919493 -0.333 -0.027
ALG12 A 23 P60718 0.185 0.027
CD40LG A 23 P62220 -0.310 -0.025
SYPL1 A 24 P141005 -0.218 0.025
SMAD2 A 32 P12580 -0.372 -0.025
BM984396 A 23 P28607 -1.154 -0.025
SKP1 A 24 P566701 -0.309 0.024
MDFIC A 32 P120567 -0.214 -0.024
CAPS A 23 P78958 -0.621 -0.024
TBC1D23 A 23 P121489 -0.153 -0.023
A 32 P144619 A 32 P144619 0.450 0.023
OR7E24 A 23 P16110 0.484 -0.023
A 24 PI43785 A 24 P143785 -0.436 0.023
GCNT1 A 23 P9232 -0.292 0.023
FAM3C A 32 P101689 -0.303 -0.022
A 24 P375076 A 24 P375076 -0.299 0.022
A 32 P126846 A 32 P126846 0.225 0.022
RELT A_24JP38951 0.233 -0.021
THAP6 A 23 P328735 -0.251 -0.021
LOC643387 A 24 P246767 -0.494 -0.021
SLC25A38 A_23_P91814 0.196 -0.019
RTDR1 A 23 P29153 0.344 -0.019
ENST00000316294 A_32JP 144953 0.232 0.018
RNF5 A 32 P185149 0.189 -0.018
WBSCR16 A 24 P350796 -0.200 -0.017
RBM33 A 23 P417113 -0.351 0.016
FNBP1L A 24 P366967 -0.386 0.016
AK124352 A_32_P220580 -0.389 0.016
MACR0D2 A 23 P22398 -0.678 0.016
A 32 P196896 A_32_P196896 -0.260 0.016
ABCC10 A_23 P219013 0.205 -0.016
HNRNPA1L2 A 24 P32849 -0.437 0.015
ZNF616 A 32 P186921 -0.214 0.014
AR1D5B A 24 P I70667 -0.265 -0.014
FKBP11 A 23 P25121 -0.245 0.013
CYB561 A 24 P39843 -0.258 0.013
A 32 P62248 -0.463 0.013
A 23 PI 70713 A_23JP170713 -0.257 0.013
AI281166 A 32 P226338 0.293 -0.012
A 32 PI 06466 A 32 P106466 0.552 0.012
CIB2 A 23 P65890 0.244 -0.012
COL9A2 A 23 P45786 0.229 -0.012
A 24 P400690 A 24 P400690 0.368 0.012
A 24 P400760 -0.238 -0.011
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A 32 P193908 A 32 P193908 0.469 0.011
A 23 P348349 A 23 P348349 -0.353 -0.011
RPL14 A 23 P I8294 -0.335 0.011
TAP2 A 23 P368067 0.950 -0.011
RALGPS2 A 23 P97517 -0.373 -0.010
HNRNPH1 A 32 P34149 -0.246 -0.010
CBWD5 A 32 P35220 -0.205 0.010
A 24 P417751 A 24 P417751 -0.454 -0.009
CISorflO A 24 P128140 0.415 0.009
A 32 PI8493 A 32 P I8493 -0.273 0.009
cw azw A 24 PI4260 -0.299 -0.009
KIAA1529 A 24 P280706 -0.221 -0.008
PPP2R5C A 24 P369694 -0.217 0.007
BC033996 A_32_P64324 0.306 0.007
C16orf68 A 23 P3885 0.295 -0.007
Clorf212 A 23 P314666 -0.179 0.006
C14orfll8 A 24 P15563 -0.186 -0.005
A 32 PI63368 A 32 P163368 0.443 -0.005
A 32 P179205 A 32 P I79205 -0.553 -0.005
MAF A 24 P256219 -0.424 0.005
A 23 P75220 0.217 -0.004
CYP20A1 A 32 P I 10433 -0.239 0.004
AZC2 A 24 P227211 0.429 0.004
WC554203 A_32_P223935 -0.298 -0.004
NEK1 A 24 P914599 -0.310 -0.003
TAF1D A 24 P261383 -0.189 0.003
HSP90B1 A 24 P150361 -0.249 -0.003
DHX33 A 24 P364970 -0.248 -0.003
DOCK7 A 23 P331348 -0.348 0.002
MS4A1 A 23 P116371 -0.435 0.002
A 32 PI69521 A 32 P169521 0.506 -0.002
A 24 P341176 A 24 P341176 -0.239 -0.001
SUPV3L1 A 23 P63847 -0.286 -0.0004
CADM1 A 23 P203120 -0.472 0.0001
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